WO2007102679A1 - Novel thienopyrimidine derivatives or pharmaceutically acceptable salts thereof, process for the preparation thereof and pharmaceutical composition comprising the same - Google Patents
Novel thienopyrimidine derivatives or pharmaceutically acceptable salts thereof, process for the preparation thereof and pharmaceutical composition comprising the same Download PDFInfo
- Publication number
- WO2007102679A1 WO2007102679A1 PCT/KR2007/001074 KR2007001074W WO2007102679A1 WO 2007102679 A1 WO2007102679 A1 WO 2007102679A1 KR 2007001074 W KR2007001074 W KR 2007001074W WO 2007102679 A1 WO2007102679 A1 WO 2007102679A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- methyl
- thieno
- pyrimidin
- thiophen
- ylamino
- Prior art date
Links
- 150000003839 salts Chemical class 0.000 title claims abstract description 24
- RBNBDIMXFJYDLQ-UHFFFAOYSA-N thieno[3,2-d]pyrimidine Chemical class C1=NC=C2SC=CC2=N1 RBNBDIMXFJYDLQ-UHFFFAOYSA-N 0.000 title claims abstract description 17
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 15
- 238000000034 method Methods 0.000 title abstract description 197
- 238000002360 preparation method Methods 0.000 title abstract description 185
- 230000008569 process Effects 0.000 title abstract description 6
- 150000001875 compounds Chemical class 0.000 claims abstract description 397
- 208000027866 inflammatory disease Diseases 0.000 claims abstract description 14
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 9
- 201000011510 cancer Diseases 0.000 claims abstract description 6
- 230000002757 inflammatory effect Effects 0.000 claims abstract description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 267
- -1 2-methylthiophenyl Chemical group 0.000 claims description 57
- 229910052717 sulfur Inorganic materials 0.000 claims description 27
- 125000000217 alkyl group Chemical group 0.000 claims description 25
- 239000001257 hydrogen Substances 0.000 claims description 20
- 229910052739 hydrogen Inorganic materials 0.000 claims description 20
- 229910052760 oxygen Inorganic materials 0.000 claims description 17
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 16
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims description 15
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 14
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 14
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 14
- 150000002367 halogens Chemical class 0.000 claims description 13
- 229910052736 halogen Inorganic materials 0.000 claims description 12
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 12
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims description 10
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims description 10
- 150000001412 amines Chemical class 0.000 claims description 8
- 125000005842 heteroatom Chemical group 0.000 claims description 8
- 229910052757 nitrogen Inorganic materials 0.000 claims description 8
- KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical compound O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 claims description 8
- 125000001072 heteroaryl group Chemical group 0.000 claims description 7
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 7
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 7
- 229910052794 bromium Inorganic materials 0.000 claims description 6
- IWELDVXSEVIIGI-UHFFFAOYSA-N piperazin-2-one Chemical compound O=C1CNCCN1 IWELDVXSEVIIGI-UHFFFAOYSA-N 0.000 claims description 6
- VGWBHAOBTWCPMZ-UHFFFAOYSA-N (2,5-dithiophen-2-ylthieno[2,3-d]pyrimidin-4-yl)hydrazine;hydrochloride Chemical compound Cl.C1=2C(NN)=NC(C=3SC=CC=3)=NC=2SC=C1C1=CC=CS1 VGWBHAOBTWCPMZ-UHFFFAOYSA-N 0.000 claims description 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 5
- KPKNTUUIEVXMOH-UHFFFAOYSA-N 1,4-dioxa-8-azaspiro[4.5]decane Chemical compound O1CCOC11CCNCC1 KPKNTUUIEVXMOH-UHFFFAOYSA-N 0.000 claims description 4
- AQHZKVDJIWKRKX-UHFFFAOYSA-N 3-methyl-1-[[5-methyl-6-(4-nitrophenyl)-2-thiophen-2-ylthieno[2,3-d]pyrimidin-4-yl]amino]pyrrole-2,5-dione;hydrochloride Chemical compound Cl.O=C1C(C)=CC(=O)N1NC1=NC(C=2SC=CC=2)=NC2=C1C(C)=C(C=1C=CC(=CC=1)[N+]([O-])=O)S2 AQHZKVDJIWKRKX-UHFFFAOYSA-N 0.000 claims description 4
- APFAGFRKWSRPFB-UHFFFAOYSA-N 3-methyl-1-[[5-methyl-6-[4-[2-(2-oxoimidazolidin-1-yl)ethoxy]phenyl]-2-thiophen-2-ylthieno[2,3-d]pyrimidin-4-yl]amino]pyrrole-2,5-dione Chemical compound O=C1C(C)=CC(=O)N1NC1=NC(C=2SC=CC=2)=NC2=C1C(C)=C(C=1C=CC(OCCN3C(NCC3)=O)=CC=1)S2 APFAGFRKWSRPFB-UHFFFAOYSA-N 0.000 claims description 4
- AXPZEYHQHXLXAD-UHFFFAOYSA-N 3-methyl-1-[[5-methyl-6-[4-[2-(2-piperazin-1-ylethoxy)ethoxy]phenyl]-2-thiophen-2-ylthieno[2,3-d]pyrimidin-4-yl]amino]pyrrole-2,5-dione hydrochloride Chemical compound Cl.CC=1C(N(C(C1)=O)NC=1C2=C(N=C(N1)C=1SC=CC1)SC(=C2C)C2=CC=C(C=C2)OCCOCCN2CCNCC2)=O AXPZEYHQHXLXAD-UHFFFAOYSA-N 0.000 claims description 4
- LELIMJODRCEGFY-UHFFFAOYSA-N 3-methyl-1-[[5-methyl-6-[4-[2-(3-oxopiperazin-1-yl)ethoxy]phenyl]-2-thiophen-2-ylthieno[2,3-d]pyrimidin-4-yl]amino]pyrrole-2,5-dione hydrochloride Chemical compound Cl.CC=1C(N(C(C1)=O)NC=1C2=C(N=C(N1)C=1SC=CC1)SC(=C2C)C2=CC=C(C=C2)OCCN2CC(NCC2)=O)=O LELIMJODRCEGFY-UHFFFAOYSA-N 0.000 claims description 4
- VRJHQPZVIGNGMX-UHFFFAOYSA-N 4-piperidinone Chemical compound O=C1CCNCC1 VRJHQPZVIGNGMX-UHFFFAOYSA-N 0.000 claims description 4
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 claims description 4
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 4
- 229910052801 chlorine Inorganic materials 0.000 claims description 4
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 4
- 229910052731 fluorine Inorganic materials 0.000 claims description 4
- YAMHXTCMCPHKLN-UHFFFAOYSA-N imidazolidin-2-one Chemical compound O=C1NCCN1 YAMHXTCMCPHKLN-UHFFFAOYSA-N 0.000 claims description 4
- 229910052740 iodine Inorganic materials 0.000 claims description 4
- HEWAITZQGRCBHD-UHFFFAOYSA-N methyl 2-[4-[(3-methyl-2,5-dioxopyrrol-1-yl)amino]-2-thiophen-2-ylthieno[2,3-d]pyrimidin-5-yl]acetate hydrochloride Chemical compound Cl.COC(=O)Cc1csc2nc(nc(NN3C(=O)C=C(C)C3=O)c12)-c1cccs1 HEWAITZQGRCBHD-UHFFFAOYSA-N 0.000 claims description 4
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 4
- QGKLPGKXAVVPOJ-UHFFFAOYSA-N pyrrolidin-3-one Chemical compound O=C1CCNC1 QGKLPGKXAVVPOJ-UHFFFAOYSA-N 0.000 claims description 4
- 208000024891 symptom Diseases 0.000 claims description 4
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 4
- 125000001544 thienyl group Chemical group 0.000 claims description 4
- PYMOOMBYEWNJLK-UHFFFAOYSA-N 3-[2-[4-[5-methyl-4-[(3-methyl-2,5-dioxopyrrol-1-yl)amino]-2-thiophen-2-ylthieno[2,3-d]pyrimidin-6-yl]phenoxy]ethylamino]propanenitrile;hydrochloride Chemical compound Cl.O=C1C(C)=CC(=O)N1NC1=NC(C=2SC=CC=2)=NC2=C1C(C)=C(C=1C=CC(OCCNCCC#N)=CC=1)S2 PYMOOMBYEWNJLK-UHFFFAOYSA-N 0.000 claims description 3
- KECRBAZCXNNALU-UHFFFAOYSA-N 3-[methyl-[2-[4-[5-methyl-4-[(3-methyl-2,5-dioxopyrrol-1-yl)amino]-2-thiophen-2-ylthieno[2,3-d]pyrimidin-6-yl]phenoxy]ethyl]amino]propanoic acid Chemical compound C1=CC(OCCN(C)CCC(O)=O)=CC=C1C1=C(C)C2=C(NN3C(C(C)=CC3=O)=O)N=C(C=3SC=CC=3)N=C2S1 KECRBAZCXNNALU-UHFFFAOYSA-N 0.000 claims description 3
- YEXUENHISODQDA-UHFFFAOYSA-N 3-methyl-1-[(2-pyridin-4-yl-5-thiophen-2-ylthieno[2,3-d]pyrimidin-4-yl)amino]pyrrole-2,5-dione hydrochloride Chemical compound Cl.CC1=CC(=O)N(Nc2nc(nc3scc(-c4cccs4)c23)-c2ccncc2)C1=O YEXUENHISODQDA-UHFFFAOYSA-N 0.000 claims description 3
- QGBORCDOFSUFEW-UHFFFAOYSA-N 3-methyl-1-[(2-thiophen-2-yl-5-thiophen-3-ylthieno[2,3-d]pyrimidin-4-yl)amino]pyrrole-2,5-dione;hydrochloride Chemical compound Cl.O=C1C(C)=CC(=O)N1NC1=NC(C=2SC=CC=2)=NC2=C1C(C1=CSC=C1)=CS2 QGBORCDOFSUFEW-UHFFFAOYSA-N 0.000 claims description 3
- FNSBMXCLVLZOIO-UHFFFAOYSA-N 3-methyl-1-[(5-methylthieno[2,3-d]pyrimidin-4-yl)amino]pyrrole-2,5-dione;hydrochloride Chemical compound Cl.O=C1C(C)=CC(=O)N1NC1=NC=NC2=C1C(C)=CS2 FNSBMXCLVLZOIO-UHFFFAOYSA-N 0.000 claims description 3
- CWFWVZPLJAIDDX-UHFFFAOYSA-N 3-methyl-1-[(5-thiophen-2-yl-2-thiophen-3-ylthieno[2,3-d]pyrimidin-4-yl)amino]pyrrole-2,5-dione;hydrochloride Chemical compound Cl.O=C1C(C)=CC(=O)N1NC1=NC(C2=CSC=C2)=NC2=C1C(C=1SC=CC=1)=CS2 CWFWVZPLJAIDDX-UHFFFAOYSA-N 0.000 claims description 3
- GPOJPFFUNVNFSS-UHFFFAOYSA-N 3-methyl-1-[[2-(5-methylthiophen-2-yl)-5-thiophen-2-ylthieno[2,3-d]pyrimidin-4-yl]amino]pyrrole-2,5-dione;hydrochloride Chemical compound Cl.O=C1C(C)=CC(=O)N1NC1=NC(C=2SC(C)=CC=2)=NC2=C1C(C=1SC=CC=1)=CS2 GPOJPFFUNVNFSS-UHFFFAOYSA-N 0.000 claims description 3
- LPSQAUYPUTUWNP-UHFFFAOYSA-N 3-methyl-1-[[5-[3-[2-(4-methylpiperazin-1-yl)ethoxy]phenyl]-2-thiophen-2-ylthieno[2,3-d]pyrimidin-4-yl]amino]pyrrole-2,5-dione;dihydrochloride Chemical compound Cl.Cl.C1CN(C)CCN1CCOC1=CC=CC(C=2C3=C(NN4C(C(C)=CC4=O)=O)N=C(N=C3SC=2)C=2SC=CC=2)=C1 LPSQAUYPUTUWNP-UHFFFAOYSA-N 0.000 claims description 3
- IZFFNJQJCYGMSU-UHFFFAOYSA-N 3-methyl-1-[[5-methyl-6-[4-[2-(2-oxopyrrolidin-1-yl)ethoxy]phenyl]-2-thiophen-2-ylthieno[2,3-d]pyrimidin-4-yl]amino]pyrrole-2,5-dione hydrochloride Chemical compound Cl.CC1=CC(=O)N(Nc2nc(nc3sc(c(C)c23)-c2ccc(OCCN3CCCC3=O)cc2)-c2cccs2)C1=O IZFFNJQJCYGMSU-UHFFFAOYSA-N 0.000 claims description 3
- YQFJMGIVWPSHJQ-UHFFFAOYSA-N 3-methyl-1-[[5-methyl-6-[4-[2-(3-methylbutylamino)ethoxy]phenyl]-2-thiophen-2-ylthieno[2,3-d]pyrimidin-4-yl]amino]pyrrole-2,5-dione hydrochloride Chemical compound Cl.CC(C)CCNCCOc1ccc(cc1)-c1sc2nc(nc(NN3C(=O)C=C(C)C3=O)c2c1C)-c1cccs1 YQFJMGIVWPSHJQ-UHFFFAOYSA-N 0.000 claims description 3
- XCUYJMIKRHLUJR-UHFFFAOYSA-N 3-methyl-1-[[5-methyl-6-[4-[2-[methyl(propyl)amino]ethoxy]phenyl]-2-thiophen-2-ylthieno[2,3-d]pyrimidin-4-yl]amino]pyrrole-2,5-dione;hydrochloride Chemical compound Cl.C1=CC(OCCN(C)CCC)=CC=C1C1=C(C)C2=C(NN3C(C(C)=CC3=O)=O)N=C(C=3SC=CC=3)N=C2S1 XCUYJMIKRHLUJR-UHFFFAOYSA-N 0.000 claims description 3
- FLIBBPPTRCKOPM-UHFFFAOYSA-N 3-methyl-1-[[5-thiophen-2-yl-2-(thiophen-2-ylmethyl)thieno[2,3-d]pyrimidin-4-yl]amino]pyrrole-2,5-dione;hydrochloride Chemical compound Cl.O=C1C(C)=CC(=O)N1NC1=NC(CC=2SC=CC=2)=NC2=C1C(C=1SC=CC=1)=CS2 FLIBBPPTRCKOPM-UHFFFAOYSA-N 0.000 claims description 3
- VCUQBFVSVVLOPJ-UHFFFAOYSA-N 3-methyl-1-[[5-thiophen-2-yl-2-(thiophen-3-ylmethyl)thieno[2,3-d]pyrimidin-4-yl]amino]pyrrole-2,5-dione;hydrochloride Chemical compound Cl.O=C1C(C)=CC(=O)N1NC1=NC(CC2=CSC=C2)=NC2=C1C(C=1SC=CC=1)=CS2 VCUQBFVSVVLOPJ-UHFFFAOYSA-N 0.000 claims description 3
- 201000005569 Gout Diseases 0.000 claims description 3
- 201000004681 Psoriasis Diseases 0.000 claims description 3
- 206010040070 Septic Shock Diseases 0.000 claims description 3
- OEDODBDIKJNGRD-UHFFFAOYSA-N ethyl 3-[5-methyl-4-[(3-methyl-2,5-dioxopyrrol-1-yl)amino]-2-thiophen-2-ylthieno[2,3-d]pyrimidin-6-yl]propanoate Chemical compound C=12C(C)=C(CCC(=O)OCC)SC2=NC(C=2SC=CC=2)=NC=1NN1C(=O)C=C(C)C1=O OEDODBDIKJNGRD-UHFFFAOYSA-N 0.000 claims description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 3
- 230000036303 septic shock Effects 0.000 claims description 3
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 3
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 claims description 2
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 claims description 2
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims description 2
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 claims description 2
- 125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 claims description 2
- SVQVNXYJUNEWBJ-UHFFFAOYSA-N 3-methyl-1-[[2-[4-(2-piperidin-1-ylethoxy)phenyl]-5-thiophen-2-ylthieno[2,3-d]pyrimidin-4-yl]amino]pyrrole-2,5-dione hydrochloride Chemical compound Cl.CC1=CC(=O)N(Nc2nc(nc3scc(-c4cccs4)c23)-c2ccc(OCCN3CCCCC3)cc2)C1=O SVQVNXYJUNEWBJ-UHFFFAOYSA-N 0.000 claims description 2
- BPSOFPFVHZSBLJ-UHFFFAOYSA-N 3-methyl-1-[[5-methyl-2-thiophen-2-yl-6-[4-[2-(2,2,2-trifluoroethylamino)ethoxy]phenyl]thieno[2,3-d]pyrimidin-4-yl]amino]pyrrole-2,5-dione;hydrochloride Chemical compound Cl.O=C1C(C)=CC(=O)N1NC1=NC(C=2SC=CC=2)=NC2=C1C(C)=C(C=1C=CC(OCCNCC(F)(F)F)=CC=1)S2 BPSOFPFVHZSBLJ-UHFFFAOYSA-N 0.000 claims description 2
- VCONFZXTVQOHKM-UHFFFAOYSA-N 3-methyl-1-[[5-methyl-6-(4-piperidin-4-yloxyphenyl)-2-thiophen-2-ylthieno[2,3-d]pyrimidin-4-yl]amino]pyrrole-2,5-dione hydrochloride Chemical compound Cl.CC1=CC(=O)N(Nc2nc(nc3sc(c(C)c23)-c2ccc(OC3CCNCC3)cc2)-c2cccs2)C1=O VCONFZXTVQOHKM-UHFFFAOYSA-N 0.000 claims description 2
- CODRFWCVAPWOLZ-UHFFFAOYSA-N 3-methyl-1-[[5-methyl-6-[(4-methylpiperazin-1-yl)methyl]-2-thiophen-2-ylthieno[2,3-d]pyrimidin-4-yl]amino]pyrrole-2,5-dione;dihydrochloride Chemical compound Cl.Cl.C1CN(C)CCN1CC1=C(C)C2=C(NN3C(C(C)=CC3=O)=O)N=C(C=3SC=CC=3)N=C2S1 CODRFWCVAPWOLZ-UHFFFAOYSA-N 0.000 claims description 2
- OEBPHJZIPVABGZ-UHFFFAOYSA-N 3-methyl-1-[[5-methyl-6-[4-(2-morpholin-4-ylethoxy)phenyl]-2-thiophen-2-ylthieno[2,3-d]pyrimidin-4-yl]amino]pyrrole-2,5-dione;hydrochloride Chemical compound Cl.O=C1C(C)=CC(=O)N1NC1=NC(C=2SC=CC=2)=NC2=C1C(C)=C(C=1C=CC(OCCN3CCOCC3)=CC=1)S2 OEBPHJZIPVABGZ-UHFFFAOYSA-N 0.000 claims description 2
- AEWJGPJCUGDPPE-UHFFFAOYSA-N 3-methyl-1-[[5-methyl-6-[4-(2-piperazin-1-ylethoxy)phenyl]-2-thiophen-2-ylthieno[2,3-d]pyrimidin-4-yl]amino]pyrrole-2,5-dione;hydrochloride Chemical compound Cl.O=C1C(C)=CC(=O)N1NC1=NC(C=2SC=CC=2)=NC2=C1C(C)=C(C=1C=CC(OCCN3CCNCC3)=CC=1)S2 AEWJGPJCUGDPPE-UHFFFAOYSA-N 0.000 claims description 2
- SJFCHRIWDVOQDQ-UHFFFAOYSA-N 3-methyl-1-[[5-methyl-6-[4-(2-piperidin-1-ylethoxy)phenyl]-2-thiophen-2-ylthieno[2,3-d]pyrimidin-4-yl]amino]pyrrole-2,5-dione hydrochloride Chemical compound Cl.CC1=CC(=O)N(Nc2nc(nc3sc(c(C)c23)-c2ccc(OCCN3CCCCC3)cc2)-c2cccs2)C1=O SJFCHRIWDVOQDQ-UHFFFAOYSA-N 0.000 claims description 2
- NOZQEMIXRDFZJZ-UHFFFAOYSA-N 3-methyl-1-[[5-methyl-6-[4-[2-(4-methylpiperazin-1-yl)ethoxy]phenyl]-2-thiophen-2-ylthieno[2,3-d]pyrimidin-4-yl]amino]pyrrole-2,5-dione;hydrochloride Chemical compound Cl.C1CN(C)CCN1CCOC1=CC=C(C2=C(C3=C(NN4C(C(C)=CC4=O)=O)N=C(N=C3S2)C=2SC=CC=2)C)C=C1 NOZQEMIXRDFZJZ-UHFFFAOYSA-N 0.000 claims description 2
- HMQJWZRTKGHVMP-UHFFFAOYSA-N 3-methyl-1-[[5-methyl-6-[4-[2-(methylamino)ethoxy]phenyl]-2-thiophen-2-ylthieno[2,3-d]pyrimidin-4-yl]amino]pyrrole-2,5-dione;hydrochloride Chemical compound Cl.C1=CC(OCCNC)=CC=C1C1=C(C)C2=C(NN3C(C(C)=CC3=O)=O)N=C(C=3SC=CC=3)N=C2S1 HMQJWZRTKGHVMP-UHFFFAOYSA-N 0.000 claims description 2
- HOBRKFPZECOTSC-UHFFFAOYSA-N 3-methylidene-1-[[5-methyl-6-[4-[2-(methylamino)ethoxy]phenyl]-2-thiophen-2-ylthieno[2,3-d]pyrimidin-4-yl]amino]pyrrolidine-2,5-dione;hydrochloride Chemical compound Cl.C1=CC(OCCNC)=CC=C1C1=C(C)C2=C(NN3C(C(=C)CC3=O)=O)N=C(C=3SC=CC=3)N=C2S1 HOBRKFPZECOTSC-UHFFFAOYSA-N 0.000 claims description 2
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 claims description 2
- SUZRMQDLZDUCFQ-UHFFFAOYSA-N 5-methyl-4-[(3-methyl-2,5-dioxopyrrol-1-yl)amino]-2-thiophen-2-ylthieno[2,3-d]pyrimidine-6-carboxamide;hydrochloride Chemical compound Cl.O=C1C(C)=CC(=O)N1NC1=NC(C=2SC=CC=2)=NC2=C1C(C)=C(C(N)=O)S2 SUZRMQDLZDUCFQ-UHFFFAOYSA-N 0.000 claims description 2
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims description 2
- 208000011231 Crohn disease Diseases 0.000 claims description 2
- WRYCSMQKUKOKBP-UHFFFAOYSA-N Imidazolidine Chemical compound C1CNCN1 WRYCSMQKUKOKBP-UHFFFAOYSA-N 0.000 claims description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 2
- 208000003456 Juvenile Arthritis Diseases 0.000 claims description 2
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims description 2
- 201000002481 Myositis Diseases 0.000 claims description 2
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 claims description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 2
- 208000027418 Wounds and injury Diseases 0.000 claims description 2
- 125000003118 aryl group Chemical group 0.000 claims description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 2
- 230000006378 damage Effects 0.000 claims description 2
- 125000002541 furyl group Chemical group 0.000 claims description 2
- 208000007565 gingivitis Diseases 0.000 claims description 2
- 125000000623 heterocyclic group Chemical group 0.000 claims description 2
- 208000014674 injury Diseases 0.000 claims description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 2
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 claims description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 2
- HDVIFKPEYKFKHZ-UHFFFAOYSA-N methyl 5-methyl-4-[(3-methyl-2,5-dioxopyrrol-1-yl)amino]-2-thiophen-2-ylthieno[2,3-d]pyrimidine-6-carboxylate;hydrochloride Chemical compound Cl.C=12C(C)=C(C(=O)OC)SC2=NC(C=2SC=CC=2)=NC=1NN1C(=O)C=C(C)C1=O HDVIFKPEYKFKHZ-UHFFFAOYSA-N 0.000 claims description 2
- RPAWVEMNAJPPEL-UHFFFAOYSA-N morpholine;thiomorpholine Chemical compound C1COCCN1.C1CSCCN1 RPAWVEMNAJPPEL-UHFFFAOYSA-N 0.000 claims description 2
- JFGWBJCBPSLBEM-UHFFFAOYSA-N n-[2-(dimethylamino)ethyl]-5-methyl-4-[(3-methyl-2,5-dioxopyrrol-1-yl)amino]-2-thiophen-2-ylthieno[2,3-d]pyrimidine-6-carboxamide;hydrochloride Chemical compound Cl.C=12C(C)=C(C(=O)NCCN(C)C)SC2=NC(C=2SC=CC=2)=NC=1NN1C(=O)C=C(C)C1=O JFGWBJCBPSLBEM-UHFFFAOYSA-N 0.000 claims description 2
- 201000008482 osteoarthritis Diseases 0.000 claims description 2
- 125000004076 pyridyl group Chemical group 0.000 claims description 2
- 201000004595 synovitis Diseases 0.000 claims description 2
- BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 claims description 2
- 150000003852 triazoles Chemical class 0.000 claims description 2
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims 1
- SWGPEOXCVDTUAF-UHFFFAOYSA-N 1-[[5-[3-[2-(dimethylamino)ethoxy]phenyl]-2-thiophen-2-ylthieno[2,3-d]pyrimidin-4-yl]amino]-3-methylpyrrole-2,5-dione;hydrochloride Chemical compound Cl.CN(C)CCOC1=CC=CC(C=2C3=C(NN4C(C(C)=CC4=O)=O)N=C(N=C3SC=2)C=2SC=CC=2)=C1 SWGPEOXCVDTUAF-UHFFFAOYSA-N 0.000 claims 1
- ZBLZRYPKGZQJTI-UHFFFAOYSA-N 1-[[6-[4-[2-(4-acetylpiperazin-1-yl)ethoxy]phenyl]-5-methyl-2-thiophen-2-ylthieno[2,3-d]pyrimidin-4-yl]amino]-3-methylpyrrole-2,5-dione;hydrochloride Chemical compound Cl.C1CN(C(=O)C)CCN1CCOC1=CC=C(C2=C(C3=C(NN4C(C(C)=CC4=O)=O)N=C(N=C3S2)C=2SC=CC=2)C)C=C1 ZBLZRYPKGZQJTI-UHFFFAOYSA-N 0.000 claims 1
- HEHKQWYZEKTYQO-UHFFFAOYSA-N 2-[(5-thiophen-2-ylthieno[2,3-d]pyrimidin-4-yl)amino]isoindole-1,3-dione;hydrochloride Chemical compound Cl.O=C1C2=CC=CC=C2C(=O)N1NC(C1=2)=NC=NC=2SC=C1C1=CC=CS1 HEHKQWYZEKTYQO-UHFFFAOYSA-N 0.000 claims 1
- RCPBANIDLOGVKQ-UHFFFAOYSA-N 2-[(5-thiophen-2-ylthieno[2,3-d]pyrimidin-4-yl)amino]pyrrolo[3,4-c]pyridine-1,3-dione;hydrochloride Chemical compound Cl.O=C1C2=CN=CC=C2C(=O)N1NC(C1=2)=NC=NC=2SC=C1C1=CC=CS1 RCPBANIDLOGVKQ-UHFFFAOYSA-N 0.000 claims 1
- VWHMCYIRKSBKRS-UHFFFAOYSA-N 3,4-dichloro-1-[(5-thiophen-2-ylthieno[2,3-d]pyrimidin-4-yl)amino]pyrrole-2,5-dione;hydrochloride Chemical compound Cl.O=C1C(Cl)=C(Cl)C(=O)N1NC1=NC=NC2=C1C(C=1SC=CC=1)=CS2 VWHMCYIRKSBKRS-UHFFFAOYSA-N 0.000 claims 1
- LGUNADSRCMDREC-UHFFFAOYSA-N 3,4-dichloro-1-[[6-[4-[2-(dimethylamino)ethoxy]phenyl]-5-methyl-2-thiophen-2-ylthieno[2,3-d]pyrimidin-4-yl]amino]pyrrole-2,5-dione hydrochloride Chemical compound Cl.ClC=1C(N(C(C1Cl)=O)NC=1C2=C(N=C(N1)C=1SC=CC1)SC(=C2C)C2=CC=C(C=C2)OCCN(C)C)=O LGUNADSRCMDREC-UHFFFAOYSA-N 0.000 claims 1
- MKYYKCNYVPDTII-UHFFFAOYSA-N 3-methyl-1-[(2-methyl-5-thiophen-2-ylthieno[2,3-d]pyrimidin-4-yl)amino]pyrrole-2,5-dione;hydrochloride Chemical compound Cl.O=C1C(C)=CC(=O)N1NC1=NC(C)=NC2=C1C(C=1SC=CC=1)=CS2 MKYYKCNYVPDTII-UHFFFAOYSA-N 0.000 claims 1
- GLENANKZDOSDBT-UHFFFAOYSA-N 3-methyl-1-[(2-phenyl-5-thiophen-2-ylthieno[2,3-d]pyrimidin-4-yl)amino]pyrrole-2,5-dione Chemical compound O=C1C(C)=CC(=O)N1NC1=NC(C=2C=CC=CC=2)=NC2=C1C(C=1SC=CC=1)=CS2 GLENANKZDOSDBT-UHFFFAOYSA-N 0.000 claims 1
- MBMGVZBNLWTYTD-UHFFFAOYSA-N 3-methyl-1-[(2-phenyl-5-thiophen-2-ylthieno[2,3-d]pyrimidin-4-yl)amino]pyrrole-2,5-dione;hydrochloride Chemical compound Cl.O=C1C(C)=CC(=O)N1NC1=NC(C=2C=CC=CC=2)=NC2=C1C(C=1SC=CC=1)=CS2 MBMGVZBNLWTYTD-UHFFFAOYSA-N 0.000 claims 1
- AXNFIUHPOZMGKD-UHFFFAOYSA-N 3-methyl-1-[(2-thiophen-2-ylthieno[2,3-d]pyrimidin-4-yl)amino]pyrrole-2,5-dione;hydrochloride Chemical compound Cl.O=C1C(C)=CC(=O)N1NC1=NC(C=2SC=CC=2)=NC2=C1C=CS2 AXNFIUHPOZMGKD-UHFFFAOYSA-N 0.000 claims 1
- RTTXTEHHGFJJDV-UHFFFAOYSA-N 3-methyl-1-[(5-methyl-2-thiophen-2-ylthieno[2,3-d]pyrimidin-4-yl)amino]pyrrole-2,5-dione;hydrochloride Chemical compound Cl.O=C1C(C)=CC(=O)N1NC1=NC(C=2SC=CC=2)=NC2=C1C(C)=CS2 RTTXTEHHGFJJDV-UHFFFAOYSA-N 0.000 claims 1
- DAMLCAJIRVIJLT-UHFFFAOYSA-N 3-methyl-1-[(5-thiophen-2-ylthieno[2,3-d]pyrimidin-4-yl)amino]pyrrole-2,5-dione Chemical compound O=C1C(C)=CC(=O)N1NC1=NC=NC2=C1C(C=1SC=CC=1)=CS2 DAMLCAJIRVIJLT-UHFFFAOYSA-N 0.000 claims 1
- APSHXWMOYGDVIH-UHFFFAOYSA-N 3-methyl-1-[(5-thiophen-2-ylthieno[2,3-d]pyrimidin-4-yl)amino]pyrrole-2,5-dione;hydrochloride Chemical compound Cl.O=C1C(C)=CC(=O)N1NC1=NC=NC2=C1C(C=1SC=CC=1)=CS2 APSHXWMOYGDVIH-UHFFFAOYSA-N 0.000 claims 1
- CGGBAGWGDJTPIO-UHFFFAOYSA-N 3-methyl-1-[[2-(4-methylphenyl)-5-thiophen-2-ylthieno[2,3-d]pyrimidin-4-yl]amino]pyrrole-2,5-dione;hydrochloride Chemical compound Cl.O=C1C(C)=CC(=O)N1NC1=NC(C=2C=CC(C)=CC=2)=NC2=C1C(C=1SC=CC=1)=CS2 CGGBAGWGDJTPIO-UHFFFAOYSA-N 0.000 claims 1
- DGFKAAYAFODKQV-UHFFFAOYSA-N 3-methyl-1-[[2-[3-(2-piperidin-1-ylethoxy)phenyl]-5-thiophen-2-ylthieno[2,3-d]pyrimidin-4-yl]amino]pyrrole-2,5-dione hydrochloride Chemical compound Cl.CC1=CC(=O)N(Nc2nc(nc3scc(-c4cccs4)c23)-c2cccc(OCCN3CCCCC3)c2)C1=O DGFKAAYAFODKQV-UHFFFAOYSA-N 0.000 claims 1
- MXPVZJUZJSOXDA-UHFFFAOYSA-N 3-methyl-1-[[5-(4-methylphenyl)-2-thiophen-2-ylthieno[2,3-d]pyrimidin-4-yl]amino]pyrrole-2,5-dione;hydrochloride Chemical compound Cl.O=C1C(C)=CC(=O)N1NC1=NC(C=2SC=CC=2)=NC2=C1C(C=1C=CC(C)=CC=1)=CS2 MXPVZJUZJSOXDA-UHFFFAOYSA-N 0.000 claims 1
- SBXOZKDGWVQQCI-UHFFFAOYSA-N 3-methyl-1-[[5-[3-(2-piperidin-1-ylethoxy)phenyl]-2-thiophen-2-ylthieno[2,3-d]pyrimidin-4-yl]amino]pyrrole-2,5-dione;hydrochloride Chemical compound Cl.O=C1C(C)=CC(=O)N1NC1=NC(C=2SC=CC=2)=NC2=C1C(C=1C=C(OCCN3CCCCC3)C=CC=1)=CS2 SBXOZKDGWVQQCI-UHFFFAOYSA-N 0.000 claims 1
- CBFPUILCIXXHJL-UHFFFAOYSA-N 3-methyl-1-[[5-[4-(2-piperidin-1-ylethoxy)phenyl]-2-thiophen-2-ylthieno[2,3-d]pyrimidin-4-yl]amino]pyrrole-2,5-dione;hydrochloride Chemical compound Cl.O=C1C(C)=CC(=O)N1NC1=NC(C=2SC=CC=2)=NC2=C1C(C=1C=CC(OCCN3CCCCC3)=CC=1)=CS2 CBFPUILCIXXHJL-UHFFFAOYSA-N 0.000 claims 1
- YNQWKZPXCNTMLV-UHFFFAOYSA-N 3-methyl-1-[[5-methyl-6-[4-(2-pyrrolidin-1-ylethoxy)phenyl]-2-thiophen-2-ylthieno[2,3-d]pyrimidin-4-yl]amino]pyrrole-2,5-dione Chemical compound O=C1C(C)=CC(=O)N1NC1=NC(C=2SC=CC=2)=NC2=C1C(C)=C(C=1C=CC(OCCN3CCCC3)=CC=1)S2 YNQWKZPXCNTMLV-UHFFFAOYSA-N 0.000 claims 1
- AZRRZGIBBLWSSQ-UHFFFAOYSA-N 4-ethyl-7-phenyl-3,5-diazabicyclo[2.2.2]octane-2,6-dione Chemical compound N1C(=O)C2C(=O)NC1(CC)CC2C1=CC=CC=C1 AZRRZGIBBLWSSQ-UHFFFAOYSA-N 0.000 claims 1
- DGWIIIZWTANWGL-UHFFFAOYSA-N CC=1C(N(C(C1)=O)NC=1C2=C(N=C(N1)C=1SC=CC1)SC=C2C2=CC(=CC=C2)OCCN2CCNCC2)=O Chemical compound CC=1C(N(C(C1)=O)NC=1C2=C(N=C(N1)C=1SC=CC1)SC=C2C2=CC(=CC=C2)OCCN2CCNCC2)=O DGWIIIZWTANWGL-UHFFFAOYSA-N 0.000 claims 1
- UEXVYBVDLVBAJE-UHFFFAOYSA-N ethyl 4-[(3-methyl-2,5-dioxopyrrol-1-yl)amino]-2-thiophen-2-ylthieno[2,3-d]pyrimidine-5-carboxylate;hydrochloride Chemical compound Cl.C=12C(C(=O)OCC)=CSC2=NC(C=2SC=CC=2)=NC=1NN1C(=O)C=C(C)C1=O UEXVYBVDLVBAJE-UHFFFAOYSA-N 0.000 claims 1
- SRIOLRQOQRHMLT-UHFFFAOYSA-N methyl 2-[5-methyl-4-[(3-methyl-2,5-dioxopyrrol-1-yl)amino]-2-thiophen-2-ylthieno[2,3-d]pyrimidin-6-yl]acetate;hydrochloride Chemical compound Cl.C=12C(C)=C(CC(=O)OC)SC2=NC(C=2SC=CC=2)=NC=1NN1C(=O)C=C(C)C1=O SRIOLRQOQRHMLT-UHFFFAOYSA-N 0.000 claims 1
- 239000000203 mixture Substances 0.000 abstract description 20
- 239000003814 drug Substances 0.000 abstract description 13
- 206010003246 arthritis Diseases 0.000 abstract description 9
- 230000001093 anti-cancer Effects 0.000 abstract description 4
- 229940124597 therapeutic agent Drugs 0.000 abstract description 4
- 102000001284 I-kappa-B kinase Human genes 0.000 abstract description 3
- 108060006678 I-kappa-B kinase Proteins 0.000 abstract description 3
- 230000004913 activation Effects 0.000 abstract description 3
- 230000001939 inductive effect Effects 0.000 abstract description 3
- 208000026278 immune system disease Diseases 0.000 abstract description 2
- 230000002103 transcriptional effect Effects 0.000 abstract description 2
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 246
- 239000011541 reaction mixture Substances 0.000 description 153
- 238000006243 chemical reaction Methods 0.000 description 131
- 239000007787 solid Substances 0.000 description 131
- 238000005481 NMR spectroscopy Methods 0.000 description 127
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 88
- 229940093499 ethyl acetate Drugs 0.000 description 82
- 235000019439 ethyl acetate Nutrition 0.000 description 82
- 230000002829 reductive effect Effects 0.000 description 76
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 70
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 65
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 63
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 58
- 238000004440 column chromatography Methods 0.000 description 56
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 55
- 239000012044 organic layer Substances 0.000 description 48
- 239000007864 aqueous solution Substances 0.000 description 45
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 44
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 44
- 239000000243 solution Substances 0.000 description 40
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 39
- 239000002904 solvent Substances 0.000 description 36
- 239000003921 oil Substances 0.000 description 29
- 235000019198 oils Nutrition 0.000 description 29
- RMBXSDLTWYJNHT-UHFFFAOYSA-N 3-methylpyrrole-2,5-dione;hydrochloride Chemical compound Cl.CC1=CC(=O)NC1=O RMBXSDLTWYJNHT-UHFFFAOYSA-N 0.000 description 27
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 27
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 27
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 24
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 24
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 24
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 20
- 238000005160 1H NMR spectroscopy Methods 0.000 description 18
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 18
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 17
- JWXKDESLQZNNCU-UHFFFAOYSA-N 3-ethylpyrrole-2,5-dione hydrochloride Chemical compound CCC1=CC(=O)NC1=O.Cl JWXKDESLQZNNCU-UHFFFAOYSA-N 0.000 description 16
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 15
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 15
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 15
- 108010057466 NF-kappa B Proteins 0.000 description 14
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 14
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 13
- 102000003945 NF-kappa B Human genes 0.000 description 13
- 238000010438 heat treatment Methods 0.000 description 13
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 108090000623 proteins and genes Proteins 0.000 description 12
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 12
- 0 CC1C=I(/C(/C2)=C/S/N=*/N=C2/Cl)SC1 Chemical compound CC1C=I(/C(/C2)=C/S/N=*/N=C2/Cl)SC1 0.000 description 11
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 11
- 102100040247 Tumor necrosis factor Human genes 0.000 description 11
- 239000012230 colorless oil Substances 0.000 description 11
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 11
- 238000004519 manufacturing process Methods 0.000 description 11
- 239000002609 medium Substances 0.000 description 11
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 10
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 10
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 10
- 239000002253 acid Substances 0.000 description 10
- 239000002158 endotoxin Substances 0.000 description 10
- 229920006008 lipopolysaccharide Polymers 0.000 description 10
- YTPWWVXUJXQDMK-UHFFFAOYSA-N methyl 2-amino-4-thiophen-2-ylthiophene-3-carboxylate Chemical compound COC(=O)C1=C(N)SC=C1C1=CC=CS1 YTPWWVXUJXQDMK-UHFFFAOYSA-N 0.000 description 10
- 239000011593 sulfur Substances 0.000 description 10
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 9
- 206010061218 Inflammation Diseases 0.000 description 9
- 230000002411 adverse Effects 0.000 description 9
- ZIUSEGSNTOUIPT-UHFFFAOYSA-N ethyl 2-cyanoacetate Chemical compound CCOC(=O)CC#N ZIUSEGSNTOUIPT-UHFFFAOYSA-N 0.000 description 9
- 230000002401 inhibitory effect Effects 0.000 description 9
- 239000003960 organic solvent Substances 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 9
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 9
- WYJOVVXUZNRJQY-UHFFFAOYSA-N 2-Acetylthiophene Chemical compound CC(=O)C1=CC=CS1 WYJOVVXUZNRJQY-UHFFFAOYSA-N 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 229960004132 diethyl ether Drugs 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 230000004054 inflammatory process Effects 0.000 description 8
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 8
- 235000018102 proteins Nutrition 0.000 description 8
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 8
- WORJRXHJTUTINR-UHFFFAOYSA-N 1,4-dioxane;hydron;chloride Chemical compound Cl.C1COCCO1 WORJRXHJTUTINR-UHFFFAOYSA-N 0.000 description 7
- 101100508533 Drosophila melanogaster IKKbeta gene Proteins 0.000 description 7
- 238000003556 assay Methods 0.000 description 7
- 239000002585 base Substances 0.000 description 7
- 239000012267 brine Substances 0.000 description 7
- ANGDWNBGPBMQHW-UHFFFAOYSA-N methyl cyanoacetate Chemical compound COC(=O)CC#N ANGDWNBGPBMQHW-UHFFFAOYSA-N 0.000 description 7
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 7
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 7
- KWOLFJPFCHCOCG-UHFFFAOYSA-N Acetophenone Chemical compound CC(=O)C1=CC=CC=C1 KWOLFJPFCHCOCG-UHFFFAOYSA-N 0.000 description 6
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 6
- 239000005695 Ammonium acetate Substances 0.000 description 6
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 6
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 6
- 235000019257 ammonium acetate Nutrition 0.000 description 6
- 229940043376 ammonium acetate Drugs 0.000 description 6
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 6
- 239000012091 fetal bovine serum Substances 0.000 description 6
- CUONGYYJJVDODC-UHFFFAOYSA-N malononitrile Chemical compound N#CCC#N CUONGYYJJVDODC-UHFFFAOYSA-N 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 125000004943 pyrimidin-6-yl group Chemical group N1=CN=CC=C1* 0.000 description 6
- 238000010791 quenching Methods 0.000 description 6
- CUPOOAWTRIURFT-UHFFFAOYSA-N thiophene-2-carbonitrile Chemical compound N#CC1=CC=CS1 CUPOOAWTRIURFT-UHFFFAOYSA-N 0.000 description 6
- LDLCZOVUSADOIV-UHFFFAOYSA-N 2-bromoethanol Chemical compound OCCBr LDLCZOVUSADOIV-UHFFFAOYSA-N 0.000 description 5
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 5
- 238000007796 conventional method Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- ZQUVWAQFCJBUGY-UHFFFAOYSA-N ethyl 4-chloro-2-thiophen-2-ylthieno[2,3-d]pyrimidine-5-carboxylate Chemical compound N=1C(Cl)=C2C(C(=O)OCC)=CSC2=NC=1C1=CC=CS1 ZQUVWAQFCJBUGY-UHFFFAOYSA-N 0.000 description 5
- 150000002431 hydrogen Chemical group 0.000 description 5
- 239000005457 ice water Substances 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 239000010410 layer Substances 0.000 description 5
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 description 5
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 5
- 230000006433 tumor necrosis factor production Effects 0.000 description 5
- AYKYXWQEBUNJCN-UHFFFAOYSA-N 3-methylfuran-2,5-dione Chemical compound CC1=CC(=O)OC1=O AYKYXWQEBUNJCN-UHFFFAOYSA-N 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 208000002193 Pain Diseases 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- 239000002246 antineoplastic agent Substances 0.000 description 4
- 230000006907 apoptotic process Effects 0.000 description 4
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 4
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 4
- ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 4
- ORTQZVOHEJQUHG-UHFFFAOYSA-L copper(II) chloride Chemical compound Cl[Cu]Cl ORTQZVOHEJQUHG-UHFFFAOYSA-L 0.000 description 4
- 125000004093 cyano group Chemical group *C#N 0.000 description 4
- USLKCMBGQFYUFI-UHFFFAOYSA-N dichloromethane;tribromoborane Chemical compound ClCCl.BrB(Br)Br USLKCMBGQFYUFI-UHFFFAOYSA-N 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- JYVHOGDBFNJNMR-UHFFFAOYSA-N hexane;hydrate Chemical compound O.CCCCCC JYVHOGDBFNJNMR-UHFFFAOYSA-N 0.000 description 4
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 230000036407 pain Effects 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 235000009518 sodium iodide Nutrition 0.000 description 4
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 4
- OMMDPTFXYBRCBW-UHFFFAOYSA-N 2-amino-4-thiophen-2-ylthiophene-3-carbonitrile Chemical compound N#CC1=C(N)SC=C1C1=CC=CS1 OMMDPTFXYBRCBW-UHFFFAOYSA-N 0.000 description 3
- FGOQRRRPBSLZIW-UHFFFAOYSA-N 4-(4-chloro-2-thiophen-2-ylthieno[2,3-d]pyrimidin-5-yl)phenol Chemical compound C1=CC(O)=CC=C1C1=CSC2=NC(C=3SC=CC=3)=NC(Cl)=C12 FGOQRRRPBSLZIW-UHFFFAOYSA-N 0.000 description 3
- OURJOTPHIOYYSK-UHFFFAOYSA-N 4-chloro-5-(3-methoxyphenyl)-2-thiophen-2-ylthieno[2,3-d]pyrimidine Chemical compound COC1=CC=CC(C=2C3=C(Cl)N=C(N=C3SC=2)C=2SC=CC=2)=C1 OURJOTPHIOYYSK-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 3
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- OPKOKAMJFNKNAS-UHFFFAOYSA-N N-methylethanolamine Chemical compound CNCCO OPKOKAMJFNKNAS-UHFFFAOYSA-N 0.000 description 3
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 230000001594 aberrant effect Effects 0.000 description 3
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 229950005499 carbon tetrachloride Drugs 0.000 description 3
- 239000003054 catalyst Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 229940044683 chemotherapy drug Drugs 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 125000004494 ethyl ester group Chemical group 0.000 description 3
- 206010020718 hyperplasia Diseases 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000034190 positive regulation of NF-kappaB transcription factor activity Effects 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 230000000770 proinflammatory effect Effects 0.000 description 3
- VVWRJUBEIPHGQF-MDZDMXLPSA-N propan-2-yl (ne)-n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)\N=N\C(=O)OC(C)C VVWRJUBEIPHGQF-MDZDMXLPSA-N 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 description 3
- ALODHLHICWESJG-UHFFFAOYSA-N (4-chloro-5-methyl-2-thiophen-2-ylthieno[2,3-d]pyrimidin-6-yl)methanol Chemical compound N=1C(Cl)=C2C(C)=C(CO)SC2=NC=1C1=CC=CS1 ALODHLHICWESJG-UHFFFAOYSA-N 0.000 description 2
- YZUPZGFPHUVJKC-UHFFFAOYSA-N 1-bromo-2-methoxyethane Chemical compound COCCBr YZUPZGFPHUVJKC-UHFFFAOYSA-N 0.000 description 2
- DNCYBUMDUBHIJZ-UHFFFAOYSA-N 1h-pyrimidin-6-one Chemical compound O=C1C=CN=CN1 DNCYBUMDUBHIJZ-UHFFFAOYSA-N 0.000 description 2
- PXTUQQILCNMBLU-UHFFFAOYSA-N 2-(1,4-dioxa-8-azaspiro[4.5]decan-8-yl)ethanol Chemical compound C1CN(CCO)CCC21OCCO2 PXTUQQILCNMBLU-UHFFFAOYSA-N 0.000 description 2
- LXKNAUOWEJWGTE-UHFFFAOYSA-N 2-(3-methoxyphenyl)acetonitrile Chemical compound COC1=CC=CC(CC#N)=C1 LXKNAUOWEJWGTE-UHFFFAOYSA-N 0.000 description 2
- CXJOONIFSVSFAD-UHFFFAOYSA-N 2-(4-methoxyphenyl)acetyl chloride Chemical compound COC1=CC=C(CC(Cl)=O)C=C1 CXJOONIFSVSFAD-UHFFFAOYSA-N 0.000 description 2
- AUWDOZOUJWEPBA-UHFFFAOYSA-N 2-(4-methoxyphenyl)ethanol Chemical compound COC1=CC=C(CCO)C=C1 AUWDOZOUJWEPBA-UHFFFAOYSA-N 0.000 description 2
- CJWBIHBABDUFSV-UHFFFAOYSA-N 2-[4-[5-methyl-4-[(3-methyl-2,5-dioxopyrrol-1-yl)amino]-2-thiophen-2-ylthieno[2,3-d]pyrimidin-6-yl]phenoxy]ethylcarbamic acid Chemical compound O=C1C(C)=CC(=O)N1NC1=NC(C=2SC=CC=2)=NC2=C1C(C)=C(C=1C=CC(OCCNC(O)=O)=CC=1)S2 CJWBIHBABDUFSV-UHFFFAOYSA-N 0.000 description 2
- IQWOSVPNFLFMTA-UHFFFAOYSA-N 2-[4-[5-methyl-4-[(3-methyl-2,5-dioxopyrrol-1-yl)amino]-2-thiophen-2-ylthieno[2,3-d]pyrimidin-6-yl]phenyl]propanamide;hydrochloride Chemical compound Cl.C1=CC(C(C(N)=O)C)=CC=C1C1=C(C)C2=C(NN3C(C(C)=CC3=O)=O)N=C(C=3SC=CC=3)N=C2S1 IQWOSVPNFLFMTA-UHFFFAOYSA-N 0.000 description 2
- MNKXYHRXVGVHTN-UHFFFAOYSA-N 2-amino-5-(4-methoxyphenyl)-4-methylfuran-3-carbonitrile Chemical compound C1=CC(OC)=CC=C1C1=C(C)C(C#N)=C(N)O1 MNKXYHRXVGVHTN-UHFFFAOYSA-N 0.000 description 2
- VNKQXMFDTUFING-UHFFFAOYSA-N 3-(4-chloro-5-thiophen-2-ylthieno[2,3-d]pyrimidin-2-yl)phenol Chemical compound OC1=CC=CC(C=2N=C3SC=C(C3=C(Cl)N=2)C=2SC=CC=2)=C1 VNKQXMFDTUFING-UHFFFAOYSA-N 0.000 description 2
- JZTPKAROPNTQQV-UHFFFAOYSA-N 3-fluorobenzonitrile Chemical compound FC1=CC=CC(C#N)=C1 JZTPKAROPNTQQV-UHFFFAOYSA-N 0.000 description 2
- KLXSUMLEPNAZFK-UHFFFAOYSA-N 3-methoxybenzonitrile Chemical compound COC1=CC=CC(C#N)=C1 KLXSUMLEPNAZFK-UHFFFAOYSA-N 0.000 description 2
- GNKZMNRKLCTJAY-UHFFFAOYSA-N 4'-Methylacetophenone Chemical compound CC(=O)C1=CC=C(C)C=C1 GNKZMNRKLCTJAY-UHFFFAOYSA-N 0.000 description 2
- PCBSXBYCASFXTM-UHFFFAOYSA-N 4-(4-Methoxyphenyl)-2-butanone Chemical compound COC1=CC=C(CCC(C)=O)C=C1 PCBSXBYCASFXTM-UHFFFAOYSA-N 0.000 description 2
- HBHDPRXJNAPGPZ-UHFFFAOYSA-N 4-(4-chloro-5-thiophen-2-ylthieno[2,3-d]pyrimidin-2-yl)phenol Chemical compound Oc1ccc(cc1)-c1nc(Cl)c2c(csc2n1)-c1cccs1 HBHDPRXJNAPGPZ-UHFFFAOYSA-N 0.000 description 2
- JYMNQRQQBJIMCV-UHFFFAOYSA-N 4-(dimethylamino)benzonitrile Chemical compound CN(C)C1=CC=C(C#N)C=C1 JYMNQRQQBJIMCV-UHFFFAOYSA-N 0.000 description 2
- VLMFHTLGDMKMGK-UHFFFAOYSA-N 4-chloro-5-(4-methoxyphenyl)-2-thiophen-2-ylthieno[2,3-d]pyrimidine Chemical compound C1=CC(OC)=CC=C1C1=CSC2=NC(C=3SC=CC=3)=NC(Cl)=C12 VLMFHTLGDMKMGK-UHFFFAOYSA-N 0.000 description 2
- KQIDGHFBDZFMOK-UHFFFAOYSA-N 4-chloro-5-methyl-2-thiophen-2-ylthieno[2,3-d]pyrimidine Chemical compound ClC=1C2=C(N=C(N=1)C=1SC=CC=1)SC=C2C KQIDGHFBDZFMOK-UHFFFAOYSA-N 0.000 description 2
- ULCFHIIPPOTXHF-UHFFFAOYSA-N 4-chloro-5-methyl-2-thiophen-2-ylthieno[2,3-d]pyrimidine-6-carboxamide Chemical compound N=1C(Cl)=C2C(C)=C(C(N)=O)SC2=NC=1C1=CC=CS1 ULCFHIIPPOTXHF-UHFFFAOYSA-N 0.000 description 2
- YNKROTHJYWJTPF-UHFFFAOYSA-N 4-chloro-5-thiophen-2-yl-2-(thiophen-3-ylmethyl)thieno[2,3-d]pyrimidine Chemical compound N=1C=2SC=C(C=3SC=CC=3)C=2C(Cl)=NC=1CC=1C=CSC=1 YNKROTHJYWJTPF-UHFFFAOYSA-N 0.000 description 2
- AKHXRLQRDNWIKT-UHFFFAOYSA-N 4-chloro-6-(4-methoxyphenyl)-5-methyl-2-propylthieno[2,3-d]pyrimidine Chemical compound S1C2=NC(CCC)=NC(Cl)=C2C(C)=C1C1=CC=C(OC)C=C1 AKHXRLQRDNWIKT-UHFFFAOYSA-N 0.000 description 2
- KJRKTALBJKVJFN-UHFFFAOYSA-N 4-chloro-6-(methoxymethyl)-5-methyl-2-thiophen-2-ylthieno[2,3-d]pyrimidine Chemical compound N=1C(Cl)=C2C(C)=C(COC)SC2=NC=1C1=CC=CS1 KJRKTALBJKVJFN-UHFFFAOYSA-N 0.000 description 2
- ZBXRUOJZALOUEN-UHFFFAOYSA-N 4-chloro-6-[(4-methoxyphenyl)methyl]-5-methyl-2-thiophen-2-ylthieno[2,3-d]pyrimidine Chemical compound C1=CC(OC)=CC=C1CC1=C(C)C2=C(Cl)N=C(C=3SC=CC=3)N=C2S1 ZBXRUOJZALOUEN-UHFFFAOYSA-N 0.000 description 2
- NTPLXRHDUXRPNE-UHFFFAOYSA-N 4-methoxyacetophenone Chemical compound COC1=CC=C(C(C)=O)C=C1 NTPLXRHDUXRPNE-UHFFFAOYSA-N 0.000 description 2
- NRPFNQUDKRYCNX-UHFFFAOYSA-N 4-methoxyphenylacetic acid Chemical compound COC1=CC=C(CC(O)=O)C=C1 NRPFNQUDKRYCNX-UHFFFAOYSA-N 0.000 description 2
- NKJIFDNZPGLLSH-UHFFFAOYSA-N 4-nitrobenzonitrile Chemical compound [O-][N+](=O)C1=CC=C(C#N)C=C1 NKJIFDNZPGLLSH-UHFFFAOYSA-N 0.000 description 2
- JOOXCMJARBKPKM-UHFFFAOYSA-N 4-oxopentanoic acid Chemical compound CC(=O)CCC(O)=O JOOXCMJARBKPKM-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 229910021589 Copper(I) bromide Inorganic materials 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 238000012286 ELISA Assay Methods 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- GRRNUXAQVGOGFE-UHFFFAOYSA-N Hygromycin-B Natural products OC1C(NC)CC(N)C(O)C1OC1C2OC3(C(C(O)C(O)C(C(N)CO)O3)O)OC2C(O)C(CO)O1 GRRNUXAQVGOGFE-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 241000575946 Ione Species 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- LTXREWYXXSTFRX-QGZVFWFLSA-N Linagliptin Chemical compound N=1C=2N(C)C(=O)N(CC=3N=C4C=CC=CC4=C(C)N=3)C(=O)C=2N(CC#CC)C=1N1CCC[C@@H](N)C1 LTXREWYXXSTFRX-QGZVFWFLSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- UAGJVSRUFNSIHR-UHFFFAOYSA-N Methyl levulinate Chemical compound COC(=O)CCC(C)=O UAGJVSRUFNSIHR-UHFFFAOYSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 2
- 108010052419 NF-KappaB Inhibitor alpha Proteins 0.000 description 2
- 102100039337 NF-kappa-B inhibitor alpha Human genes 0.000 description 2
- 102100033457 NF-kappa-B inhibitor beta Human genes 0.000 description 2
- 101710204094 NF-kappa-B inhibitor beta Proteins 0.000 description 2
- 108700020796 Oncogene Proteins 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- 208000035977 Rare disease Diseases 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- YRKCREAYFQTBPV-UHFFFAOYSA-N acetylacetone Chemical compound CC(=O)CC(C)=O YRKCREAYFQTBPV-UHFFFAOYSA-N 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 150000001340 alkali metals Chemical class 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- SJNALLRHIVGIBI-UHFFFAOYSA-N allyl cyanide Chemical compound C=CCC#N SJNALLRHIVGIBI-UHFFFAOYSA-N 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 230000031709 bromination Effects 0.000 description 2
- 238000005893 bromination reaction Methods 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- YKYOUMDCQGMQQO-UHFFFAOYSA-L cadmium dichloride Chemical compound Cl[Cd]Cl YKYOUMDCQGMQQO-UHFFFAOYSA-L 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 229910002091 carbon monoxide Inorganic materials 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000006482 condensation reaction Methods 0.000 description 2
- QTMDXZNDVAMKGV-UHFFFAOYSA-L copper(ii) bromide Chemical compound [Cu+2].[Br-].[Br-] QTMDXZNDVAMKGV-UHFFFAOYSA-L 0.000 description 2
- NKLCNNUWBJBICK-UHFFFAOYSA-N dess–martin periodinane Chemical compound C1=CC=C2I(OC(=O)C)(OC(C)=O)(OC(C)=O)OC(=O)C2=C1 NKLCNNUWBJBICK-UHFFFAOYSA-N 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- XYIBRDXRRQCHLP-UHFFFAOYSA-N ethyl acetoacetate Chemical compound CCOC(=O)CC(C)=O XYIBRDXRRQCHLP-UHFFFAOYSA-N 0.000 description 2
- 238000002866 fluorescence resonance energy transfer Methods 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N hydrazine Substances NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- 229940097277 hygromycin b Drugs 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 229960000905 indomethacin Drugs 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- OWFXIOWLTKNBAP-UHFFFAOYSA-N isoamyl nitrite Chemical compound CC(C)CCON=O OWFXIOWLTKNBAP-UHFFFAOYSA-N 0.000 description 2
- 238000000021 kinase assay Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- KHNSKPUYBBZGLW-UHFFFAOYSA-N methyl 2-amino-4-phenylthiophene-3-carboxylate Chemical compound COC(=O)C1=C(N)SC=C1C1=CC=CC=C1 KHNSKPUYBBZGLW-UHFFFAOYSA-N 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 208000015122 neurodegenerative disease Diseases 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- RLOWWWKZYUNIDI-UHFFFAOYSA-N phosphinic chloride Chemical compound ClP=O RLOWWWKZYUNIDI-UHFFFAOYSA-N 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- VVWRJUBEIPHGQF-UHFFFAOYSA-N propan-2-yl n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)N=NC(=O)OC(C)C VVWRJUBEIPHGQF-UHFFFAOYSA-N 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- YPOXGDJGKBXRFP-UHFFFAOYSA-N pyrimidine-4-carboxylic acid Chemical compound OC(=O)C1=CC=NC=N1 YPOXGDJGKBXRFP-UHFFFAOYSA-N 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 238000003571 reporter gene assay Methods 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000012312 sodium hydride Substances 0.000 description 2
- 229910000104 sodium hydride Inorganic materials 0.000 description 2
- 235000010288 sodium nitrite Nutrition 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 210000002437 synoviocyte Anatomy 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- IOGXOCVLYRDXLW-UHFFFAOYSA-N tert-butyl nitrite Chemical compound CC(C)(C)ON=O IOGXOCVLYRDXLW-UHFFFAOYSA-N 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- VCGRFBXVSFAGGA-UHFFFAOYSA-N (1,1-dioxo-1,4-thiazinan-4-yl)-[6-[[3-(4-fluorophenyl)-5-methyl-1,2-oxazol-4-yl]methoxy]pyridin-3-yl]methanone Chemical compound CC=1ON=C(C=2C=CC(F)=CC=2)C=1COC(N=C1)=CC=C1C(=O)N1CCS(=O)(=O)CC1 VCGRFBXVSFAGGA-UHFFFAOYSA-N 0.000 description 1
- LJHJYXXMORHEMZ-UHFFFAOYSA-N (2-methylpropan-2-yl)oxy-oxo-sulfidoazanium Chemical compound CC(C)(C)O[N+]([O-])=S LJHJYXXMORHEMZ-UHFFFAOYSA-N 0.000 description 1
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 1
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- MOWXJLUYGFNTAL-DEOSSOPVSA-N (s)-[2-chloro-4-fluoro-5-(7-morpholin-4-ylquinazolin-4-yl)phenyl]-(6-methoxypyridazin-3-yl)methanol Chemical compound N1=NC(OC)=CC=C1[C@@H](O)C1=CC(C=2C3=CC=C(C=C3N=CN=2)N2CCOCC2)=C(F)C=C1Cl MOWXJLUYGFNTAL-DEOSSOPVSA-N 0.000 description 1
- LQIAZOCLNBBZQK-UHFFFAOYSA-N 1-(1,2-Diphosphanylethyl)pyrrolidin-2-one Chemical compound PCC(P)N1CCCC1=O LQIAZOCLNBBZQK-UHFFFAOYSA-N 0.000 description 1
- FPDNKWSQWXOPSC-UHFFFAOYSA-N 1-(methylamino)ethanol Chemical compound CNC(C)O FPDNKWSQWXOPSC-UHFFFAOYSA-N 0.000 description 1
- ABDDQTDRAHXHOC-QMMMGPOBSA-N 1-[(7s)-5,7-dihydro-4h-thieno[2,3-c]pyran-7-yl]-n-methylmethanamine Chemical compound CNC[C@@H]1OCCC2=C1SC=C2 ABDDQTDRAHXHOC-QMMMGPOBSA-N 0.000 description 1
- ZDFBKZUDCQQKAC-UHFFFAOYSA-N 1-bromo-4-nitrobenzene Chemical compound [O-][N+](=O)C1=CC=C(Br)C=C1 ZDFBKZUDCQQKAC-UHFFFAOYSA-N 0.000 description 1
- PJUPKRYGDFTMTM-UHFFFAOYSA-N 1-hydroxybenzotriazole;hydrate Chemical compound O.C1=CC=C2N(O)N=NC2=C1 PJUPKRYGDFTMTM-UHFFFAOYSA-N 0.000 description 1
- CUZLJOLBIRPEFB-UHFFFAOYSA-N 1-methoxypropan-2-one Chemical compound COCC(C)=O CUZLJOLBIRPEFB-UHFFFAOYSA-N 0.000 description 1
- RTBFRGCFXZNCOE-UHFFFAOYSA-N 1-methylsulfonylpiperidin-4-one Chemical compound CS(=O)(=O)N1CCC(=O)CC1 RTBFRGCFXZNCOE-UHFFFAOYSA-N 0.000 description 1
- PKDPUENCROCRCH-UHFFFAOYSA-N 1-piperazin-1-ylethanone Chemical compound CC(=O)N1CCNCC1 PKDPUENCROCRCH-UHFFFAOYSA-N 0.000 description 1
- YWSPNEMTARSIKW-UHFFFAOYSA-N 1-sulfidopyridin-1-ium Chemical compound [S-][N+]1=CC=CC=C1 YWSPNEMTARSIKW-UHFFFAOYSA-N 0.000 description 1
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
- IVSVAOOOAGLVJQ-UHFFFAOYSA-N 2-(1-thiophen-2-ylethylidene)propanedinitrile Chemical compound N#CC(C#N)=C(C)C1=CC=CS1 IVSVAOOOAGLVJQ-UHFFFAOYSA-N 0.000 description 1
- SURCGQGDUADKBL-UHFFFAOYSA-N 2-(2-hydroxyethylamino)-5-nitrobenzo[de]isoquinoline-1,3-dione Chemical compound [O-][N+](=O)C1=CC(C(N(NCCO)C2=O)=O)=C3C2=CC=CC3=C1 SURCGQGDUADKBL-UHFFFAOYSA-N 0.000 description 1
- PACGLQCRGWFBJH-UHFFFAOYSA-N 2-(4-methoxyphenyl)acetonitrile Chemical compound COC1=CC=C(CC#N)C=C1 PACGLQCRGWFBJH-UHFFFAOYSA-N 0.000 description 1
- KZTWONRVIPPDKH-UHFFFAOYSA-N 2-(piperidin-1-yl)ethanol Chemical compound OCCN1CCCCC1 KZTWONRVIPPDKH-UHFFFAOYSA-N 0.000 description 1
- XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical compound COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 description 1
- LWVPBUUTKRGENF-UHFFFAOYSA-N 2-[2-[tert-butyl(dimethyl)silyl]oxyethyl-methylamino]ethanol Chemical compound OCCN(C)CCO[Si](C)(C)C(C)(C)C LWVPBUUTKRGENF-UHFFFAOYSA-N 0.000 description 1
- GPPXJGVECOPHES-UHFFFAOYSA-N 2-[2-methoxyethyl(methyl)amino]ethanol Chemical compound COCCN(C)CCO GPPXJGVECOPHES-UHFFFAOYSA-N 0.000 description 1
- PBGZUBFACSCIOG-UHFFFAOYSA-N 2-[4-(2-methoxyethyl)piperazin-1-yl]ethanol Chemical compound COCCN1CCN(CCO)CC1 PBGZUBFACSCIOG-UHFFFAOYSA-N 0.000 description 1
- KULDUWBODHYSMK-UHFFFAOYSA-N 2-[4-[2-[tert-butyl(dimethyl)silyl]oxyethyl]piperazin-1-yl]ethanol Chemical compound CC(C)(C)[Si](C)(C)OCCN1CCN(CCO)CC1 KULDUWBODHYSMK-UHFFFAOYSA-N 0.000 description 1
- GVFZJCJJUNBFNM-UHFFFAOYSA-N 2-[methyl(propyl)amino]ethanol Chemical compound CCCN(C)CCO GVFZJCJJUNBFNM-UHFFFAOYSA-N 0.000 description 1
- JBKINHFZTVLNEM-UHFFFAOYSA-N 2-bromoethoxy-tert-butyl-dimethylsilane Chemical compound CC(C)(C)[Si](C)(C)OCCBr JBKINHFZTVLNEM-UHFFFAOYSA-N 0.000 description 1
- NAMYKGVDVNBCFQ-UHFFFAOYSA-N 2-bromopropane Chemical compound CC(C)Br NAMYKGVDVNBCFQ-UHFFFAOYSA-N 0.000 description 1
- WOGWYSWDBYCVDY-UHFFFAOYSA-N 2-chlorocyclohexa-2,5-diene-1,4-dione Chemical compound ClC1=CC(=O)C=CC1=O WOGWYSWDBYCVDY-UHFFFAOYSA-N 0.000 description 1
- FAUQRRGKJKMEIW-UHFFFAOYSA-N 2-cyclopropylacetonitrile Chemical compound N#CCC1CC1 FAUQRRGKJKMEIW-UHFFFAOYSA-N 0.000 description 1
- YXDXXGXWFJCXEB-UHFFFAOYSA-N 2-furonitrile Chemical compound N#CC1=CC=CO1 YXDXXGXWFJCXEB-UHFFFAOYSA-N 0.000 description 1
- PYYKJKJWEKHDOS-UHFFFAOYSA-N 2-tert-butyl-4-chloro-6-(4-methoxyphenyl)-5-methylthieno[2,3-d]pyrimidine Chemical compound C1=CC(OC)=CC=C1C1=C(C)C2=C(Cl)N=C(C(C)(C)C)N=C2S1 PYYKJKJWEKHDOS-UHFFFAOYSA-N 0.000 description 1
- SMJRBWINMFUUDS-UHFFFAOYSA-N 2-thienylacetic acid Chemical compound OC(=O)CC1=CC=CS1 SMJRBWINMFUUDS-UHFFFAOYSA-N 0.000 description 1
- CLSHQIDDCJTHAJ-UHFFFAOYSA-N 2-thienylacetonitrile Chemical compound N#CCC1=CC=CS1 CLSHQIDDCJTHAJ-UHFFFAOYSA-N 0.000 description 1
- GWZCLMWEJWPFFA-UHFFFAOYSA-N 2-thiophen-3-ylacetonitrile Chemical compound N#CCC=1C=CSC=1 GWZCLMWEJWPFFA-UHFFFAOYSA-N 0.000 description 1
- HCDMJFOHIXMBOV-UHFFFAOYSA-N 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-4,7-dihydropyrrolo[4,5]pyrido[1,2-d]pyrimidin-2-one Chemical compound C=1C2=C3N(CC)C(=O)N(C=4C(=C(OC)C=C(OC)C=4F)F)CC3=CN=C2NC=1CN1CCOCC1 HCDMJFOHIXMBOV-UHFFFAOYSA-N 0.000 description 1
- BYHQTRFJOGIQAO-GOSISDBHSA-N 3-(4-bromophenyl)-8-[(2R)-2-hydroxypropyl]-1-[(3-methoxyphenyl)methyl]-1,3,8-triazaspiro[4.5]decan-2-one Chemical compound C[C@H](CN1CCC2(CC1)CN(C(=O)N2CC3=CC(=CC=C3)OC)C4=CC=C(C=C4)Br)O BYHQTRFJOGIQAO-GOSISDBHSA-N 0.000 description 1
- IJODFNOVGPMWGW-UHFFFAOYSA-N 3-(4-chloro-2-thiophen-2-ylthieno[2,3-d]pyrimidin-5-yl)phenol Chemical compound OC1=CC=CC(C=2C3=C(Cl)N=C(N=C3SC=2)C=2SC=CC=2)=C1 IJODFNOVGPMWGW-UHFFFAOYSA-N 0.000 description 1
- CAHFNPCAQPRTDY-UHFFFAOYSA-N 3-(4-chloro-5-methyl-2-thiophen-2-ylthieno[2,3-d]pyrimidin-6-yl)phenol Chemical compound N=1C(Cl)=C2C(C)=C(C=3C=C(O)C=CC=3)SC2=NC=1C1=CC=CS1 CAHFNPCAQPRTDY-UHFFFAOYSA-N 0.000 description 1
- RNIDWJDZNNVFDY-UHFFFAOYSA-N 3-Acetylthiophene Chemical compound CC(=O)C=1C=CSC=1 RNIDWJDZNNVFDY-UHFFFAOYSA-N 0.000 description 1
- WNEODWDFDXWOLU-QHCPKHFHSA-N 3-[3-(hydroxymethyl)-4-[1-methyl-5-[[5-[(2s)-2-methyl-4-(oxetan-3-yl)piperazin-1-yl]pyridin-2-yl]amino]-6-oxopyridin-3-yl]pyridin-2-yl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one Chemical compound C([C@@H](N(CC1)C=2C=NC(NC=3C(N(C)C=C(C=3)C=3C(=C(N4C(C5=CC=6CC(C)(C)CC=6N5CC4)=O)N=CC=3)CO)=O)=CC=2)C)N1C1COC1 WNEODWDFDXWOLU-QHCPKHFHSA-N 0.000 description 1
- SGHBRHKBCLLVCI-UHFFFAOYSA-N 3-hydroxybenzonitrile Chemical compound OC1=CC=CC(C#N)=C1 SGHBRHKBCLLVCI-UHFFFAOYSA-N 0.000 description 1
- WMPDAIZRQDCGFH-UHFFFAOYSA-N 3-methoxybenzaldehyde Chemical compound COC1=CC=CC(C=O)=C1 WMPDAIZRQDCGFH-UHFFFAOYSA-N 0.000 description 1
- LXDPKUDVTRBFBT-UHFFFAOYSA-N 3-methyl-1-[[5-methyl-6-[4-(2-pyrrolidin-1-ylethoxy)phenyl]-2-thiophen-2-ylthieno[2,3-d]pyrimidin-4-yl]amino]pyrrole-2,5-dione hydrochloride Chemical compound Cl.CC1=CC(=O)N(Nc2nc(nc3sc(c(C)c23)-c2ccc(OCCN3CCCC3)cc2)-c2cccs2)C1=O LXDPKUDVTRBFBT-UHFFFAOYSA-N 0.000 description 1
- ZLPORNPZJNRGCO-UHFFFAOYSA-N 3-methylpyrrole-2,5-dione Chemical compound CC1=CC(=O)NC1=O ZLPORNPZJNRGCO-UHFFFAOYSA-N 0.000 description 1
- NGEZPLCPKXKLQQ-UHFFFAOYSA-N 4-(3-methoxyphenyl)but-3-en-2-one Chemical compound COC1=CC=CC(C=CC(C)=O)=C1 NGEZPLCPKXKLQQ-UHFFFAOYSA-N 0.000 description 1
- RLJXQRWNYQRFQO-UHFFFAOYSA-N 4-(4-chloro-5-phenylthieno[2,3-d]pyrimidin-2-yl)aniline Chemical compound C1=CC(N)=CC=C1C1=NC(Cl)=C(C(=CS2)C=3C=CC=CC=3)C2=N1 RLJXQRWNYQRFQO-UHFFFAOYSA-N 0.000 description 1
- URHVXNHGILJRSP-UHFFFAOYSA-N 4-(4-chloro-5-thiophen-2-ylthieno[2,3-d]pyrimidin-2-yl)-n,n-dimethylaniline Chemical compound C1=CC(N(C)C)=CC=C1C1=NC(Cl)=C(C(=CS2)C=3SC=CC=3)C2=N1 URHVXNHGILJRSP-UHFFFAOYSA-N 0.000 description 1
- DAHAQQAXQBDSHH-UHFFFAOYSA-N 4-(4-chloro-5-thiophen-2-ylthieno[2,3-d]pyrimidin-2-yl)aniline Chemical compound C1=CC(N)=CC=C1C1=NC(Cl)=C(C(=CS2)C=3SC=CC=3)C2=N1 DAHAQQAXQBDSHH-UHFFFAOYSA-N 0.000 description 1
- VHOLSVJIFIJJCN-UHFFFAOYSA-N 4-[(4-chloro-5-methyl-2-thiophen-2-ylthieno[2,3-d]pyrimidin-6-yl)methyl]phenol Chemical compound S1C2=NC(C=3SC=CC=3)=NC(Cl)=C2C(C)=C1CC1=CC=C(O)C=C1 VHOLSVJIFIJJCN-UHFFFAOYSA-N 0.000 description 1
- KVCQTKNUUQOELD-UHFFFAOYSA-N 4-amino-n-[1-(3-chloro-2-fluoroanilino)-6-methylisoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound N=1C=CC2=C(NC(=O)C=3C4=NC=NC(N)=C4SC=3)C(C)=CC=C2C=1NC1=CC=CC(Cl)=C1F KVCQTKNUUQOELD-UHFFFAOYSA-N 0.000 description 1
- NXPXEOAAIXKOKX-UHFFFAOYSA-N 4-chloro-2,5-dithiophen-2-ylthieno[2,3-d]pyrimidine Chemical compound C1=2C(Cl)=NC(C=3SC=CC=3)=NC=2SC=C1C1=CC=CS1 NXPXEOAAIXKOKX-UHFFFAOYSA-N 0.000 description 1
- ZBAAMXBOLOOOET-UHFFFAOYSA-N 4-chloro-2-(3-fluorophenyl)-5-phenylthieno[2,3-d]pyrimidine Chemical compound FC1=CC=CC(C=2N=C3SC=C(C3=C(Cl)N=2)C=2C=CC=CC=2)=C1 ZBAAMXBOLOOOET-UHFFFAOYSA-N 0.000 description 1
- HAUMRJXKSKDMKL-UHFFFAOYSA-N 4-chloro-2-(3-methoxyphenyl)-5-phenylthieno[2,3-d]pyrimidine Chemical compound COC1=CC=CC(C=2N=C3SC=C(C3=C(Cl)N=2)C=2C=CC=CC=2)=C1 HAUMRJXKSKDMKL-UHFFFAOYSA-N 0.000 description 1
- UJUJNRXZHRNZEQ-UHFFFAOYSA-N 4-chloro-2-(3-methoxyphenyl)-5-thiophen-2-ylthieno[2,3-d]pyrimidine Chemical compound COC1=CC=CC(C=2N=C3SC=C(C3=C(Cl)N=2)C=2SC=CC=2)=C1 UJUJNRXZHRNZEQ-UHFFFAOYSA-N 0.000 description 1
- XAPRLWXUSRQOKW-UHFFFAOYSA-N 4-chloro-2-(4-methylphenyl)-5-thiophen-2-ylthieno[2,3-d]pyrimidine Chemical compound C1=CC(C)=CC=C1C1=NC(Cl)=C(C(=CS2)C=3SC=CC=3)C2=N1 XAPRLWXUSRQOKW-UHFFFAOYSA-N 0.000 description 1
- XFBOVBIOMQKRAQ-UHFFFAOYSA-N 4-chloro-2-(5-methylthiophen-2-yl)-5-thiophen-2-ylthieno[2,3-d]pyrimidine Chemical compound S1C(C)=CC=C1C1=NC(Cl)=C(C(=CS2)C=3SC=CC=3)C2=N1 XFBOVBIOMQKRAQ-UHFFFAOYSA-N 0.000 description 1
- GBWSADSJMGAEAY-UHFFFAOYSA-N 4-chloro-2-(furan-2-yl)-5-thiophen-2-ylthieno[2,3-d]pyrimidine Chemical compound C1=2C(Cl)=NC(C=3OC=CC=3)=NC=2SC=C1C1=CC=CS1 GBWSADSJMGAEAY-UHFFFAOYSA-N 0.000 description 1
- IOWXFQNUXYCLJV-UHFFFAOYSA-N 4-chloro-2-[(3-methoxyphenyl)methyl]-5-thiophen-2-ylthieno[2,3-d]pyrimidine Chemical compound COC1=CC=CC(CC=2N=C3SC=C(C3=C(Cl)N=2)C=2SC=CC=2)=C1 IOWXFQNUXYCLJV-UHFFFAOYSA-N 0.000 description 1
- WOUMOLBIZKKCSE-UHFFFAOYSA-N 4-chloro-2-[(4-methoxyphenyl)methyl]-5-thiophen-2-ylthieno[2,3-d]pyrimidine Chemical compound C1=CC(OC)=CC=C1CC1=NC(Cl)=C(C(=CS2)C=3SC=CC=3)C2=N1 WOUMOLBIZKKCSE-UHFFFAOYSA-N 0.000 description 1
- LWEYTDLNYJYXEL-UHFFFAOYSA-N 4-chloro-2-cyclopropyl-5-thiophen-2-ylthieno[2,3-d]pyrimidine Chemical compound C1=2C(Cl)=NC(C3CC3)=NC=2SC=C1C1=CC=CS1 LWEYTDLNYJYXEL-UHFFFAOYSA-N 0.000 description 1
- MBXIQZFORBTVIL-UHFFFAOYSA-N 4-chloro-2-ethyl-6-(4-methoxyphenyl)-5-methylthieno[2,3-d]pyrimidine Chemical compound S1C2=NC(CC)=NC(Cl)=C2C(C)=C1C1=CC=C(OC)C=C1 MBXIQZFORBTVIL-UHFFFAOYSA-N 0.000 description 1
- MVAGBPKYNISOSK-UHFFFAOYSA-N 4-chloro-2-phenyl-5-thiophen-2-ylthieno[2,3-d]pyrimidine Chemical compound C1=2C(Cl)=NC(C=3C=CC=CC=3)=NC=2SC=C1C1=CC=CS1 MVAGBPKYNISOSK-UHFFFAOYSA-N 0.000 description 1
- ISAPBQUOWZQMNV-UHFFFAOYSA-N 4-chloro-2-pyridin-4-yl-5-thiophen-2-ylthieno[2,3-d]pyrimidine Chemical compound C1=2C(Cl)=NC(C=3C=CN=CC=3)=NC=2SC=C1C1=CC=CS1 ISAPBQUOWZQMNV-UHFFFAOYSA-N 0.000 description 1
- VGKISRLMKUXTPY-UHFFFAOYSA-N 4-chloro-2-thiophen-2-yl-5-thiophen-3-ylthieno[2,3-d]pyrimidine Chemical compound C1=2C(Cl)=NC(C=3SC=CC=3)=NC=2SC=C1C=1C=CSC=1 VGKISRLMKUXTPY-UHFFFAOYSA-N 0.000 description 1
- NMSRJZDPTFQPIL-UHFFFAOYSA-N 4-chloro-2-thiophen-2-ylthieno[2,3-d]pyrimidine Chemical compound N=1C=2SC=CC=2C(Cl)=NC=1C1=CC=CS1 NMSRJZDPTFQPIL-UHFFFAOYSA-N 0.000 description 1
- DTOSRPZWZAOGIY-UHFFFAOYSA-N 4-chloro-5-(4-methylphenyl)-2-thiophen-2-ylthieno[2,3-d]pyrimidine Chemical compound C1=CC(C)=CC=C1C1=CSC2=NC(C=3SC=CC=3)=NC(Cl)=C12 DTOSRPZWZAOGIY-UHFFFAOYSA-N 0.000 description 1
- ZRQNORWJRQWABY-UHFFFAOYSA-N 4-chloro-5-methyl-6-(4-nitrophenyl)-2-thiophen-2-ylthieno[2,3-d]pyrimidine Chemical compound N=1C(Cl)=C2C(C)=C(C=3C=CC(=CC=3)[N+]([O-])=O)SC2=NC=1C1=CC=CS1 ZRQNORWJRQWABY-UHFFFAOYSA-N 0.000 description 1
- UAIXPCWTEUFSNI-UHFFFAOYSA-N 4-chloro-5-methylthieno[2,3-d]pyrimidine Chemical compound C1=NC(Cl)=C2C(C)=CSC2=N1 UAIXPCWTEUFSNI-UHFFFAOYSA-N 0.000 description 1
- QAYWIUZKWWQPPP-UHFFFAOYSA-N 4-chloro-5-phenyl-2-thiophen-2-ylthieno[2,3-d]pyrimidine Chemical compound C1=2C(Cl)=NC(C=3SC=CC=3)=NC=2SC=C1C1=CC=CC=C1 QAYWIUZKWWQPPP-UHFFFAOYSA-N 0.000 description 1
- YYIVOHMUXDTNDR-UHFFFAOYSA-N 4-chloro-5-thiophen-2-yl-2-(thiophen-2-ylmethyl)thieno[2,3-d]pyrimidine Chemical compound N=1C=2SC=C(C=3SC=CC=3)C=2C(Cl)=NC=1CC1=CC=CS1 YYIVOHMUXDTNDR-UHFFFAOYSA-N 0.000 description 1
- ODIFJAUETALMFU-UHFFFAOYSA-N 4-chloro-5-thiophen-2-ylthieno[2,3-d]pyrimidin-2-amine Chemical compound C=1SC2=NC(N)=NC(Cl)=C2C=1C1=CC=CS1 ODIFJAUETALMFU-UHFFFAOYSA-N 0.000 description 1
- BMPJVARCTWHNKE-UHFFFAOYSA-N 4-chloro-6-(3-methoxyphenyl)-5-methyl-2-thiophen-2-ylthieno[2,3-d]pyrimidine Chemical compound COC1=CC=CC(C2=C(C3=C(Cl)N=C(N=C3S2)C=2SC=CC=2)C)=C1 BMPJVARCTWHNKE-UHFFFAOYSA-N 0.000 description 1
- TWWAPKLFGBTYPT-UHFFFAOYSA-N 4-chloro-6-(4-methoxyphenyl)-2,5-dimethylthieno[2,3-d]pyrimidine Chemical compound C1=CC(OC)=CC=C1C1=C(C)C2=C(Cl)N=C(C)N=C2S1 TWWAPKLFGBTYPT-UHFFFAOYSA-N 0.000 description 1
- IPLNFHZAKZFAAN-UHFFFAOYSA-N 4-chloro-6-(4-methoxyphenyl)-5-methyl-2-(2-methylpropyl)thieno[2,3-d]pyrimidine Chemical compound C1=CC(OC)=CC=C1C1=C(C)C2=C(Cl)N=C(CC(C)C)N=C2S1 IPLNFHZAKZFAAN-UHFFFAOYSA-N 0.000 description 1
- CVNOWLNNPYYEOH-UHFFFAOYSA-N 4-cyanophenol Chemical compound OC1=CC=C(C#N)C=C1 CVNOWLNNPYYEOH-UHFFFAOYSA-N 0.000 description 1
- AEKVBBNGWBBYLL-UHFFFAOYSA-N 4-fluorobenzonitrile Chemical compound FC1=CC=C(C#N)C=C1 AEKVBBNGWBBYLL-UHFFFAOYSA-N 0.000 description 1
- SDEBYHVDMCQKNZ-UHFFFAOYSA-N 4-methoxy-6-piperazin-1-ylpyrimidine;hydrochloride Chemical compound Cl.C1=NC(OC)=CC(N2CCNCC2)=N1 SDEBYHVDMCQKNZ-UHFFFAOYSA-N 0.000 description 1
- XDJAAZYHCCRJOK-UHFFFAOYSA-N 4-methoxybenzonitrile Chemical compound COC1=CC=C(C#N)C=C1 XDJAAZYHCCRJOK-UHFFFAOYSA-N 0.000 description 1
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 1
- VCZNNAKNUVJVGX-UHFFFAOYSA-N 4-methylbenzonitrile Chemical compound CC1=CC=C(C#N)C=C1 VCZNNAKNUVJVGX-UHFFFAOYSA-N 0.000 description 1
- HRKYSEOOABTTCJ-UHFFFAOYSA-N 5-methyl-3h-thieno[2,3-d]pyrimidin-4-one Chemical compound N1=CNC(=O)C2=C1SC=C2C HRKYSEOOABTTCJ-UHFFFAOYSA-N 0.000 description 1
- RBQRZWYCXAXPIN-UHFFFAOYSA-N 5-methylthiophene-2-carbonitrile Chemical compound CC1=CC=C(C#N)S1 RBQRZWYCXAXPIN-UHFFFAOYSA-N 0.000 description 1
- FIJLUTUCWPVGJU-UHFFFAOYSA-N 5-thiophen-2-yl-2-thiophen-3-yl-3h-thieno[2,3-d]pyrimidin-4-one Chemical compound C1=2C(=O)NC(C3=CSC=C3)=NC=2SC=C1C1=CC=CS1 FIJLUTUCWPVGJU-UHFFFAOYSA-N 0.000 description 1
- GFFNXYDHCRDSFA-UHFFFAOYSA-N 5-thiophen-2-ylthieno[2,3-d]pyrimidine Chemical compound C1=CSC(C=2C3=CN=CN=C3SC=2)=C1 GFFNXYDHCRDSFA-UHFFFAOYSA-N 0.000 description 1
- KCBWAFJCKVKYHO-UHFFFAOYSA-N 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-[[4-[1-propan-2-yl-4-(trifluoromethyl)imidazol-2-yl]phenyl]methyl]pyrazolo[3,4-d]pyrimidine Chemical compound C1(CC1)C1=NC=NC(=C1C1=NC=C2C(=N1)N(N=C2)CC1=CC=C(C=C1)C=1N(C=C(N=1)C(F)(F)F)C(C)C)OC KCBWAFJCKVKYHO-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- CYJRNFFLTBEQSQ-UHFFFAOYSA-N 8-(3-methyl-1-benzothiophen-5-yl)-N-(4-methylsulfonylpyridin-3-yl)quinoxalin-6-amine Chemical compound CS(=O)(=O)C1=C(C=NC=C1)NC=1C=C2N=CC=NC2=C(C=1)C=1C=CC2=C(C(=CS2)C)C=1 CYJRNFFLTBEQSQ-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 235000006491 Acacia senegal Nutrition 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- OUPFOPSXVIVJHE-UHFFFAOYSA-N C1[O]2C1C1(CCNCC1)OCC2 Chemical compound C1[O]2C1C1(CCNCC1)OCC2 OUPFOPSXVIVJHE-UHFFFAOYSA-N 0.000 description 1
- WFPLPCDAYRSTJT-CAOOACKPSA-N CC/C(/C)=C/CCOc(cc1)ccc1-c1c(C)c2c(NN(C(C=C3C)=O)C3=O)nc(-c3ccc[s]3)nc2[o]1 Chemical compound CC/C(/C)=C/CCOc(cc1)ccc1-c1c(C)c2c(NN(C(C=C3C)=O)C3=O)nc(-c3ccc[s]3)nc2[o]1 WFPLPCDAYRSTJT-CAOOACKPSA-N 0.000 description 1
- YNQLUTRBYVCPMQ-UHFFFAOYSA-N CCc1ccccc1 Chemical compound CCc1ccccc1 YNQLUTRBYVCPMQ-UHFFFAOYSA-N 0.000 description 1
- PKYLTPUGLDYFEI-UHFFFAOYSA-N COC(c1c(N=C)[s]cc1-c1ccc[s]1)=O Chemical compound COC(c1c(N=C)[s]cc1-c1ccc[s]1)=O PKYLTPUGLDYFEI-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 1
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 229910021591 Copper(I) chloride Inorganic materials 0.000 description 1
- 229910021590 Copper(II) bromide Inorganic materials 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
- XZMCDFZZKTWFGF-UHFFFAOYSA-N Cyanamide Chemical compound NC#N XZMCDFZZKTWFGF-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- XXRCUYVCPSWGCC-UHFFFAOYSA-N Ethyl pyruvate Chemical compound CCOC(=O)C(C)=O XXRCUYVCPSWGCC-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 229910003556 H2 SO4 Inorganic materials 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 125000002842 L-seryl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])O[H] 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- HLFSDGLLUJUHTE-SNVBAGLBSA-N Levamisole Chemical compound C1([C@H]2CN3CCSC3=N2)=CC=CC=C1 HLFSDGLLUJUHTE-SNVBAGLBSA-N 0.000 description 1
- 239000012448 Lithium borohydride Substances 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M Methanesulfonate Chemical compound CS([O-])(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
- WRQNANDWMGAFTP-UHFFFAOYSA-N Methylacetoacetic acid Chemical compound COC(=O)CC(C)=O WRQNANDWMGAFTP-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- AYCPARAPKDAOEN-LJQANCHMSA-N N-[(1S)-2-(dimethylamino)-1-phenylethyl]-6,6-dimethyl-3-[(2-methyl-4-thieno[3,2-d]pyrimidinyl)amino]-1,4-dihydropyrrolo[3,4-c]pyrazole-5-carboxamide Chemical compound C1([C@H](NC(=O)N2C(C=3NN=C(NC=4C=5SC=CC=5N=C(C)N=4)C=3C2)(C)C)CN(C)C)=CC=CC=C1 AYCPARAPKDAOEN-LJQANCHMSA-N 0.000 description 1
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 1
- UBAYXLKKPNQUMV-UHFFFAOYSA-N N-pyrrolo[3,4-c]pyridin-2-yl-5-thiophen-2-ylthieno[2,3-d]pyrimidin-4-amine Chemical compound S1C(=CC=C1)C1=CSC=2N=CN=C(C=21)NN1C=C2C=NC=CC2=C1 UBAYXLKKPNQUMV-UHFFFAOYSA-N 0.000 description 1
- 102100033104 NF-kappa-B inhibitor epsilon Human genes 0.000 description 1
- 101710093997 NF-kappa-B inhibitor epsilon Proteins 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 108010001859 Proto-Oncogene Proteins c-rel Proteins 0.000 description 1
- 102000000850 Proto-Oncogene Proteins c-rel Human genes 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- LXRZVMYMQHNYJB-UNXOBOICSA-N [(1R,2S,4R)-4-[[5-[4-[(1R)-7-chloro-1,2,3,4-tetrahydroisoquinolin-1-yl]-5-methylthiophene-2-carbonyl]pyrimidin-4-yl]amino]-2-hydroxycyclopentyl]methyl sulfamate Chemical compound CC1=C(C=C(S1)C(=O)C1=C(N[C@H]2C[C@H](O)[C@@H](COS(N)(=O)=O)C2)N=CN=C1)[C@@H]1NCCC2=C1C=C(Cl)C=C2 LXRZVMYMQHNYJB-UNXOBOICSA-N 0.000 description 1
- AZFNGPAYDKGCRB-XCPIVNJJSA-M [(1s,2s)-2-amino-1,2-diphenylethyl]-(4-methylphenyl)sulfonylazanide;chlororuthenium(1+);1-methyl-4-propan-2-ylbenzene Chemical compound [Ru+]Cl.CC(C)C1=CC=C(C)C=C1.C1=CC(C)=CC=C1S(=O)(=O)[N-][C@@H](C=1C=CC=CC=1)[C@@H](N)C1=CC=CC=C1 AZFNGPAYDKGCRB-XCPIVNJJSA-M 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- GCPWJFKTWGFEHH-UHFFFAOYSA-N acetoacetamide Chemical compound CC(=O)CC(N)=O GCPWJFKTWGFEHH-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 230000001780 adrenocortical effect Effects 0.000 description 1
- 229940009456 adriamycin Drugs 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- IAJILQKETJEXLJ-RSJOWCBRSA-N aldehydo-D-galacturonic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-RSJOWCBRSA-N 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-N anhydrous glutaric acid Natural products OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 230000003356 anti-rheumatic effect Effects 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 229960005261 aspartic acid Drugs 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 229960002170 azathioprine Drugs 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 229940076134 benzene Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- KVNRLNFWIYMESJ-UHFFFAOYSA-N butyronitrile Chemical compound CCCC#N KVNRLNFWIYMESJ-UHFFFAOYSA-N 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 235000001465 calcium Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 229960001701 chloroform Drugs 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- OXBLHERUFWYNTN-UHFFFAOYSA-M copper(I) chloride Chemical compound [Cu]Cl OXBLHERUFWYNTN-UHFFFAOYSA-M 0.000 description 1
- NKNDPYCGAZPOFS-UHFFFAOYSA-M copper(i) bromide Chemical compound Br[Cu] NKNDPYCGAZPOFS-UHFFFAOYSA-M 0.000 description 1
- GBRBMTNGQBKBQE-UHFFFAOYSA-L copper;diiodide Chemical compound I[Cu]I GBRBMTNGQBKBQE-UHFFFAOYSA-L 0.000 description 1
- 229960004544 cortisone Drugs 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- AUQDITHEDVOTCU-UHFFFAOYSA-N cyclopropyl cyanide Chemical compound N#CC1CC1 AUQDITHEDVOTCU-UHFFFAOYSA-N 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- WGLUMOCWFMKWIL-UHFFFAOYSA-N dichloromethane;methanol Chemical compound OC.ClCCl WGLUMOCWFMKWIL-UHFFFAOYSA-N 0.000 description 1
- GGSUCNLOZRCGPQ-UHFFFAOYSA-N diethylaniline Chemical compound CCN(CC)C1=CC=CC=C1 GGSUCNLOZRCGPQ-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000001952 enzyme assay Methods 0.000 description 1
- XBRDBODLCHKXHI-UHFFFAOYSA-N epolamine Chemical compound OCCN1CCCC1 XBRDBODLCHKXHI-UHFFFAOYSA-N 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
- RKVSFXAVMBUUFB-UHFFFAOYSA-N ethyl 2-(4-chloro-2-thiophen-2-ylthieno[2,3-d]pyrimidin-5-yl)acetate Chemical compound N=1C(Cl)=C2C(CC(=O)OCC)=CSC2=NC=1C1=CC=CS1 RKVSFXAVMBUUFB-UHFFFAOYSA-N 0.000 description 1
- FNHRSJOSCPGDTA-UHFFFAOYSA-N ethyl 2-amino-4-(2-ethoxy-2-oxoethyl)thiophene-3-carboxylate Chemical compound CCOC(=O)CC1=CSC(N)=C1C(=O)OCC FNHRSJOSCPGDTA-UHFFFAOYSA-N 0.000 description 1
- ILYCZKOBLRJJSW-UHFFFAOYSA-N ethyl 2-amino-4-methylthiophene-3-carboxylate Chemical compound CCOC(=O)C=1C(C)=CSC=1N ILYCZKOBLRJJSW-UHFFFAOYSA-N 0.000 description 1
- MGDWUTQKXCZNAJ-UHFFFAOYSA-N ethyl 4-bromo-3-oxobutanoate Chemical compound CCOC(=O)CC(=O)CBr MGDWUTQKXCZNAJ-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- DWRWSNAREGLUHZ-UHFFFAOYSA-N ethyl pyrimidine-4-carboxylate Chemical compound CCOC(=O)C1=CC=NC=N1 DWRWSNAREGLUHZ-UHFFFAOYSA-N 0.000 description 1
- 229940117360 ethyl pyruvate Drugs 0.000 description 1
- QRMKTNANRJCRCY-UHFFFAOYSA-N ethylammonium acetate Chemical compound CC[NH3+].CC([O-])=O QRMKTNANRJCRCY-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- ZYCMDWDFIQDPLP-UHFFFAOYSA-N hbr bromine Chemical compound Br.Br ZYCMDWDFIQDPLP-UHFFFAOYSA-N 0.000 description 1
- 201000005787 hematologic cancer Diseases 0.000 description 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
- GNOIPBMMFNIUFM-UHFFFAOYSA-N hexamethylphosphoric triamide Chemical compound CN(C)P(=O)(N(C)C)N(C)C GNOIPBMMFNIUFM-UHFFFAOYSA-N 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 229940071870 hydroiodic acid Drugs 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- GRRNUXAQVGOGFE-NZSRVPFOSA-N hygromycin B Chemical compound O[C@@H]1[C@@H](NC)C[C@@H](N)[C@H](O)[C@H]1O[C@H]1[C@H]2O[C@@]3([C@@H]([C@@H](O)[C@@H](O)[C@@H](C(N)CO)O3)O)O[C@H]2[C@@H](O)[C@@H](CO)O1 GRRNUXAQVGOGFE-NZSRVPFOSA-N 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000000185 intracerebroventricular administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- QHDRKFYEGYYIIK-UHFFFAOYSA-N isovaleronitrile Chemical compound CC(C)CC#N QHDRKFYEGYYIIK-UHFFFAOYSA-N 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 229960001614 levamisole Drugs 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- FRIJBUGBVQZNTB-UHFFFAOYSA-M magnesium;ethane;bromide Chemical compound [Mg+2].[Br-].[CH2-]C FRIJBUGBVQZNTB-UHFFFAOYSA-M 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- GWGHBZPSYBSUJE-UHFFFAOYSA-N methyl 2-(4-chloro-5-methyl-2-thiophen-2-ylthieno[2,3-d]pyrimidin-6-yl)acetate Chemical compound N=1C(Cl)=C2C(C)=C(CC(=O)OC)SC2=NC=1C1=CC=CS1 GWGHBZPSYBSUJE-UHFFFAOYSA-N 0.000 description 1
- YDYZHGKGTXEBGM-UHFFFAOYSA-N methyl 2-amino-4-(3-methoxyphenyl)thiophene-3-carboxylate Chemical compound COC(=O)C1=C(N)SC=C1C1=CC=CC(OC)=C1 YDYZHGKGTXEBGM-UHFFFAOYSA-N 0.000 description 1
- KIJRJMDIDAKQEX-UHFFFAOYSA-N methyl 4-chloro-5-methyl-2-thiophen-2-ylthieno[2,3-d]pyrimidine-6-carboxylate Chemical compound N=1C(Cl)=C2C(C)=C(C(=O)OC)SC2=NC=1C1=CC=CS1 KIJRJMDIDAKQEX-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 210000003061 neural cell Anatomy 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- ZJVAWPKTWVFKHG-UHFFFAOYSA-N p-Methoxypropiophenone Chemical compound CCC(=O)C1=CC=C(OC)C=C1 ZJVAWPKTWVFKHG-UHFFFAOYSA-N 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- XSBOOIFPDDTOMH-UHFFFAOYSA-N pentane-2,4-dione;sodium Chemical compound [Na].CC(=O)CC(C)=O XSBOOIFPDDTOMH-UHFFFAOYSA-N 0.000 description 1
- SUSQOBVLVYHIEX-UHFFFAOYSA-N phenylacetonitrile Chemical compound N#CCC1=CC=CC=C1 SUSQOBVLVYHIEX-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- IPNPIHIZVLFAFP-UHFFFAOYSA-N phosphorus tribromide Chemical compound BrP(Br)Br IPNPIHIZVLFAFP-UHFFFAOYSA-N 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- JAMNHZBIQDNHMM-UHFFFAOYSA-N pivalonitrile Chemical compound CC(C)(C)C#N JAMNHZBIQDNHMM-UHFFFAOYSA-N 0.000 description 1
- 201000006292 polyarteritis nodosa Diseases 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 208000005987 polymyositis Diseases 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000004304 potassium nitrite Substances 0.000 description 1
- 235000010289 potassium nitrite Nutrition 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- FVSKHRXBFJPNKK-UHFFFAOYSA-N propionitrile Chemical compound CCC#N FVSKHRXBFJPNKK-UHFFFAOYSA-N 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- YQUVCSBJEUQKSH-UHFFFAOYSA-N protochatechuic acid Natural products OC(=O)C1=CC=C(O)C(O)=C1 YQUVCSBJEUQKSH-UHFFFAOYSA-N 0.000 description 1
- GPHQHTOMRSGBNZ-UHFFFAOYSA-N pyridine-4-carbonitrile Chemical compound N#CC1=CC=NC=C1 GPHQHTOMRSGBNZ-UHFFFAOYSA-N 0.000 description 1
- JQRYUMGHOUYJFW-UHFFFAOYSA-N pyridine;trihydrobromide Chemical compound [Br-].[Br-].[Br-].C1=CC=[NH+]C=C1.C1=CC=[NH+]C=C1.C1=CC=[NH+]C=C1 JQRYUMGHOUYJFW-UHFFFAOYSA-N 0.000 description 1
- IIVUJUOJERNGQX-UHFFFAOYSA-N pyrimidine-5-carboxylic acid Chemical compound OC(=O)C1=CN=CN=C1 IIVUJUOJERNGQX-UHFFFAOYSA-N 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 229910001961 silver nitrate Inorganic materials 0.000 description 1
- XGVXKJKTISMIOW-ZDUSSCGKSA-N simurosertib Chemical compound N1N=CC(C=2SC=3C(=O)NC(=NC=3C=2)[C@H]2N3CCC(CC3)C2)=C1C XGVXKJKTISMIOW-ZDUSSCGKSA-N 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229910052979 sodium sulfide Inorganic materials 0.000 description 1
- GRVFOGOEDUUMBP-UHFFFAOYSA-N sodium sulfide (anhydrous) Chemical compound [Na+].[Na+].[S-2] GRVFOGOEDUUMBP-UHFFFAOYSA-N 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- OTNVGWMVOULBFZ-UHFFFAOYSA-N sodium;hydrochloride Chemical class [Na].Cl OTNVGWMVOULBFZ-UHFFFAOYSA-N 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000003270 steroid hormone Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000012089 stop solution Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 238000000967 suction filtration Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 210000001258 synovial membrane Anatomy 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000008718 systemic inflammatory response Effects 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- TZRQZPMQUXEZMC-UHFFFAOYSA-N tert-butyl n-(2-bromoethyl)carbamate Chemical compound CC(C)(C)OC(=O)NCCBr TZRQZPMQUXEZMC-UHFFFAOYSA-N 0.000 description 1
- BYIPIBLHBIMKQQ-UHFFFAOYSA-N tert-butyl n-[2-[2-hydroxyethyl(methyl)amino]ethyl]carbamate Chemical compound OCCN(C)CCNC(=O)OC(C)(C)C BYIPIBLHBIMKQQ-UHFFFAOYSA-N 0.000 description 1
- YUKCCAPGEMBAOQ-UHFFFAOYSA-N tert-butyl n-[2-[4-(2-hydroxyethyl)piperazin-1-yl]ethyl]carbamate Chemical compound CC(C)(C)OC(=O)NCCN1CCN(CCO)CC1 YUKCCAPGEMBAOQ-UHFFFAOYSA-N 0.000 description 1
- GSXCEVHRIVLFJV-UHFFFAOYSA-N thiophene-3-carbonitrile Chemical compound N#CC=1C=CSC=1 GSXCEVHRIVLFJV-UHFFFAOYSA-N 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 238000010798 ubiquitination Methods 0.000 description 1
- 230000034512 ubiquitination Effects 0.000 description 1
- WKOLLVMJNQIZCI-UHFFFAOYSA-N vanillic acid Chemical compound COC1=CC(C(O)=O)=CC=C1O WKOLLVMJNQIZCI-UHFFFAOYSA-N 0.000 description 1
- TUUBOHWZSQXCSW-UHFFFAOYSA-N vanillic acid Natural products COC1=CC(O)=CC(C(O)=O)=C1 TUUBOHWZSQXCSW-UHFFFAOYSA-N 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Definitions
- the present invention relates to a novel thienopyrimidine derivative or a pharmaceutically acceptable salt thereof, a process for the preparation thereof and a pharmaceutical composition comprising the same.
- a thienopyrimidine derivative of the present invention inhibits the activity of IKB kinase- ⁇ (IKK ⁇ or IKK-2), whereby it inhibits the activity of nuclear factor KB (NF-KB). Accordingly, it can be used for prevention or treatment of NF- KB -related diseases, in particular, inflammatory diseases and cancers.
- NF- ⁇ B Nuclear Factor kappa B
- p50 subunit family p50, p52
- p65 subunit family p65, c-Rel, ReIB
- IKB protein I ⁇ B ⁇ , I ⁇ B ⁇ , I ⁇ B ⁇ , I ⁇ B ⁇ , I ⁇ B ⁇ and BcB
- cytokines e.g., TNF- ⁇ , IL-I
- bacterial or viral infections e.g., LPS, dsRNA
- stress e.g., ROI, UV, adriamycin, radiation
- oxidants activate IKB kinase complex composed of IKK ⁇ , IKK ⁇ , NEMO (IKK ⁇ ) or the like.
- the activated IKB kinase complex phosphorylates at the two serine residues in the N- terminus of IKB proteins (I ⁇ B ⁇ phosphorylates at Ser32 and Ser36, I ⁇ B ⁇ phosphorylates at Serl9 and Ser23), wherein the phosphorylation of IKB proteins triggers IKB ubiquitination and degradation via the ubiquitin-proteosome pathway (VJ. Palombella et al., Cell, 78, 773-785, 1994; Ghosh S. et al, Cell. 109, 81-96, 2002).
- NF- ⁇ B The free NF- ⁇ B from IKB translocates to the nucleus and binds to NF- ⁇ B binding site (consensus sequence: 5'-GGGPuNNPyPyCC-3') of target genes, thereby initiating the transcription of the genes coding the immune and inflammatory response related proteins (Barnes PJ. et al. N. Engl. J. Med. 336, 1066-1071, 1997).
- Most of the genes regulated by NF- KB include proinflammatory mediators, cytokines, and cell adhesion molecules.
- IKK ⁇ and IKK ⁇ have been elucidated concretely.
- IKK- ⁇ is thought to be a pivotal target in NF- ⁇ B activation pathway as an anti-inflammatory and anti-cancer therapeutic agent.
- the IKK ⁇ inhibition appears, therefore, as an attractive strategy to increase the anti-inflammatory and anti-cancer effect.
- KB play key role in the normal physiological functions such as development and immune response
- abnormal activation of NF- ⁇ B are associated with mutations in IKB protein, a translocation and amplification of NF- ⁇ B gene, and aberrant activation of IKK enzyme in inflammatory diseases such as arthritis, asthma (Yang L. et al., J. Exp. Med. 188, 1739-1750, 1998; Barnes P., et al, Trends Pharmacol, Therapeut.
- NF-KB may be involved in the regulation of neural cell apoptosis. It has been found that NF-KB is activated and promotes cell death in focal cerebral ischemia (Schneider A. et al, Nature medicine Vol.5 No.5, 554-559, 1999). Accordingly, if the aberrant activation of NF- ⁇ B is regulated, it is possible to inhibit occurrence and progression of degenerative and rare diseases and to treat rare diseases caused by an aberrant apoptosis and inflammation.
- Example thereof includes rheumatism, which is one of degenerative diseases.
- Rheumatism is characterized by inflammation and hyperplasia, in which NF- KB is involved. It has been known that NF- ⁇ B in the synoviocyte of rheumatoid synovium is activated by various stimuli, and the activated NF- ⁇ B expresses proinflammatory mediators and inhibits synoviocyte apoptosis at the same time, thereby inducing inflammation and hyperplasia (Berenbaum F., Curr Opin Rheumatol. 2004 Sep; 16(5): 616-22; Liu H., et al., Curr Opin Pharmacol. 2003 Jun;3(3):317-22.).
- a chemotherapeutic cure has been adopted by using various types of drugs that contain a steroid anti-inflammatory agent such as cortisone and other adrenocortical hormones, a non-steroid anti-inflammatory agent such as asprin, pyrroxicam and indomethacin, an auric agent such as orothiomalic acid, an anti-rheumatoid agent such as chloroquinone and D- phenisylamine, a gout inhibitor such as colchicin, and an immunosuppressant such as cyclophosphoamide, azathioprine, methotrexate and levamisol.
- a steroid anti-inflammatory agent such as cortisone and other adrenocortical hormones
- a non-steroid anti-inflammatory agent such as asprin, pyrroxicam and indomethacin
- an auric agent such as orothiomalic acid
- an anti-rheumatoid agent such as chloroquino
- the above chemotherapeutic drugs cannot treat the disease fundamentally and produces a lot of side-effects due to the medicine in the case where steroid hormones known as an arthritis drug are administered for the treatment. Accordingly, there are difficulties in using the above chemotherapeutic drugs for the treatment.
- the conventional chemotherapeutic drugs have problems such as a side-effect and a decreased effectiveness after being administered over a long period of time administration, a deficiency of anti-inflammation effect, a lack of efficacy toward already provoked arthritis and the like.
- indomethacin, ibuprofen which can soothe pains effectively during the treatment of arthritis, and various kinds of nonsteroid antiphlogistic agents are only prepared for the administration. Disclosure of Invention Technical Problem
- the present inventors have made an effort to develop a substance having an excellent inhibitory activity against IKK ⁇ , which is involved in inhibiting a transcriptional factor, NF- ⁇ B associated with inducing various immune and inflammatory diseases, and as a result, they have prepared a novel thienopyrimidine derivative. Further, they have found that the compound has an excellent inhibitory activity against IKK ⁇ , thereby completing the present invention.
- Technical Solution
- the present invention provides a novel thienopyrimidine derivative having an excellent anti-inflammatory and anti-cancer activity, or a pharmaceutically acceptable salt thereof, a process for the preparation thereof and a pharmaceutical composition comprising the same.
- Fig. 1 illustrates that an amount of TNF- ⁇ in the blood of inflammation-induced mice, in the case where the compounds of the present invention (Examples 84 to 85) were orally administrated to inflammation-induced mice at concentrations of 30 and 100 D/D, respectively, and then lipopolysaccharide was abdominally administrated.
- the present invention provides a novel thienopyrimidine derivative represented by the following Formula 1, which has an excellent anti-inflammatory and anti-cancer activity, a pharmaceutically acceptable salt thereof, or an isomer thereof.
- X is O, S or NH
- R is hydrogen; linear or branched C to C alkyl; -(CH )n -OR; -(CH )n -COOR; C to C heteroaryl substituted or unsubstituted with C to C alkyl or halogen, which comprise one or two heteroatom(s) selected from the group consisting of S, O and N; or
- R is hydrogen; -(CH )n -Z; -(CH )n -OR; -(CH )n -COOR; -(CH )n -CONR'R"; -
- R is hydrogen; linear or branched C to C alkyl; linear or branched C to C
- C to C heterocyclic comprising one or two heteroatom(s) selected from the group consisting of N, O or S,
- R is H, or linear or branched C to C alkyl
- R is H, -OH, -NO , linear or branched C to C alkyl, -Y-C to C alkyl, -NR 1 R", -
- CN -COOR, halogen, -Y-(CH )n -NR 1 R", -Y-(CH )n -OR, -Y-(CH )n -COOR, - Y-(CH )n -Z, -Y-(CH )n -M-R, -Y-(CH )n -M-(CH )n -NR 1 R", -Y-(CH )n -M-(CH )n -OR, -Y-(CH )n -M-(CH )n -COOR, -Y-(CH )n -M-(CH )n -CN or -Y-(CH )n -
- R is H, linear or branched C to C alkyl, -OR, -NO , amine, mono- or di- alkylamine, -CN, -COOR, -0-(CH )n -NR 1 R", -0-(CH )n -OR, -0-(CH )n -COOR or - 0-(CH )n -Z,
- R is H, linear or branched C to C alkyl, -OR, -NO , amine, mono- or di- alkylamine, -CN, -COOR, -(CH ⁇ -NR'R", -(CH ⁇ -OR, -(CH ⁇ -COR, -(CH ⁇ - COOR or -(CH 2 )n 2 -Z,
- R and R are each independently hydrogen, linear or branched C to C alkyl, or halogen
- R, R' and R" are each independently hydrogen, linear or branched C to C alkyl, or
- M is O, S or -NR-
- Y is O, S, NH, -NH-CO- or -CO-NH-,
- Z is pyrrolidine; piperidine; piperazine; morpholine; thiomorpholine; 2- or
- 3-oxo-pyrrolidine 2-, 3- or 4-oxo-piperidine; oxazole; triazole; pyridine; imidazole; imidazolidine; 2,5-dioxo-pyrrolidine; 2- or 3-oxo-piperazine;
- n , n and n are each integer of 0 to 5.
- X is O or S
- R is hydrogen, methyl, -(CH )n -OR, -(CH )n -COOR, thiophenyl or
- R is hydrogen, -(CH )n -Z, -(CH )n -OR, -(CH )n -COOR, -(CH )n -CONR'R", -
- R is hydrogen, methyl, ethyl, propyl, isobutyl, t-butyl, 2-propenyl, cyclopropyl, -
- R is H, -OH, -NO , methyl, -OCH , -NR 1 R", F, Cl, Br, I, -Y-(CH )n -NR 1 R", -
- R is H
- R is H, methyl, butyl, -(CH )n -NR 1 R", -(CH )n -OR or -(CH )n -COR,
- R and R are each independently hydrogen
- R, R' and R" are each independently hydrogen, methyl, ethyl, propyl, isopropyl, butyl, t-butyl, isopentyl or -CH CF , [44] M is O or -NR-,
- Y is O, -NH-CO- or -CO-NH-
- Z is pyrrolidine, piperidine, piperazine, morpholine, thiomorpholine, 2- or
- n , n and n are each integer of 0 to 3.
- Preferred examples of the thienopyrimidine derivative of Formula 1 of the present invention include the following compounds, but are not limited thereto:
- the compounds of Formula 1 of the present invention can be prepared in the form of their pharmaceutically acceptable salts and solvates by a conventional method known in the art.
- the acid addition salt formed by a pharmaceutically acceptable free acid thereof is useful.
- the acid addition salt is prepared by a conventional method, for example, a method in which a compound is dissolved in an excessive amount of an acid solution, and then a salt is precipitated in a water miscible organic solvent, such as methanol, ethanol, acetone and acetonitrile.
- Acid or alcohol for example, glycol monomethylether
- the precipitated salt can be subjected to suction filtration.
- an organic acid and inorganic acid can be used as a free acid.
- Examples of the inorganic acid include hydrochloric acid, phosphoric acid, sulfuric acid, nitric acid, and tartaric acid
- examples of the organic acid include methane- sulphonic acid, /?-toluenesulphonic acid, acetic acid, trifluoroacetic acid, maleic acid, succinic acid, oxalic acid, benzoic acid, tartaric acid, fumaric acid, mandelic acid, propionic acid, citric acid, lactic acid, glycolic acid, gluconic acid, galacturonic acid, glutamic acid, glutaric acid, glucuronic acid, aspartic acid, ascorbic acid, carboxylic acid, vanillic acid, and hydroiodic acid, but not limited thereto.
- a pharmaceutically acceptable metal salt can be prepared with a base.
- An alkali metal or alkaline earth metal salt can be obtained by the method, for example, a method comprising dissolving a compound in an excessive amount of an alkali metal hydroxide or alkaline earth metal hydroxide solution, filtering undissolved salts, evaporating the residue, and then drying the filtrate.
- sodium, potassium or calcium salts are prepared as a metal salt, but not limited thereto.
- the corresponding silver salts can be obtained by reacting alkali metal or alkaline earth metal salts with appropriate silver salts (e.g., silver nitrate).
- compositions of the compound of Formula 1 contain an acidic or basic group in the compound of Formula 1.
- the pharmaceutically acceptable salts include sodium, calcium, and potassium salts of a hydroxy group
- other pharmaceutically acceptable salts of an amino group include hydrobromide, sulfate, hydrogen sulfate, phosphate, hydrogen phosphate, dihydrogen phosphate, acetate, succinate, citrate, tartrate, lactate, mandelate, methanesulphonate(mesylate), /?-toluenesulphonate (tosylate), which can be prepared by the preparation method or process known in the art.
- the compound of Formula 1 has an asymmetric center, it can be present in the form of the optically different enantiomers, and the scope of the invention comprises all of the optically active isomers and R or S type stereoisomers and the mixtures thereof.
- the present invention comprises a racemic mixture, one or more enantiomer, one or more diastereo isomer or the mixture thereof, and the isolation and preparation method of isomer known in the art.
- the present invention provides a process for preparing a thienopyrimidine derivative of Formula 1.
- the thienopyrimidine derivative of Formula 1 is chemically prepared by the method described in the following Reaction Schemes, but not limited thereto. It will be understood that a thienopyrimidine derivative of Formula 1 of the present invention can be prepared by the various methods known in the art.
- reaction schemes show the steps for preparing the representative compounds of the present invention, and other compounds may also be prepared by ⁇ Reaction Scheme 1> through ⁇ Reaction Scheme 9> with appropriate modifications of reagents, solvents and procedures.
- Some compounds of the present invention were prepared by the methods, which are not described in ⁇ Reaction Scheme 1> through ⁇ Reaction Scheme 9>, and the methods thereof are described in detail in each Example.
- R , R , R and R are as defined in Formula 1.
- a ketone compound (I) is subjected to condensation reaction using a base such as malononitrile (II), acetate, ammonium acetate and benzylamine, or using an organic solvent such as benzene, toluene in the presence of 3-amino propionic acid to prepare a compound (III).
- a base such as malononitrile (II), acetate, ammonium acetate and benzylamine
- an organic solvent such as benzene, toluene in the presence of 3-amino propionic acid
- the compound (III) prepared in the first step is reacted with sulfur(S) in the presence of a base such as pyridine, piperidine, triethylamine to prepare a thiazole compound (IV).
- a base such as pyridine, piperidine, triethylamine
- an organic solvent such as ethanol, butanol, dioxane, tetrahydrofuran and the mixture thereof can be used and the reaction is performed at room temperature or under heating, preferably under heating.
- the compound (IV) prepared in the second step is reacted with a nitrile compound (V) and a hydrochloric solution in a sealed tube or replaced with hydrochloric acid gas to prepare a compound (VI).
- the reaction is performed using dioxane, tetrahydrofuran or the like, as an organic solvent which does not adversely affect the reaction, under heating.
- the amine compound (VI) prepared in the third step is converted to a chloro compound (VII), preferably which can be prepared by adding copper chloride in the presence of t-butylthionitrate, isoamyl nitrite or t-butyl nitrite or by adding sodium nitrite or potassium nitrite and then adding copper chloride in a hydrochloric solution.
- a chloro compound (VII) preferably which can be prepared by adding copper chloride in the presence of t-butylthionitrate, isoamyl nitrite or t-butyl nitrite or by adding sodium nitrite or potassium nitrite and then adding copper chloride in a hydrochloric solution.
- the reaction is performed using an aqueous solution, acetonitrile, dichloromethane, chloroform, dioxane, tetrahydrofuran or the like, as a sol vent which does not adversely affect the reaction. Further, the reaction is performed
- the chloro compound (VII) prepared in the fourth step is dissolved in an organic solvent, and then hydrazine hydrate is slowly added thereto to prepare a hydrazine compound (VIII).
- the reaction is performed using an aqueous solution, acetonitrile, tetrahydrofuran or the like, as a solvent which does not adversely affect the reaction. Further, the reaction is preferably performed, but not limited thereto, at room temperature or under heating.
- the hydrazine compound (VIII) prepared in the fifth step is dissolved in an organic solvent, then reacted with citraconic anhydride to prepare a compound (X).
- the reaction is performed using chloroform, dichloromethane, acetonitrile, tetrahydrofuran, 1,4-dioxane, diethylether or the like, as an organic solvent which does not adversely affect the reaction. Further, the reaction is preferably performed, but not limited thereto, at room temperature or under heating.
- the compound (X) prepared in the sixth step is dissolved in 1,4-dioxane or diethylether, then hydrochloric acid is added thereto to prepare a compound (XI). Further, the reaction is preferably performed, but not limited thereto, at cold or room temperature.
- a ketone compound (I) is subjected to condensation reaction using a base such as ethyl cyanoacetate (XII), acetate, ammonium acetate and benzylamine, or using an organic solvent such as benzene, toluene in the presence of 3-amino propionic acid to prepare a compound (XIII).
- a base such as ethyl cyanoacetate (XII), acetate, ammonium acetate and benzylamine, or using an organic solvent such as benzene, toluene in the presence of 3-amino propionic acid.
- the reaction is preferably performed at room temperature or under heating.
- the compound (XV) prepared in the third step is reacted in a phosphorous oxychloride solution to prepare a compound (VII).
- pen- tachlorophosphine or phenyldiethylamine may be added thereto to perform the reaction.
- the reaction can be performed without using any solvent or with a solvent, which does not adversely affect the reaction, such as dimethyl formamide. Further, the reaction is preferably performed, but not limited thereto, at room temperature or under heating.
- a ketone compound (XVI) and ethyl cyanoacetate (XII) are dissolved in an organic solvent, sulfur(S) is added thereto, and reacted using a base such as diethylamine, morpholine and triethylamine, or under the condition of ethy- lammonium acetate and l-butyl-3-methylimidazoliumtetrabutylfluororate to prepare a compound (XVII).
- the reaction can be performed using alcohol, dimethyl- formamide, 1,4-dioxane, benzene, 2-methylpropan-2-ol and the mixture thereof, as a solvent which does not adversely affect the reaction. Further, the reaction is preferably performed, but not limited thereto, at room temperature or under heating.
- the next step is a step for preparing a compound (XIX) using the compound (XVII) prepared in the first step.
- the reactions are carried out under the same condition as Reaction Scheme 2 for converting a compound (XIV) to a compound (XI).
- a compound (XX) is dissolved in formamide (XXI) and heated to prepare a compound (XXII).
- the reaction is performed under the same condition as Reaction Scheme 1 for converting a compound (VI) to a compound (XI), and in the case where R of the compound (XXII) is -OH, the reaction is preformed under the same condition as Reaction Scheme 2 for converting a compound (XV) to a compound (XI), to prepare a compound (XXIII).
- a carboxylic acid compound (XXIV) is dissolved in tetrahydrofuran, and then reacted with N,N-dimethylformamide-dimethyl sulfonate complex (Dionisia Sanz, et al., J. Org. Chem, 67, 1462-1471, 2002) in the presence of lithium diisopropylamide (LDA) to prepare an enamine compound (XXV).
- LDA lithium diisopropylamide
- the reaction can be performed using diethylether in addition to tetrahydrofuran as a solvent. Further, the reaction is generally performed at cold or room temperature.
- the compound (XXV) prepared in the first step is reacted with methyl cyanoacetate (XII) under the same condition as the first step of Reaction Scheme 2 to prepare a compound (XXVI).
- the reaction is performed with a compound (XXVI) under the same condition as Reaction Scheme 1 for converting a compound (XIV) to a compound (XI), to prepare a compound (XXVIII).
- the ketone compound (XXIX) is reacted under the general bromination condition to prepare a compound (XXX).
- the bromination is preformed using bromine (Br ), tribromophosphine (PBr ), pyridinium tribromide, N- bromosuccinimide (NBS), copper (I) bromide, copper (II) bromide or the like and using an acid such as acetic acid, hydrobromic acid (HBr) or using triethylamine, ammonium acetate, urea or the like.
- the reaction can be performed using alcohol, water, dimethyl formamide, tetrahydrofuran, diethylether, chloroform, tetra- chloromethane, benzene, ethylacetate or the like, as a solvent which does not adversely affect the reaction. Further, the reaction is performed, but not limited thereto, at cold or room temperature or under heating.
- the compound (XXX) prepared in the first step is reacted with malononitrile (II) using a base such as diethylamine, triethylamine, pyridine to prepare a compound (XXXI).
- a base such as diethylamine, triethylamine, pyridine
- the reaction can be performed using dimethyl formamide, tetrahydrofuran, chloroform, benzene or the like, as a solvent which does not adversely affect the reaction. Further, the reaction is performed, but not limited thereto, at room temperature or under heating.
- R , R , R and R are as defined in Formula 1.
- a compound (XXX) is reacted with ethyl cyanoacetate (XII) under the same condition as the first step of Reaction Scheme 6 to prepare a compound (XXXIV).
- the reaction is performed with a compound (XXXIV) under the same condition as Reaction Scheme 2 for converting a compound (XIV) to a compound (XI), to prepare a compound (XXXII).
- a ketone compound (XXXVI) is reacted with malononitrile (II) or ethyl cyanoacetate (XII) using a base such as diethylamine, triethylamine, pyridine to prepare a compound (XXXVII) or a compound (XXXVIII).
- a base such as diethylamine, triethylamine, pyridine
- the reaction can be performed using methanol, ethanol or the like, as a solvent which does not adversely affect the reaction. Further, the reaction is performed, but not limited thereto, at room temperature or under heating.
- Reaction Scheme 1 for converting a compound (IV) to a compound (XI), or a compound (XXXVIII) is reacted under the same condition as Reaction Scheme 2 for converting a compound (XIV) to a compound (XI), to prepare a compound (XXXIX).
- R , R and R are as defined in Formula 1, and X is O or S.
- Reaction Scheme 9> explains the process for preparing a compound (XLII) by reacting a compound (XL) with a compound (XLI). The reaction is preformed under the same condition as Reaction Scheme 1 for converting a compound (VIII) to a compound (X).
- the present invention provides a pharmaceutical composition for preventing and treating inflammatory diseases and cancers comprising a thienopyrimidine derivative of Formula 1, a pharmaceutically acceptable salt thereof, or an isomer thereof.
- the inflammatory diseases include the pain caused by arthritis, for example, rheumatoid arthritis, spondyloarthopathies, gout, osteoarthritis, systemic lupus erythematosus and juvenile arthritis.
- the inflammatory diseases or symptoms include, for example, myositis, gingivitis, synovitis, ankylosing spondylitis, burstitis, septic shock, burns, and injury.
- a pharmaceutical composition comprising the compound according to the present invention as an active ingredient is useful in treating inflammatory symptoms accompanied by diseases such as inflammatory bowel disease, Crohn's disease, Type I diabetes, and psoriasis, and in treating various types of cancer.
- the pharmaceutical composition comprising the compound of the present invention further includes suitable carriers, excipients or diluents according to the conventional methods.
- Examples of carriers, excipients, and diluents contained in the composition of the present invention include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, gum acacia, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil.
- composition comprising the compound of the present invention can be formulated, according to the conventional method, in the form of composition for the oral administrations such as powder, granule, tablet, capsule, suspension, emulsion, syrup, aerosol, medicines for external applications, suppository or injection solutions.
- a formulation can be prepared, according to the conventional method, using a diluent or an excipient such as a filler, an extender, a binding agent, a wetting agent, a disintegrating agent, and a surfactant.
- the solid preparation for oral administration includes tablet, pill, powder, granule, capsule, and can be prepared by mixing at least one of the excipient such as starch, calcium carbonate, sucrose, lactose, and gelatin.
- lubricants can be used such as magnesium stearate, talc.
- the liquid preparation for oral administration can include suspensions, liquid drugs, emulsions, and syrups, and include many excipients (e.g., wetting agent, sweetening agent, fragrant, preserving agent) other than commonly used simple diluents such as water, liquid paraffin.
- the preparation for parenteral administration contains sterilized solutions, non-aqueous solvents, suspensions, emulsifiers, freeze-drying agents or suppositories.
- the non-aqueous solvent or suspension solvent can include propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyloleate.
- the basic material of suppository includes witepsol, macrogol, Tween 61, cacao paper, laurin paper, or glycerogelatin.
- the desirable dose of the compounds according to the present invention varies depending on the condition and the weight of the subject, severity, drug form, route and period of administration, and may be chosen by those skilled in the art. However, in order to obtain desirable effects, it is generally recommended to administer at the amount of 0.0001 to 500 mg/kg, preferably 0.01 to 300 mg/kg. The dose may be administered in single or several times per day. In terms of composition, the compounds having Formula 1 can be present 0.0001 to 50% by weight based on the total weight of the composition.
- the compounds according to the present invention in pharmaceutical dosage forms may be used in the form of their pharmaceutically acceptable salts, and may also be used alone or in appropriate association, as well as in combination with other pharmaceutically active compounds.
- the pharmaceutical composition of the present invention can be administered to a subject animal such as mammals (rat, mouse, domestic animals or human) through various routes. All modes of administration are contemplated, for example, administration can be made orally, rectally or by intravenous, intramuscular, subcutaneous, intrathecal, epidural or intracerebroventricular injection. Mode for the Invention
- Example 8 (method 1) . l-(2,5-di-thiophen-2-yl-thieno[2,3-d] pyrimidin- 4-ylamino)-3-methyl-pyrrole-2,5-dione hydrochloride
- Example 12 (2,5-di-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-yl)-hydrazine hydrochloride [411]
- Example 13 3-methyl-l-(2-pyridin-4-yl-5-thiophen-2-yl-thieno[2,3-d] pyrimidin-4-ylamino)-pyrrole-2,5-dione hydrochloride [412]
- Example 14 l-[2-(4-methoxy-phenyl)-5-thiophen-2-yl-thieno[2,3-d] pyrimidin-
- Example 26 3-methyl-l-(2-thiophen-3-yl-5-thiophen-2-yl-thieno[2,3-d] pyrimidin-4-ylamino)-pyrrole-2,5-dione hydrochloride [470]
- Example 27 3-methyl-l-(2-thiophen-2-yl-5-thiophen-3-yl-thieno[2,3-d] pyrimidin-4-ylamino)-pyrrole-2,5-dione hydrochloride [471]
- Example 28 .
- Step 1 Preparation of 4-chloro-2-[4-(2-piperidin-l-yl-ethoxy)-phenyl1 - 5-thiophen-2-yl-thieno[2.3-d1pyrimidine [724]
- Step 4 Preparation of l-r6-(4-methoxy-phenylV5-methyl-2-thiophen-2-yl-thienor2.3-dlpyrimidin-4-ylaminol -3-methyl-pyrrole-2.5-dione hydrochloride
- Example 58 l-[6-(4-hydroxy-phenyl)-5-methyl-2-thiophen-2-yl-thieno[2,3-d] pyrimidin-4-ylamino] -3-methyl-pyrrole-2,5-dione hydrochloride [857]
- Example 59 l-[6-(4-hydroxy-phenyl)-5-methyl-2-thiophen-2-yl-thieno[2,3-d] pyrimidin-4-ylamino] -3-methyl-pyrrole-2,5-dione hydrochloride
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
The present invention relates to a novel thienopyrimidine derivative having an excellent anti¬ inflammatory and anti-cancer activity, or a pharmaceutically acceptable salt thereof, a process for the preparation thereof and a pharmaceutical composition comprising the same. The compound according to the present invention strongly inhibits IKB kinase-β (IKK-β) involved in the activation of a transcriptional factor, NF-ϰB, which is associated with inducing various immune and inflammatory diseases, whereby a composition comprising the compound is a useful therapeutic agent against inflammatory diseases, in particular, arthritis and cancer.
Description
Description
NOVEL THIENOPYRIMIDINE DERIVATIVES OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, PROCESS
FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME Technical Field
[1] The present invention relates to a novel thienopyrimidine derivative or a pharmaceutically acceptable salt thereof, a process for the preparation thereof and a pharmaceutical composition comprising the same. A thienopyrimidine derivative of the present invention inhibits the activity of IKB kinase-β (IKKβ or IKK-2), whereby it inhibits the activity of nuclear factor KB (NF-KB). Accordingly, it can be used for prevention or treatment of NF- KB -related diseases, in particular, inflammatory diseases and cancers. Background Art
[2] NF-κB (Nuclear Factor kappa B) is a transcription factor composed of a family of five related proteins called p50 subunit family (p50, p52) and p65 subunit family (p65, c-Rel, ReIB), which may form homodimers or heterodimers. Under normal conditions, NF-κB transcription factors are present in the cytoplasm in an inactive form associated with their inhibitory proteins, IKB protein (IκBα, IκBβ, IκBγ, IκBε and BcB) (Ghosh, S., et al. Annu Rev. Immunol . 16, 225-260, 1998). However, various stimuli such as various cytokines (e.g., TNF-α, IL-I), bacterial or viral infections (e.g., LPS, dsRNA), stress (e.g., ROI, UV, adriamycin, radiation), and oxidants activate IKB kinase complex composed of IKKα, IKKβ, NEMO (IKKγ) or the like. Subsequently, the activated IKB kinase complex phosphorylates at the two serine residues in the N- terminus of IKB proteins (IκBα phosphorylates at Ser32 and Ser36, IκBβ phosphorylates at Serl9 and Ser23), wherein the phosphorylation of IKB proteins triggers IKB ubiquitination and degradation via the ubiquitin-proteosome pathway (VJ. Palombella et al., Cell, 78, 773-785, 1994; Ghosh S. et al, Cell. 109, 81-96, 2002). The free NF-κB from IKB translocates to the nucleus and binds to NF-κB binding site (consensus sequence: 5'-GGGPuNNPyPyCC-3') of target genes, thereby initiating the transcription of the genes coding the immune and inflammatory response related proteins (Barnes PJ. et al. N. Engl. J. Med. 336, 1066-1071, 1997). Most of the genes regulated by NF- KB include proinflammatory mediators, cytokines, and cell adhesion molecules.
[3] Recently, intracellular functions and protein structures of IKKα and IKKβ have
been elucidated concretely. According to the recent report, IKK- β is thought to be a pivotal target in NF-κB activation pathway as an anti-inflammatory and anti-cancer therapeutic agent. The IKKβ inhibition appears, therefore, as an attractive strategy to increase the anti-inflammatory and anti-cancer effect.
[4] While the proteins, of which expressions are regulated by a transcription factor, NF-
KB, play key role in the normal physiological functions such as development and immune response, abnormal activation of NF-κB are associated with mutations in IKB protein, a translocation and amplification of NF-κB gene, and aberrant activation of IKK enzyme in inflammatory diseases such as arthritis, asthma (Yang L. et al., J. Exp. Med. 188, 1739-1750, 1998; Barnes P., et al, Trends Pharmacol, Therapeut. 18, 46-50, 1997), allergic rhinitis, atopic dermatitis, urticaria, systemic lupus erythematosus, psoriasis, ulcerative collitis, systemic inflammatory response, septic shock, polymyositis, polyarteritis nodosa, Alzheimer's disease (Keith T. Akama et al, Proc. Natl. Acad. ScL USA, 95, 5795-5800, 1998), as well as in various types of cancer such as skin cancer, solid tumors, blood cancer (Mercurio, F., et al., Oncogene, 18, 6163-6171, 1999; Rayet, B. et al., Oncogene, 18, 6938to6947, 1999). Further, NF- KB may be involved in the regulation of neural cell apoptosis. It has been found that NF-KB is activated and promotes cell death in focal cerebral ischemia (Schneider A. et al, Nature medicine Vol.5 No.5, 554-559, 1999). Accordingly, if the aberrant activation of NF-κB is regulated, it is possible to inhibit occurrence and progression of degenerative and rare diseases and to treat rare diseases caused by an aberrant apoptosis and inflammation.
[5] Example thereof includes rheumatism, which is one of degenerative diseases.
Rheumatism is characterized by inflammation and hyperplasia, in which NF- KB is involved. It has been known that NF-κB in the synoviocyte of rheumatoid synovium is activated by various stimuli, and the activated NF-κB expresses proinflammatory mediators and inhibits synoviocyte apoptosis at the same time, thereby inducing inflammation and hyperplasia (Berenbaum F., Curr Opin Rheumatol. 2004 Sep; 16(5): 616-22; Liu H., et al., Curr Opin Pharmacol. 2003 Jun;3(3):317-22.). It has been known that in an animal model of rheumatism, if the activation of NF- KB is inhibited by genetic manipulation or drugs, generation of proinflammatory mediators is reduced, and apoptosis increases, thus to significantly prevent both inflammation and hyperplasia.
[6] Conventionally, in order to treat such an arthritis, a chemotherapeutic cure has been adopted by using various types of drugs that contain a steroid anti-inflammatory agent such as cortisone and other adrenocortical hormones, a non-steroid anti-inflammatory agent such as asprin, pyrroxicam and indomethacin, an auric agent such as orothiomalic acid, an anti-rheumatoid agent such as chloroquinone and D-
phenisylamine, a gout inhibitor such as colchicin, and an immunosuppressant such as cyclophosphoamide, azathioprine, methotrexate and levamisol.
[7] However, the above chemotherapeutic drugs cannot treat the disease fundamentally and produces a lot of side-effects due to the medicine in the case where steroid hormones known as an arthritis drug are administered for the treatment. Accordingly, there are difficulties in using the above chemotherapeutic drugs for the treatment. The conventional chemotherapeutic drugs have problems such as a side-effect and a decreased effectiveness after being administered over a long period of time administration, a deficiency of anti-inflammation effect, a lack of efficacy toward already provoked arthritis and the like. At the present time, indomethacin, ibuprofen, which can soothe pains effectively during the treatment of arthritis, and various kinds of nonsteroid antiphlogistic agents are only prepared for the administration. Disclosure of Invention Technical Problem
[8] Therefore, it is necessary to solve these problems and to develop a new therapeutic agent for arthritis, which alleviates acute inflammation symptom and pain sufficiently. A drug without side-effect is strongly needed, since most drugs presently used have some sort of side-effect although the side-effect varies depending on their severities and individual differences, and it is usually administered over a long period of time in order to treat especially rheumatoid arthritis.
[9] The present inventors have made an effort to develop a substance having an excellent inhibitory activity against IKKβ, which is involved in inhibiting a transcriptional factor, NF-κB associated with inducing various immune and inflammatory diseases, and as a result, they have prepared a novel thienopyrimidine derivative. Further, they have found that the compound has an excellent inhibitory activity against IKKβ, thereby completing the present invention. Technical Solution
[10] The present invention provides a novel thienopyrimidine derivative having an excellent anti-inflammatory and anti-cancer activity, or a pharmaceutically acceptable salt thereof, a process for the preparation thereof and a pharmaceutical composition comprising the same. Brief Description of the Drawings
[11] Fig. 1 illustrates that an amount of TNF-α in the blood of inflammation-induced mice, in the case where the compounds of the present invention (Examples 84 to 85) were orally administrated to inflammation-induced mice at concentrations of 30 and 100 D/D, respectively, and then lipopolysaccharide was abdominally administrated. Best Mode for Carrying Out the Invention
[12] The present invention provides a novel thienopyrimidine derivative represented by the following Formula 1, which has an excellent anti-inflammatory and anti-cancer activity, a pharmaceutically acceptable salt thereof, or an isomer thereof.
[13] [Formula 1]
[14]
[15] wherein
[16] X is O, S or NH,
[17] R is hydrogen; linear or branched C to C alkyl; -(CH )n -OR; -(CH )n -COOR; C to C heteroaryl substituted or unsubstituted with C to C alkyl or halogen, which comprise one or two heteroatom(s) selected from the group consisting of S, O and N; or
[18] R is hydrogen; -(CH )n -Z; -(CH )n -OR; -(CH )n -COOR; -(CH )n -CONR'R"; -
Y-(CH 2 )n 1 -NR1R"; -Y-(CH 2 )n 1 -OR; -Y-(CH2 )n 1 -COOR; C 5 to C 20 heteroary Jl substituted or unsubstituted with C to C alkyl or halogen, which comprise one or two heteroatom(s) selected from the group consisting of S, O and N; or
[19] R is hydrogen; linear or branched C to C alkyl; linear or branched C to C
3 J to 1 10 J 2 10 alkenyl; C to C cycloalkyl; -CH -C to C cycloalkyl; -NR1R"; C to C heteroaryl or -CH -C to C heteroaryl substituted or unsubstituted with C to C alkyl or halogen, which comprise one or two heteroatom(s) selected from the group consisting of S, O and N,; or
^y-(CH2Jn1
[20] R and R are each independently H; =CH ; linear or branched C to C alkyl; halogen; -OR; or connected to each other to form C to C aryl, C to C cycloalkyl, or
6 20 5 7
C to C heterocyclic comprising one or two heteroatom(s) selected from the group consisting of N, O or S,
[21] R is H, or linear or branched C to C alkyl,
[22] R is H, -OH, -NO , linear or branched C to C alkyl, -Y-C to C alkyl, -NR1R", -
7 2 1 5 1 5
CN, -COOR, halogen, -Y-(CH )n -NR1R", -Y-(CH )n -OR, -Y-(CH )n -COOR, - Y-(CH )n -Z, -Y-(CH )n -M-R, -Y-(CH )n -M-(CH )n -NR1R", -Y-(CH )n -M-(CH )n -OR, -Y-(CH )n -M-(CH )n -COOR, -Y-(CH )n -M-(CH )n -CN or -Y-(CH )n -
2 2 2 3 2 2 2 3 2 2
M-(CH )n -Z, [23] R is H, linear or branched C to C alkyl, -OR, -NO , amine, mono- or di- alkylamine, -CN, -COOR, -0-(CH )n -NR1R", -0-(CH )n -OR, -0-(CH )n -COOR or - 0-(CH )n -Z,
2 2
[24] R is H, linear or branched C to C alkyl, -OR, -NO , amine, mono- or di- alkylamine, -CN, -COOR, -(CH^-NR'R", -(CH^-OR, -(CH^-COR, -(CH^ - COOR or -(CH 2 )n 2 -Z,
[25] R and R are each independently hydrogen, linear or branched C to C alkyl, or halogen, [26] R, R' and R" are each independently hydrogen, linear or branched C to C alkyl, or
-CH 2 CF 3 ;
[27] M is O, S or -NR-,
[28] Y is O, S, NH, -NH-CO- or -CO-NH-,
[29] Z is pyrrolidine; piperidine; piperazine; morpholine; thiomorpholine; 2- or
3-oxo-pyrrolidine; 2-, 3- or 4-oxo-piperidine; oxazole; triazole; pyridine; imidazole; imidazolidine; 2,5-dioxo-pyrrolidine; 2- or 3-oxo-piperazine;
2,5-dioxo-2,5-dihydro-pyrrole; 2-oxo-imidazolidine; 4,4-ethylenedioxy-piperidine; 2- or 3-thienyl; 2- or 3-furyl;
— N N-R0 or
[31]
[32] Preferably, in Formula 1,
[33] X is O or S,
[34] R is hydrogen, methyl, -(CH )n -OR, -(CH )n -COOR, thiophenyl or
^-(CH2Jn1
[35] R is hydrogen, -(CH )n -Z, -(CH )n -OR, -(CH )n -COOR, -(CH )n -CONR'R", -
Y-(CH )n -NR1R", thiophenyl or
[36] R is hydrogen, methyl, ethyl, propyl, isobutyl, t-butyl, 2-propenyl, cyclopropyl, -
CH -cyclopropyl, amine, 2-methylthiophenyl, -CH -thiophenyl, furanyl, pyridinyl or
^-(CH2Jn1
[37] R and R are each independently H, =CH methyl, F, Cl, Br, I, or connected to each other to form phenyl or pyridine, [38] R is H or methyl,
[39] R is H, -OH, -NO , methyl, -OCH , -NR1R", F, Cl, Br, I, -Y-(CH )n -NR1R", -
Y-(CH )n -OR, -Y-(CH )n -Z, -Y-(CH )n -M-(CH )n -NR1R", -Y-(CH )n -M-(CH )n -
2 2 2 2 2 2 2 3 2 2 2 3
OR, -Y-(CH )n -M-(CH )n -COOR, -Y-(CH )n -M-(CH )n -CN or -Y-(CH )n -M-(CH
2)n3-Z,
[40] R is H,
[41] R is H, methyl, butyl, -(CH )n -NR1R", -(CH )n -OR or -(CH )n -COR,
[42] R and R are each independently hydrogen,
[43] R, R' and R" are each independently hydrogen, methyl, ethyl, propyl, isopropyl, butyl, t-butyl, isopentyl or -CH CF , [44] M is O or -NR-,
[45] Y is O, -NH-CO- or -CO-NH-,
[46] Z is pyrrolidine, piperidine, piperazine, morpholine, thiomorpholine, 2- or
3-oxo-pyrrolidine, 2,5-dioxo-pyrrolidine, 2- or 3-oxo-piperazine, 2-oxo-imidazolidine,
— N N-R9 or
, and [47] n , n and n are each integer of 0 to 3.
1 2 3
[48]
[49] Preferred examples of the thienopyrimidine derivative of Formula 1 of the present invention include the following compounds, but are not limited thereto:
[50] 1) 3-methyl-l-(5-thiophen-2-yl-thieno[2,3-d] pyrimidin-
4-ylamino)-pyrrole-2,5-dione,
[51] 2) 3,4-dichloro-l-(5-thiophen-2-yl-thieno[2,3-d] pyrimidin-
4-ylamino)-pyrrole-2,5-dione hydrochloride,
[52] 3) 2-(5-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-ylamino)-isoindole-l,3-dione hydrochloride,
[53] 4) 2-(5-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-ylamino)-pyrrolo[3,4-c] pyridine-
1,3-dione hydrochloride,
[54] 5) 3-methyl-l-(5-thiophen-2-yl-thieno[2,3-d] pyrimidin-
4-ylamino)-pyrrole-2,5-dione hydrochloride,
[55] 6) l-(5-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-ylamino)-pyrrole-2,5-dione hydrochloride,
[56] 7) l-(2,6-di-thiophen-2-yl-thieno[2,3-d] pyrimidin-
4-ylamino)-3-methyl-pyrrole-2,5-dione hydrochloride,
[57] 8) l-(2,5-di-thiophen-2-yl-thieno[2,3-d] pyrimidin-
4-ylamino)-3-methyl-pyrrole-2,5-dione hydrochloride,
[58] 9) 3-methyl-l-[2-(5-methyl-thiophen-2-yl)-5-thiophen-2-yl-thieno[2,3-d] pyrimidin-
4-ylamino]-pyrrole-2,5-dione hydrochloride,
[59] 10) l-[5-(4-methoxy-phenyl)-2-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-ylamino] -
3-methyl-pyrrole-2,5-dione hydrochloride,
[60] 11) l-[5-(4-hydroxy-phenyl)-2-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-ylamino] -
3-methyl-pyrrole-2,5-dione hydrochloride,
[61] 12) (2,5-di-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-yl)-hydrazine hydrochloride,
[62] 13) 3-methyl-l-(2-pyridin-4-yl-5-thiophen-2-yl-thieno[2,3-d] pyrimidin-
4-ylamino)-pyrrole-2,5-dione hydrochloride, [63] 14) l-[2-(4-methoxy-phenyl)-5-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-ylamino] -
3-methyl-pyrrole-2,5-dione hydrochloride, [64] 15) 3-methyl-l-(5-thiophen-2-yl-2-p-tolyl-thieno[2,3-d] pyrimidin-
4-ylamino)-pyrrole-2,5-dione hydrochloride, [65] 16) 3-methyl-l-(5-thiophen-2-yl-2-thiophen-2-ylmethyl-thieno[2,3-d] pyrimidin-
4-ylamino)-pyrrole-2,5-dione hydrochloride, [66] 17) 3-methyl-l-(2-thiophen-2-yl-thieno[2,3-d] pyrimidin-
4-ylamino)-pyrrole-2,5-dione hydrochloride,
[67] 18) 3-methyl-l-(5-methyl-thieno[2,3-d]pyrimidin-4-ylamino)-pyrrole-2,5-dione hydrochloride, [68] 19) l-(2-benzyl-5-thiophen-2-yl-thieno[2,3-d] pyrimidin-
4-ylamino)-3-methyl-pyrrole-2,5-dione hydrochloride, [69] 20) 3-methyl-l-(5-methyl-2-thiophen-2-yl-thieno[2,3-d] pyrimidin-
4-ylamino)-pyrrole-2,5-dione hydrochloride, [70] 21) 3-methyl-l-(2-phenyl-5-thiophen-2-yl-thieno[2,3-d] pyrimidin-
4-ylamino)-pyrrole-2,5-dione, [71] 22) 3-methyl-l-(2-phenyl-5-thiophen-2-yl-thieno[2,3-d] pyrimidin-
4-ylamino)-pyrrole-2,5-dione hydrochloride, [72] 23) l-[2-(4-hydroxy-phenyl)-5-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-ylamino] -
3-methyl-pyrrole-2,5-dione hydrochloride, [73] 24) l-[2-(4-fluoro-phenyl)-5-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-ylamino] -
3-methyl-pyrrole-2,5-dione hydrochloride, [74] 25) l-[2-(3-fluoro-phenyl)-5-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-ylamino] -
3-methyl-pyrrole-2,5-dione hydrochloride, [75] 26) 3-methyl-l-(2-thiophen-3-yl-5-thiophen-2-yl-thieno[2,3-d] pyrimidin-
4-ylamino)-pyrrole-2,5-dione hydrochloride, [76] 27) 3-methyl-l-(2-thiophen-2-yl-5-thiophen-3-yl-thieno[2,3-d] pyrimidin-
4-ylamino)-pyrrole-2,5-dione hydrochloride, [77] 28) 3-methyl-l-(5-thiophen-2-yl-2-thiophen-3-ylmethyl-thieno[2,3-d] pyrimidin-
4-ylamino)-pyrrole-2,5-dione hydrochloride, [78] 29) 3-methyl-l-(5-phenyl-2-thiophen-2-yl-thieno[2,3-d] pyrimidin-
4-ylamino)-pyrrole-2,5-dione hydrochloride, [79] 30) 3-methyl-l-(2-thiophen-2-yl-5-p-tolyl-thieno[2,3-d] pyrimidin-
4-ylamino)-pyrrole-2,5-dione hydrochloride, [80] 31) l-[2-(4-methoxy-benzyl)-5-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-ylamino] -
3-methyl-pyrrole-2,5-dione hydrochloride,
[81] 32) l-[2-(4-diethylaminophenyl)-5-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-ylamino
] -3-methyl-pyrrole-2,5-dione hydrochloride, [82] 33) l-[2-(3-hydroxy-phenyl)-5-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-ylamino] -
3-methyl-pyrrole-2,5-dione hydrochloride, [83] 34) l-[2-(4-methoxy-phenyl)-5-phenyl-thieno[2,3-d]pyrimidin-4-ylamino] -
3-methyl-pyrrole-2,5-dione hydrochloride, [84] 35) l-[2-(3-methoxy-phenyl)-5-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-ylamino] -
3-methyl-pyrrole-2,5-dione hydrochloride, [85] 36) l-[2-(3-methoxy-phenyl)-5-phenyl-thieno[2,3-d]pyrimidin-4-ylamino] -
3-methyl-pyrrole-2,5-dione hydrochloride, [86] 37) l-[2-(3-fluoro-phenyl)-5-phenyl-thieno[2,3-d]pyrimidin-4-ylamino] -
3-methyl-pyrrole-2,5-dione hydrochloride, [87] 38) l-[2-(3-methoxy-benzyl)-5-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-ylamino] -
3-methyl-pyrrole-2,5-dione hydrochloride, [88] 39)
4-(3-methyl-2,5-dioxo-2,5-dihydro-pyrrole-l-ylamino)-2-thiophen-2-yl-thieno[2,3-d]p yrimidine-5-carboxylic acid ethyl ester hydrochloride, [89] 40) l-[5-(3-hydroxy-phenyl)-2-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-ylamino] -
3-methyl-pyrrole-2,5-dione hydrochloride, [90] 41) l-[5-(3-methoxy-phenyl)-2-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-ylamino] -
3-methyl-pyrrole-2,5-dione hydrochloride, [91] 42) l-[2-(4-dimethylamino-phenyl)-5-phenyl-thieno[2,3-d]pyrimidin-4-ylamino] -
3-methyl-pyrrole-2,5-dione hydrochloride, [92] 43) l-[2-(4-amino-phenyl)-5-phenyl-thieno[2,3-d]pyrimidin-4-ylamino] -
3-methyl-pyrrole-2,5-dione hydrochloride, [93] 44) l-(2-furan-2-yl-5-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-ylamino] -
3-methyl-pyrrole-2,5-dione hydrochloride, [94] 45) 3-methyl-l-(2-methyl-5-thiophen-2-yl-thieno[2,3-d] pyrimidin-
4-ylamino)-pyrrole-2,5-dione hydrochloride, [95] 46) l-[2-(4-amino-phenyl)-5-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-ylamino] -
3-methyl-pyrrole-2,5-dione hydrochloride, [96] 47) l-(2-amino-5-thiophen-2-yl-thieno[2,3-d] pyrimidin-
4-ylamino)-3-methyl-pyrrole-2,5-dione hydrochloride, [97] 48) l-(2-cyclopropyl-5-thiophen-2-yl-thieno[2,3-d] pyrimidin-
4-ylamino)-3-methyl-pyrrole-2,5-dione, [98] 49)
[4-(3-methyl-2,5-dioxo-2,5-dihydro-pyrrole-l-ylamino)-2-thiophen-2-yl-thieno[2,3-d] pyrimidin-5-yl] -acetic acid methyl ester hydrochloride,
[99] 50) l-(5-hydroxymethyl-2-thiophen-2-yl-thieno[2,3-d] pyrimidin-
4-ylamino)-3-methyl-pyrrole-2,5-dione hydrochloride, [100] 51) l-(5-methoxymethyl-2-thiophen-2-yl-thieno[2,3-d] pyrimidin-
4-ylamino)-3-methyl-pyrrole-2,5-dione hydrochloride, [101] 52) 3-methyl-l-{2-[4-(2-piperidin-l-yl-ethoxy)-phenyl] -
5-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-ylamino}-pyrrole-2,5-dione hydrochloride, [102] 53) 3-methyl-l-{2-[3-(2-piperidin-l-yl-ethoxy)-phenyl] -
5-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-ylamino}-pyrrole-2,5-dione hydrochloride, [103] 54) l-[6-(4-hydroxy-phenyl)-2-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-ylamino] -
3-methyl-pyrrole-2,5-dione hydrochloride, [104] 55) l-[6-(4-methoxy-phenyl)-2-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-ylamino] -
3-methyl-pyrrole-2,5-dione hydrochloride, [105] 56) l-{6-[4-(2-dimethylamino-ethoxy)phenyl]-5-methyl-2-thiophen-2-yl-furo[2,3-d
]pyrimidin-4-ylamino } -3-methyl-pyrrole-2,5-dione hydrochloride, [106] 57) l-[6-(4-methoxy-phenyl)-5-methyl-2-thiophen-2-yl-thieno[2,3-d] pyrimidin-
4-ylamino]-3-methyl-pyrrole-2,5-dione hydrochloride, [107] 58) l-[6-(4-hydroxy-phenyl)-5-methyl-2-thiophen-2-yl-thieno[2,3-d] pyrimidin-
4-ylamino]-3-methyl-pyrrole-2,5-dione hydrochloride, [108] 59) [5-methyl-4-(3-methyl-2,5-dioxo -
2,5-dihydro-pyrrole-l-ylamino)-2-thiophen-2-yl-thieno[2,3-d]pyrimidin-6-yl] -acetic acid methyl ester hydrochloride, [109] 60) l-[6-(3-hydroxy-phenyl)-5-methyl-2-thiophen-2-yl-thieno[2,3-d] pyrimidin-
4-ylamino]-3-methyl-pyrrole-2,5-dione, [110] 61)
5-methyl-4-(3-methyl-2,5-dioxo-2,5-dihydro-pyrrole-l-ylamino)-2-thiophen-2-yl-thien o[2,3-d]pyrimidine-6-carboxylic acid amide hydrochloride, [111] 62) l-[6-(3-methoxy-phenyl)-5-methyl-2-thiophen-2-yl-thieno[2,3-d] pyrimidin-
4-ylamino]-3-methyl-pyrrole-2,5-dione, [112] 63)
5-methyl-4-(3-methyl-2,5-dioxo-2,5-dihydro-pyrrole-l-ylamino)-2-thiophen-2-yl-thien o[2,3-d]pyrimidine-6-carboxylic acid methyl ester hydrochloride, [113] 64) l-(6-methoxy-5-methyl-2-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-ylamino] -
3-methyl-pyrrole-2,5-dione hydrochloride, [114] 65) l-[6-(4-methoxy-benzyl)-5-methyl-2-thiophen-2-yl-thieno[2,3-d] pyrimidin-
4-ylamino]-pyrrole-2,5-dione hydrochloride, [115] 66) l-[6-(4-hydroxy-benzyl)-5-methyl-2-thiophen-2-yl-thieno[2,3-d] pyrimidin-
4-ylamino]-pyrrole-2,5-dione hydrochloride, [116] 67) 3-methyl-l-[5-methyl-6-(4-nitrophenyl)-2-thiophen-2-yl-thieno[2,3-d]
pyrimidin-4-ylamino] -pyrrole-2,5-dione hydrochloride, [117] 68) 3-methyl-l-(6-phenyl-2-thiophen-2-yl-thieno[2,3-d] pyrimidin-
4-ylamino)-pyrrole-2,5-dione hydrochloride, [118] 69)
3-[5-methyl-4-(3-methyl-2,5-dioxo-2,5-dihydro-pyrrole-l-ylamino)-2-thiophen-2-yl-th ieno[2,3-d]pyrimidin-6-yl]-propionic acid ethyl ester, [119] 70) l-(6-hydroxymethyl-5-methyl-2-thiophen-2-yl-thieno[2,3-d] pyrimidin-
4-ylamino)-3-methyl-pyrrole-2,5-dione hydrochloride, [120] 71) l-(6-methoxymethyl-5-methyl-2-thiophen-2-yl-thieno[2,3-d] pyrimidin-
4-ylamino)-3-methyl-pyrrole-2,5-dione hydrochloride, [121] 72) l-[6-(3-methoxybenzyl)-5-methyl-2-thiophen-2-yl-thieno[2,3-d] pyrimidin-
4-ylamino]-3-methyl-pyrrole-2,5-dione hydrochloride, [122] 73) l-[6-(3-hydroxy-benzyl)-2-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-ylamino] -
3-methyl-pyrrole-2,5-dione hydrochloride, [123] 74) l-{6-[3-(2-dimethylamino-ethoxy)-benzyl]-2-thiophen-2-yl-thieno[2,3-d] pyrimidin-4-ylamino } -3-methyl-pyrrole-2,5-dione hydrochloride, [124] 75)
5-methyl-4-(3-methyl-2,5-dioxo-2,5-dihydro-pyrrole-l-ylamino)-2-thiophen-2-yl-thien o[2,3-d]pyrimidine-6-carboxylic acid-(2-dimethylamino-ethyl)-amide hydrochloride, [125] 76) 3-methyl-l-{5-[4-(2-piperidin-l-yl-ethoxy)-phenyl] -
2-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-ylamino}-pyrrole-2,5-dione hydrochloride, [126] 77) 3-methyl-l-{5-[3-(2-piperidin-l-yl-ethoxy)-phenyl] -
2-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-ylamino}-pyrrole-2,5-dione hydrochloride, [127] 78) l-{5-[3-(2-dimethylamino-ethoxy)-phenyl]-2-thiophen-2-yl-thieno[2,3-d] pyrimidin-4-ylamino } -3-methyl-pyrrole-2,5-dione hydrochloride, [128] 79) l-{5-[3-(3-dimethylamino-propoxy)-phenyl]-2-thiophen-2-yl-thieno[2,3-d] pyrimidin-4-ylamino } -3-methyl-pyrrole-2,5-dione hydrochloride, [129] 80) 3-methyl-l-{5-[3-(2-morpholin-4-yl-ethoxy)-phenyl] -
2-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-ylamino}-pyrrole-2,5-dione hydrochloride, [130] 81) 3-methyl-l-{5-[3-(2-piperazin-l-yl-ethoxy)-phenyl] -
2-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-ylamino}-pyrrole-2,5-dione dihydrochloride, [131] 82)
3-methyl-l-[5-methyl-6-(4-methyl-piperazin-l-ylmethyl)-2-thiophen-2-yl-thieno[2,3-d
]pyrimidin-4-ylamino] -pyrrole-2,5-dione dihydrochloride, [132] 83) 3-methyl-l-(5-{3-[2-(4-methyl-piperazin-l-yl)-ethoxy] - phenyl}-2-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-ylamino)-pyrrole-2,5-dione dihydrochloride, [133] 84) l-{6-[4-(2-dimethylamino-ethoxy)phenyl] -
5-methyl-2-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-ylamino}-3-methyl-pyrrole-2,5-di one hydrochloride, [134] 85) 3-methyl-l-{5-methyl-6-[4-(2-piperidin-l-yl-ethoxy)-phenyl] -
2-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-ylamino}-pyrrole-2,5-dione hydrochloride, [135] 86) l-{6-[4-(2-methoxy-ethoxy)-phenyl)-5-methyl-2-thiophen-2-yl-thieno[2,3-d] pyrimidin-4-ylamino] -3-methyl-pyrrole-2,5-dione hydrochloride, [136] 87) l-{6-[3-(2-methoxy-ethoxy)-phenyl]-5-methyl-2-thiophen-2-yl-thieno[2,3-d] pyrimidin-4-ylamino } -3-methyl-pyrrole-2,5-dione, [137] 88) 3-methyl-l-{5-methyl-6-[4-(2-morpholin-4-yl-ethoxy)-phenyl] -
2-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-ylamino}-pyrrole-2,5-dione hydrochloride, [138] 89) l-{2-t-butyl-6-[4-(2-dimethylamino-ethoxy)-phenyl]-5-methyl-thieno[2,3-d] pyrimidin-4-ylamino } -3-methyl-pyrrole-2,5-dione hydrochloride, [139] 90) l-{6-[4-(2-dimethylamino-ethoxy)-phenyl]-2-isobutyl-5-methyl-thieno[2,3-d] pyrimidin-4-ylamino } -3-methyl-pyrrole-2,5-dione hydrochloride, [140] 91) l-{2-allyl-6-[4-(2-dimethylamino-ethoxy)-phenyl]-5-methyl-thieno[2,3-d] pyrimidin-4-ylamino } -3-methyl-pyrrole-2,5-dione hydrochloride, [141] 92) 3-methyl-l-{5-methyl-6-[4-(2-piperazin-l-yl-ethoxy)-phenyl] -
2-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-ylamino}-pyrrole-2,5-dione hydrochloride, [142] 93) l-{6-[4-(3-dimethylamino-propoxy)-phenyl] -
5-methyl-2-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-ylamino}-3-methyl-pyrrole-2,5-di one hydrochloride, [143] 94) l-{6-[4-(2-amino-ethoxy)-phenyl]-5-methyl-2-thiophen-2-yl-thieno[2,3-d] pyrimidin-4-ylamino } -3-methyl-pyrrole-2,5-dione hydrochloride, [144] 95) l-{6-[4-(2-diethylamino-ethoxy)-phenyl]-2-thiophen-2-yl-thieno[2,3-d] pyrimidin-4-ylamino } -3-methyl-pyrrole-2,5-dione hydrochloride, [145] 96) 3-methyl-l-{5-methyl-6-[4-(2-pyrrolidin-l-yl-ethoxy)-phenyl] -
2-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-ylamino}-pyrrole-2,5-dione hydrochloride, [146] 97) 3-methyl-l-{5-methyl-6-[4-(2-(4-methyl piperazin-l-yl)-ethoxy)-phenyl] -
2-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-ylamino}-pyrrole-2,5-dione hydrochloride, [147] 98) l-(6-{4-[2-(ethyl-methyl-amino)-ethoxy] - phenyl}-5-methyl-2-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-ylamino)-3-methyl-pyrrol e-2,5-dione hydrochloride, [148] 99) 3-methyl-l-(5-methyl-6-{4-[2-(methyl-propyl-amino)-ethoxy] - phenyl}-2-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-ylamino)-pyrrole-2,5-dione hydrochloride, [149] 100) 3-methyl-l-(5-methyl-6-{4-[2-(2-oxo-pyrrolidin-l-yl)-ethoxy] - phenyl}-2-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-ylamino)-pyrrole-2,5-dione hydrochloride,
[150] 101) l-(6-{4-[2-(isopropyl-methyl-amino)-ethoxy] - phenyl}-5-methyl-2-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-ylamino)-3-methyl-pyrrol e-2,5-dione hydrochloride, [151] 102) 3-methyl-l-(5-methyl-6-{4-(2-thiomorpholin-4-yl-ethoxy)-phenyl] -
2-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-ylamino)-pyrrole-2,5-dione hydrochloride, [152] 103) l-{6-[4-(2-dimethylamino-ethoxy)-phenyl]-2,5-dimethyl-thieno[2,3-d] pyrimidin-4-ylamino } -3-methyl-pyrrole-2,5-dione hydrochloride, [153] 104) l-{6-[4-(2-dimethylamino-ethoxy)-phenyl]-5-methyl-2-propyl-thieno[2,3-d] pyrimidin-4-ylamino } -3-methyl-pyrrole-2,5-dione hydrochloride, [154] 105) l-{6-[4-(2-dimethylamino-ethoxy)-phenyl] -
5-methyl-2-cyclopropyl-thieno[2,3-d]pyrimidin-4-ylamino}-3-methyl-pyrrole-2,5-dion e hydrochloride, [155] 106) l-{6-[4-(2-dimethylamino-ethoxy)-phenyl]-5-methyl-2-ethyl-thieno[2,3-d] pyrimidin-4-ylamino } -3-methyl-pyrrole-2,5-dione hydrochloride, [156] 107) l-{2-cyclopropylmethyl-6-[4-(2-dimethylamino-ethoxy)-phenyl] -
5-methyl-thieno[2,3-d]pyrimidin-4-ylamino}-3-methyl-pyrrole-2,5-dione hydrochloride [157] 108) l-{6-[4-(2-dimethylamino-ethoxy)-phenyl] -
5-methyl-2-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-ylamino}-pyrrole-2,5-dione hydrochloride, [158] 109) l-{6-[4-(2-dimethylamino-ethoxy)-phenyl] -
5-methyl-2-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-ylamino}-3,4-dimethyl-pyrrole-2,5
-dione hydrochloride, [159] 110) 3,4-dichloro-l-{6-[4-(2-dimethylamino-ethoxy)-phenyl] -
5-methyl-2-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-ylamino}-pyrrole-2,5-dione hydrochloride, [160] 111) l-[6-(4-{2-[4-(2-amino-ethyl)-piperazin-l-yl] - ethoxy}-phenyl)-5-methyl-2-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-ylamino]-3-meth yl-pyrrole-2,5-dione hydrochloride, [161] 112) l-[6-(4-{2-[2-amino-ethyl)-methyl-amino] - ethoxy}-phenyl)-5-methyl-2-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-ylamino]-3-meth yl-pyrrole-2,5-dione hydrochloride, [162] 113) l-[6-(4-{2-[(2-dimethylamino-ethyl)-methyl-amino] - ethoxy}-phenyl)-5-methyl-2-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-ylamino]-3-meth yl-pyrrole-2,5-dione hydrochloride, [163] 114) l-[6-(4-{2-[4-(2-dimethylamino-ethyl)-piperazin-l-yl] - ethoxy}-phenyl)-5-methyl-2-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-ylamino]-3-meth yl-pyrrole-2,5-dione hydrochloride,
[164] 115) l-[6-(4-{2-[4-(2-methoxy-ethyl)-piperazin-l-yl] - ethoxy } -phenyl)-5-methyl-2-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-ylamino] -3-meth yl-pyrrole-2,5-dione hydrochloride, [165] 116) 3-methyl-l-(5-methyl-6-{4-[2-(2-piperazin-l-yl-ethoxy)-ethoxy] - phenyl}-2-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-ylamino)-pyrrole-2,5-dione hydrochloride, [166] 117) l-(6-{4-[2-(4-acetyl-piperazin-l-yl)-ethoxy] - phenyl}-5-methyl-2-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-ylamino)-3-methyl-pyrrol e-2,5-dione hydrochloride, [167] 118) l-(6-{4-[2-(2,5-dioxo-pyrrolidin-l-yl)-ethoxy] - phenyl}-5-methyl-2-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-ylamino)-3-methyl-pyrrol e-2,5-dione, [168] 119) l-[6-(4-{2-[4-(2-hydroxy-ethyl)-piperazin-l-yl] - ethoxy }-phenyl)-5-methyl-2-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-ylamino] -3-meth yl-pyrrole-2,5-dione hydrochloride, [169] 120) 3-methyl-l-(5-methyl-6-{4-[2-(3-oxo-piperazin-l-yl)-ethoxy] - phenyl}-2-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-ylamino)-pyrrole-2,5-dione hydrochloride, [170] 121) l-[6-(4-{2-[(2-hydroxy-ethyl)-methyl-amino] - ethoxy }-phenyl)-5-methyl-2-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-ylamino] -3-meth yl-pyrrole-2,5-dione hydrochloride, [171] 122) l-[6-(4-{2-[(2-methoxy-ethyl)-methyl-amino] - ethoxy }-phenyl)-5-methyl-2-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-ylamino] -3-meth yl-pyrrole-2,5-dione hydrochloride, [172] 123) l-(6-{4-[2-(l,4-dioxa-8-aza-spiro[4,5]dec-8-yl)-ethoxy] - phenyl}-5-methyl-2-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-ylamino)-3-methyl-pyrrol e-2,5-dione hydrochloride [173] 124) l-(6-{4-[2-(2,5-dioxo-2,5-dihydro-pyrrole-l-yl)-ethoxy] - phenyl}-5-methyl-2-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-ylamino)-3-methyl-pyrrol e-2,5-dione, [174] 125) 3-methyl-l-(5-methyl-6-{4-[2-(2-oxo-imidazolidin-l-yl)-ethoxy] - phenyl}-2-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-ylamino)-pyrrole-2,5-dione, [175] 126) l-{6-[4-(2-dimethylamino-ethoxy)-phenyl] -
5-ethyl-2-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-ylamino}-3-methyl-pyrrole-2,5-dion e hydrochloride, [176] 127) l-(6-{4-[2-(4-butyl-piperazin-l-yl)-ethoxy] - phenyl}-5-methyl-2-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-ylamino)-3-methyl-pyrrol e-2,5-dione dihydrochloride,
[177] 128) l-({6-[4-(2-dimethylamino-ethoxy)-phenyl] -
5-methyl-2-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-yl}-methyl-amino)-3-methyl-pyrro le-2,5-dione hydrochloride,
[178] 129) methyl-
(2-{4-[5-methyl-4-(3-methyl-2,5-dioxo-2,5-dihydro-pyrrol-l-ylamino)-2-thiophen-2-yl -thieno[2,3-d]pyrimidin-6-yl]-phenoxy}-ethyl)-carbamic acid ?-butyl ester,
[179] 130) 3-methyl-l-{5-methyl-6-[4-(2-methylamino-ethoxy)-phenyl] -
2-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-ylamino}-pyrrole-2,5-dione hydrochloride,
[180] 131) l-[6-(4-methoxy-phenyl)-5-methyl-2-thiophen-2-yl-thieno[2,3-d] pyrimidin-
4-ylamino]-3-methylene-pyrrolidine-2,5-dione,
[181] 132) 3-methylene-l-{5-methyl-6-[4-(2-methylamino-ethoxy)-phenyl] -
2-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-ylamino}-pyrrolidine-2,5-dione hydrochloride,
[182] 133) l-{6-[4-(2-butylamino-ethoxy)-phenyl]-5-methyl-2-thiophen-2-yl-thieno[2,3-d
]pyrimidin-4-ylamino } -3-methyl-pyrrole-2,5-dione hydrochloride,
[183] 134) l-[(6-{4-[2-(2-methoxy-ethylamino)-ethoxy] - phenyl}-5-methyl-2-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-yl)-methyl-amino]-3-meth yl-pyrrole-2,5-dione hydrochloride,
[184] 135) l-[(6-{4-[2-(2-hydroxy-ethylamino)-ethoxy] - phenyl}-5-methyl-2-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-yl)-methyl-amino]-3-meth yl-pyrrole-2,5-dione hydrochloride,
[185] 136) 3-methyl-l-(5-methyl-6-{4-[2-(3-methyl-butylamino)-ethoxy] - phenyl}-2-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-ylamino)-pyrrole-2,5-dione hydrochloride,
[186] 137)
3-methyl-l-(5-methyl-2-thiophen-2-yl-6-{4-[2-(2,2,2-trifluoro-ethylamino)-ethoxy]-ph enyl}-thieno[2,3-d]pyrimidin-4-ylamino)-pyrrole-2,5-dione hydrochloride,
[187] 138) 3-dimethylamino-JV -
{4-[5-methyl-4-(3-methyl-2,5-dioxo-2,5-dihydro-pyrrol-l-ylamino)-2-thiophen-2-yl-th ieno[2,3-d]pyrimidin-6-yl]-phenyl}-propionamide hydrochloride,
[188] 139)
3-[methyl-(2-{4-[5-methyl-4-(3-methyl-2,5-dioxo-2,5-dihydro-pyrrol-l-ylamino)-2-thi ophen-2-yl-thieno[2,3-d]pyrimidin-6-yl]-phenoxy}-ethyl)-amino] -propionic acid,
[189] 140) isopropyl-
(2-{4-[5-methyl-4-(3-methyl-2,5-dioxo-2,5-dihydro-pyrrol-l-ylamino)-2-thiophen-2-yl -thieno[2,3-d]pyrimidin-6-yl]-phenoxy}-ethyl)-carbamic acid ?-butyl ester,
[190] 141) l-{6-[4-(2-isopropylamino-ethoxy)-phenyl] -
5-methyl-2-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-ylamino}-3-methyl-pyrrole-2,5-di
one hydrochloride,
[191] 142) 3-methyl-l-{5-methyl-6-[4-(piperidin-4-yloxy)-phenyl] -
2-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-ylamino}-pyrrole-2,5-dione hydrochloride,
[192] 143) l-{6-[4-(2-benzylamino-ethoxy)-phenyl] -
5-methyl-2-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-ylamino}-3-methyl-pyrrole-2,5-di one hydrochloride, and
[193] 144)
3-(2-{4-[5-methyl-4-(3-methyl-2,5-dioxo-2,5-dihydro-pyrrol-l-ylamino)-2-thiophen-2- yl-thieno[2,3-d]pyrimidin-6-yl] -phenoxy } -ethylamino)-propionitrile hydrochloride.
[194]
[195] The compounds of Formula 1 of the present invention can be prepared in the form of their pharmaceutically acceptable salts and solvates by a conventional method known in the art.
[196] The acid addition salt formed by a pharmaceutically acceptable free acid thereof is useful. The acid addition salt is prepared by a conventional method, for example, a method in which a compound is dissolved in an excessive amount of an acid solution, and then a salt is precipitated in a water miscible organic solvent, such as methanol, ethanol, acetone and acetonitrile. Acid or alcohol (for example, glycol monomethylether) in the same molar amount of compound and water is heated and the mixture is evaporated and dried, or the precipitated salt can be subjected to suction filtration.
[197] At this time, as a free acid, an organic acid and inorganic acid can be used.
Examples of the inorganic acid include hydrochloric acid, phosphoric acid, sulfuric acid, nitric acid, and tartaric acid, and examples of the organic acid include methane- sulphonic acid, /?-toluenesulphonic acid, acetic acid, trifluoroacetic acid, maleic acid, succinic acid, oxalic acid, benzoic acid, tartaric acid, fumaric acid, mandelic acid, propionic acid, citric acid, lactic acid, glycolic acid, gluconic acid, galacturonic acid, glutamic acid, glutaric acid, glucuronic acid, aspartic acid, ascorbic acid, carboxylic acid, vanillic acid, and hydroiodic acid, but not limited thereto.
[198] Further, a pharmaceutically acceptable metal salt can be prepared with a base. An alkali metal or alkaline earth metal salt can be obtained by the method, for example, a method comprising dissolving a compound in an excessive amount of an alkali metal hydroxide or alkaline earth metal hydroxide solution, filtering undissolved salts, evaporating the residue, and then drying the filtrate. At this time, it is pharmaceutically acceptable that sodium, potassium or calcium salts are prepared as a metal salt, but not limited thereto. Further, the corresponding silver salts can be obtained by reacting alkali metal or alkaline earth metal salts with appropriate silver salts (e.g., silver nitrate).
[199] Pharmaceutically acceptable salts of the compound of Formula 1, if it is not indicated specifically herein, contain an acidic or basic group in the compound of Formula 1. For example, the pharmaceutically acceptable salts include sodium, calcium, and potassium salts of a hydroxy group, and other pharmaceutically acceptable salts of an amino group include hydrobromide, sulfate, hydrogen sulfate, phosphate, hydrogen phosphate, dihydrogen phosphate, acetate, succinate, citrate, tartrate, lactate, mandelate, methanesulphonate(mesylate), /?-toluenesulphonate (tosylate), which can be prepared by the preparation method or process known in the art.
[200] Further, since the compound of Formula 1 has an asymmetric center, it can be present in the form of the optically different enantiomers, and the scope of the invention comprises all of the optically active isomers and R or S type stereoisomers and the mixtures thereof. The present invention comprises a racemic mixture, one or more enantiomer, one or more diastereo isomer or the mixture thereof, and the isolation and preparation method of isomer known in the art.
[201]
[202] Further, the present invention provides a process for preparing a thienopyrimidine derivative of Formula 1. The thienopyrimidine derivative of Formula 1 is chemically prepared by the method described in the following Reaction Schemes, but not limited thereto. It will be understood that a thienopyrimidine derivative of Formula 1 of the present invention can be prepared by the various methods known in the art.
[203] The reaction schemes show the steps for preparing the representative compounds of the present invention, and other compounds may also be prepared by <Reaction Scheme 1> through <Reaction Scheme 9> with appropriate modifications of reagents, solvents and procedures. Some compounds of the present invention were prepared by the methods, which are not described in <Reaction Scheme 1> through <Reaction Scheme 9>, and the methods thereof are described in detail in each Example.
[204] [Reaction Scheme 1]
[205]
IV
ViIi x xi
[206] wherein R , R , R and R are as defined in Formula 1.
1 3 4 5
[207] <Reaction Scheme 1> explains the process for preparing a compound (XI) consisting of seven steps using a ketone compound (I), which is commercially available or prepared by a method known in the art, as a starting material.
[208] At the first step, a ketone compound (I) is subjected to condensation reaction using a base such as malononitrile (II), acetate, ammonium acetate and benzylamine, or using an organic solvent such as benzene, toluene in the presence of 3-amino propionic acid to prepare a compound (III). In this step, the reaction is preferably carried out under heating.
[209] At the second step, the compound (III) prepared in the first step is reacted with sulfur(S) in the presence of a base such as pyridine, piperidine, triethylamine to prepare a thiazole compound (IV). At this time, as an organic solvent, an alcohol solvent such as ethanol, butanol, dioxane, tetrahydrofuran and the mixture thereof can be used and the reaction is performed at room temperature or under heating, preferably under heating.
[210] At the third step, the compound (IV) prepared in the second step is reacted with a nitrile compound (V) and a hydrochloric solution in a sealed tube or replaced with hydrochloric acid gas to prepare a compound (VI). At this time, the reaction is performed using dioxane, tetrahydrofuran or the like, as an organic solvent which does not adversely affect the reaction, under heating.
[211] At the fourth step, the amine compound (VI) prepared in the third step is converted to a chloro compound (VII), preferably which can be prepared by adding copper chloride in the presence of t-butylthionitrate, isoamyl nitrite or t-butyl nitrite or by adding sodium nitrite or potassium nitrite and then adding copper chloride in a hydrochloric solution. At this time, the reaction is performed using an aqueous solution,
acetonitrile, dichloromethane, chloroform, dioxane, tetrahydrofuran or the like, as a sol vent which does not adversely affect the reaction. Further, the reaction is performed, but not limited thereto, under heating.
[212] At the fifth step, the chloro compound (VII) prepared in the fourth step is dissolved in an organic solvent, and then hydrazine hydrate is slowly added thereto to prepare a hydrazine compound (VIII). At this time, the reaction is performed using an aqueous solution, acetonitrile, tetrahydrofuran or the like, as a solvent which does not adversely affect the reaction. Further, the reaction is preferably performed, but not limited thereto, at room temperature or under heating.
[213] At the sixth step, the hydrazine compound (VIII) prepared in the fifth step is dissolved in an organic solvent, then reacted with citraconic anhydride to prepare a compound (X). At this time, the reaction is performed using chloroform, dichloromethane, acetonitrile, tetrahydrofuran, 1,4-dioxane, diethylether or the like, as an organic solvent which does not adversely affect the reaction. Further, the reaction is preferably performed, but not limited thereto, at room temperature or under heating.
[214] In the seventh step, the compound (X) prepared in the sixth step is dissolved in 1,4-dioxane or diethylether, then hydrochloric acid is added thereto to prepare a compound (XI). Further, the reaction is preferably performed, but not limited thereto, at cold or room temperature.
[215] [Reaction Scheme 2] [216]
0 EtOOC^CN R1 n JL + NC-^-COOEt if
Q- NH2
XIV
XV VII
[217] wherein R , R , R and R are as defined in Formula 1.
1 3 4 5
[218] <Reaction Scheme 2> explains the process for preparing a compound (XI) consisting of 7 steps using a ketone compound (I), which is commercially available or prepared by the method known in the art, as a starting material.
[219] At the first step, a ketone compound (I) is subjected to condensation reaction using
a base such as ethyl cyanoacetate (XII), acetate, ammonium acetate and benzylamine, or using an organic solvent such as benzene, toluene in the presence of 3-amino propionic acid to prepare a compound (XIII). In this time, the reaction is preferably performed at room temperature or under heating.
[220] At the next step, the compound (XIII) prepared in the first step is reacted under the same conditions as the second and third step of Reaction Scheme 1 to prepare a compound (XV).
[221] At the fourth step, the compound (XV) prepared in the third step is reacted in a phosphorous oxychloride solution to prepare a compound (VII). At this time, pen- tachlorophosphine or phenyldiethylamine may be added thereto to perform the reaction. The reaction can be performed without using any solvent or with a solvent, which does not adversely affect the reaction, such as dimethyl formamide. Further, the reaction is preferably performed, but not limited thereto, at room temperature or under heating.
[222] At the fifth, sixth and seventh step, the compound (VII) prepared in the fourth step is reacted under the same conditions as the fifth, sixth and seventh of Reaction Scheme 1 to prepare a compound (XI).
[223] [Reaction Scheme 3]
[224]
XVIII XIX
[225] wherein R , R , R and R are as defined in Formula 1.
2 3 4 5
[226] <Reaction Scheme 3> explains the process for preparing a compound (XIX) using a ketone compound (XVI), which is commercially available or prepared by the method known in the art, as a starting material.
[227] At the first step, a ketone compound (XVI) and ethyl cyanoacetate (XII) are dissolved in an organic solvent, sulfur(S) is added thereto, and reacted using a base such as diethylamine, morpholine and triethylamine, or under the condition of ethy- lammonium acetate and l-butyl-3-methylimidazoliumtetrabutylfluororate to prepare a compound (XVII). At this time, the reaction can be performed using alcohol, dimethyl- formamide, 1,4-dioxane, benzene, 2-methylpropan-2-ol and the mixture thereof, as a solvent which does not adversely affect the reaction. Further, the reaction is preferably
performed, but not limited thereto, at room temperature or under heating.
[228] The next step is a step for preparing a compound (XIX) using the compound (XVII) prepared in the first step. The reactions are carried out under the same condition as Reaction Scheme 2 for converting a compound (XIV) to a compound (XI).
[229] [Reaction Scheme 4] [230]
(R8= CN, COOR) (R7= NH2, OH)
[231] wherein R 1 , R2 , R 4 and R 5 are as defined in Formula 1. [232] <Reaction Scheme 4> explains the process for preparing a compound (XXIII) using a compound (XX), which can be commercially available or prepared by the methods of Reaction Schemes 1, 2 and 3.
[233] At the first step, a compound (XX) is dissolved in formamide (XXI) and heated to prepare a compound (XXII). At the next step, in the case where R of the compound (XXII) is -NH , the reaction is performed under the same condition as Reaction Scheme 1 for converting a compound (VI) to a compound (XI), and in the case where R of the compound (XXII) is -OH, the reaction is preformed under the same condition as Reaction Scheme 2 for converting a compound (XV) to a compound (XI), to prepare a compound (XXIII).
[234] [Reaction Scheme 5] [235]
[236] wherein R 2 , R 3 , R 4 and R 5 are as defined in Formula 1. [237] <Reaction Scheme 5> explains the process for preparing a compound (XXVIII) using a compound (XXIV), which is commercially available or prepared by the method known in the art.
[238] At the first step, a carboxylic acid compound (XXIV) is dissolved in
tetrahydrofuran, and then reacted with N,N-dimethylformamide-dimethyl sulfonate complex (Dionisia Sanz, et al., J. Org. Chem, 67, 1462-1471, 2002) in the presence of lithium diisopropylamide (LDA) to prepare an enamine compound (XXV). At this time, the reaction can be performed using diethylether in addition to tetrahydrofuran as a solvent. Further, the reaction is generally performed at cold or room temperature.
[239] In the second step, the compound (XXV) prepared in the first step is reacted with methyl cyanoacetate (XII) under the same condition as the first step of Reaction Scheme 2 to prepare a compound (XXVI). At the next step, the reaction is performed with a compound (XXVI) under the same condition as Reaction Scheme 1 for converting a compound (XIV) to a compound (XI), to prepare a compound (XXVIII).
[240] [Reaction Scheme 6]
[241]
[242] wherein R , R , R , R and R are as defined in Formula 1.
1 2 3 4 5
[243] <Reaction Scheme 6> explains the process for preparing a compound (XXXIII) using a ketone compound (XXIX), which is commercially available or prepared by the method known in the art.
[244] At the first step, the ketone compound (XXIX) is reacted under the general bromination condition to prepare a compound (XXX). At this time, the bromination is preformed using bromine (Br ), tribromophosphine (PBr ), pyridinium tribromide, N- bromosuccinimide (NBS), copper (I) bromide, copper (II) bromide or the like and using an acid such as acetic acid, hydrobromic acid (HBr) or using triethylamine, ammonium acetate, urea or the like. At this time, the reaction can be performed using alcohol, water, dimethyl formamide, tetrahydrofuran, diethylether, chloroform, tetra- chloromethane, benzene, ethylacetate or the like, as a solvent which does not adversely affect the reaction. Further, the reaction is performed, but not limited thereto, at cold or room temperature or under heating.
[245] In the second step, the compound (XXX) prepared in the first step is reacted with malononitrile (II) using a base such as diethylamine, triethylamine, pyridine to prepare a compound (XXXI). At this time, the reaction can be performed using dimethyl
formamide, tetrahydrofuran, chloroform, benzene or the like, as a solvent which does not adversely affect the reaction. Further, the reaction is performed, but not limited thereto, at room temperature or under heating. [246] At the next step, the reaction is performed with a compound (XXXI) under the same condition as Reaction Scheme 1 for converting a compound (IV) to a compound (XI), to prepare a compound (XXXIII). [247] [Reaction Scheme 7]
[248]
[249] wherein R , R , R , R and R are as defined in Formula 1.
1 2 3 4 5
[250] <Reaction Scheme 7> explains the process for preparing a compound (XXXII) using the compound (XXX) prepared in the first step of Reaction Scheme 6.
[251] At the first step, a compound (XXX) is reacted with ethyl cyanoacetate (XII) under the same condition as the first step of Reaction Scheme 6 to prepare a compound (XXXIV). At the next step, the reaction is performed with a compound (XXXIV) under the same condition as Reaction Scheme 2 for converting a compound (XIV) to a compound (XI), to prepare a compound (XXXII).
[252] [Reaction Scheme 8]
[253]
R A ° /OH — J
XXXVIII
[254] wherein R , R , R and R are as defined in Formula 1.
1 3 4 5
[255] <Reaction Scheme 8> explains the process for preparing a compound (XXXIX) using a ketone compound (XXXVI), which is commercially available or prepared by the method known in the art.
[256] At the first step, a ketone compound (XXXVI) is reacted with malononitrile (II) or
ethyl cyanoacetate (XII) using a base such as diethylamine, triethylamine, pyridine to prepare a compound (XXXVII) or a compound (XXXVIII). At this time, the reaction can be performed using methanol, ethanol or the like, as a solvent which does not adversely affect the reaction. Further, the reaction is performed, but not limited thereto, at room temperature or under heating.
[257] At the next step, a compound (XXXVII) is reacted under the same condition as
Reaction Scheme 1 for converting a compound (IV) to a compound (XI), or a compound (XXXVIII) is reacted under the same condition as Reaction Scheme 2 for converting a compound (XIV) to a compound (XI), to prepare a compound (XXXIX).
[258] [Reaction Scheme 9]
[259]
XL XLII
[260] wherein R , R and R are as defined in Formula 1, and X is O or S.
[261] <Reaction Scheme 9> explains the process for preparing a compound (XLII) by reacting a compound (XL) with a compound (XLI). The reaction is preformed under the same condition as Reaction Scheme 1 for converting a compound (VIII) to a compound (X).
[262]
[263] Further, the present invention provides a pharmaceutical composition for preventing and treating inflammatory diseases and cancers comprising a thienopyrimidine derivative of Formula 1, a pharmaceutically acceptable salt thereof, or an isomer thereof.
[264] The inflammatory diseases include the pain caused by arthritis, for example, rheumatoid arthritis, spondyloarthopathies, gout, osteoarthritis, systemic lupus erythematosus and juvenile arthritis.
[265] The inflammatory diseases or symptoms include, for example, myositis, gingivitis, synovitis, ankylosing spondylitis, burstitis, septic shock, burns, and injury.
[266] In a specific embodiment, a pharmaceutical composition comprising the compound according to the present invention as an active ingredient is useful in treating inflammatory symptoms accompanied by diseases such as inflammatory bowel disease, Crohn's disease, Type I diabetes, and psoriasis, and in treating various types of cancer.
[267] In a preferred embodiment, the pharmaceutical composition comprising the compound of the present invention further includes suitable carriers, excipients or
diluents according to the conventional methods.
[268] Examples of carriers, excipients, and diluents contained in the composition of the present invention include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, gum acacia, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil.
[269] The composition comprising the compound of the present invention can be formulated, according to the conventional method, in the form of composition for the oral administrations such as powder, granule, tablet, capsule, suspension, emulsion, syrup, aerosol, medicines for external applications, suppository or injection solutions.
[270] Specifically, a formulation can be prepared, according to the conventional method, using a diluent or an excipient such as a filler, an extender, a binding agent, a wetting agent, a disintegrating agent, and a surfactant. The solid preparation for oral administration includes tablet, pill, powder, granule, capsule, and can be prepared by mixing at least one of the excipient such as starch, calcium carbonate, sucrose, lactose, and gelatin. Further, in addition to a simple excipient, lubricants can be used such as magnesium stearate, talc. The liquid preparation for oral administration can include suspensions, liquid drugs, emulsions, and syrups, and include many excipients (e.g., wetting agent, sweetening agent, fragrant, preserving agent) other than commonly used simple diluents such as water, liquid paraffin. The preparation for parenteral administration contains sterilized solutions, non-aqueous solvents, suspensions, emulsifiers, freeze-drying agents or suppositories. The non-aqueous solvent or suspension solvent can include propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyloleate. The basic material of suppository includes witepsol, macrogol, Tween 61, cacao paper, laurin paper, or glycerogelatin.
[271] The desirable dose of the compounds according to the present invention varies depending on the condition and the weight of the subject, severity, drug form, route and period of administration, and may be chosen by those skilled in the art. However, in order to obtain desirable effects, it is generally recommended to administer at the amount of 0.0001 to 500 mg/kg, preferably 0.01 to 300 mg/kg. The dose may be administered in single or several times per day. In terms of composition, the compounds having Formula 1 can be present 0.0001 to 50% by weight based on the total weight of the composition.
[272] Further, the compounds according to the present invention in pharmaceutical dosage forms may be used in the form of their pharmaceutically acceptable salts, and may also be used alone or in appropriate association, as well as in combination with other pharmaceutically active compounds.
[273] The pharmaceutical composition of the present invention can be administered to a subject animal such as mammals (rat, mouse, domestic animals or human) through various routes. All modes of administration are contemplated, for example, administration can be made orally, rectally or by intravenous, intramuscular, subcutaneous, intrathecal, epidural or intracerebroventricular injection. Mode for the Invention
[274] Herein, the present invention will be described in more detail with reference to
Examples. Examples are provided only for the purpose of illustrating the present invention, and accordingly it is not intended that the present invention is limited thereto.
[275] Example 1 . 3-Methyl-l-(5-thiophen-2-yl-thieno[2,3-d] pyrimidin-
4-ylamino)-pyrrole-2,5-dione
[276] Step 1. Preparation of 2-(l-thiophen-2-yl-ethylidene)-malononitrile
[277]
[278] 2-Acetylthiophene (500mg, 3.96mmol), malononitrile (300mg, 4.75mmol), ammonium acetate (915mg, 12mmol) and acetic acid (0.7ml, 12mmol) were dissolved in toluene (20ml). The reaction mixture was refluxed for 16 hours. After reaction, reaction mixture was poured into ethyl acetate, and washed with water and IM HCl aquous solution. Combined organic layer was dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was purified by column chromatography (n-hexane: ethyl acetate = 5:1) to give 350mg (yield: 51%, brown oil) of the target compound.
[279] 1U NMR(400D, CDCI); δ 8.05(d, J=4.0Hz, IH), 7.80(d, J=4.8Hz, IH), 7.80(t, J
=4.4Hz, IH), 2.71 (s, 3H).
[280]
[281] Step 2. Preparation of 5'-amino-[2.3'1bithiophenlv-4'-carbonitrile
[282]
2.06mmol) were dissolved in ethanol (20ml). Therein, piperidine (0.2mL, 2.06mmol) was added, and the reaction mixture was stirred at 8O0C for 5 hours. After reaction,
reaction mixture was poured into ethyl acetate, and washed with water and saturated ammonium chloride aqueous solution. Combined organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by column chromatography (n-hexane: ethyl acetate = 5:1) to give 230mg (yield: 65%, yellow oil) of the target compound.
[284] 1U NMR(400D, CDCI); δ 7.45(d, J=3.6Hz, IH), 7.26(d, J=4.4Hz, 2H), 7.05(dd, J
=3.6Hz, J=4.8Hz, IH), 4.92(s, 2H).
[285]
[286] Step 3. Preparation of 5-thiophen-2-yl-thieno[2.3-dlpyrimidin-4-ylamine
[287]
[288] The compound (lOOmg, 0.48mmol) prepared in the step 2 was dissolved in formamide (3ml). The reaction mixture was stirred at 18O0C for 18 hours. After reaction, the reaction mixture was poured into ethyl acetate, and washed with water and saturated sodium hydrogen carbonate aqueous solution. Combined organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by column chromatography (n-hexane: ethyl acetate = 1:2) to give 40mg (yield: 35%, white solid) of the target compound.
[289] 1U NMR(400D, CDCI); δ 8.44(s, IH), 7.43(t, J=3.6Hz, IH), 7.26(s, IH), 7.15(d, J
=3.2Hz, 2H), 5.77(br, 2H).
[290]
[291] Step 4. Preparation of 4-chloro-5-thiophen-2-yl-thienor2.3-dlpyrimidine
[292]
[293] Copper chloride (69mg, 0.51mmol) and ?-butyl nitrite (76D, 0.64mmol) were dissolved in acetonitrile (5ml). The reaction mixture was stirred at 7O0C for 30 minutes. Therein, the compound (lOOmg, 0.43mmol) prepared in the step 3 which was dissolved in THF (2ml) was slowly added, and the reaction mixture was stirred at the same temperature for 2 hours. Thereafter, the reaction mixture was cooled at room temperature, and poured into ethyl acetate(lθml) and washed with water and sodium chloride aqueous solution. Combined organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by column
chromatography (n-hexane: ethyl acetate = 51:1) to give 62mg (yield: 57%, white solid) of the target compound. [294] 1U NMR(400D, CDCI); δ 8.88(s, IH), 7.62(s, IH), 7.43(d, IH, J=4.8Hz), 7.15(d, J
=4.0Hz, IH), 7.12(dd, J=3.2Hz, J=5.2Hz, IH). [295] [296] Step 5. Preparation of 3-methyl-l-(5-thiophen-2-yl-thieno[2.3-d1 pyrimidin-
4-ylaminos)-pyrrole-2.5-dione [297]
[298] The compound (70mg, 0.28mmol) prepared in the step 4 was dissolved in THF
(5ml). Therein, hydrazine monohydrate (27D, 0.56mmol) was slowly added, and the reaction mixture was stirred at 8O0C for 4 hours. After reaction, the solvent was removed under reduced pressure, and dried in vacuum drier. The residue was dissolved in chloroform, therein citraconic anhydride (75D, 0.84mmol) was slowly added, and the reaction mixture was stirred at 8O0C for 20 hours. The reaction mixture was washed with water and saturated sodium chloride aqueous solution. Combined organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by column chromatography (n-hexane: ethyl acetate = 1:1) to give 51mg (yield: 54%, white solid) of the target compound.
[299] 1U NMR(400D, CDCI); δ 8.50(s, IH), 7.43(d, J=4.8Hz, IH), 7.38(s, IH), 7.34(d, J
=4.0Hz, IH), 7.14(m, 2H), 6.49(s, IH), 2.16(d, J=1.6Hz, 3H).
[300]
[301] Example 2 . 3,4-dichloro-l-(5-thiophen-2-yl-thieno[2,3-d] pyrimidin-
4-ylamino)-pyrrole-2,5-dione hydrochloride
[302]
[303] Step 1. Preparation of 3.4-dichloro-l-(5-thiophen-2-yl-thieno[2.3-d1 pyrimidin-
4-ylaminos)-pyrrole-2-5-dione
[304] According to the similar procedure in the step 5 of example 1 by using the compound prepared in the step 4 of example 1 and 3,4-dichlorofuran-2-5-dione, 27mg (yield for 2 steps: 34%, yellow solid) of the target compound was obtained.
[305] 1U NMR(400D, CDCI); δ 8.54(s, IH), 7.47(d, J=5.2Hz, IH), 7.43(s, IH), 7.33(d, J
=3.2Hz, IH), 7.20-7.18(m, 2H). [306] [307] Step 2. Preparation of 3.4-dichloro-l-(5-thiophen-2-yl-thieno[2.3-dl pyrimidin-
4- ylamino)-pyrrole-2-5-dione hydrochloride [308] The compound (27mg, 0.068mmol) prepared in the step 1 was dissolved in 4N HCl
1,4-dioxane solution, and the reaction mixture was stirred at room temperature for 18 hours. After reaction, the reaction mixture was filtered to give 12mg (yield: 41%, yellow solid) of the target compound. [309] 1U NMR(400D, DMSO-d): δ 8.45(s, IH), 8.32(s, IH), 7.84(s, IH), 7.67-7.66(m,
IH), 7.34-7.33(m, IH), 7.18-7.16(m, IH). [310] [311] Compounds listed below were prepared by the similar procedure in above Example
1 and Example 2. [312] Example 3 . 2-(5-thiophen-2-yl-thieno[2,3-d] pyrimidin-
4-ylamino)-isoindole-l,3-dione hydrochloride [313] Example 4 . 2-(5-thiophen-2-yl-thieno[2,3-d] pyrimidin-
4-ylamino)-pyrrolo[3,4-c]pyridine-l,3-dione hydrochloride [314] Example 5 . 3-methyl-l-(5-thiophen-2-yl-thieno[2,3-d] pyrimidin-
4-ylamino)-pyrrole-2-5-dione hydrochloride [315] Example 6 . l-(5-thiophen-2-yl-thieno[2,3-d] pyrimidin-
4-ylamino)-pyrrole-2,5-dione hydrochloride [316] [Table 1]
[317]
[318] [319] Example 7 . l-(2,6-di-thiophen-2-yl-thieno[2,3-d] pyrimidin- 4-ylamino)-3-methyl-pyrrole-2,5-dione hydrochloride
[320] Step 1. Preparation of dimethyl-(2-thiophen-2-yl-vinviy amine [321]
0
//
OH
[322] 2-thiopheneacetic acid (500mg, 3.51mmol) w cas dissolvedN i'n THF (20ml). Thereafter, the temperature was lowered into O0C. Therein, 1.8M lithium diisopro pylamide (LDA) in heptane solution was slowly added over 30 minutes, and the reaction mixture was stirred at O0C for 1 hour. After reaction, the solvent was removed under reduced pressure. The residue was dissolved in THF (20ml) and the temperature was lowered into -7O0C, therein N,N-dimethylformamide-dimethylsulfonate complex (2.41ml, 14.0mmol: Dionisia Sanz, et al. J. Org. Chem. 2002, 67, 1462-1471) was slowly added, and the reaction mixture was stirred at room temperature for 1 hour. After reaction, the solvent was concentrated under reduced pressure to give 344mg (yield: 64%, colorless oil) of the target compound.
[323] 1U NMR(400D, CDCD; δ 6.84(m, 2H), 6.65(d, J=14.0Hz, IH), 6.61(d, J=2.8Hz, IH), 5.35(d, J=14.0Hz, IH), 2.76(s, 6H).
[327] The compound (300mg, 1.95mmol) prepared in the step 1, methyl cyanoacetate
(0.19ml, 2.14mmol) and sulfur (66mg, 2.06mmol) were dissolved in ethanol (20ml). Therein, morpholine (57D, 0.58mmol) was slowly added, and the reaction mixture was stirred at 8O0C for 5 hours. After reaction, the reaction mixture was poured into ethyl acetate, and washed with water and saturated ammonium chloride aqueous solution. Combined organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by column chromatography (n-hexane: ethyl acetate = 5:1) to give 230mg (yield: 65%, yellow solid) of the target compound.
[328] 1U NMR(400D, CDCI); δ 8.50(m, 2H), 7.49(s, IH), 7.28(m, 2H), 6.24(s, 2H),
3.85(s, 3H).
[329]
[330] Step 3. Preparation of 2.6-di-thiophen-2-yl-thienor2.3-dlpyrimidin-4-ol
[331]
[332] The compound (lOOmg, 0.48mmol) prepared in the step 2 and 2-thiophene car- bonitrile (0.058ml, 0.62mmol) were dissolved in 3.6M HCl 1,4-dioxane solution(6ml). The reaction mixture was stirred at 11O0C for 36 hours. After reaction, reaction mixture was poured into ethyl acetate, and washed with water and saturated sodium hydrogen carbonate aqueous solution. Combined organic layer was concentrated under reduced pressure to give 67mg (yield: 51%, brown solid) of the target compound.
[333] 1U NMR(400D, CDCI) δ 8.23(d, J=2.8Hz, IH), 7.80(d, J=4.8Hz, IH), 7.62(d, J
=4.8Hz), IH, 7.53(s, IH), 7.46(d, J=3.6Hz, IH), 7.23(dd, J=4.0Hz, J=4.8Hz, IH), 7.23(dd, J=3.6Hz, J=5.2Hz, IH).
[334]
[335] Step 4. Preparation of 4-chloro-2.6-di-thiophen-2-yl-thoeno[2.3-dlpyrimidine
[336]
[337] The compound (67mg, 0.21mmol) prepared in the step 3 was dissolved in phospho- rousoxy chloride (POCl , 3ml). Thereafter, the reaction mixture was stirred at 1000C for 2 hours. After reaction, the reaction mixture was poured into ice water and ethyl acetate was added. The organic layer was washed with water and saturated sodium hydrogen carbonate aqueous solution. Combined organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by column chromatography (n-hexane: ethyl acetate = 2:1) to give 55mg (yield: 80%, white solid) of the target compound.
[338] 1U NMR(400D, CDCI) δ 7.99(d, J=3.6Hz, IH), 7.85(d, J=4.8Hz, IH), 7.78(d, J
=4.8Hz, IH), 7.68(d, J=3.6Hz, IH), 7.64(s, IH), 7.23(m, 2H).
[339]
[340] Step 5. Preparation of l-(2.6-di-thiophen-2-yl-thienor2.3-dl pyrimidin-
4-ylaminoV3-methyl-pyrrole-2.5-dione
[341]
[342] The compound (55mg, 0. lβmmol) prepared in the step 4 was dissolved in THF
(5ml). Therein, hydrazine monohydrate (23D, 0.48mmol) was slowly added, and the reaction mixture was stirred at 8O0C for 10 hours. After reaction, the solvent was removed under reduced pressure, and dried in vacuum drier. The residue was dissolved in chloroform(5ml), therein citraconic anhydride (43D, 0.48mmol) was slowly added, and the reaction mixture was stirred at 8O0C for 20 hours. The reaction mixture was washed with water and saturated sodium chloride aqueous solution. Combined organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by column chromatography (n-hexane: ethyl acetate = 1:1) to give 37mg (yield: 54%, white solid) of the target compound.
[343] 1U NMR(400D, CDCI); δ 10.73(s, IH), 7.81(s, IH), 7.70(s, IH), 7.70(d, J=4.0Hz,
2H), 7.46(dd, J=LlBz, J=3.6Hz, IH), 7.20(dd, J=4.0Hz, J=5.2Hz, IH), 7.14(t, J =4.4Hz, IH), 7.02(d, J=2.0Hz, IH), 2.07(s, 3H).
[344]
[345] Step 6. Preparation of l-(2.6-di-thiophen-2-yl-thieno[2.3-dl pyrimidin-
4- ylamino)-3-methyl-pyrrole-2.5-dione hydrochloride
[347] The compound (37mg, 0.087mmol) prepared in the step 5 was dissolved in 4N HCl 1,4-dioxane (0.5ml) and the reaction mixture was stirred at room temperature for 5 hours. The reaction mixture was filtered to give 35mg (yield: 88%, white solid) of the target compound.
[348] 1U NMR(400D, DMSO-d); δ 10.80(s, IH), 7.86(s, IH), 7.70(s, IH), 7.70(d, J =4.4Hz, 2H), 7.46(dd, J=1.2Hz, J=3.6Hz, IH), 7.18(dd, J=4.0Hz, J=5.2Hz, IH), 7.14(t, J=4.4Hz, IH), 7.00(d, J=2.0Hz, IH), 2.17(s, 3H).
[349] [350] Example 8 (method 1) . l-(2,5-di-thiophen-2-yl-thieno[2,3-d] pyrimidin- 4-ylamino)-3-methyl-pyrrole-2,5-dione hydrochloride
[351] Step 1. Preparation of 2- (l-thophen-2-yl-ethylidene)-malononitrile [352]
[353] 2-Acetylthiophene (2Og, O.lβmol), malononitrile (12.6g, 0.19mol), ammonium acetate (36.6g, 0.48mol) and acetic acid (27.2ml, 0.48mol) were dissolved in toluene (120ml). The reaction mixture was refluxed for 18 hours. After reaction, the reaction mixture was poured into ethyl acetate, and washed with water and IN HCl aqueous solution. Combined organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by column chromatography (n-hexane: ethyl acetate = 3:1) to give 20.8g (yield: 75%, brown solid) of the target compound.
[354] 1U NMR(400D, CDCI); δ 8.05(d, J=4.0Hz, IH), 7.80(d, J=4.8Hz, IH), 7.80(t, J =4.4Hz, IH), 2.71 (s, 3H).
[355] [356] Step 2. Preparation of 5'-amino-[2.3'1bithiophenlv-4'-carbonitrile [357]
[358] The compound (20.8g, 0.12mol) prepared in the step 1 and sulfur (4.6g, 0.14mol)
were dissolved in ethanol (60ml). Therein, piperidine (14.1ml, 0.146mol) was slowly added, and the reaction mixture was stirred at 8O0C for 16 hours. After reaction, reaction mixture was poured into ethyl acetate, and washed with water and saturated ammonium chloride aqueous solution. Combined organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by column chromatography (n-hexane: ethyl acetate = 5:1) to give 14.4g (yield: 60%, yellow oil) of the target compound.
[359] 1U NMR(400D, CDCI); δ 7.45(d, J=3.6Hz, IH), 7.26(d, J=4.4Hz, 2H), 7.05(dd, J
=3.6Hz, J=4.8Hz, IH), 4.92(br, 2H).
[360]
[361] Step 3. Preparation of 2.5-di-thiophen-2-yl-thienor2.3-dlpyrimidin-4-ylamine
[362]
[363] The compound (300mg, 1.45mmol) prepared in the step 2 and 2-thiophene car- bonitrile (162D, 1.75mmol) were dissolved in 4N HCl 1,4-dioxane solution (6ml). The reaction mixture was stirred at 11O0C for 24 hours. After reaction, reaction mixture was poured into ethyl acetate, and washed with water and saturated sodium hydrogen carbonate aqueous solution. Combined organic layer was concentrated under reduced pressure to give 256mg (yield: 56%, brown solid) of the target compound.
[364] 1H NMR(400D, CDCI); δ 7.95(s, IH), 7.41(t, J=3.6Hz, IH), 7.13(m, 4H), 5.49(br,
2H).
[365]
[366] Step 4. Preparation of 4-chloro-2.5-di-thiophen-2-yl-thienor2.3-dlpyrimidine
[367]
[368] Copper chloride (CuCl, 174mg, 1.29mmol) and t-butyl nitrite (192D, 1.624mmol) were dissolved in acetonitrile (5ml). The reaction mixture was stirred at 7O0C for 30 minutes. Therein, the compound (340mg, 1.08mmol) prepared in the step 3 which was dissolved in THF (2ml) was slowly added, and the reaction mixture was stirred at the same temperature for 3 hours. Thereafter, the reaction mixture was cooled at room temperature, and poured into ethyl acetate, and washed with water and brine. Combined organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by column chromatography
(n-hexane: ethyl acetate = 3:1) to give 75mg (yield: 21%, white oil) of the target compound. [369] 1U NMR(400D, CDCI); δ 8.06(d, J=4.0Hz, IH), 7.50(d, J=5.6Hz, IH), 7.46(s, IH),
7.40(d, J=5.6Hz, IH), 7.16(m, 2H), 7.12(dd, IH, J=3.2Hz, J=5.2Hz). [370] [371] Step 5. Preparation of l-(2.5-di-thiophen-2-yl-thieno[2.3-dl pyrimidin-
4-ylamino)-3-methyl-pyrrole-2.5-dione [372]
[373] The compound (75mg, 0.22mmol) prepared in the step 4 was dissolved in THF (3ml). Therein, hydrazine monohydrate (33D, 0.67mmol) was slowly added, and the reaction mixture was stirred at 8O0C for 4 hours. After reaction, the solvent was removed under reduced pressure, and dried in vacuum drier. The residue was dissolved in chloroform, therein, citraconic anhydride (65D, 0.67mmol) was slowly added, and the reaction mixture was stirred at 8O0C for 18 hours. The reaction mixture was washed with water and saturated sodium chloride aqueous solution. Combined organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by column chromatography (n-hexane: ethyl acetate = 2:1) to give 46mg (yield: 48%, yellow solid) of the target compound.
[374] 1U NMR(400D, CDCD; δ 7.80(d, J=4.0Hz, IH), 7.45(d, J=4.8Hz, IH), 7.38(m, 2H), 7.30(s, IH), 7.18(m, IH), 7.14(br, 12H), 7.07 (dd, J=4.0Hz, J=5.2Hz, IH), 6.59(d, J=1.6Hz, IH), 2.23(s, IH).
[375] [376] Step 6. Preparation of l-(2.5-di-thiophen-2-yl-thieno[2.3-dl pyrimidin- 4- ylamino)-3-methyl-pyrrole-2.5-dione hydrochloride
[377]
l
[378] The compound (30mg, 0.071mmol) prepared in the step 5 was dissolved in 4N HCl 1,4-dioxane solution and the reaction mixture was stirred at room temperature for 18 hours. The resulting solid in the reaction mixture was filtered to give 29mg (yield:
89%, yellow solid) of the target compound. [379] 1H NMR(400D, DMSO-d); δ 8.68(s, IH), 7.75(s, IH), 7.69(m, 3H), 7.30(d, J
=3.6Hz, IH), 7.20(t, J=4.0Hz, IH), 7.14(t, J=4.8Hz, IH), 6.93(s, IH), 2.12(s, 3H). [380] [381] Example 8 (method 2) . l-(2,5-di-thiophen-2-yl-thieno[2,3-d] pyrimidin-
4-ylamino)-3-methyl-pyrrole-2,5-dione hydrochloride
[382] Step 1. Preparation of 2-cvano-3-thiophen-2-yl-but-2-enoic acid methyl ester
[383]
[384] 2-Acetylthiophene (Ig, 7.92mmol), methyl cyanoacetate (0.836ml, 9.51mmol), ammonium acetate (1.8g, 23.77mmol) and acetic acid (1.36ml, 23.77mmol) were dissolved in toluene (20ml). The reaction mixture was refluxed for 16 hours. After reaction, the reaction mixture was poured into ethyl acetate, and washed with water and IN HCl aqueous solution. Combined organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by column chromatography (n-hexane: ethyl acetate = 5:1) to give 812mg (yield: 53%, yellow oil) of the target compound.
[385] 1U NMR(400D, CDCI); δ 8.03(d, J=4.0Hz, IH), 7.80(d, J=4.8Hz, IH), 7.78(t, J
=4.4Hz, IH), 3.88(s, 3H) 2.71(s, 3H).
[386]
[387] Step 2. Preparation of 5'-amino-r2.3'lbithiophenly-4'-carboxylic acid methyl ester
[388]
[389] The compound (250mg, 1.21mmol) prepared in the step 1 and sulfur (46.4mg,
1.45mmol) were dissolved in ethanol (10ml). Therein, piperidine (143D, 1.45mmol) was added, and the reaction mixture was stirred at 8O0C for 18 hours. After reaction, the reaction mixture was poured into ethyl acetate, and washed with water and saturated ammonium chloride aqueous solution. Combined organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by column chromatography (n-hexane: ethyl acetate = 5:1) to give 88mg (yield: 31%, yellow solid) of the target compound.
[390] 1U NMR(400D, CDCI); δ 7.25(d, J=3.6Hz, IH), 7.01 (m, 2H), 6.22(s, IH), 6.1 l(s,
2H), 3.67(s, 3H).
[391]
[392] Step 3. Preparation of 2.5-di-thiophen-2-yl-thienor2.3-dlpyrimidin-4-ol
[393]
[394] The compound (lOOmg, 0.48mmol) prepared in the step 2 and 2-thiophene car- bonitrile (58D, 0.62mmol) were dissolved in 3.6M HCl 1,4-dioxane solution (6ml). The reaction mixture was stirred at 11O0C for 36 hours. After reaction, the reaction mixture was poured into ethyl acetate, and washed with water and saturated sodium hydrogen- carbonate aqueous solution. Combined organic layer was concentrated under reduced pressure to give 67mg (yield: 51%, brown solid) of the target compound.
[395] 1U NMR(400D, DMSO-d); δ 8.19(d, J=4.4Hz, IH), 7.84(d, J=5.2Hz, IH), 7.7 l(d, J
=3.6Hz, IH), 7.51(m, 2H), 7.22(m, IH), 7.10(m, IH).
[396]
[397] Step 4. Preparation of 4-chloro-2.5-di-thiophen-2-yl-thienor2.3-dlpyrimidine
[398]
[399] The compound (272mg, 0.861mmol) prepared in the step 3 was dissolved in phos- phorousoxychloride (3ml). Thereafter, the reaction mixture was stirred at 1000C for 2 hours. After reaction, the reaction mixture was poured into ice water and ethyl acetate, and washed with water and saturated sodium hydrogen carbonate aqueous solution. Combined organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by column chromatography (n-hexane: ethyl acetate = 2:1) to give 234mg (yield: 81%, yellow solid) of the target compound.
[400] 1U NMR(400D, CDCI); δ 8.06(d, J=4.0Hz, IH), 7.50(d, J=5.6Hz, IH), 7.46(s, IH),
7.40(d, J=5.6Hz, IH), 7.16(m, 2H), 7.12(dd, J=3.2Hz, J=5.2Hz, IH).
[401]
[402] Step 5. Preparation of l-(2.5-di-thiophen-2-yl-thienor2.3-dl pyrimidin-
4-ylaminoV3-methyl-pyrrole-2.5-dione hydrochloride
[404] According to the similar procedure in the step 5 and step 6 of example 8 (method 1) by using the compound prepared in the step 4, the target compound was obtained. [405] [406] Compounds listed below were prepared by the similar procedure in above Example
8 (method 1) [407] Example 9 .
3-methyl-l-[2-(5-methyl-thiophen-2-yl)-5-thiophen-2-yl-thieno[2,3-d]pyrimidin-4- ylamino] -pyrrole-2,5-dione hydrochloride [408] Example 10 . l-[5-(4-methoxy-phenyl)-2-thiophen-2-yl-thieno[2,3-d] pyrimidin-
4-ylamino] -3-methyl-pyrrole-2,5-dione hydrochloride [409] Example 11 . l-[5-(4-hydroxy-phenyl)-2-thiophen-2-yl-thieno[2,3-d] pyrimidin-
4-ylamino] -3-methyl-pyrrole-2,5-dione hydrochloride
[410] Example 12 . (2,5-di-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-yl)-hydrazine hydrochloride [411] Example 13 . 3-methyl-l-(2-pyridin-4-yl-5-thiophen-2-yl-thieno[2,3-d] pyrimidin-4-ylamino)-pyrrole-2,5-dione hydrochloride [412] Example 14 . l-[2-(4-methoxy-phenyl)-5-thiophen-2-yl-thieno[2,3-d] pyrimidin-
4-ylamino] -3-methyl-pyrrole-2,5-dione hydrochloride [413] Example 15 . 3-methyl-l-(5-thiophen-2-yl-2-p-tolyl-thieno[2,3-d] pyrimidine-
4-ylamino)-pyrrole-2,5-dione hydrochloride [414] Example 16 . 3-methyl-l-(5-thiophen-2-yl-2-thiophen-2-ylmethyl-thieno[2,3-d] pyrimidine-4-ylamino)-pyrrole-2,5-dione hydrochloride [415] [Table 2]
[416]
[417] [418] Intermediate (!) : Preparation of 4-chloro-2-(5-methyl-thiophen-2-yl)-5-thiophen-2-yl-thieno[2,3-d]pyrimidine
[419] Step 1. Preparation of 2-(5-methyl-thiophen-2-ylV5-thiophen-2-v1-thienor2.3-dl Dyrimidin-4-ylamine [420]
[421] According to the similar procedure in the step 3 of example 8 (method 1) by using the 5'-amino-[2,3']bithiophenyl-4'-carbonitrile (490mg, 2.4mmol) prepared in the step 2 of example 8(method 1) and 5-methyl-thiophen-2-carbonitrile (402mg, 2.8mmol), 505mg (yield: 65%, yellow solid) of the target compound was obtained.
[422] 1U NMR(400D, CDCI): δ 7.71(d, J=4.8Hz, IH), 7.66(d, J=3.2Hz, IH), 7.55(s, IH),
7.26(d, J=3.2Hz, IH), 7.22(m, IH), 6.85(d, J=3.6Hz, IH), 2.47(s, 3H).
[423]
[424] Step 2. Preparation of
4-chloro-2-(5-methyl-thiophen-2-yl)-5-thiophen-2-yl-theno[2.3-dlpyrimidine
[425]
[426] According to the similar procedure in the step 4 of example 8 (method 1) by using the compound (500mg, 4.52mmol) prepared in the step 1, 200mg (yield: 39%, yellow solid) of the target compound was obtained. [427] 1U NMR(400D, CDCI): δ 7.89(d, J=4.0Hz, IH), 7.44(s, IH), 7.42(m, IH), 7.16(m,
IH), 7.12(dd, IH, J=3.6Hz, J=5.2Hz), 6.83(m, IH), 3.80(s, 3H). [428] [429] Intermediate (D : Preparation of
4-chloro-5-(4-methoxy-phenyl)-2-thiophen-2-yl-thieno[2,3-d]pyrimidine [430]
[431] According to the similar procedure in the step 1 to step 4 of example 8 (method 1) by using 4-methoxy acetophenone, 700mg (yield for final step: 53%, brown solid) of the target compound was obtained. [432] 1U NMR(400D, CDCI): δ 8.09(m, IH), 7.51(m, IH), 7.35(d, J=8.8Hz, 2H), 7.29(s,
IH), 7.16(m, IH), 6.97 (d, J=8.8Hz, 2H), 3.87(s, 3H). [433] [434] Intermediate (3) : Preparation of 4-(4-chloro-2-thiophen-2-yl-thieno[2,3-d] pyrimidin-5-yl)-phenol
[435]
[436] 4-chloro-5-(4-methoxy-phenyl)-2-thiophen-2-yl-thieno[2,3-d]pyrimidine(590mg,
1.32mmol) prepared in intermediate (2) was dissolved in dichloromethane (10ml). Therein IM boron tribromide dichloromethane solution (8ml) was slowly added, and the reaction mixture was stirred at room temperature for 2 hours. After reaction, the reaction mixture was poured into ethyl acetate, and washed with water and saturated sodium hydrogen carbonate aqueous solution. Combined organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by column chromatography (n-hexane: ethyl acetate = 2:1) to give 483mg (yield: 73 %, brown solid) of the target compound.
[437] 1U NMR(400D, CDCI): δ 8.02(m, IH), 7.51(m, IH), 7.33(d, J=8.0Hz, 2H), 7.29(s,
IH), 7.21(m, IH), 6.88(d, J=8.8Hz, 2H).
[438]
[439] Intermediate (4) : Preparation of
4-chloro-2-pyridin-4-yl-5-thiophen-2-yl-thieno[2,3-d]pyrimidine
[440]
[441] According to the similar procedure in the step 3 and 4 of example 8 (method 1) by using the compound prepared in the step 2 of example 8 (method 1) and 4-cyanopyridine, 21mg (yield: 16%, yellow solid) of the target compound was obtained.
[442] 1U NMR(400D, CDCI): δ 8.08(br s, 2H), 8.38~8.34(m, 2H), 7.67(s, IH),
7.47~7.45(m, IH), 7.21-7.19(m, IH), 7.16~7.14(m, IH).
[443]
[444] Intermediate (5) : Preparation of 4-chloro-2,5-di-thiophen-2-yl-thieno[2,3-d] pyrimidine
[446] According to the similar procedure in the step 3 and 4 of example 8 (method 1) by using 5'-amino-[2,3']bithiophenyl-4'-carbonitrile prepared in the step 2 of example 8 (method 1) and 4-methoxybenzonitrlie, 130mg (yield: 17%, dark brown solid) of the target compound was obtained.
[447] 1U NMR(400D, CDCI); δ 8.48(d, J=8.8Hz, 2H), 7.49(s, IH), 7.43(d, J=5.2Hz, IH),
7.18(d, J=5.2Hz, IH), 7.13(dd, J=2.8Hz, 5.2Hz, IH) 7.01(d, J=8.8Hz, 2H), 3.90(s, 3H).
[448]
[449] Intermediate (6) : Preparation of
4-chloro-5-thiophen-2-yl-2-p-tolyl-thieno[2,3-d]-pyrimidine
[450]
[451] According to the similar procedure in the step 3 and 4 of example 8 (method 1) by using the compound prepared in the step 2 of example 8 (method 1) and 4-tolunitrile, 45mg (yield for 2 steps: 7%, white solid) of the target compound was obtained.
[452] 1U NMR(400D, CDCI); δ 8.21(d, J=8.0Hz, 2H), 7.45(dd, J=1.2Hz, J=4.8Hz, IH),
7.28(d, J=8.0Hz, 2H), 7.23(s, IH), 7.16(m, 2H), 2.41(s, 3H).
[453]
[454] Intermediate (7) : Preparation of
4-chloro-5-thiophen-2-yl-2-thiophen-2-ylmethyl-thieno[2,3-d]-pyrimidine
[455]
[456] According to the similar procedure in the step 3 and 4 of example 8(method 1) by using the 5'-amino-[2,3']bithiophenyl-4'-carbonitrile prepared in the step 2 of example 8 (method 1) and 2-thiophenacetonitrile, 50mg (yield for 2 steps: 10%, brown oil) of the target compound was obtained.
[457] 1U NMR(400D, CDCI); δ 7.53(s, IH), 7.41(d, J=5.2Hz, IH), 7.19(d, J=5.2Hz, IH),
7.14-7.09(m, 2H), 7.03(d, J=3.2Hz, IH), 6.95(t, J=4.0Hz, IH), 4.55(s, 2H). [458] [459] Compounds listed below were prepared by the similar procedure in above Example
8 (method 2). [460] Example 17 . 3-methyl-l-(2-thiophen-2-yl-thieno[2,3-d] pyrimidin-
4-ylamino)-pyrrole-2,5-dione hydrochloride [461] Example 18 . 3-methyl-l-(5-methyl-thieno[2,3-d] pyrimidin-
4-ylamino)pyrrole-2,5-dione hydrochloride [462] Example 19 . l-(2-benzyl-5-thiophen-2-yl-thieno[2,3-d] pyrimidin-
4-ylamino)-3-methyl-pyrrole-2,5-dione hydrochloride [463] Example 20 . 3-methyl-l-(5-methyl-2-thiophen-2-yl-thieno[2,3-d] pyrimidin-
4-ylamino)-pyrrole-2,5-dione hydrochloride [464] Example 21 . 3-methyl-l-(2-phenyl-5-thiophen-2-yl-thieno[2,3-d] pyrimidin-
4-ylamino)-pyrrole-2,5-dione [465] Example 22 . 3-methyl-l-(2-phenyl-5-thiophen-2-yl-thieno[2,3-d] pyrimidin-
4-ylamino)-pyrrole-2,5-dione hydrochloride [466] Example 23 . l-[2-(4-hydroxy-phenyl)-5-thiophen-2-yl-thieno[2,3-d] pyrimidin-
4-ylamino] -3-methyl-pyrrole-2,5-dione hydrochloride [467] Example 24 . l-[2-(-4-fluoro-phenyl)-5-thiophen-2-yl-thieno[2,3-d] pyrimidin-
4-ylamino] -3-methyl-pyrrole-2,5-dione hydrochloride [468] Example 25 . l-[2-(3-fluoro-phenyl)-5-thiophen-2-yl-theno[2,3-d] pyrimidin-
4-ylamino] -3-methyl-pyrrole-2,5-dione hydrochloride [469] Example 26 . 3-methyl-l-(2-thiophen-3-yl-5-thiophen-2-yl-thieno[2,3-d] pyrimidin-4-ylamino)-pyrrole-2,5-dione hydrochloride [470] Example 27 . 3-methyl-l-(2-thiophen-2-yl-5-thiophen-3-yl-thieno[2,3-d] pyrimidin-4-ylamino)-pyrrole-2,5-dione hydrochloride [471] Example 28 . 3-methyl-l-(5-thiophen-2-yl-2-thiophen-3-ylmethyl-thieno[2,3-d] pyrimidin-4-ylamino)-pyrrole-2,5-dione hydrochloride [472] Example 29 . 3-methyl-l-(5-phenyl-2-thiophen-2-yl-thieno[2,3-d] pyrimidin-
4-ylamino)-pyrrole-2,5-dione hydrochloride [473] Example 30 . 3-methyl-l-(2-thiophen-2-yl-5-p-tolyl-thieno[2,3-d] pyrimidin-
4-ylamino)-pyrrole-2,5-dione hydrochloride [474] Example 31 . l-[2-(4-methoxy-benzyl)-5-thiophen-2-yl-thieno[2,3-d] pyrimidin-
4-ylamino]3-methyl-pyrrole-2,5-dione hydrochloride [475] Example 32 . l-[2-(4-diethylaminophenyl)-5-thiophen-2-yl-thieno[2,3-d] pyrimidin-4-ylamino] -3-methyl-pyrrole-2,5-dione hydrochloride
[476] Example 33 . l-[2-(3-hydroxy-phenyl)-5-thiophen-2-yl-thieno[2,3-d] pyrimidin-
4-ylamino] -3-methyl-pyrrole-2,5-dione hydrochloride
[477] Example 34 . l-[2-(4-methoxy-phenyl)-5-phenyl-thieno[2,3-d] pyrimidin-
4-ylamino] -3-methyl-pyrrole-2,5-dione hydrochloride [478] Example 35 . l-[2-(3-methoxy-phenyl)-5-thiophen-2-yl-thieno[2,3-d] pyrimidin-
4-ylamino] -3-methyl-pyrrole-2,5-dione hydrochloride [479] Example 36 . l-[2-(3-methoxy-phenyl)-5-phenyl-thieno[2,3-d] pyrimidin-
4-ylamino] -3-methyl-pyrrole-2,5-dione hydrochloride [480] Example 37 . l-[2-(3-fluoro-phenyl)-5-phenyl-thieno[2,3-d] pyrimidin-
4-ylamino] -3-methyl-pyrrole-2,5-dione hydrochloride [481] Example 38 . l-[2-(3-methoxy-benzyl)-5-thiophen-2-yl-thieno[2,3-d] pyrimidin-
4-ylamino] -3-methyl-pyrrole-2,5-dione hydrochloride [482] Example 39 .
4-(3-methyl-2,5-dioxo-2,5-dihydro-pyrrol-l-ylamino)-2-thiophen-2-yl-thieno[2,3-d
]pyrimidine-5-carboxylic acid ethyl ester hydrochloride [483] Example 40 . l-[5-(3-hydroxy-phenyl)-2-thiophen-2-yl-thieno[2,3-d] pyrimidin-
4-ylamino] -3-methyl-pyrrole-2,5-dione hydrochloride [484] Example 41 . l-[5-(3-methoxy-phenyl)-2-thiophen-2-yl-thieno[2,3-d] pyrimidin-
4-ylamino] -3-methyl-pyrrole-2,5-dione hydrochloride [485] Example 42 . l-[2-(4-dimethylamino-phenyl)-5-phenyl-thieno[2,3-d] pyrimidin-
4-ylamino] -3-methyl-pyrrole-2,5-dione hydrochloride [486] Example 43 . l-[2-(4-amino-phenyl)-5-phenyl-thieno[2,3-d] pyrimidin-
4-ylamino] -3-methyl-pyrrole-2,5-dione hydrochloride [487] Example 44 . l-(2-furan-2-yl-5-thiophen-2-yl-thieno[2,3-d] pyrimidin-
4-ylamino)-3-methyl-pyrrole-2,5-dione hydrochloride [488] Example 45 . 3-methyl-l-(2-methyl-5-thiophen-2-yl-thieno[2,3-d] pyrimidin-
4-ylamino)pyrrole-2,5-dione hydrochloride [489] Example 46 . l-[2-(4-amino-phenyl)-5-thiophen-2-yl-thieno[2,3-d] pyrimidin-
4-ylamino] -3-methyl-pyrrole-2,5-dione hydrochloride [490] Example 47 . l-(2-amino-5-thiophen-2-yl-thieno[2,3-d] pyrimidin-
4-ylamino)-3-methyl-pyrrole-2,5-dione hydrochloride [491] Example 48 . l-(2-cyclopropyl-5-thiophen-2-yl-thieno[2,3-d] pyrimidin-
4-ylamino)-3-methyl-pyrrole-l,5-dione [492] Example 49 .
[4-(3-methyl-2,5-dioxo-2,5-dihydro-pyrrol-l-ylamino)-2-thiophen-2-yl-thieno[2,3- d]pyrimidin-5-yl]-acetic acid methyl ester hydrochloride [493] Example 50 . l-(5-hydroxymethyl-2-thiophen-2-yl-thieno[2,3-d] pyrimidin-
4-ylamino)-3-methyl-pyrrole-2,5-dione hydrochloride [494] Example 51 . l-(5-methoxymethyl-2-thiophen-2-yl-thieno[2,3-d] pyrimidin-
4-ylamino)-3-methyl-pyrrole-2,5-dione hydrochloride
[495] [Table 3] [496]
[500]
[501] Intermediate (H) : Preparation of 4-chloro-2-thiophen-2-yl-thieno[2,3-d] pyrimidine
[502]
[503] According to the similar procedure in the step 3 and 4 of example 8(method 2) by
using methyl^-aminothiophen-S-carboxylate (315mg, 2.0mmol), 347 mg (yield for final step: 96%, brown solid) of the target compound was obtained.
[504] 1U NMR(400D, DMSO-d): δ 8.03 (m, 2H), 7.86 (m, IH), 7.55 (t, J=4.4Hz, IH),
7.24(m, IH).
[505]
[506] Intermediate (9) : Preparation of 4-chloro-5-methyl-thieno[2,3-d]pyrimidine
[507] Step 1. Preparation of 5-methyl-thieno[2.3-dlpyrimidin-4-ol
[508]
[509] 2-amino-4-methyl-thiophen-3-carboxylic acid ethyl ester (2g, 10.6mmol) was dissolved in formamide (10ml). The reaction mixture was stirred at 18O0C for 12 hours. After reaction, the reaction mixture was poured into ethyl acetate, and washed with water and saturated sodium hydrogen chloride aqueous solution. Combined organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure to give 1.4g (yield: 79%, pale yellow solid) of the target compound.
[510]
[511] Step 2. Preparation of 4-chloro-5-methyl-thienor2.3-dlpyrimidine
[512]
[513] The compound, 5-methyl-thieno[2,3-d]pyrimidin-4-ol, (1.4g, 8.42mmol) prepared in the step 1 was dissolved in phosphorusoxy chloride (5ml). Thereafter, the reaction mixture was stirred at 11O0C for 1 hour. After reaction, the reaction mixture was poured into ice water and chloroform, and washed with water and saturated sodium hydrogen carbonate aqueous solution. Combined organic layer was concentrated under reduced pressure. The residue was purified by recrystallization (n-hexane and ethyl acetate) to give 590mg (yield: 39%, yellow solid) of the target compound.
[514] 1U NMR(400D, CDCI): δ 8.81 (s, IH), 7.24 (s, IH), 2.70 (s, 3H).
[515]
[516] Intermediate (10) : Preparation of l-benzvM-chloro-S-thiophen-l-yl-thienori.S-dlpyrimidine
[517] Step 1. Preparation of 5'-amino-[2.3'lbithiophenyl-4'-carboxylic acid methyl ester
[518]
e
[519] The compound (lOOmg, 0.48mmol) prepared in the step 2 of example 8(method 2) was refluxed in catalyst amount of cone, sulfuric acid and methanol (5ml) to give
21mg (yield: 46%, colorless solid) of the target compound. [520] 1U NMR(400D, CDCI); δ 7.25(d, J=3.6Hz, IH), 7.01 (m, 2H), 6.22(s, IH), 6.1 l(s,
2H), 3.67(s, 3H). [521]
[522] Step 2. Preparation of 2-benzyl-4-chloro-5-thiophen-2-yl-thieno[2.3-dlpyrimidine
[523]
[524] According to the similar procedure in the step 3 and 4 of example 8 (method 2) by using the compound prepared in the step 1 and benzyl cyanide (0.14ml, 1.25mmol), 26mg (yield for final step: 23%, yellow oil) of the target compound was obtained.
[525] 1H-NMR^OOD, CDCI) δ 7.50(s, IH), 7.44~7.40(m, 3H), 7.33~7.21(m, 3H),
7.13~7.08(m, 2H), 4.36(s, 2H)
[526]
[527] Intermediate (11) : Preparation of
4-chloro-2-phenyl-5-thiophen-2-yl-thieno[2,3-d]pyrimidine
[528]
[529] According to the similar procedure in the step 3 and 4 of example 8 (method 2) by using the compound, 5'-amino-[2,3']bithiophenyl-4'-carboxylic acid methyl ester, (190mg, 0.79mmol), prepared in the step 2 of example 8 and benzonitrile (240D, 2.38mmol), 140mg (yield for 2 steps: 55%, light yellow solid) of the target compound was obtained.
[530] 1U NMR(400D, CDCI); δ 8.54-8.52(m, 2H), 7.56(s, IH), 7.53-7.51(m, 3H), 7.44(d,
J=5.2Hz, IH), 7.19(d, J=3.6Hz, IH), 7.14(t, J=4.4Hz, IH).
[531]
[532] Intermediate (12) : Preparation of 4-(4-chloro-5-thiophen-2-yl-thieno[2,3-d]
pyrimidin-2-yl)-phenol
[533]
[534] According to the similar procedure in the step 3 and 4 of example 8(method 2) by using the compound, 5'-amino-[2,3']bithiophenyl-4'-carboxylic acid methyl ester, (200mg, 0.84mmol), prepared in the step 2 of example 8 (method 2) and 4-cyanophenol (200mg, 1.67mmol), 115mg (yield for 2 steps: 40%, white solid) of the target compound was obtained.
[535] 1U NMR(400D, OMSOd ); δ 10.23(s, IH), 8.27(d, J=8.8Hz, 2H), 8.03(s, IH),
7.70(d, J=5.2Hz, IH), 7.28(d, J=2.4Hz, IH), 7.18(t, J=5.2Hz, IH) 6.92(d, J=8.8Hz, 2H).
[536]
[537] Intermediate (13) : Preparation of l-[2-(4-fluoro-phenyl)-5-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-ylamino]-3-meth yl-pyrrole-2,5-dione hydrochloride
[538] Step 1. Preparation of 2-(4-fluoro-phenylV5-thiophen-2-yl-thienor2.3-dl pyrimidin-
4-ol
[539]
[540] According to the similar procedure in the step 3 of example 8 (method 2) by using the compound (213.9mg, 0.89mmol) prepared in the step 2 of example 8(method 2) and 4-fluorobenzonitrile, 171mg (yield: 58%, yellow solid) of the target compound was obtained.
[541] 1U NMR(400D, OMSOd ); δ 12.77(s, IH), 8.24(dd, J=8.8, 5.4Hz, 2H), 7.70(d, J
=3.9Hz, IH), 7.66(s, IH), 7.56(d, J=4.9Hz, IH), 7.45(d, /=8.8, 2H), 7.13(dd, /=4.9, 3.9Hz, IH).
[542]
[543] Step 2. Preparation of 4-chloro-2-(4-fluoro-phenylV5-thiophen-2-yl-thienor2.3-dl pyrimidine
[545] According to the similar procedure in the step 4 of example 8(method 2) by using the compound (168mg, 0.51mmol) prepared in the step 1, 149mg (yield: 84%, yellow solid) of the target compound was obtained. [546] 1U NMR(400D, CDCI); δ 8.53(m, 2H), 7.54(s, IH), 7.43(d, J=4.9Hz, IH),
7.20-7.12(m, 4H). [547] [548] Intermediate (14) : Preparation of l-[2-(3-fluoro-phenyl)-5-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-ylamino]-3-meth yl-pyrrole-2,5-dione hydrochloride [549] Step 1. Preparation of 2-G-fluoro-phenylV5-thiophen-2-yl-thienor2.3-dl pyrimidin-
4-ol [550]
[551] According to the similar procedure in the step 3 of example 8(method 2) by using the compound prepared in the step 2 of example 8(method 2) and 3-fluorobenzonitrile, 203mg (yield: 65%, yellow solid) of the target compound was obtained.
[552] 1U NMR(400D, DMSO-d); δ 12.78(s, IH), 8.04(d, /=7.8, IH), 8.00(d, /=10.2Hz,
IH), 7.71(d, /=3.9Hz, IH), 7.67(s, IH), 7.60(m, IH), 7.55(d, /=4.9, IH), 7.45(m, IH), 7.12(dd, /=4.9, 3.9Hz, IH).
[553]
[554] Step 2. Preparation of 4-chloro-2-G-fluoro-phenylV5-thiophen-2-yl-thienor2.3-dl pyrimidine
[555]
[556] According to the similar procedure in the step 4 of example 8(method 2) by using the compound (203mg, 0.62mmol) prepared in the step 1, 206mg (yield: 96%, yellow solid) of the target compound was obtained.
[557] 1U NMR(400D, CDCI); δ 8.32(d, /=7.8Hz, 2H), 7.57(s, IH), 7.49-7.43(m, 2H),
7.22-7.12(m, 3H).
[558]
[559] Intermediate (15) : Preparation of 4-chloro-2-thiophen-3-yl-5-thieno[2,3-d] pyrimidine
[560]
[561] 5'-amino-[2,3']bithiophenyl-4'-carboxylic acid methyl ester (200mg, 0.835mmol) obtained according to the similar procedure in the step 1 and 2 of example 8 (method 2) by using 2-acetylthiophene (Ig, 7.92mmol) was dissolved in 1,-dioxane (5ml). Therein, 3-thiophenecarbonitrile (273mg, 2.5mmol) and 3.2M HCl solution was added, and the reaction mixture was stirred at 1000C for 24 hours to give 2-thiophen-3-yl-5-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-ol (192mg, yield: 72%). Thereafter, according to the similar procedure in the step 4 of example 8(method 2), 180mg (yield: 86%, yellow solid) of the target compound was obtained.
[562] 1U NMR (400D, CDCI): δ 8.39-8.38(m, IH), 7.96-7.95(m, IH), 7.51(s, IH),
7.44-7.38(m, 2H), 7.18-7.12(m, 2H).
[563]
[564] Intermediate (16) : Preparation of
4-chloro-2-thiophen-2-yl-5-thiophen-3-yl-thieno[2,3-d]pyrimidine
[565]
[566] According to the similar procedure in the step 1 to 4 of example 8(method 2) by using the 3-acetylthiophene (Ig, 7.92mmol), 52mg (yield for final step: 98%, yellow oil) of the target compound was obtained. [567] 1H-NMR (400D, CDCI) δ 8.27(d, J=2.5Hz, IH), 8.04(d, J=IAUz, IH), 7.9 l(d, J
=4.7Hz, IH), 7.63(s, IH), 7.56~7.54(m, IH), 7.51(d, J=4.7Hz, IH), 7.24(t, J=4.3Hz,
IH). [568] [569] Intermediate (17) : Preparation of
[571] According to the similar procedure in the step 3 and 4 of example 8 (method 2) by using the compound, 5'-amino-[2,3']bithiophenyl-4'-carboxylic acid methyl ester, prepared in the step 2 of example 8(method 2) and 3-thiophenacetonitrile, 250mg (yield for 2 steps: 86%, yellow oil) of the target compound was obtained.
[572] 1U NMR(400D, CDCI); δ 7.51(s, IH), 7.41(d, J=4.8Hz, IH), 7.26(dd, J=2.6Hz,
5.4Hz, IH), 7.21(s, IH), 7.16-7.09(m, 3H), 4.38(s, 2H).
[573]
[574] Intermediate (18) : Preparation of
4-chloro-5-phenyl-2-thiophen-2-yl-thieno[2,3-d]pyrimidine
[575]
[576] According to the similar procedure in the step 1 to 4 of example 8(method 2) by using the acetophenone, 160mg (overall yield: 5%, white solid) of the target compound was obtained.
[577] 1U NMR(400D, DMSO d-6 ); δ 8.26(d, J=3.6Hz, IH), 7.90(d, J=3.6Hz, IH), 7.56(d, J
=6.4Hz, 2H), 7.48(s, IH), 7.38(m, 3H), 7.24(t, J=4.4Hz, IH). [578] [579] Intermediate (19) : Preparation of
4-chloro-2-thiophen-2-yl-5-p-tolyl-thieno[2,3-d]pyrimidine
[580]
[581] According to the similar procedure in the step 1 to 4 of example 8 (method 2) by using the 4-methyl acetophenone, 200mg (overall yield: 6%, white solid) of the target compound was obtained.
[582] 1U NMR(400D, DMSO d-6 ); δ 8.20(d, J=3.6Hz, IH), 7.85(d, J=3.6Hz, IH), 7.45(d, J
=8.0Hz, 2H), 7.36(s, IH), 7.21(m, 3H), 2.34(s, IH). [583]
[584] Intermediate (20) : Preparation of
4-chloro-2-(4-methoxy-benzyl)-5-thiophen-2-yl-thieno[2,3-d]pyrimidine
[585]
[586] According to the similar procedure in the step 3 and 4 of example 8(method 2) by using the compound prepared in the step 2 of example 8 (method 2) and (4-methoxyphenyl)acetonitrile, 238mg (yield for final step: 84%, yellow oil) of the target compound was obtained.
[587] 1U NMR(400D, CDCI): δ 7.63(d, J=3.6Hz, IH), 7.54(s, IH), 7.52(d, J=5. IHz, IH),
7.30(d, J=8.4Hz, 2H), 7.09~7.07(m, IH), 6.90(d, J=8.7Hz, 2H), 3.88(s, 2H), 3.71(s, 3H).
[588]
[589] Intermediate (21) : Preparation of [4-(4-chloro-5-thiophen-2-yl-thieno[2,3-d] pyrimidin-2-yl)-phenyl]-dimethylamine
[590]
[591] According to the similar procedure in the step 3 and 4 of example 8 (method 2) by using the compound prepared in the step 2 of example 8 (method 2) and 4-(dimethylamino)-benzonitrile, 68mg (yield for 2 steps: 81%, yellow solid) of the target compound was obtained.
[592] 1U NMR(400D, CDCI); δ 8.40 (m, 2H), 7.41 (m, IH), 7.40 (s, IH), 7.17 (m, IH)
7.11 (m, IH), 6.77 (m, 2H),3.06 (s, 6H).
[593]
[594] Intermediate (22) : Preparation of 3-(4-chloro-5-thiophen-2-yl-thieno[2,3-d] pyrimidin-2-yl)-phenol
[595]
[596] According to the similar procedure in the step 3 and 4 of example 8 (method 2) by using the compound, 5'-amino-[2,3']bithiophenyl-4'-carboxylic acid methyl ester,
prepared in the step 2 of example 8(method 2) and 3-hydroxybenzonitrile, 82mg (yield for final step: 39%, colorless solid) of the target compound was obtained. [597] 1U NMR(400D, CDCI): δ 9.64-9.52(br, IH), 8.10-7.98(m, 2H), 7.79(s, IH), 7.45-
7.36(m, 2H), 7.16-7.09(m, 2H), 7.31-6.92(m, IH). [598] [599] Intermediate (23) : Preparation of 4-chloro-2-(-4-methoxy-phenyl)-5-pheny 1- thieno[2,3-d]pyrimidine [600]
[601] According to the similar procedure in the step 1 and 2 of example 8 (method 2) by using the 1-pheny-ethanon, intermediate compound was obtained. Thereafter, according to the similar procedure in the step 3 and 4 of example 8 (method 2) by using the intermediate compound and 4-methoxybenzonitrile, 188mg (yield for final step: 92%, yellow oil) of the target compound was obtained.
[602] 1U NMR(400D, CDCI): δ 8.18(d, J=8.8Hz, 2H), 7.72(s, IH), 7.67~7.61(m, 2H),
7.41~7.33(m, 3H), 6.99(d, J=8.8Hz, 2H), 3.88(s, 3H).
[603]
[604] Intermediate (24) : Preparation of
4-chloro-2-(3-methoxy-phenyl)-5-thiophen-2-yl-thieno[2,3-d]pyrimidine
[605]
[606] According to the similar procedure in the step 3 and 4 of example 8 (method 2) by using the compound, 5'-amino-[2,3']bithiophenyl-4'-carboxylic acid methyl ester, prepared in the step 2 of example 8(method 2) and 3-methoxybenzonitrile, 51mg (yield for final step: 81%, colorless solid) of the target compound was obtained.
[607] 1U NMR(400D, CDCI): δ 8.14-8.07 (m, 2H), 7.55(s, IH), 7.44- 7.40(m, 2H),
7.19-7.12(m, 2H), 7.08-7.05(m, IH), 3.94(s, 3H).
[608]
[609] Intermediate (25) : Preparation of
4-chloro-2-(-3-methoxy-phenyl)-5-phenyl-thieno[2,3-d]pyrimidine
[611] According to the similar procedure in the step 1 and 2 of example 8 (method 2) by using the compound, 1-pheny-ethanon, intermediate compound was obtained. Thereafter, according to the similar procedure in the step 3 and 4 of example 8 (method 2) by using the intermediate compound and 3-methoxybenzonitrile, 251mg (yield for final step: 92%, yellow oil) of the target compound was obtained.
[612] 1U NMR(400D, CDCI):δ 7.78~7.73(m, 2H), 7.59(d, J=8.0Hz, 2H), 7.53(s, IH),
7.48~7.36(m, 3H), 7.16~7.14(m, IH), 3.86(s, 3H).
[613]
[614] Intermediate (26) : Preparation of
4-chloro-2-(-3-fluoro-phenyl)-5-phenyl-thieno[2,3-d]pyrimidine
[615]
[616] According to the similar procedure in the step 1 and 2 of example 8 (method 2) by using the 1-pheny-ethanon, intermediate compound was obtained. Thereafter, according to the similar procedure in the step 3 and 4 of example 8 (method 2) by using the intermediate compound and 3-fluorobenzonitrile, 251mg (yield for final step: 93%, yellow solid) of the target compound was obtained.
[617] 1U NMR(400D, CDCI): δ 8.04~8.01(m, 2H), 7.61~7.56(m, 4H), 7.47~7.36(m, 4H).
[618]
[619] Intermediate (27) : Preparation of
4-chloro-2-(3-methoxy-benzyl)-5-thiophen-2-yl-thieno[2,3-d]pyrimidine
[620]
[621] According to the similar procedure in the step 3 and 4 of example 8 (method 2) by using the compound prepared in the step 2 of example 8 (method 2) and (3-methoxyphenyl)acetonitrile, 148mg (yield for final step: 71%, yellow oil) of the target compound was obtained.
[622] 1U NMR(400D, CDCI): δ 7.68~7.62(m, IH), 7.56(s, IH), 7.52~7.51(m, IH), 7.24(t,
J=7.8Hz, IH), 7.10-7.07 (m, IH), 6.96(s, IH), 6.93(d, J=7.7Hz, IH), 6.84(d, J=8.0Hz,
IH), 3.96(s, 2H), 3.73(s, 3H). [623] [624] Intermediate (28) : Preparation of 4-chloro-2-thiophen-2-yl-thieno[2,3-d] pyrimidin-5-carboxylic acid ethyl ester [625]
[626] According to the similar procedure in the step 1 to 4 of example 8 (method 2) by using the compound, ethyl pyruvate, 25mg (overall yield: 1%, white solid) of the target compound was obtained. [627] 1U NMR(400D, DMSO-d): δ 8.26(d, J=3.6Hz, IH), 8.02(s, IH), 7.91(d, J=3.6Hz,
IH), 7.24(t, J=4.0Hz, IH), 4.29(q, J=3.2Hz, 2H), 1.17(t, J=7.2Hz, 3H). [628] [629] Intermediate (29) : Preparation of
4-chloro-5-(3-methoxy-phenyl)-2-thiophen-2-yl-thieno[2,3-d]pyrimidine [630]
[631] According to the similar procedure in the step 3 and 4 of example 8 (method 2) by using the compound, 2-amino-4-(3-methoxy-phenyl)-thiophen-3-carboxylic acid methyl ester, prepared in the step 1 and 2 of example 8 (method 2) and l-(3-methoxy-phenyl)-ethanone, 1.17g (yield for 2 steps: 18%, yellow solid) of the target compound was obtained.
[632] 1U NMR(400D, CDCI): δ 8.10(m, IH), 7.53-7.51(m, IH), 7.35-7.17(m, 2H),
6.99-6.89(m, 3H).
[633]
[634] Intermediate (30) : Preparation of 3-(4-chloro-2-thiophen-2-yl-thieno[2,3-d] pyrimidin-5-yl)-phenol
[635]
[636] IM boron tribromide dichloromethane solution was slowly added to the solution of
4-chloro-5-(3-methoxy-phenyl)-2-thiophen-2-yl-thieno[2,3-d]pyrimidine (86mg, 0.24mmol) in dichloromethane (5ml) at O0C. Then the reaction mixture was stirred at 250C for 8 hours. After reaction, the reaction mixture was poured into dichloromethane, and washed with water. Combined organic layer was concentrated under reduced pressure. The residue was purified by column chromatography (n-hexane: ethyl acetate = 4:1) to give 63mg (yield: 71%, yellow solid) of the target compound.
[637] 1U NMR(400D, CDCI): δ 8.09-8.08(m, IH), 7.53-7.51(m, IH), 7.35-7.26(m, 2H),
7.17-7.15(m, IH), 6.99(m, 3H).
[638]
[639] Intermediate (31) : Preparation of [4-(4-chloro-5-phenyl-thieno[2,3-d] pyrimidin-2-yl)-phenyl-dimethyl-amine
[640]
[641] According to the similar procedure in the step 1 and 2 of example 8 (method 2) by using the acetophenone (200mg, 1.66mmol), intermediate compound, 2-amino-4-phenyl-thiophen-3-carboxylic acid methyl ester was obtained. Thereafter, according to the similar procedure in the step 3 and 4 of example 8 (method 2) by using the intermediate compound(217mg, 0.93mmol, 54%) and
4-(dimethylamino)-benzonitrile (270mg, 1.86mmol), 215mg (yield for 2 steps: 64%, old gold solid) of the target compound was obtained.
[642] 1U NMR(400D, CDCI); δ 8.40(d, J=9.2Hz, 2H), 7.45-7.43(m, 5H), 7.25(s, IH),
6.78(d, J=8.8Hz, 2H), 3.07(s, 6H).
[643]
[644] Intermediate (32) : Preparation of 4-(4-chloro-5-phenyl-thieno[2,3-d] pyrimidin-2-yl)-phenylamine
[645] Step 1. Preparation of 4-chloro2-(4-nitro-phenylV5-phenyl-thienor2.3-dlpyrimidine
[646]
[647] According to the similar procedure in the step 1 and 2 of example 8(method 2) by using the acetophenone (200mg, 1.66mmol), intermediate compound,
2-amino-4-phenyl-thiophen-3-carboxylic acid methyl ester was obtained. Thereafter, according to the similar procedure in the step 3 and 4 of example 8 (method 2) by using the intermediate compound (217mg, 0.93mmol) and 4-nitro-benzonitrile (275mg, 1.86mmol), 217mg (yield for 2 steps: 63%, yellow solid) of the target compound was obtained.
[648] 1U NMR(400D, CDCI); δ 8.74(d, J=8.0Hz, 2H), 8.36(d, J=8.0Hz, 2H), 7.52(s, IH),
7.48-7.46(m, 5H).
[649]
[650] Step 2. Preparation of 4-(4-chloro-5-phenyl-thieno[2.3-dl pyrimidin-
2-yl)-phenylamine
[651]
[652] The compound (215mg, 0.58mmol) prepared in the step 1 was dissolved in ethanol
(20ml). Therein, iron (290mg, 5.17mmol) and cone. HCl aqueous solution (0.2mL, 0. ImL/ 10OmL starting) were added stepwise, and then the reaction mixture was stirred at room temperature for 3 hours. After reaction, reaction mixture was filtered and neutralized with 2N NaOH aqueous solution, and aqueous layer was extracted with ethyl acetate. Combined organic layer was washed with brine and dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by column chromatography (n-hexane: ethyl acetate = 3:1) to give 170mg (yield: 86%, white solid) of the target compound.
[653] 1U NMR(400D, CDCI); δ 8.35(d, J=8.8Hz, 2H), 7.49-7.39(m, 5H), 7.28(s, IH),
6.76(d, J=8.4Hz, 2H), 4.01(brs, 2H).
[654]
[655] Intermediate (33) : Preparation of
4-chloro-2-furan-2-yl-5-thiophen-2-yl-thieno[2,3-d]pyrimidine
[656]
[657] According to the similar procedure in the step 3 and 4 of example 8(method 2) by using the 5'-amino-[2,3']bithiophenyl-4'-carboxylic acid methyl ester prepared in the step 2 of example 8(method 2) and 2-cyanofurane, 137mg (yield for final step: 72%, colorless solid) of the target compound was obtained.
[658] 1H-NMR^OOD, CDCI): δ 7.67(dd, /=1.6, 1.2Hz, IH), 7.53(s, IH), 7.44- 7.42(m,
2H), 7.17(dd, /=3.8, 1.2Hz, IH), 7.13-7.11(m, IH), 6.61(dd, /=3.6, 1.2Hz, IH).
[659]
[660] Intermediate (34) : Preparation of 4-chloro-2- methyl-
5-thiophen-2-yl-thieno[2,3-d]pyrimidine
[661]
[662] According to the similar procedure in the step 3 and 4 of example 8 (method 2) by using the compound, 5'-amino-[2,3']bithiophenyl-4'-carboxylic acid methyl ester prepared in the step 2 of example 8(method 2) and acetonitrile, 436mg (yield for 2 steps: 90%, yellow solid) of the target compound was obtained.
[663] 1U NMR(400D, CDCI): δ 7.73 (m, IH), 7.59 (m, IH), 7.46 (s, IH), 7.17 (m, IH),
2.37(s, 3H).
[664]
[665] Intermediate (35) : Preparation of 4-(4-chloro-5-thiophen-2-yl-thieno[2,3-d] pyrimidin-2-yl)-phenylamine
[666] Step 1. Preparation of 4-chloro-2-(4-nitrophenylV5-thiophen-2-yl-thienor2.3-dl pyrimidine
[667]
[668] According to the similar procedure in the step 3 and 4 of example 8(method 2) by using the 5'-amino-[2,3']bithiophenyl-4'-carboxylic acid methyl ester prepared in the step 2 of example 8(method 2) and 4-nitrobenzonitrile, 230mg (yield for 2 steps: 77%, yellow solid) of the target compound was obtained.
[669] 1U NMR(400D, CDCI): δ 8.72 (m, 2H), 8.35 (m, 2H), 7.66 (s, IH), 7.47 (m, IH)
7.19 (m, IH), 7.15 (m, IH).
[670]
[671 ] Step 2. Preparation of 4-(4-chloro-5-thiophen-2-yl-thienor2.3-dl pyrimidin-
2-ylVphenylamine
[673] The compound (50mg, 0.13mmol) prepared in the step 1 was dissolved in ethanol
(3ml). Therein, iron (Fe, 75mg, 1.34mmol), 12N HCl aqueous solution (0.0ImL) and water (0.2ml) were added, and the reaction mixture was stirred at 9O0C for 4 hours. After reaction, the reaction mixture was filtered and filtrate was concentrated. Therein, water was added and extracted with ethyl acetate (10ml). Combined organic layer was washed with brine(5ml) twice and dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was purified by column chromatography (dichloromethane:n-hexane = 1:1) to give 32mg (yield: 69%, yellow solid) of the target compound.
[674] 1U NMR(400D, CDCI): δ 7.99(d, J=4.0Hz, IH), 7.84(d, J=5.2Hz, IH), 7.27 -
7.25(m, 3H), 6.70(d, J=8.4Hz, 2H), 5.65(s, IH), 2.56(s, 2H).
[675]
[676] Intermediate (36) : Preparation of 4-chloro-5-thiophen-2-yl-thieno[2,3-d] pyrimidin-2-yl-amine
[677]
[678] According to the similar procedure in the step 3 and 4 of example 8(method 2) by using the compound (500mg, 2.1mmol) prepared in the step 2 of example 8 (method 2) and cyanamide, 130mg (yield for 2 steps: 23%, white solid) of the target compound was obtained.
[679] 1U NMR(400D, DMSO-d): δ 7.63(d, J=3.6Hz, IH), 7.45(d, J=5.2Hz, IH), 7.05(m,
2H), 6.62(br, 2H).
[680]
[681] Intermediate (37) : Preparation of
4-chloro-2-cyclopropyl-5-thiophen-2-yl-thieno[2,3-d]pyrimidine
[682]
[683] According to the similar procedure in the step 3 and 4 of example 8(method 2) by
using the 5'-amino-[2,3']bithiophenyl-4'-carboxylic acid methyl ester prepared in the step 2 of example 8(method 2) and 4-cyclopropylnitrile, 366mg (yield for 2 steps:
72%, yellow solid) of the target compound was obtained. [684] 1U NMR(400D, CDCI): δ 7.98 (s, IH), 7.68 (m, IH), 7.24 (m, IH), 7.16 (m, IH)
2.29 (m, IH), 1.60 (m, 2H), 1.10 (m, 2H). [685] [686] Intermediate (38) : Preparation of (4-chloro-2-thiophen-2-yl-thieno[2,3-d] pyrimidin-5-yl)-acetic acid ethyl ester
[687] Step 1. Preparation of 4-bromo-3-oxo-butyric acid ethyl ester
[688]
[689] Ethyl acetoacetate (ImI, 7.84mmol) was dissolved in chloroform, therein, bromine
(0.6ml, 11.76mmol) was added. The reaction mixture was stirred at room temperature for 18 hours. Sodium sulfite solution was added to quench the reaction, and ethyl acetate was added. Organic layer was washed with water and IN HCl aqueous solution, dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by column chromatography (n-hexane: ethyl acetate = 4:1) to give 800mg (yield: 49%, colorless oil) of the target compound.
[690] 1U NMR(400D, CDCI); δ 4.20(q, J=4.0Hz, 2H), 4.04(s, 2H), 3.69(s, 2H), 1.28(t, J
=8.0Hz, 3H).
[691]
[692] Step 2. Preparation of 2-amino-4-ethoxycarbonylmethyl-thiophen-3-carboxylic acid ethyl ester
[693]
[694] The compound (800mg, 3.83mmol) prepared in the step 1, ethyl cyanoacetate
(0.45mL, 4.0mmol) and sodium sulfide 9 hydrate (Na S-9H O, lOOOmg, 4.0mmol) were dissolved in ethanol (15ml). Therein, triethylamine (0.6mL, 4.0mmol) was slowly added, and the reaction mixture was stirred at 4O0C for 36 hours. After reaction, the reaction mixture was diluted with water and extracted with ethyl acetate. Combined organic layer was dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was purified by column chromatography (n-hexane: ethyl acetate = 4: 1) to give 70mg (yield: 8%, pale yellow solid) of the target compound.
[695] 1H-NMR^OOD, CDCI) δ 6.18(br, 2H), 6.00(s, IH), 4.19(m, 4H), 3.68(s, 2H),
1.27(m, 6H). [696] [697] Step 3. Preparation of (4-chloro-2-thiophen-2-yl-thieno[2.3-dl pyrimidin-
5-yl)-acetic acid ethyl ester [698]
[699] According to the similar procedure in the step 3 and 4 of example 8 (method 2) by using the compound (700mg, 1.62mmol) prepared in the step 2, 60mg (yield for 2 steps: 9%, white solid) of the target compound was obtained. [700] 1U NMR(400D, CDCI): δ 8.07(dd, J=LlBz, J=3.6Hz, IH), 7.50(dd, J=LlBz, J
=4.8Hz, IH), 7.33(s, IH), 7.15(m, 2H), 4.24(q, J=6.8Hz, 2H), 4.07(s, 2H), 1.27 (t, J
=6.8Hz, 3H). [701] [702] Intermediate (39) : Preparation of 4-chloro-2-thiophen-2-yl-thieno[2,3-d] pyrimidin-5-carboxylic acid ethyl ester [703] Step 1. Preparation of 4-(N'- 1 -bu- toxycarbonyl-hydrazinoV2-thiophen-2-yl-thienor2.3-dlpyrimidin-5-carboxylic acid ethyl ester [704]
[705] 4-Chloro-2-thiophen-2-yl-thieno[2,3-d]pyrimidin-5-carboxylic acid ethyl ester
(80mg, 0.25mmol), prepared in the intermediate step (28) was dissolved in THF (5ml). Therein, ?-butyl carbazate (98mg, 0.74mmol) was added, and the reaction mixture was refluxed for 12 hours. After reaction, the solvent was removed under reduced pressure then the mixture was extracted with dichloromethane. The organic layer was washed with saturated sodium chloride aqueous solution. Combined organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by column chromatography (n-hexane: ethyl acetate = 4:1) to give lOOmg (yield: 95%, white solid) of the target compound.
[706] 1U NMR(400D, CDCI): δ 10.77(s, IH), 8.22(s, IH), 7.99(d, J=3.6Hz, IH), 7.45(d,
J=4.8Hz, IH), 7.12(t, J=4.4Hz, IH), 4.42(qt, J=7.2Hz, 2H), 1.58(s, 9H), 1.43(t, J =7.0Hz, 3H).
[707]
[708] Step 2. Preparation of N'-f5-hvdroxymethyl-2-thiophen-2-yl-thienor2.3-dl pyrimidin-4-yls)hvdrazine carboxylic acid t -butyl ester [709]
[710] The compound (lOOmg, 0.23mmol) prepared in the step 1 was dissolved in THF
(5ml), therein, 2N lithium borohydride in THF solution (0.32OmL, 0.65mmol) was added. The reaction mixture was stirred at room temperature for 24 hours. Cold IN HCl aqueous solution was added to quench the reaction, and aqueous layer was extracted with ethyl acetate. Combined organic layer was washed with brine and dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by column chromatography (dichloromethane: methanol = 30:1) to give 85mg (yield: 96%, white solid) of the target compound.
[711] 1U NMR(400D, CDCI): δ 9.34(s, IH), 7.98(d, J=3.6Hz, IH), 7.44(d, J=4.8Hz, IH),
7.30(t, J=4.4Hz, IH), 6.79(s, IH), 4.77(d, J=4.8Hz, 2H), 3.37(s, 3H), 1.53(s, 9H).
[712]
[713] Step 3. Preparation of N'-(5-methoxymethyl-2-thiophen-2-yl-thieno[2.3-dl pyrimidin-4-yl)hvdrazine carboxylic acid t -butyl ester
[714]
[715] The compound (1 lOmg, 0.29mmol) prepared in the step 2 was dissolved in dried
THF (10ml). Thereafter, the temperature was lowered into O0C, and therein, sodium hydride (12mg, 0.31mmol) was added, and the reaction mixture was stirred at O0C for 1 hour. Iodomethane (36D, 0.58mmol) was added, then the reaction mixture was warmed up to room temperature slowly and stirred at that temperature for 2 days. Ice water was added to quench the reaction, and aqueous layer was extracted with ethyl acetate. Combined organic layer was washed with brine and dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by column chromatography (dichloromethane: methanol = 30:1) to give 34mg (yield: 30%, white solid) of the target compound.
[716] 1U NMR(400D, CDCI): δ 7.95(d, J=3.6Hz, IH), 7.90(s, IH), 7.54(d, J=4.0Hz, IH),
7.43(s, IH), 7.14(t, J=4.8Hz, IH), 4.86(s, 2H), 3.36(s, 3H), 1.43(s, 9H).
[717] [718] Step 4. Preparation of (5-methoxymethyl-2-thiophen-2-yl-thieno[2.3-d1 pyrimidin- 4-yls)hvdrazine
[719]
[720] The compound (34mg, 0.09mmol) prepared in the step 3 was dissolved in 1,4-dioxane (5ml) and chloroform (2ml). Therein, 3.6M HCl in 1,4-dioxane solution (2ml) was added, and the reaction mixture was stirred at room temperature for 2 days. The cold saturated sodium hydrogen carbonate aqueous solution was added and the reaction mixture was stirred for 1 hour, and the aqueous layer was extracted with chloroform, and the organic layer was washed with brine and dried over anhydrous sodium sulfate and concentrated under reduced pressure to give 20mg (yield: 79%, bright brown oil) of the target compound.
[721] [722] Example 52 . 3-methyl-l-{2-[4-(2-piperidin-l-yl-ethoxy)-phenyl] - 5-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-ylamino}-pyrrole-2,5-dione hydrochloride
[723] Step 1. Preparation of 4-chloro-2-[4-(2-piperidin-l-yl-ethoxy)-phenyl1 - 5-thiophen-2-yl-thieno[2.3-d1pyrimidine [724]
[725] The intermedial (12), 4-(4-chloro-5-thiophen-2-yl-thieno[2,3-d] pyrimidin- 2-yl)-phenol (lOOmg, 0.29mmol), prepared by the procedure in step 1 to step 4 of example 8 (method 2), triphenylphosphine (99mg, 0.38mmol) and 1-piperidinethanol (42D, 0.32mmol) were dissolved in THF (10ml). Thereafter, the temperature was lowered into O0C, and therein diisopropylazodicarboxylate (DIAD, 63D, 0.32mmol) was added slowly, and the reaction mixture was stirred at room temperature for overnight. Solvent was concentrated under reduced pressure. The residue was purified by column chromatography (dichloromethane: methanol = 10:1) to give 50mg (yield: 38%, colorless oil) of the target compound.
[726] 1U NMR(400D, DMSC^ ); δ 8.46(d, J=8.8Hz, 2H), 7.48(s, IH), 7.43(d, J=3.6Hz, IH), 7.18(d, J=3.6Hz, IH), 7.13(t, J=4.2Hz, IH), 7.01(d, J=8.8Hz, 2H), 4.20(t, J
=6.0Hz, 2H), 2.82(t, J=6.0Hz, 2H), 2.54(br, 4H), 1.65-1.60(m, 4H), 1.47-146(m, 2H). [727] [728] Step 2. Preparation of 3-methyl-l-(2-[4-(2-piperidin-l-yl-ethoxy)-phenyl1 -
5-thiophen-2-yl-thieno[2.3-dlpyrimidin-4-ylamino ) -pyrrole-2.5-dione hydrochloride [729]
[730] According to the similar procedure in the step 5 and step 6 of example 8(method 1) by using the compound (50mg, 0.1 lmmol) prepared in the step 1, 53mg (yield for 2 steps: 82%, yellow solid) of the target compound was obtained.
[731] 1U NMR(400D, DMSO-d): δ 10.78(s, IH), 8.62(s, IH), 8.13(d, J=8.8Hz, 2H),
IJl(S, IH), 7.69(d, J=5.2Hz, IH), 7.32(d, J=3.2Hz, IH), 7.21(t, J=4.4Hz, IH), 7.08(d, J=8.8Hz, 2H), 6.96(s, IH), 4.52-3.47(m, 2H), 3.52-3.41(m, 4H), 2.99-2.97(m, 2H), 2.14(s, 3H), 1.90- 1.79(m, 4H), 1.70-1.67 (m, 2H).
[732]
[733] Example 53 . 3-methyl-l-{2-[3-(2-piperidin-l-yl-ethoxy)-phenyl] -
5-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-ylamino}-pyrrole-2,5-dione hydrochloride
[734] Step 1. Preparation of 4-chloro-2-[3-(2-piperidin-l-yl-ethoxy)-phenyl1 -
5-thiophen-2-yl-thieno[2.3-d1pyrimidine
[735]
[736] According to the similar procedure in the step 1 example 52 by using the intermediate (22), 3-(4-chloro-5-thiophen-2-yl-thieno[2,3-d]pyrimidin-2-yl)-phenol, prepared by the procedure in the step 1 to step 4 of example 8 (method 2), 34mg (yield: 23%, colorless solid) of the target compound was obtained.
[737] 1U NMR(400D, CDCI): δ 8.14-8.09(m, 2H), 7.69-7.64(m,lH), 7.55(s, IH),
7.46-7.39(m, 2H), 7.19-7.05(m, 2H), 4.26(t, J=6.0Hz, 2H), 2.86(t, J=6.0Hz, 2H), 2.61-2.57 (m, 4H), 1.68-1.47(m, 6H).
[738]
[739] Step 2. Preparation of 3-methyl-l-(2-r3-(2-piperidin-l-yl-ethoxyVphenyll -
5-thiophen-2-yl-thienor2.3-dlpyrimidin-4-ylamino)-pyrrole-2.5-dione hydrochloride
[740]
[741] According to the similar procedure in the step 5 and step 6 of example 8 (method 1) by using the compound (34mg, 0.07 mmol) prepared in the step 1, 27 mg (yield for final step: 50%, yellow solid) of the target compound was obtained.
[742] 1U NMR(400D, DMSO-d): δ 10.47(br, IH), 8.73(s, IH), 7.85-7.70(m, 4H), 7.43(t, J=8.0Hz, IH), 7.33(d, J=2.8Hz, IH), 7.23(t, J=4.0Hz, IH), 7.13(d, J=8.0Hz, IH), 7.07(s, IH), 4.43(br, 2H), 3.51(br, 4H), 3.03(br, 2H), 2.17(s, 3H), 1.81-1.69(m, 4H), 1.40(m, 2H).
[743] [744] Example 54 . l-[6-(4-hydroxy-phenyl)-2-thiophen-2-yl-thieno[2,3-d] pyrimidin- 4-ylamino] -3-methyl-pyrrole-2,5-dione hydrochloride
[745] Step 1. Preparation of (4-methoxy-phenyl)-acetyl chloride [746]
OH
0
"C ^0XXf1
[747] (4-methoxy-phenyl)-acetic acid (5g, 30mmol) and oxalyl chloride (5.25ml, 60mmol) were dissolved in benzene (15ml). The reaction mixture was stirred at room temperature for 3.5 hours. After reaction, reaction mixture was concentrated under reduced pressure. The residue was used to next step.
[748] [749] Step 2. Preparation of (4-methoxy-phenyl)-acetaldehvde [750]
Cl H
0 0
[751] The temperature of DMF (35ml) was lowered into O0C. Therein, cadmium chloride (1Og, 54.5mmol) was slowly added, and stirred 30 minutes. The reaction mixture was filtered and washed with carbon tetrachloride to give CdCl Dl.5DMF. CdCEl.5DMF
& 2 2
(20.5g, 21 mmol) and sodium borohydride (NaBH , 1.14g, 30mmol) were added to ace-
4 tonitrile (150ml) and HMPA (7.5ml) at -50C, and stirred 5 minutes. Thereafter, solvent of the compound (5.05g, 27.3mmol) prepared in the step 1 in acetonitrile was added to the mixture and then stirred for 5minutes. The reaction mixture was diluted with water, acidified with 10% HCl aqueous solution to pH 3, and extracted with ethyl acetate. Combined organic layer was dried over anhydrous magnesium sulfate and con-
centrated under reduced pressure to give 2.16g (yield for 2 steps: 48%, colorless oil) of the target compound. [752] 1U NMR(400D, CDCI): δ 9.62(s, IH), 7.06(d, J=8.4Hz, 2H), 6.85(d, J=8.4Hz, 2H),
3.71(s, 3H), 3.53(s, 2H). [753] [754] Step 3. Preparation of 2-amino-5-(4-methoxy-phenyl)-thiophen-3-carboxyric acid ethyl ester [755]
„ xj 6 ;Λ
[756] The compound (498mg, 3.316mmol) prepared in the step 2, ethyl cyanoacetate
(0.353ml, 3.316mmol) and sulfur (106mg, 3.316mmol) were dissolved in N,N-dimethylformamide (3ml). Therein, triethylamine (0.254ml, 1.824mmol) was added slowly, and the reaction mixture was stirred at 5O0C for 28 hours. After reaction, the reaction mixture was diluted with water and extracted with ethyl acetate. Combined organic layer was dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was purified by column chromatography (n-hexane: ethyl acetate = 10:1) to give 550mg (yield: 60%, pale yellow solid) of the target compound.
[757] 1U NMR(400D, CDCI): δ 7.37(d, J=8.8Hz, 2H), 7.01(s, IH), 6.87(d, J=8.8Hz, 2H),
5.95(br, 2H), 4.29(q, J=6.8Hz, 2H), 3.81(s, 3H), 1.37(t, J=6.8Hz, 3H)
[758]
[759] Step 4. Preparation of 6-C4-methoxy-phenylV2-thiophen-2-yl-thienor2.3-dl pyrimidin-4-ol
[760]
[761] According to the similar procedure in the step 3 of example 8 (method 2) by using the compound prepared in the step 3, 410mg (yield: 61%, yellow solid) of the target compound was obtained. [762] 1H-NMR (400D, DMSC^ ): δ 8.23(d, J=8.0Hz, IH), 7.90(d, J=5.2Hz, IH), 7.70(d,
J=8.4Hz, 2H), 7.68(s, IH), 7.25(t, J=4.0Hz, IH), 7.01(d, J=8.4Hz, 2H), 3.80(s, 3H) [763] [764] Step 5. Preparation of 4-chloro-6-(4-methoxy-phenyl)-2-thiophen-2-yl-thieno[2.3-d lpyrimidine [765]
[766] According to the similar procedure in the step 4 of example 8(method 2) by using the compound prepared in the step 4, 400mg (yield: 92%, yellow solid) of the target compound was obtained. [767] 1U NMR(400D, CDCI): δ 8.06(dd, /=3.6, 1.2Hz, IH), 7.65(d, /=8.8Hz, 2H),
7.50(dd, /=5.2, 1.2Hz, IH), 7.41(s, IH), 7.16(dd, /=5.2, 3.6Hz, IH), 6.98(d, /=8.8Hz,
2H), 3.87(s, 3H) [768] [769] Step 6. Preparation of 4-(4-chloro-2-thiophen-2-yl-thieno[2.3-dl pyrimidin-
6-yl)-phenol
[770]
[771] According to the similar procedure in the step 1 of intermediate 3 by using the compound prepared in the step 5, 400mg (yield: 92%, yellow solid) of the target compound was obtained. [772] 1U NMR(400D, DMSO-d): δ 10.1(br, IH), 7.99(dd, /=3.6, 1.2Hz, IH), 7.79(dd, /
=4.8, 1.2Hz, IH), 7.75(dd, /=8.8, 2.0Hz, 2H), 7.24(dd, /=4.8, 3.6Hz, IH), 6.91(dd, /
=8.8, 2.0Hz, 2H) [773] [774] Step 7. Preparation of l-[6-(4-hvdroxy-phenyl)-2-thiophen-2-yl-thieno[2.3-dl pyrimidin-4-ylaminol-3-methyl-pyrrole-2.5-dione [775]
[776] According to the similar procedure in the step 5 of example 1 by using the compound prepared in the step 6, lOOmg (yield: 76%, yellow solid) of the target compound was obtained. [777] 1H-NMR (400D, CDCI) δ 10.67(br, IH), 9.98(br, IH), 7.79(s, IH), 7.69-7.67(m,
2H), 7.56(dd, /=8.8, 2.0Hz, 2H), 7.14(t, /=4.4Hz, IH), 7.01 (d, /=2.0Hz, IH), 6.92(dd,
/=8.8, 2.0Hz, 2H), 2.18(d, /=2.0Hz, 3H) [778] [779] Step 8. Preparation of l-[6-(4-hvdroxy-phenyl)-2-thiophen-2-yl-thieno[2.3-dl
nvrimidin-4-v1aminol-3-methvl-pyrrole-2.5-dione hydrochloride
[780]
[781] According to the similar procedure in the step 2 of example 2 by using the compound prepared in the step 8, 70mg (yield: 65%, yellow solid) of the target compound was obtained.
[782] 1H NMR(400D, DMSO-d): δ 10.73(br, IH), 7.84(s, IH), 7.69-7.67(m, 2H), 7.56(dd, /=8.8, 2.0Hz, 2H), 7.16-7.12(m, IH), 7.01(d, /=2.0Hz, IH), 6.93(dd, /=8.8, 2.0Hz, 2H), 2.18(d, /=2.0Hz, 3H)
[783] [784] Compounds listed below were prepared by the similar procedure in above Example 54.
[785] Example 55 . l-[6-(4-methoxy-phenyl)-2-thiophen-2-yl-thieno[2,3-d] pyrimidin- 4-ylamino] -3-methyl-pyrrole-2,5-dione hydrochloride
[786] [Table 4] [787]
[788] [789] Example 56 . l-{6-[4-(2-dimethylamino-ethoxy)-phenyl] -
5-methyl-2-thiophen-2-yl-furo[2,3-d]pyrimidin-4-ylamino}-3-methyl-pyrrole-2,5-d ione hydrochloride
[790] Steo 1. Preparation of 2-bromo- l-(4-methoxv-phenvlVproDan- 1-one [791]
[792] 4'-methoxypropiophenone (10.7ml, 70mmol) and CuBr (31.2g, 140mmol) were added to 1,4-dioxane (200ml). The reaction mixture was refluxed for 6 hours. After cooling to room temprature, the reaction mixture was diluted with water and extracted with ethyl acetate. Combined organic layer was dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was purified by column
chromatography (n-hexane: ethyl acetate = 15:1) to give 13. Ig (yield: 76%, pale yellow solid) of the target compound. [793] 1U NMR(400D, CDCI): δ 8.03(d, J = 8.8 Hz, 2H), 7.08(d, J = 8.8 Hz, 2H), 5.79(q,
J = 6.4 Hz, IH), 3.87(s, 3H), 1.77(d, J= 6.4 Hz, 3H) [794] [795] Step 2. Preparation of
2-amino-5-(4-methoxy-phenyl)-4-methyl-furan-3-carbonitrile [796]
[797] The compound (2.43g, lOmmol) prepared in the step 1 and malononitrile (1.Og,
15mmol) were dissolved in dried N,N-dimethylformamide (10ml). Thereafter, the temperature was lowered into O0C. Therein, diethylamine (3.1ml, 30mmol) was added slowly with maintaining a temperature of the mixture below 4O0C, and the reaction mixture was stirred for 3 hours. The reaction mixture was poured into water (60ml) and filtered, washed with water and n-hexane. The residue was purified by recrys- tallization with ethanol to give 1.42g (yield: 68%, yellowish brown solid) of the target compound.
[798] 1U NMR(400D, CDCI): δ 7.45(br, 2H), 7.36(d, J = 8.8 Hz, 2H), 6.98 (d, J = 8.8 Hz,
2H), 3.77(s, 3H), 2.11(s, 3H)
[799]
[800] Step 3. Preparation of 6-(4-methoxy-phenyl)-5-methyl-2-thiophene-2-yl-furo[2.3-d lpyrimidin-4-ylamine
[801]
[802] The compound (910mg, 4mmol) prepared in the step 2 was dissolved in saturated
HCl in 1,4-dioxane solution (15ml) and 2-thiophenecarbonitrile (1.11ml, 12mmol) was added. The reaction mixture was stirred for 12 hours. The reaction mixture was diluted with saturated sodium hydrogen carbonate solution, and extracted with ethyl acetate. The organic layer was dried over dried over anhydrous magnesium sulfate. The residue was filtered with acetone and diethyl ether and washed with water and n-hexane to give 511mg (yield: 38%, brown solid) of the target compound.
[803] 1H-NMR (400D, DMSC^ ): δ 8.26(d, J=3.6Hz, IH), 7.89(d, J=4.4Hz, IH), 7.66(d,
J=8.8Hz, 2H), 7.25-7.23(m, IH), 7.09(d, J=8.8Hz, 2H), 3.82(s, 3H), 2.50(s, 3H)
[804]
[805] Step 4. Preparation of
4-chloro-6-(4-methoxy-phenyls)-5-methyl-2-thiophen-2-yl-furor2.3-dlpyrirnidine [806]
[807] The compound (500mg, 1.5mmol) prepared in the step 3 and isoamylnitrite
(0.42ml, 3.2mmol) were dissolved in carbon tetrachloride (50ml). The reaction mixture was refluxed for 14 hours. Thereafter, the reaction mixture was cooled at room temper ature, and removed solvent under reduced pressure. The residue was purified by column chromatography (n-hexane: ethyl acetate = 12:1) to give 37mg (yield: 7%, yellow solid) of the target compound.
[808] 1U NMR(400D, CDCI): δ 8.06(dd, /=3.8, 1.2Hz, IH), 7.76(d, /=8.8Hz, 2H),
7.50-7.49(m, IH), 7.16-7.14(m, IH), 7.04(d, /=8.8Hz, 2H), 3.89(s, 3H), 2.63(s, 3H)
[809]
[810] Step 5. Preparation of 4-(4-chloro-5-methyl-2-thiophene-2-yl-furor2.3-dl pyrimidin-6-yl)-phenol
[811]
[812] The compound (35mg, O.lmmol) prepared in the step 4 was dissolved in dichloromethane (20ml). Therein, IM boron tribromide(BBr ) in dichloromethane solution (0.25ml, 0.25mmol) was added, and the reaction mixture was stirred at room temperature for 12 hours. After reaction, the reaction mixture was poured into ethyl acetate, and washed with water and saturated sodium hydrogen carbonate aqueous solution. Combined organic layer was dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was purified by column chromatography (n-hexane: ethyl acetate = 6:1) to give 31mg (yield: 91 %, yellow solid) of the target compound.
[813] 1H-NMR (400D, CDCI) δ 8.07-8.05(m, IH), 7.70(d, /=8.8, 2H), 7.50- 7.48(m, IH),
7.16-7.14(m, IH), 6.97 (d, /=8.8, 2H), 2.57(s, 3H)
[814]
[815] Step 6. Preparation of (2-r4-(4-chloro-5-methyl-2-thiophene-2-yl-furor2.3-dl pyrimidin-6-yl)-phenoxyl-ethyl)-dimethyl-amine
[817] The compound (31mg, 0.09mmol) prepared in the step 5,
N,N-dimethylethanolamine (0.085ml, 0.18mmol) and triphenylphosphine (PPh , 47 mg, 0.18mmol) were diluted with in THF (ImI). Therein diidopropylazodicarboxylate (0.035ml, 0.18mmol) was added. The reaction mixture was stirred for 36 hours. The solvent was removed under reduced pressure. The residue was purified by column chromatography (chloroform:methanol = 9:1) to give 15mg (yield: 40%, yellow solid) of the target compound.
[818] 1U NMR(400D, CDCD: δ 8.10-8.09(m, IH), 7.93(d, /=8.8, 2H), 7.50- 7.48(m, IH), 7.18-7.16(m, IH), 7.23(d, /=8.8, 2H), 4.18-4.15(m, 2H), 2.83-2.81(m, 2H), 2.67(s, 3H), 2.40(s, 6H)
[819] [820] Step 7. Preparation of (244-(4-hydrazino-5-methyl-2-thiophene-2-yl-furor2.3-dl pyrimidin-6-yl)-phenoxyl-ethyl)-dimethyl-amine
[821]
[822] The compound (15mg, 0.036mmol) prepared in the step 6 and hydrazine monohydrate (5D, O.lmmol) were dissolved in THF (3ml). The reaction mixture was refluxed for 5 hours. After reaction, reaction mixture was concentrated under reduced pressure. The residue was used to the next step without further purification.
[823] [824] Step 8. Preparation of l-(6-[4-(2-dimethylamino-ethoxy)-phenyll - 5-methyl-2-thiophene-2-yl-furo[2.3-dlpyrimidin-4-ylamino)-3-methyl-pyrrole-2.5-dio ne
[825]
[826] The compound prepared in the step 7 was dissolved in chloroform (3ml). Therein, citraconic anyhdride (89D, O.lmmol) was added. The reaction mixture was refluxed for 12 hours. The solvent was removed under reduced pressure. The residue was purified
by column chromatography (chloroform: methanol = 7:1) to give 12mg (yield: 66%, yellow solid) of the target compound.
[827] 1U NMR(400D, CDCD: δ 7.77(dd, /=3.6, 1.2Hz, IH), 7.63(d, /=8.8Hz, 2H), 7.35(dd, /=5.0, 1.2Hz, IH), 7.06(dd, /=5.0, 4.0Hz, IH), 7.02(d, /=8.8Hz, 2H), 6.63(q, /=1.6Hz, IH), 4.20(t, /=5.6Hz, 2H), 2.89(t, /=5.2Hz, 2H), 2.52(s, 3H), 2.44(s, 6H), 2.27(d, /=1.6Hz, 3H)
[828] [829] Step 9. Preparation of l-(6-[4-(2-dimethylamino-ethoxy)-phenyll - 5-methyl-2-thiophene-2-yl-furo[2.3-dlpyrimidin-4-ylamino)-3-methyl-pyrrole-2.5-dio ne hydrochloride
[830]
[831] The compound (12mg, 0.036mmol) prepared in the step 8 was dissolved in 1,4-dioxane (ImI). Therein, 4N HCl 1,4-dioxane solution(0.10ml, 0.4mmol) was added, and the reaction mixture was stirred for 1 hour. The resulting solid was filtered and washed with 1,4-dioxane and ethyl acetate to give 12mg (yield: 93%, yellow solid) of the target compound.
[832] 1U NMR(400D, DMSO-d): δ 10.23(br, IH), 9.59(s, IH), 7.77(d, J=SABz, 2H), 7.71-7.67(m, 2H), 7.20(d, J=SABz, IH), 7.15-7.13(m, 2H), 7.01(s, IH), 4.44(br, 2H), 3.55(br, 2H), 2.87(d, /=4.4Hz, 6H), 2.59(s, 3H), 2.18(s, 3H)
[833] [834] Example 57 . l-[6-(4-methoxy-phenyl)-5-methyl-2-thiophen-2-yl-thieno[2,3-d] pyrimidin-4-ylamino] -3-methyl-pyrrole-2,5-dione hydrochloride
[835] Step 1. Preparation of 2-amino-5-(4-methoxy-phenylV4-methyl-thiophen-3-carboxylic acid ethyl ester [836]
[837] l-(4-methoxy-phenyl)-propan-2-one (3.08ml, 20mmol), ethyl cyanoacetate (2.13ml, 22mmol) and sulfur (704mg, 20mmol) were dissolved in ethanol (15ml). Therein, di- ethylamine (2.07ml, 20mmol) was added slowly, and the reaction mixture was stirred at room temperature for 36 hours. After reaction, the reaction mixture was poured into ethyl acetate, and washed with water. Combined organic layer was dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue
was purified by column chromatography (n-hexane: ethyl acetate = 10:1) to give 3.79g
(yield: 65%, pale yellow solid) of the target compound. [838] 1U NMR(400D, CDCI): δ 7.39(br, 2H), 7.23(d, J=8.8Hz, 2H), 6.96(d, J=8.8Hz,
2H), 4.19(q, J=6.8Hz, 2H), 3.76(s, 3H), 2.19(s, 3H), 1.26(t, J=6.8Hz, 3H) [839] [840] Step 2. Preparation of
6-(4-methoxy-phenyl)-5-methyl-2-thiophen-2-yl-thieno[2.3-dlpyrimidin-4-ol [841]
[842] The compound (874mg, 3mmol) prepared in the step 1 was dissolved in saturated
HCl in 1,4-dioxane solution (10ml). Therein, 2-thiophencarbonitrile (0.419ml, 4.5mmol) was added, and the reaction mixture was stirred for 12 hours. After reaction, the reaction mixture was poured into saturated sodium bicarbonate aqueous solution. The resulting solid was filtered and washed with water and ethyl acetate to give 948mg (yield: 93%, yellow solid) of the target compound.
[843] 1U NMR(400D, DMSO-d): δ 8.25(d, J=3.6Hz, IH), 7.89(d, J=4.8Hz, IH), 7.46(d, J
=8.8Hz, 2H), 7.25(t, J=4.8Hz, IH), 7.07(d, J=8.8Hz, 2H), 3.81(s, 3H), 2.54(s, 3H)
[844]
[845] Step 3. Preparation of
4-chloro-6-(4-methoxy-phenylV5-methyl-2-thiophen-2-yl-thienor2.3-dlpyrimidine
[846]
[847] The compound (948mg, 2.79mmol) prepared in the step 2 was dissolved in phos- phrousoxy chloride (POCl , 5ml). Thereafter, the reaction mixture was refluxed for 3 hours. After reaction, the reaction mixture was poured into saturated sodium bicarbonate aqueous solution. The resulting solid was filtered and washed with water and n-hexane to give 948mg (yield: 91%, yellow solid) of the target compound.
[848] 1U NMR(400D, CDCI): δ 8.07(d, J=3.6Hz, IH), 7.51(d, J=4.8Hz, IH), 7.44(d, J
=8.8Hz, 2H), 7.16(t, J=4.8Hz, IH), 7.02(d, J=8.8Hz, 2H), 3.88(s, 3H), 2.65(s, 3H)
[849]
[850] Step 4. Preparation of l-r6-(4-methoxy-phenylV5-methyl-2-thiophen-2-yl-thienor2.3-dlpyrimidin-4-ylaminol -3-methyl-pyrrole-2.5-dione hydrochloride
[852] According to the similar procedure in the step 5 and 6 of example 8(method 1) by using the compound prepared in the step 3, 150mg (yield for final step: 78%, yellow solid) of the target compound was obtained. [853] 1U NMR(400D, DMSO-d): δ 9.66(s, IH), 7.70-7.68(m, 2H), 7.49(d, J=8.8Hz, 2H),
7.16-7.09(m, 3H), 7.01(d, J=2.0Hz, IH), 3.82(s, 3H), 2.62(s, 3H), 2.18(d, J=2.0Hz,
3H) [854] [855] Compounds listed below were prepared by the similar procedure in above Example
57. [856] Example 58 . l-[6-(4-hydroxy-phenyl)-5-methyl-2-thiophen-2-yl-thieno[2,3-d] pyrimidin-4-ylamino] -3-methyl-pyrrole-2,5-dione hydrochloride [857] Example 59 .
[5-methyl-4-(3-methyl-2,5-dioxo-2,5-dihydro-pyrrol-l-ylamino)-2-thiophen-2-yl-t hieno[2,3-d]pyrimidin-6-yl]-acetic acid methyl ester hydrochloride [858] Example 60 . l-[6-(3-hydroxy-phenyl)-5-methyl-2-thiophen-2-yl-thieno[2,3-d] pyrimidin-4-ylamino]-3-methyl-pyrrole-2,5-dione [859] Example 61 .
5-methyl-4-(3-methyl-2,5-dioxo-2,5-dihydro-pyrrol-l-ylamino)-2-thiophen-2-yl-thi eno[2,3-d]pyrimidin-6-carboxylic acid amide hydrochloride [860] Example 62 . l-[6-(3-methoxy-phenyl)-5-methyl-2-thiophen-2-yl-thieno[2,3-d] pyrimidin-4-ylamino]-3-methyl-pyrrole-2,5-dione [861] Example 63 .
5-methyl-4-(3-methyl-2,5-dioxo-2,5-dihydro-pyrrol-l-ylamino)-2-thiophen-2-yl-thi eno[2,3-d]pyrimidin-6-carboxylic acid methyl ester hydrochloride [862] Example 64 . l-(6-methoxy-5-methyl-2-thiophen-2-yl-thieno[2,3-d] pyrimidin-
4-ylamino)-3-methyl-pyrrole-2,5-dione hydrochloride [863] Example 65 . l-[6-(4-methoxy-benzyl)-5-methyl-2-thiophen-2-yl-thieno[2,3-d] pyrimidin-4-ylamino] -pyrrole-2,5-dione hydrochloride [864] Example 66 . l-[6-(4-hydroxy-benzyl)-5-methyl-2-thiophen-2-yl-thieno[2,3-d] pyrimidin-4-ylamino] -pyrrole-2,5-dione hydrochloride [865] Example 67 .
3-methyl-l-[5-methyl-6-(4-nitrophenyl)-2-thiophen-2-yl-thieno[2,3-d]pyrimidin-4- ylamino] -pyrrole-2,5-dione hydrochloride
[866] Example 68 . 3-methyl-l-(6-phenyl-2-thiophen-2-yl-thieno[2,3-d] pyrimidin-
4-ylamino)-pyrrole-2,5-dione hydrochloride [867] Example 69 .
3-[5-methyl-4-(3-methyl-2,5-dioxo-2,5-dihydro-pyrrol-l-ylamino)-2-thiophen-2-yl- thieno[2,3-d]pyrimidin-6-yl]-propionic acid ethyl ester [868] Example 70 . l-(6-hydroxymethyl-5-methyl-2-thiophen-2-yl-thieno[2,3-d] pyrimidin-4-ylamino)-3-methyl-pyrrole-2,5-dione hydrochloride [869] Example 71 . l-(6-methoxymethyl-5-methyl-2-thiophen-2-yl-thieno[2,3-d] pyrimidin-4-ylamino)-3-methyl-pyrrole-2,5-dione hydrochloride [870] [Table 5]
[871]
[873] [874] Intermediate (40) : Preparation of
(4-chloro-5-methyl-2-thiophen-2-yl-thieno[2,3-d]pyrimidin-6-yl)-acetic acid methyl ester
[875] Step 1. Preparation of 4-oxo-pentanoic acid methyl ester [876]
0
OH cone H2 SO4 O Me
0 M eOH1 reflux, 1 8hr 0
[877] 4-oxo-pentanoic acid (Ig, 8.61mmol) and catalyst amount of sulfuric acid were dissolved in methanol (10ml). The reaction mixture was refluxed to give 740mg (yield: 66%, colorless oil) of the target compound.
[878] [879] Step 2. Preparation of (4-chloro-5-methyl-2-thiophen-2-yl-thienor2.3-dl pyrimidin- 6-ylVacetic acid methyl ester
[880]
[881] According to the similar procedure in the step 1 to 3 of example 57 by using the compound prepared in the step 1, 181mg (yield for final step: 85%, yellow oil) of the target compound was obtained.
[882] 1U NMR(400D, CDCD: δ 8.22(d, J=3.6Hz, IH), 7.87(d, J=5.1Hz, IH), 7.22(t, J=4.3Hz, IH), 3.94(s, 2H), 3.65(s, 3H), 2.41(s, 3H)
[883] [884] Intermediate (41) : Preparation of 4-chloro-6-(3-methoxy-phenyl)-5-methyl-2-thiophen-2-yl-thieno[2,3-d]pyrimidine
[885]
[886] According to the similar procedure in the step 1 to 3 of example 57 by using l-(2-methoxy-phenyl)-propan-2-one, 330mg (yield for final step: 89%, yellow solid) of the target compound was obtained.
[887] 1U NMR(400D, CDCI): δ 8.09(dd, J=3.6Hz, IH), 7.52(dd, J=4.8Hz, IH), 7.41(t,J
=8Hz, IH), 7.17(dd, J=5.2Hz, IH), 7.07 (d, J=6.8Hz, IH), 7.03-6.97 (m, 2H), 3.87(s, 3H), 2.67(s, 3H)
[888] [889] Intermediate (42) : Preparation of 4-chloro-6-(3-hydroxy-phenyl)-5-methyl-2-thiophen-2-yl-thieno[2,3-d]pyrimidine
[890]
[891] The intermediate (41) (250mg, 0.67mmol) was dissolved in IM boron tribromide dichloromethane solution (0.28ml, 1.67mmol) slowly, and the reaction mixture was stirred at room temprature for 12 hours. After reaction, the reaction mixture was poured into saturated sodium hydrogen carbonate aqueous solution. The resulting solid was filtered and washed with water and ethyl acetate to give 1 lOmg (yield: 55%, yellow solid) of the target compound.
[892] 1U NMR(400D, CDCD: δ 9.88(br, IH), 8.01(t, IH), 7.85(d, J=5.2Hz, IH), 7.36(t, J =8.0Hz, IH), 7.25(t, J=4.0Hz, IH), 7.00-6.90(m, 3H), 2.62(s, 3H)
[893] [894] Intermediate (43) : Preparation of
4-chloro-5-methyl-2-thiophen-2-yl-thieno[2,3-d]pyrimidin-6-carboxylic acid methyl ester
[896] According to the similar procedure in the step 1 to 3 of example 57 by using methyl acetoacetate, 330mg (yield for 3 steps: 14%, white solid) of the target compound was obtained. [897] 1U NMR(400D, DMSO-d): δ 7.93(br, IH), 7.68(br, IH), 7.14(br, IH), 3,78(s, 3H),
2.84(s, 3H) [898] [899] Intermediate (44) : Preparation of
4-chloro-5-methyl-2-thiophen-2-yl-thieno[2,3-d]pyrimidin-6-carboxylic amide [900]
[901] According to the similar procedure in the step 1 to 3 of example 57 by using ace- toacetamide, 80mg (yield for 3 steps: 5%, yellow solid) of the target compound was obtained. [902] 1U NMR(400D, DMSO-d); δ 7.99(d, J=3.6Hz, IH), 7.70(d, J=4.8Hz, IH), 7.49(br,
2H), 7.15(t, J=4.0Hz, IH), 2.75(s, 3H) [903] [904] Intermediate (45) : Preparation of
4-chloro-6-methoxy-5-methyl-2-thiophen-2-yl-thienor2.3-dlpyrimidine [905]
[906] According to the similar procedure in the step 1 to 3 of example 57 by using the compound, methoxy acetone, the target compound (yield for final step: 32%, yellow solid) was obtained. [907] 1U NMR(400D, CDCI): δ 7.98(dd, /=4.0, 1.2Hz, IH), 7.45(dd, /=5.2, 1.2Hz, IH),
7.13(dd, /=5.2, 4.0Hz, IH), 4.03(s, 3H), 2.44(s, 3H) [908] [909] Intermediate (46) : Preparation of
[911] According to the similar procedure in the step 1 to 3 of example 57 by using the compound, 4-(4-methoxyphenyl)-2-butanone, 260mg (yield for final step: 52%, yellow solid) of the target compound was obtained. [912] 1U NMR(400D, CDCI): δ 8.02(dd, J=LlBz, IH), 7.47(dd, J=LlBz, IH),
7.15-7.12(m, 3H), 6.86(d, J=8.8Hz, 2H), 4.13(s, 2H), 3.79(s, 3H), 2.61(s, 3H) [913] [914] Intermediate (47) : Preparation of
4-(4-chloro-5-methyl-2-thiophen-2-yl-thieno[2,3-d]pyrimidin-6-ylmethyl)-phenol
[915]
[916] The intermediate (46) (280mg, 0.7mmol) was dissolved in dichloromethane.
Therein, IM boron tribromide dichloromethane solution (0.58ml, 3.5mmol) was added solwly, and the reaction mixture was stirred at room temprature for 12 hours. After reaction, the reaction mixture was poured into saturated sodium hydrogen carbonate aqueous solution. The resulting solid was filtered and washed with water and ethyl acetate to give 60mg (yield for final step: 23%, yellow solid) of the target compound.
[917] 1U NMR(400D, CDCI): δ 9.42(br, IH), 7.96(d, IH), 7.80(d, J=4.4Hz, IH), 7.22(t, J
=4.0Hz, IH), 7.08(d, J=7.6Hz, 2H), 6.72(d, J=7.2Hz, 2H), 4.16(s, 2H), 2.60(s, 3H)
[918]
[919] Intermediate (48) : Preparation of
4-chloro-5-methyl-6-(4-nitrophenyl)-2-thiophen-2-yl-thieno[2,3-d]pyrimidine
[920] Step 1. Preparation of pentan-2.4-dione sodium salt
[921]
0 0 0 0
A-X. ΛΛ θ Naφ
[922] Pentan-2,4-dione (4.85g, 48.4mmol) was dissolved in ethanol (15ml). Thereafter, the reaction mixture was stirred at room temperature for 48 hours. The resulting solid was filtered and washed with n-hexane and diethyl ether to give 2.53g (yield: 44%, white solid) of the target compound.
[923]
[924] Step 2. Preparation of l-(4-nitrophenyls)-propan-2-one
[925]
- O N-O S
N a
[926] The compound (88Omg, 7.21mmol) prepared in the step 1 was dissolved in
N,N-dimethylformamide (4.3ml). 4-bromonitrobenzene (292mg, 1.44mmol) and copper iodide (CuI, 274mg, 1.44mmol) were added to the solution. The reaction mixture was stirred at 11O0C for 2 hours under nitrogen atmosphere. After cooling the room temprature, IN sodium hydroxide aqueous solution (5ml) was added to the mixture, and stirred at room temperature for 3 hours. After reaction, the reaction mixture was poured into ethyl acetate, and washed with saturated sodium chloride aqueous solution twice. Combined organic layer was dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was purified by column chromatography (n-hexane: ethyl acetate = 1:4) to give 78mg (yield: 30%, yellow oil) of the target compound.
[927] 1U NMR(400D, CDCI): δ 8.07(d, /=4.2, 2H), 7.63(d, /=4.8, 2H), 3.71(s, 2H),
2.08(s, 3H).
[928]
[929] Step 3. Preparation of 2-amino-4-methyl-5-(4-nitrophenylVthiophen-3-carboxylic acid methyl ester
[930]
[931] The compound (78mg, 0.43mmol) prepared in the step 2 was dissolved in ethanol
(0.5ml). Ethyl cyanoacetate (48mg, 0.43mmol), sulfur (13mg, 0.39mmol) and di- ethylamine (0.04ml, 0.39mmol) were added, and the reaction mixture was stirred at room temprature for 48 hours. After reaction, the reaction mixture was poured into ethyl acetate, and washed with brine and water twice. Combined organic layer was dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was purified by column chromatography (n-hexane: ethyl acetate = 3:1) to give 24mg (yield: 20%, red solid) of the target compound.
[932] 1H NMR(400D, CDCI): δ 8.23(d, /=8.4, 2H), 7.48(d, /=8.4, 2H), 6.30(brs, 2H),
4.30(q, /=7.2Hz,2H), 2.40(s, 3H), 1.39(t, /=6.8Hz, 3H).
[933]
[934] Step 4. Preparation of
4-chloro-5-methyl-6-(4-nitrophenyls)-2-thiophen-2-yl-thienor2.3-dlpyrimidine [935]
[936] According to the similar procedure in the step 2 and 3 of example 57 by using the compound prepared in the step 3, 400mg (yield for 2 steps: 88%, yellow solid) of the target compound was obtained. [937] 1U NMR(400D, CDCI): δ 2.70 (s, 3H), 7.17 (dd, IH), 7.26 (S, IH, 6-H), 7.54 (dd,
IH), 7.69 (d, 2H) 8.10 (dd, IH), 8.37 (d, 2H) [938] [939] Intermediate (49) : Preparation of
3-(4-chloro-5-methyl-2-thiophen-2-yl-thienor2.3-dlpyrimidin-6-vπ-propionic acid methyl ester [940]
[941] According to the similar procedure in the step 1 to 3 of example 57 by using ethyl
4-acetobutyrate, 243mg (yield for final step: 77%, yellow oil) of the target compound was obtained. [942] 1U NMR(400D, CDCI): δ 8.04~8.03(m, IH), 7.49~7.48(m, IH), 7.16~7.13(m, IH),
4.16(q, /=7.3, 6.9Hz, 2H), 3.21(t, /=7.5Hz, 2H), 2.69(t, /=7.5Hz, 2H), 2.58(s, 3H),
1.27(s, /=7.1Hz, 3H) [943] [944] Intermediate (50) : Preparation of
(4-chloro-5-methyl-2-thiophen-2-yl-thieno[2,3-d]pyrimidin-6-yl)-methanol [945]
[946] The intermediate 43, 4-chloro-5-methyl-2-thiophen-2-yl-thieno[2,3-d] pyrimidin-
6-carboxylic acid methyl ester (120mg, 0.35mmol) was dissolved in THF (5ml). Thereafter, the temperature was lowered into O0C. Therein, lithium aluminum hydride (14mg, 0.35mmol) was slowly added, and the reaction mixture was stirred at room temperature for 30 minutes. Water (0.014ml) was added to quench the reaction. Ethyl acetate was added and the reaction mixture was washed with water and saturated
ammonium chloride aqueous solution. The organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure to give 32mg (yield: 31%, white solid) of the target compound. [947] 1U NMR(400D, CDCI): δ 8.04(m, IH), 7.50(m, IH), 7.15(m, IH), 4.91(s, 2H),
2.55(s, 3H) [948] [949] Intermediate (51) : Preparation of
4-chloro-6-methoxymethyl-5-methyl-2-thiophen-2-yl-thieno[2,3-d]pyrimidine [950]
[951] The intermediate 50, (4-chloro-5-methyl-2-thiophen-2-yl-thieno[2,3-d] pyrimidin-
6-yl)-methanol (50mg, 0.13mmol) was dissolved in dried THF (5ml). Thereafter, the temperature was lowered into O0C. Therein, 60% sodium hydride (5.6mg, 0.14mmol) was added, and the reaction mixture was stirred at O0C for 30minutes. Iodomethane (0.008ml, 0.13mmol) was added, and stirred at room temperature for 2 hours. Ethyl acetate was added to the mixture and washed with water and saturated ammonium chloride aqueous solution. Combined organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by column chromatography (n-hexane: ethyl acetate = 3:1) to give 28mg (yield: 51%, yellow oil) of the target compound.
[952] 1U NMR(400D, CDCI): δ 8.05(d, J=3.6Hz, IH), 7.50(d, J=4.4Hz, IH), 7.16(m,
IH), 4.92(s, 2H), 3.82(s, 3H), 2.49(s, 3H)
[953]
[954] Example 72 . l-[6-(3-methoxybenzyl)-5-methyl-2-thiophen-2-yl-thieno[2,3-d] pyrimidin-4-ylamino] -3-methyl-pyrrole-2,5-dione hydrochloride
[955] Step 1. Preparation of 4-(3-methoxyphenyl)-3-buten-2-one
[956]
[957] meta-Anisaldehyde (5g, 36.72mmol) was dissolved in acetone (30ml). Thereafter, the solution of sodium hydroxide (2.05g, 51.41mmol) in water (30ml) was added slowly, and the reaction mixture was stirred at room temperature for 2 hours. After reaction, solvent was concentrated. The residue was diluted with ethyl acetate and washed with water. Combined organic layer was dried over anhydrous magnesium
sulfate and concentrated under reduced pressure. The residue was purified by column chromatography (n-hexane: ethyl acetate = 3:2) to give 4.3g (yield: 66%, yellow oil) of the target compound. [958] 1U NMR(400D, CDCI): δ7.50(d, /=16. IHz, IH), 7.32(t, J=UUz, IH), 7.15(d, /
=6.6Hz, IH), 7.06(s, IH), 6.97~6.94(m, IH), 6.72(d, /=16.1Hz, IH), 6.84(s, 3H),
2.39(s, 3H) [959]
[960] Step 2. Preparation of 4-(3-methoxyphenyl)-3-butan-2-one
[961]
[962] The compound (4.43g, 24.40mmol) prepared in the step 1 was dissolved in ethanol
(25ml). Catalyst amount of acetic acid and Palladium 10wt.% on activated carbon were added to the mixture. The reaction mixture was stirred on hydrogen atmosphere at room temperature. The reaction mixture was filtered through the cellite pad. The filtrate was concentrated under reduced pressure to give 3.87g (yield: 89%, colorless oil) of the target compound.
[963] 1U NMR(400D, CDCI): δ7.20(t, /=8.0Hz, IH), 6.78~6.75(m, 2H), 6.73(s, IH),
3.79(s, 3H), 2.89~2.85(m, 2H), 2.78~2.74(m, 2H), 2.15(s, 3H)
[964]
[965] Step 3. Preparation of
4-chloro-6-(3-methoxybenzyl)-5-methyl-2-thiophen-2-yl-thieno[2.3-dlpyrimidine
[966]
[967] According to the similar procedure in the step 1 and 3 of example 57 by using the compound (3.87g, 21.71mmol) prepared in the step 2, 783mg (yield for final step:
75%, yellow oil) of the target compound was obtained. [968] 1U NMR(400D, CDCI): δ7.96~7.95(m, IH), 7.82~7.81(m, IH), 7.27~7.21(m, 2H),
6.87~6.82(m, 3H), 4.27(s, 2H), 3.73(s, 3H), 2.59(s, 3H) [969] [970] Step 4. Preparation of l-[6-(3-methoxybenzyl)-5-methyl-2-thiophen-2-yl-thieno[2.3-dlpyrimidin-4-ylaminol-
[972] According to the similar procedure in the step 5 and 6 of example 8 (method 1) by using the compound (86mg, 0.22mmol) prepared in the step 3, 20mg (yield for final step: 40%, yellow solid) of the target compound was obtained. [973] 1H-NMR^OOD, DMSC^ ): δ9.56(s, IH), 7.66~7.63(m, 2H), 7.24(t, J=7.8Hz, IH),
7.13~7.10(m, IH), 7.00(s, IH), 6.85~6.80(m, 3H), 4.21(s, 2H), 3.73(s, 3H), 2.60(s,
3H), 2.17(s, 3H)
[974] [975] Example 73 . l-tø-CS-hydroxy-benzyO-l-thiophen-l-yl-thienol^β-d] pyrimidin- 4-ylamino] -3-methyl-pyrrole-2,5-dione hydrochloride
[976] Step 1. Preparation of 3-(4-chloro-5-methyl-2-thiophen-2-yl-thieno[2.3-d1 pyrimidin-6-ylmethvl)-phenol [977]
[978] According to the similar procedure in the intermediate 47 by using the compound (400mg, 1.03mmol) prepared in the step 3 of example 72, 320mg (yield: 83%, yellow solid) of the target compound was obtained.
[979] 1H-NMR^OOD, DMSC^ ): δ9.35(s, IH), 8.21 (d, J=4.3Hz, IH), 7.85(d, J=5.1Hz, IH), 7.24~7.20(m, IH), 7.13~7.04(m, IH), 6.67 (d, J=7.7Hz, IH), 6.61(s, IH), 4.04(s, 2H), 2.47(s, 3H)
[980] [981] Step 2. Preparation of l-[6-(3-hvdroxy-benzyl)-2-thiophen-2-yl-thieno[2.3-d1 pyrimidin-4-ylamino1 -3-methyl-pyrrole-2.5-dione hydrochloride
[982]
[983] According to the similar procedure in the step 5 and 6 of example 8 (method 1) by using the compound (lOOmg, 0.26mmol) prepared in the step 1, 2mg (yield for final step: 22%, yellow solid) of the target compound was obtained.
[984] 1H-NMR^OOD, DMSC^ ): δ8.21(d, J=3.6Hz, IH), 7.85(d, J=4.7Hz, IH),
7.68~7.63(m, IH), 7.21~7.20(m, IH), 7.10(t, J=8.0Hz, IH), 6.67 (d, J=7.3Hz, IH),
6.61~6.60(m, 2H), 4.04(s, 2H), 3.56(s, 3H), 2.20(s, 3H) [985] [986] Example 74 . l-{6-[3-(2-dimethylamino-ethoxy)-benzyl] -
2-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-ylamino}-3-methyl-pyrrole-2,5-dione hydrochloride [987] Step 1. Preparation of (2-r3-f4-chloro-5-methyl-2-thiophen-2-yl-thienor2.3-dl pyrimidin-6-ylmethyl)-phenoxy1-ethyl)-dimethyl-amine [988]
[989] According to the similar procedure in the step 6 of example 56 by using the compound (lOOmg, 0.22mmol) prepared in the step 1 of example 73, 38mg (yield: 31%) of the target compound was obtained.
[990] 1H-NMR^OOD, OMSOd ): δ9.37(s, IH), 7.94~7.93(m, IH), 7.74~7.73(m, IH),
7.20~7.18(m, IH), 7.10(t, J=7.7Hz, IH), 6.69(d, J=7.7Hz, IH), 6.62(s, IH), 4.67(t, J =5.7Hz, 2H), 4.12(s, 2H)
[991]
[992] Step 2. Preparation of l-(6-r3-(2-dimethylamino-ethoxy)-benzyl1 -
2-thiophen-2-yl-thienor2.3-d1pyrimidin-4-ylamino)-3-methyl-pyrrole-2.5-dione hydrochloride
[993]
[994] According to the similar procedure in the step 5 and 6 of example 8 (method 1) by using the compound (50mg, 0.1 lmmol) prepared in the step 1, 22mg (yield for final step: 88%, yellow solid) of the target compound was obtained.
[995] 1H-NMR^OOD, OMSOd ): δlθ.78(br s, IH), 7.99~7.98(m, IH), 7.77(d, J=5.1Hz,
IH), 7.22~7.20(m, IH), 7.12(t, J=7.7Hz, IH), 6.69~6.62(m, 3H), 4.98~4.96(m, 2H), 4.14(s, 2H), 3.66~3.65(m, 2H), 2.88(s, 3H), 2.87(s, 3H), 2.52(s, 3H), 2.20(s, 3H)
[996]
[997] Example 75 .
5-methyl-4-(3-methyl-2,5-dioxo-2,5-dihydro-pyrrol-l-ylamino)-2-thiophen-2-yl-thi eno[2,3-d]pyrimidin-6-carboxylic acid-(2-dimethylamino-ethyl)-amide hy-
drochloride
[998] Step 1. Preparation of 4-hvdroxy-5-methyl-2-thiophen-2-yl-thienor2.3-dl pyrimidin-6-carboxylic acid ethyl ester
[999]
[1000] According to the similar procedure in the step 1 and 2 of example 57 by using the compound, ethyl acetoacetate, 1.5g (yield: 61%, yellow solid) of the target compound was obtained. [1001] 1U NMR(400D, DMSO-d): δ 8.27(d, J=3.6Hz, IH), 7.94(d, J=5.2Hz, IH), 7.25(t, J
=4.4Hz, IH), 4.30(q, J=7.2Hz, 2H), 2.83(s, 3H), 1.3 l(t, J=6.8Hz, 3H) [1002] [1003] Step 2. Preparation of 4-hvdroxy-5-methyl-2-thiophen-2-yl-thienor2.3-dl pyrimidin-6-carboxylic acid [1004]
[1005] The compound (480mg, 1.5mmol) prepared in the step 1 was added to 2N sodium hydroxide aqueous solution (30ml). Thereafter, the reaction mixture was refluxed for 14 hours. After reaction, the reaction mixture was extracted with ethyl acetate. The aqueous layer was acidified with 6N HCl aqueous solution, and the solid was filtered. Thereafter, the resulting solid was washed with water and n-hexane to give 410mg (yield: 94%, white solid) of the target compound.
[1006] 1U NMR(400D, DMSO-d): δ 8.28(d, J=4.0Hz, IH), 7.94(d, J=4.87Hz, IH),
7.26-7.24(m, IH), 2.82(s, 3H)
[1007]
[1008] Step 3. Preparation of 4-chloro-5-methyl-2-thiophen-2-yl-thieno[2.3-dl pvrimidin-
6-carboxylic acid
[1009]
[1010] According to the similar procedure in the step 4 of example 8 (method 1) by using the compound prepared in the step 2, 320mg (yield: 52%, yellow solid) of the target
compound was obtained.
[1011] 11UU NNMMRR((440000DD,, CCDDCCII)): δ 9.70(br, IH), 8.08(dd, /=3.8, 1.2Hz, IH), 7.57(dd, /=5.2, 0.8Hz, IH), 7.18(dd, /=5.2, 4.0Hz, IH), 3.03(s, 3H)
[1012]
[1013] Step 4. Preparation of 4-chloro-5-methyl-2-thiophen-2-yl-thieno[2.3-dl pyrimidin-
6-carboxylic acid-(2-dimethylamino-ethyl)-amide [1014]
[1015] To the compound (60mg, 0.20mmol) prepared in the step 3, were added l-(3-dimethylaminopropyl)-3-ethylcarbodiimide (48mg, 0.26mmol) and 1-hydroxybenzotriazole hydrate (2mg, 0.02mmol) with dichlorome thane (2ml). Therein, N,N-dimethylethyenediamine (24D, 0.22mmol) was added slowly. The reaction mixture was stirred for 2 hours. After reaction, the solvent was removed under reduced pressure. The residue was purified by column chromatography (chloroform:methanol = 9:1) to give 60mg (yield: 80%, yellow solid) of the target compound.
[1016] 1U NMR(400D, CDCI): δ 8.10(d, /=4.0Hz, IH), 7.55(d, /=4.8Hz, IH),
7.19-7.17(m, IH), 6.84(br, IH), 3.54(q, /=5.6Hz, 2H), 2.91(s, 3H), 2.55(t, /=5.6Hz, 2H), 2.29(s, 6H)
[1017]
[1018] Step 5. Preparation of
5-methyl-4-G-methyl-2.5-dioxo-2.5-dihydro-pyrrol-l-ylaminoV2-thiophen-2-yl-thieno r2.3-dlpyrimidin-6-carboxylic acid-(2-dimethylamino-ethylVamide hydrochloride
[1019]
[1020] According to the similar procedure in the step 5 to 6 of example 8 (method 1) by using the compound prepared in the step 4, 35mg (yield for final step: 54%, yellow solid) of the target compound was obtained.
[1021] 1U NMR(400D, DMSO-d): δ 11.34(br, IH), 9.55(br, IH), 8.78(t, /=5.6Hz, IH),
7.84(d, /=3.6Hz, IH), 7.47(d, /=4.8Hz, IH), 7.10(t, /=3.6Hz, IH), 6.69(d, J=LlBz, IH), 3.86-3.82(m, 2H), 3.43-3.39(m, 2H), 2.97(s, 3H), 2.94(d, /=4.8Hz, 6H), 2.24(d, / = 1.2Hz, 3H)
[1022]
[1023] Example 76 . 3-methyl-l-{5-[4-(2-piperidin-l-yl-ethoxy)-phenyl] -
2-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-ylamino}-pyrrole-2,5-dione hydrochloride
[1024]
[1025] According to the similar procedure in the step 6 of example 56 and in the step 5 and 6 of example 8(method 1) by using 4-(4-chloro-2-thiophen-2-yl-thieno[2,3-d] pyrimidin-5-yl)-phenol prepared in example 11, 8mg (yield for final step: 38%, yellow solid) of the target compound was obtained.
[1026] 1U NMR (400D, DMSO-d): δ 10.43(s, IH), 9.52(s, IH), 8.76(d, J=5.2Hz, IH),
7.54(d, J=8.0Hz, 2H), 7.15(m, 3H), 7.02(s, IH), 4.52(s, 2H), 3.01(m, 2H), 2.14(s, 3H), 1.81-1.69(m, 5H), 1.20(m, IH)
[1027]
[1028] Compounds listed below were prepared by the similar procedure in above Example 76.
[1029] Example 77 . 3-methyl-l-{5-[3-(2-piperidin-l-yl-ethoxy)-phenyl] -
2-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-ylamino}-pyrrole-2,5-dione hydrochloride
[1030] Example 78 . l-{5-[3-(2-dimethylamino-ethoxy)-phenyl] -
2-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-ylamino}-3-methyl-pyrrole-2,5-dione hydrochloride
[1031] Example 79 . l-{5-[3-(3-dimethylamino-propoxy)-phenyl] -
2-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-ylamino}-3-methyl-pyrrole-2,5-dione hydrochloride
[1032] Example 80 . 3-methyl-l-{5-[3-(2-morpholin-4-yl-ethoxy)-phenyl] -
2-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-ylamino}-pyrrole-2,5-dione hydrochloride
[1033] Example 81 . 3-methyl-l-{5-[3-(2-piperazin-l-yl-ethoxy)-phenyl] -
2-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-ylamino}-pyrrole-2,5-dione dihy- drochloride
[1034] Example 82 .
3-methyl-l-[5-methyl-6-(4-methyl-piperazin-l-ylmethyl)-2-thiophen-2-yl-thieno[2,
3-d]pyrimidin-4-ylamino] -pyrrole-2,5-dione dihydrochloride
[1035] Example 83 . 3-methyl-l-(5-{3-[2-(4-methyl-piperazin-l-yl)-ethoxy] - phenyl}-2-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-ylamino)-pyrrole-2,5-dione dihydrochloride
[1036] [Table 6] [1037]
[1038]
[1039] Example 84 . l-{6-[4-(2-dimethylamino-ethoxy)-phenyl] -
5-methyl-2-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-ylamino}-3-methyl-pyrrole-2,5
-dione hydrochloride
[1040] Step 1. Preparation of 4-(4-chloro-5-methyl-2-thiophen-2-yl-thienor2.3-dl pyrimidin-6-ylVphenol [1041]
[1042] The compound (559mg, 1.5mmol) prepared in the step 3 of example 57 was dissolved in dichloromethane. Therein, IM boron tribromide in dichloromethane solution (3.75ml, 3.75mmol) was added slowly, and the reaction mixture was stirred at room temperature for 12 hours. After reaction, the reaction mixture was poured into saturated sodium hydrogen carbonate aqueous solution. The resulting solid was filtered and washed with water and ethyl acetate to give 435mg (yield: 81 %, yellow solid) of the target compound.
[1043] 1H-NMR (400D, DMSO-d): δ 10.0(s, IH), 7.98(dd, /=4.0, 1.2Hz, IH), 7.84(dd, / =5.2, 1.2Hz, IH), 7.40(dd, /=8.8, 2.0Hz, 2H), 7.23(dd, /=5.2, 4.0Hz, IH), 7.98(dd, / =8.8, 2.0Hz, 2H), 2.57(s, 3H)
[1044] [1045] Step 2. Preparation of (2-r4-(4-chloro-5-methyl-2-thiophen-2-yl-thienor2.3-dl pyrimidin-6-ylVphenoxyl-ethyl)-dimethyl-amine
[1046]
[1047] The compound (151mg, 0.42mmol) prepared in the step 1, triphenylphosphine (PPh , 220mg, 0.84mmol) and N,N-dimethylethanolamine (85D, 0.42mmol) were diluted with in THF (ImI). Therein, diisopropylazodicarboxylate (DIAD, 170D, 0.84mmol) was added slowly, and the reaction mixture was stirred at room temperature for 36 hours. Solvent was concentrated under reduced pressure. The residue was purified by column chromatography (chloroform:methanol = 20:1) to give 83mg (yield: 46%, white solid) of the target compound.
[1048] 1H-NMR (400D, CDCD: δ 8.05(dd, /=4.0, 1.2Hz, IH), 7.48(dd, /=5.2, 1.2Hz, IH), 7.41(dd, /=8.8, 2.0Hz, 2H), 7.16(dd, /=5.2, 4.0Hz, IH), 7.02(dd, /=8.8, 2.0Hz, 2H), 4.13(t, /=5.6Hz, 2H), 2.79(t, /=5.6Hz, 2H), 2.62(s, 3H), 2.37(s, 6H)
[1049] [1050] Step 3. Preparation of (2-r4-(4-hydrazino-5-methyl-2-thiophen-2-yl-thienor2.3-dl pyrimidin-6-ylVphenoxyl-ethyl)-dimethyl-amine
[1051]
[1052] The compound (83mg, 0.193mmol) prepared in the step 2 and hydrazine monohydrate (H NNH -H O, 2OD, 0.425mmol) were dissolved in THF (3ml). The reaction mixture was refluxed for 5 hours. After reaction, the reaction mixture was concentrated under reduced pressure. The residue was used to the next step without further purification.
[1053]
[1054] Step 4. Preparation of l-(6-[4-(2-dimethylamino-ethoxyy phenyl! -
5-methyl-2-thiophen-2-yl-thieno[2.3-dlpyrimidin-4-ylamino)-3-methyl-pyrrole-2.5-di one
[1055]
[1056] The compound prepared in the step 3 was dissolved in chloroform (3ml). Therein, citraconic anyhdride (26D, 0.29mmol) was added. The reaction mixture was refluxed for 4 hours. The solvent was removed under reduced pressure. The residue was purified by column chromatography (n-hexane: ethyl acetate = 1:1) to give 32mg (yield: 32%, pale yellow solid) of the target compound.
[1057] 1U NMR(400D, CDCI): δ 7.76(d, J=3.6Hz, IH), 7.70(s, IH), 7.38(d, J=4.4Hz, IH),
7.33(d, J=8.4Hz, 2H), 7.07(t, J=4.4Hz, IH), 6.95(d, J=8.4Hz, 2H), 6.63(d, J=1.6Hz, IH), 4.46(t, J=4.0Hz, 2H), 3.52(t, J=4.0Hz, 2H), 2.96(s, 6H), 2.55(s, 3H), 2.26(d, J = 1.6Hz, 3H)
[1058]
[1059] Step 5. Preparation of l-(6-[4-(2-dimethylamino-ethoxy)-phenyll -
5-methyl-2-thiophen-2-yl-thieno[2.3-dlpyrimidin-4-ylamino)-3-methyl-pyrrole-2.5-di one hydrochloride
[1060]
[1061] The compound (32mg, 0.062mmol) prepared in the step 4 was dissolved in
1,4-dioxane (3ml). Therein 4M HCl 1,4-dioxane solution (10OD, 0.4mmol) was added, and the reaction mixture was stirred at room temperature for 1 hour. The resulting solid was filtered and washed with 1,4-dioxane and diethyl ether to give 14mg (yield: 42%, yellow solid) of the target compound.
[1062] 1U NMR(400D, DMSO-d): δ 10.3(br, IH), 9.68(s, IH), 7.72-7.66(m, 2H), 7.55(d, J
=8.4Hz, 2H), 7.22-7.13(m, 3H), 7.02(d, J=2.0Hz, IH), 4.44(t, J=4.0Hz, 2H), 3.54(t, J =4.0Hz, 2H), 2.87(d, J=4.8Hz, 6H), 2.55(s, 3H), 2.19(d, J=2.0Hz, 3H)
[1063]
[1064] Compounds listed below were prepared by the similar procedure in above Example 84.
[1065] Example 85 . 3-methyl-l-{5-methyl-6-[4-(2-piperidin-l-yl-ethoxy)-phenyl] - 2-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-ylamino}-pyrrole-2,5-dione hydrochloride
[1066] Example 86 . l-{6-[4-(2-methoxy-ethoxy)-phenyl] -
5-methyl-2-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-ylamino}-3-methyl-pyrrole-2,5 -dione hydrochloride
[1067] Example 87 . l-{6-[3-(2-methoxy-ethoxy)-phenyl] -
5-methyl-2-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-ylamino}-3-methyl-pyrrole-2,5 -dione
[1068] Example 88 . 3-methyl-l-{5-methyl-6-[4-(2-morpholin-4-yl-ethoxy)-phenyl] - 2-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-ylamino}-pyrrole-2,5-dione hydrochloride
[1069] Example 89 . l-{2-t-butyl-6-[4-(2-dimethylamino-ethoxy)-phenyl] -
5-methyl-thieno[2,3-d]pyrimidin-4-ylamino}-3-methyl-pyrrole-2,5-dione hydrochloride
[1070] Example 90 . l-{6-[4-(2-dimethylamino-ethoxy)-phenyl] -
2-isobutyl-5-methyl-thieno[2,3-d]pyrimidin-4-ylamino}-3-methyl-pyrrole-2,5-dion e hydrochloride
[1071] Example 91 . l-{2-allyl-6-[4-(2-dimethylamino-ethoxy)-phenyl] -
5-methyl-thieno[2,3-d]pyrimidin-4-ylamino}-3-methyl-pyrrole-2,5-dione hydrochloride
[1072] Example 92 . 3-methyl-l-{5-methyl-6-[4-(2-piperazin-l-yl-ethoxy)-phenyl] - 2-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-ylamino}-pyrrole-2,5-dione hydrochloride
[1073] Example 93 . l-{6-[4-(3-dimethylamino-propoxy)-phenyl] -
5-methyl-2-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-ylamino}-3-methyl-pyrrole-2,5 -dione hydrochloride
[1074] Example 94 . l-{6-[4-(2-amino-ethoxy)-phenyl] -
5-methyl-2-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-ylamino}-3-methyl-pyrrole-2,5 -dione hydrochloride
[1075] Example 95 . l-{6-[4-(2-diethylamino-ethoxy)-phenyl] -
2-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-ylamino}-3-methyl-pyrrole-2,5-dione hydrochloride
[1076] Example 96 . 3-methyl-l-{5-methyl-6-[4-(2-pyrrolidin-l-yl-ethoxy)-phenyl] - 2-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-ylamino}-pyrrole-2,5-dione hydrochloride
[1077] Example 97 .
3-methyl-l-{5-methyl-6-[4-(2-(4-methyl-piperazin-l-yl)-ethoxy)-phenyl]-2-thiophe n-2-yl-thieno[2,3-d]pyrimidin-4-ylamino}-pyrrole-2,5-dione hydrochloride
[1078] Example 98 . l-(6-{4-[2-(ethyl-methyl-amino)-ethoxy] - phenyl}-5-methyl-2-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-ylamino)-3-methyl-py rrole-2,5-dione hydrochloride
[1079] Example 99 . 3-methyl-l-(5-methyl-6-{4-[2-(methyl-propyl-amino)-ethoxy] - phenyl}-2-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-ylamino)-pyrrole-2,5-dione hydrochloride
[1080] Example 100 . 3-methyl-l-(5-methyl-6-{4-[2-(2-oxo-pyrrolidin-l-yl)-ethoxy] - phenyl}-2-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-ylamino)-pyrrole-2,5-dione hydrochloride
[1081] Example 101 . l-(6-{4-[2-(isopropyl-methyl-amino)-ethoxy] - phenyl}-5-methyl-2-thiophen-2-yl--thieno[2,3-d]pyrimidin-4-ylamino)-3-methyl-p yrrole-2,5-dione hydrochloride
[1082] Example 102 . 3-methyl-l-(5-methyl-6-{4-[2-(2-thiomolpholin-4-yl)-ethoxy] - phenyl}-2-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-ylamino)-pyrrole-2,5-dione hydrochloride
[1083] Example 103 . l-{6-[4-(2-dimethylamino-ethoxy)-phenyl] -
2,5-dimethyl-thieno[2,3-d]pyrimidin-4-ylamino}-3-methyl-pyrrole-2,5-dione hydrochloride
[1084] Example 104 . l-{6-[4-(2-dimethylamino-ethoxy)-phenyl] -
5-methyl-2-propyl-thieno[2,3-d]pyrimidin-4-ylamino}-3-methyl-pyrrole-2,5-dione hydrochloride
[1085] Example 105 . l-{6-[4-(2-dimethylamino-ethoxy)-phenyl] -
5-methyl-2-cyclopropyl-thieno[2,3-d]pyrimidin-4-ylamino}-3-methyl-pyrrole-2,5- dione hydrochloride
[1086] Example 106 . l-{6-[4-(2-dimethylamino-ethoxy)-phenyl] -
5-methyl-2-ethyl-thieno[2,3-d]pyrimidin-4-ylamino}-3-methyl-pyrrole-2,5-dione hydrochloride
[1087] Example 107 . l-{2-cyclopropylmethyl-6-[4-(2-dimethylamino-ethoxy)-phenyl] -5-methyl-thieno[2,3-d]pyrimidin-4-ylamino}-3-methyl-pyrrole-2,5-dione hydrochloride
[1088] Example 108 . l-{6-[4-(2-dimethylamino-ethoxy)-phenyl] -
5-methyl-2-thophen-2-yl-thieno[2,3-d]pyrimidin-4-ylamino}-pyrrole-2,5-dione hy-
drochloride [1089] Example 109 . l-{6-[4-(2-dimethylamino-ethoxy)-phenyl] -
5-methyl-2-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-ylamino}-3,4-dimethyl-pyrrole
-2,5-dione hydrochloride [1090] Example 110 . 3,4-dichloro-l-{6-[4-(2-dimethylamino-ethoxy)-phenyl] -
5-methyl-2-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-ylamino}-pyrrole-2,5-dione hydrochloride [1091] Example 111 . l-[6-(4-{2-[4-(2-amino-ethyl)-piperazin-l-yl] - ethoxy}-phenyl)-5-methyl-2-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-ylamino]-3-m ethyl-pyrrole-2,5-dione hydrochloride [1092] Example 112 . l-[6-(4-{2-[(2-amino-ethyl)-methyl-amino] - ethoxy}-phenyl)-5-methyl-2-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-ylamino]-3-m ethyl-pyrrole-2,5-dione hydrochloride [1093] Example 113 . l-[6-(4-{2-[(2-dimethylamino-ethyl)-methyl-amino] - ethoxy}-phenyl)-5-methyl-2-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-ylamino]-3-m ethyl-pyrrole-2,5-dione hydrochloride [1094] Example 114 . l-[6-(4-{2-[4-(2-dimethylamino-ethyl)-piperazin-l-yl] - ethoxy}-phenyl)-5-methyl-2-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-ylamino]-3-m ethyl-pyrrole-2,5-dione hydrochloride [1095] Example 115 . l-[6-(4-{2-[4-(2-methoxy-ethyl)-piperazin-l-yl] - ethoxy}-phenyl)-5-methyl-2-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-ylamino]-3-m ethyl-pyrrole-2,5-dione hydrochloride [1096] Example 116 . 3-methyl-l-(5-methyl-6-{4-[2-(2-piperazin-l-yl-ethoxy)-ethoxy] - phenyl}-2-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-ylamino)-pyrrole-2,5-dione hydrochloride [1097] Example 117 . l-(6-{4-[2-(4-acetyl-piperazin-l-yl)-ethoxy] - phenyl}-5-methyl-2-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-ylamino)-3-methyl-py rrole-2,5-dione hydrochloride [1098] Example 118 . l-(6-{4-[2-(2,5-dioxo-pyrrolidin-l-yl)-ethoxy] - phenyl}-5-methyl-2-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-ylamino)-3-methyl-py rrole-2,5-dione [1099] Example 119 . l-[6-(4-{2-[4-(2-hydroxy-ethyl)-piperazin-l-yl] - ethoxy}-phenyl)-5-methyl-2-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-ylamino]-3-m ethyl-pyrrole-2,5-dione hydrochloride [1100] Example 120 . 3-methyl-l-(5-methyl-6-{4-[2-(3-oxo-piperazin-l-yl)-ethoxy] - phenyl}-2-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-ylamino)-pyrrole-2,5-dione hydrochloride [1101] Example 121 . l-[6-(4-{2-[(2-hydroxy-ethyl)-methyl-amino] -
ethoxy}-phenyl)-5-methyl-2-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-ylamino]-3-m ethyl-pyrrole-2,5-dione hydrochloride [1102] Example 122 . l-[6-(4-{2-[(2-methoxy-ethyl)-methyl-amino] - ethoxy}-phenyl)-5-methyl-2-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-ylainino]-3-in ethyl-pyrrole-2,5-dione hydrochloride [1103] Example 123 . l-(6-{4-[2-(l,4-dioxa-8-aza-spiro[4,5]dec-8-yl)-ethoxy] - phenyl}-5-methyl-2-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-ylamino)-3-methyl-py rrole-2,5-dione hydrochloride [1104] Example 124 . l-(6-{4-[2-(2,5-dioxo-2,5-dihydro-pyrrol-l-yl)-ethoxy] - phenyl}-5-methyl-2-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-ylamino)-3-methyl-py rrole-2,5-dione [1105] Example 125 . 3-methyl-l-(5-methyl-6-{4-[2-(2-oxo-imidazolidin-l-yl)-ethoxy] - phenyl}-2-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-ylamino)-pyrrole-2,5-dione [1106] [Table 7] [1107]
[1112]
[1113] Intermediate (52) : Preparation of
2-t-butyl-4-chloro-6-(4-methoxy-phenyl)-5-methyl-thieno[2,3-d]pyrimidine
[1114]
[1115] According to the similar procedure in the step 2 and 3 of example 57 by using the compound prepared in the step 1 of example 57 and pivalonitrile, 168mg (yield for final step: 73%, yellow solid) of the target compound was obtained.
[1116] 1U NMR(400D, CDCI) δ 7.40(d, J=8.0Hz, 2H), 6.99(d, J=8.4Hz, 2H), 3.85(s, 3H),
2.66(s, 3H), 1.36(s, 9H)
[1117] [1118] Intermediate (53) : Preparation of
4-chloro-2-isobutyl-6-(4-methoxy-phenyl)-5-methyl-thieno[2,3-d]pyrimidine
[1119]
[1120] According to the similar procedure in the step 2 and 3 of example 57 by using the compound prepared in the step 1 of example 57 and isovaleronitrile, 82mg (yield for final step: 76%, brown solid) of the target compound was obtained.
[1121] 1U NMR(400D, CDCI) δ 7.41(d, J=8.4Hz, 2H), 6.99(d, J=I 1.2Hz, 2H), 3.84(s,
3H), 2.87(d, J=7.2Hz, 2H), 2.62(s, 3H), 2.33(m, IH), 0.98(d, J=6.4Hz, 6H)
[1122]
[1123] Intermediate (54) : Preparation of
2-allyl-4-chloro-6-(4-methoxy-phenyl)-5-methyl-thieno[2,3-d]pyrimidine
[1124]
[1125] According to the similar procedure in the step 2 and 3 of example 57 by using the compound prepared in the step 1 of example 57 and allyl cyanide, 247mg (yield for final step: 70%, brown solid) of the target compound was obtained.
[1126] 1U NMR(400D, CDCI) δ 7.40(d, J=8.4Hz, 2H), 7.01(d, J=8.8Hz, 2H), 5.70(m, IH),
5.03(t, J=8.4Hz, 2H), 3.84(s, 3H), 2.62(s, 3H), 2.38(d, J=4.4Hz, 2H)
[1127]
[1128] Intermediate (55) : Preparation of
4-chloro-6-(4-methoxy-phenyl)-2,5-dimethyl-thieno[2,3-d]pyrimidine
[1129]
[1130] According to the similar procedure in the step 2 and 3 of example 57 by using the compound prepared in the step 1 of example 57 and acetonitrile, 142mg (yield for 2 steps: 67%, yellow solid) of the target compound was obtained.
[1131] 1U NMR(400D, CDCI); δ 7.42(d, 2H, /=8.8), 7.02(d, 2H, J=8.8Hz), 3.88(s, 3H),
2.80(s, 3H), 2.63(s, 3H).
[1132]
[1133] Intermediate (56) : Preparation of
4-chloro-6-(4-methoxy-phenyl)-5-methyl-2-propyl-thieno[2,3-d]pyrimidine
[1134]
[1135] According to the similar procedure in the step 2 and 3 of example 57 by using the compound (500mg, 1.72mmol) prepared in the step 1 of example 57 and butyronitrile, 430mg (yield for 2 steps: 80%, purple solid) of the target compound was obtained.
[1136] 1U NMR(400D, CDCI) δ 7.39(d, J=8.8Hz, 2H), 7.02(d, J=8.8Hz, 2H), 4.12(t, J
=5.6Hz, 2H), 2.97(t, J=5.6Hz, 2H), 2.76(t, J=5.6Hz, 2H), 2.62(s, 3H), 2.35(s, 6H), 1.93-1.84(m, 2H), 1.01(t, J=7.2Hz, 3H).
[1137]
[1138] Intermediate (58) : Preparation of 2-(methyl-propyl-amino)-ethanol
[1139]
O ^ VJ
[1140] Pyrrolidine (0.835ml, lOmmol) and 2-bromoethanol (0.28ml, 4.0mmol) were dissolved in THF (10ml). The reaction mixture was refluxed for 36 hours. The solvent was removed under reduced pressure. The residue was purified by column chromatography (dichlorome thane: methanol = 10:1) to give 380mg (yield: 83%, brown oil) of the target compound.
[1141] 1U NMR(400D, CDCI): δ 3.64(t, J=5.6Hz, 2H), 2.65(t, J=5.6Hz, 2H), 2.56(m, 4H),
1.78(m, 4H)
[1142]
[ 1143] Intermediate (59) : Preparation of 2-pyrrolidin-l-yl-ethanol
[1144]
[1145] 1-methylaminoethanol (1.07ml, 13mmol) and 2-bromopropane (0.59ml, 6.5mmol) were dissolved in THF (10ml). The reaction mixture was refluxed for 36 hours. The solvent was removed under reduced pressure. The residue was purified by column chromatography (dichloromethan: methanol = 10:1) to give 180mg (yield: 24%, colorless oil) of the target compound.
[1146] 1U NMR(400D, CDCI): δ 3.58(t, J=5.6Hz, 2H), 2.52(t, J=5.6Hz, 2H), 2.37(m, 2H),
2.24(s, 3H), 0.90(t, J=7.2Hz, 3H)
[1147]
[1148] Intermediate (60) : Preparation of
4-chloro-6-(4-methoxy-phenyl)-5-methyl-2-cvclopropyl-thienor2.3-dlpyriinidine
[1149]
[1150] According to the similar procedure in the step 2 and 3 of example 57 by using the compound (868mg, 3mmol) prepared in the step 1 of example 57 and cyclopropyl cyanide, 486mg (yield for 2 steps: 49%, pale yellow solid) of the target compound was obtained.
[1151] 1U NMR(400D, CDCI) δ 7.40(d, J=8.8Hz, 2H), 7.00(d, J=8.8Hz, 2H), 3.87(s, 3H),
2.60(s, 3H), 2.33-2.26(m, IH), 1.93-1.84(m, 2H), 1.26-1.08(m, 4H)
[1152]
[1153] Intermediate (61) : Preparation of
4-chloro-6-(4-methoxy-phenyl)-5-methyl-2-ethyl-thieno[2,3-d]pyrimidine
[1154]
[1155] According to the similar procedure in the step 2 and 3 of example 57 by using the compound (868mg, 3mmol) prepared in the step 1 of example 57 and propionitrile, 794mg (yield for 2 steps: 83%, pale yellow solid) of the target compound was obtained.
[1156] 1U NMR(400D, CDCI) δ 7.41(d, J=8.8Hz, 2H), 7.01(d, J=8.8Hz, 2H), 3.87(s, 3H),
3.04(q, J=75.6Hz, 2H), 2.63(s, 3H), 1.41(t, J=7.6Hz, 3H)
[1157]
[1158] Intermediate (62) : Preparation of
4-chloro-2-cyclopropylmethyl-6-(4-methoxy-phenyl)-5-methyl-thieno[2,3-d]pyrim idine
[1159]
[1160] According to the similar procedure in the step 2 and 3 of example 57 by using the compound (400mg, 1.37mmol) prepared in the step 1 of example 57 and cyclopropy- lacetonitrile, 290mg (yield for 2 steps: 61%, yellow solid) of the target compound was obtained.
[1161] 1U NMR(400D, CDCI) δ 7.42(d, J=8.8Hz, 2H), 7.02(d, J=8.8Hz, 2H), 3.88(s, 3H),
2.90(d, J=6.8Hz, 2H), 2.64(s, 3H), 1.32(m, IH), 0.54(m, 2H), 0.33(m, 2H)
[1162]
[1163] Intermediate (63) : Preparation of {2-[4-(2-hydroxy-ethyl)-piperazin-l-yl] - ethyl}-carbamic acid tert-butyl ester
[1164]
[1165] l-(2-hydroxyethyl)-piperazine (0.49Og, 3.80mmol),
2-(tert-butoxycarbonylamino)ethylbromide (0.936g, 4.18mmol), sodium hydrogen carbonate (1.00Og, 7.60mmol) and sodium iodide (0.056g, 0.38mmol) were dissolved in acetonitrile (10ml). The reaction mixture was refluxed for 6 hours. The solvent was removed under reduced pressure. The residue was purified by column chromatography (chloroform:methanol = 7:1) to give 780mg (yield: 76%, yellow oil) of the target compound.
[1166] 1U NMR(400D, CDCI); δ 5.00(br, IH), 3.61(t, J=5.6Hz, 2H), 3.23- 3.22(m, 2H),
2.63-2.44(m, 12H), 1.45(s, 9H)
[1167]
[1168] Intermediate (64) : Preparation of {2-[(2-hydroxy-ethyl)-methyl-amino] - ethyl}-carbamic acid tert-butyl ester
[1169]
M + Br-^^NiBoc Boc ^ N ^
[1170] 2-(methylamino)ethanol (0.30Og, 3.994mmol) and (2-bromo-ethyl)-carbamic acid t- butyl ester (0.985g, 4.39mmol) were dissolved in THF (15ml). The reaction mixture was refluxed for 16 hours. The solvent was removed under reduced pressure. The residue was purified by column chromatography (dichloromethan: methanol = 10:1) to give 431mg (yield: 50.4%, colorless oil) of the target compound.
[1171] 1H-NMR (400D, CDCI) δ 4.84(br, IH), 3.60(t, /=5.6, 2H), 3.224(m, 2H), 2.55(m,
4H), 2.27(s, 3H), 1.43(s, 9H)
[1172]
[1173] Intermediate (65) : Preparation of
[2-({2-[4-(4-chloro-5-methyl-2-thiophen-2-yl-thieno[2,3-d]pyrimidin-6-yl)-phenox y]-ethyl}-methyl-amino)-ethyl]-carbamic acid t-butyl ester
[1175] The compound (0.207g, 0.58mmol) prepared in the step 1 of example 84, the intermediate (64) (0.15 Ig, 0.69mmol) and triphenylphosphine (PPh , 0.227g, 0.87mmol) were dissolved in THF (5ml). Therein, DIAD (0.167ml, 0.87mmol) was added slowly, and the reaction mixture was stirred for 16 hours. The solvent was removed under reduced pressure. The residue was purified by column chromatography (dichloromethane methanol = 10:1) to give 330mg (yield: 99%, yellow solid) of the target compound.
[1176] 1H-NMR (400D, CDCI) δ 7.75(m, IH), 7.33(m, 3H), 7.31(s, IH), 7.02(m, IH),
7.00(d, J=8.8Hz, 2H), 4.11(t, J=5.6Hz, 2H), 3.25(m, 2H), 2.86(br, 2H), 2.64(s, 3H), 2.61(br, 2H), 1.65(s, 3H), 1.45(s, 9H)
[1177]
[1178] Intermediate (66) : Preparation of 2-[4-(2-methoxy-ethyl)-piperazin-l-yl] - ethanol
[1179]
[1180] l-(2-hydroxyethyl)-piperazine (0.49Og, 3.80mmol), 2-bromo-ethyl-methyl-ether (0.580g, 4.18mmol), sodium hydrogen carbonate (1.0Og, 7.60mmol) and sodium iodide (0.056g, 0.38mmol) were dissolved in acetonitrile (10ml). The reaction mixture was refluxed for 14 hours. The reaction mixture was filtered and the filtrate was concentrated under reduced pressure. The residue was purified by column chromatography (chloroform:methanol = 7:1) to give 500mg (yield: 71%, yellow oil) of the target compound.
[1181] 1U NMR(400D, CDCI); δ 3.64(t, J=5.6Hz, 2H), 3.36(s, 3H), 3.27- 3.24(m, 2H),
2.63-2.44(m, 12H)
[1182]
[1183] Intermediate (67) : Preparation of l-[4-(2-hydroxy-ethyl)-piperazin-l-yl] - ethanol
[1184]
[1185] 1-acetylpiperazine (Ig, 8mmol) and 2-bromoethanol (0.28ml, 4.0mmol) were
dissolved in THF (10ml). The reaction mixture was refluxed for 36 hours. The solvent was removed under reduced pressure. The residue was purified by column chromatography (dichlorome thane: methanol = 10:1) to give 380mg (yield: 55.1%, brown oil) of the target compound.
[1186] 1H-NMR (400D, CDCI) δ 3.67 (m, 4H), 3.5 l(m, 2H), 2.59(t, J=5.6Hz, 2H), 2.56(m,
4H), 2.10(s, 3H)
[1187]
[1188] Intermediate (68) : Preparation of
2-{4-[2-(tert-butyl-dimethyl-silanyloxy)-ethyl]-piperazin-l-yl}-ethanol
[1189]
[1190] According to the similar procedure in the intermediate 64 by using piperazine (500mg, 5.80mmol) and 2-bromoethanol (0.90ml, 12.76mmol) of the target intermediate was obtained. This intermediate and imidazole (300mg, 4.40mmol) were dissolved in DMF (10ml). Therein, tert-butyldimethylsilyl chloride (TBDMS-Cl, 664mg, 4.40mmol) was added, and the reaction mixture was stirred at room temperature for 3 hours. Thereafter, the reaction mixture was poured into ethyl acetate, and washed with water. Combined organic layer was dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was purified by column chromatography (chloroform:methanol = 6:1) to give 675mg (yield for 2 steps: 63%, yellow oil) of the target compound.
[1191] 1U NMR(400D, CDCI) δ 3.75(t, J=6.4Hz, 2H), 3.60(t, J=5.5Hz, 2H), 2.55~2.52(m,
12H), 0.89(s, 9H), 0.059(s, 6H)
[1192]
[ 1193] Intermediate (69) : Preparation of 2-{[2-(tert-butyl-dimethyl-silanyloxy)-ethyl] -methyl-amino}-ethanol
[1194] Step 1. Preparation of (2-bromo-ethoxy)-t-butyl-dimethyl-silane
[1195]
B r ^_X,H _ B r^^OTB D M S
[1196] 2-bromoethanol (1.Og, 8.0mmol) was dissolved in DMF (5ml). Therein, tert- butyldimethylsilyl chloride (1.45g, 9.6mmol) and imidazole (1.36g, 20.0mmol) were added, and the reaction mixture was stirred at room temperature for 20 hours. Thereafter, the reaction mixture was poured into diethyl ether, and washed with water and saturated sodium chloride aqueous solution. Combined organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by column chromatography (n-hexane=100%) to give 1.Og (yield: 53%,
colorless oil) of the target compound.
[1197] 11HH--NNMMIR (CD3OD, 400D) δ 3.89(t/=6.6Hz, 2H), 3.40(t, J=6.6Hz, 2H), 0.90(s, 9H), 0.09(s, 6H)
[1198]
[1199] Step 2. Preparation of 2-(r2-ft-butyl-dimethyl-silanyloxyVethyll - methyl- amino ) -ethanol [1200]
Br^-OTBDMS + ^N^°H HO^^N^^OTBDMS
H I
[1201] The compound (1.Og, 4.18mmol) prepared in the step 1 and
2-(methylamino)ethanol (0.270ml, 3.34mmol) were dissolved in acetonitrile (10ml). Therein, potassium carbonate (700mg, 5.04mmol) and sodium iodide (50mg, 0.33mmol) were added, and the reaction mixture was refluxed for 10 hours. After cooling to room temperature, the resulting solid was filtered out and the flitrate was concentrated under reduced pressure. The residue was purified by column chromatography (chloroform:methanol = 10:1) to give 560mg (yield: 71%, colorless oil) of the target compound.
[1202] 1H-NMR (CD OD, 400D) δ 3.71(t/=5.8Hz, 2H), 3.57(t, J=5.2Hz, 2H),
2.62-2.58(m, 4H), 2.33(s, 3H), 0.89(s, 9H), 0.07(s, 6H).
[1203]
[1204] Intermediate (70) : Preparation of 2-[(2-methoxy-ethyl)-methyl-amino] - ethanol
[1205]
[1206] 2-bromoethylmethyl ether (1.53g, l lmmol) and 2-(methylamino)ethanol (750mg, lOmmol) were dissolved in acetonitrile (10ml). Therein, potassium carbonate (2.76g, 20mmol) and sodium iodide (150mg, lmmol) were added, and the reaction mixture was refluxed for 6 hours. The solvent was removed under reduced pressure. The residue was purified by column chromatography (chloroform:methanol = 20:1) to give 1.2g (yield: 92%, colorless oil) of the target compound.
[1207] 1U NMR(400D, CDCI) δ 3.59(t, J=5.6Hz, 2H), 3.48(t, J=5.6Hz, 2H), 3.36(s, 3H),
2.64(t, J=5.6Hz, 2H), 2.58(t, J=5.6Hz, 2H), 2.33(s, 3H)
[1208]
[1209] Intermediate (71) : Preparation of 2-(l,4-dioxa-8-azaspiro[4,5] dec- 8-yl)-ethanol
[1210]
[1211] ,4-dioxa-8-azaspiro[4,5]dec caneP (0.45ml. 3.49mmol) and 2-bromoethanol (0.28ml, 4.0mmol) were dissolved in THF (10ml). The reaction mixture was refluxed for 36 hours. The solvent was removed under reduced pressure. The residue was purified by column chromatography (dichloromethane: methanol = 10:1) to give 340mg (yield: 52.1%, brown oil) of the target compound.
[1212] 1H-NMR (400D, CDCI) δ 3.96(s, 4H), 3.61(t, J=5.6Hz, 2H), 2.59(m, 4H), 2.56(t, J
=5.6Hz, 2H), 1.78(m, 4H)
[1213]
[1214] Example 126 . l-{6-[4-(2-dimethylamino-ethoxy)-phenyl] -
5-ethyl-2-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-ylamino}-3-inethyl-pyrrole-2,5-d ione hydrochloride
[1215] Step 1. Preparation of (4-methoxy-phenylVacetaldehyde
[1216]
[1217] 4-methoxyphenethylalcohol (2g, 13.14mmol) and triethylamine (7.33ml,
52.56mmol) were dissolved in dichloromethane (50ml). Therein, the solution of pyridine sulfide complex (4.18g, 26.28mmol) in dimethylsulfoxide (10ml) was added, and the reaction mixture was stirred for 8 hours. The solvent was removed under reduced pressure. The residue was purified by column chromatography (n-hexane: ethyl acetate = 3:1) to give 1.29g (yield: 66.0%, yellow oil) of the target compound.
[1218] 1H-NMR (400D, CDCI) δ 10.03(t, IH, J=2.0Hz), 7.12(d, 2H, J=8.4Hz), 6.86(d, 2H,
J=6.4Hz), 3.79(s, 3H), 3.62(d, 2H, J=2.0Hz)
[1219]
[1220] Step 2. Preparation of l-(4-methoxy-phenylVbutan-2-ol
[1221]
[1222] The compound (1.29g, 7.15mmol) prepared in the step 1 was dissolved in THF
(20ml). Thereafter, the temperature was lowered into -1O0C and therein, l.OM ethyl- magnesiumbromide in THF (8ml, 8.0mmol) was added, and the reaction mixture was stirred at room temperature for 4 hours. Thereafter, the reaction mixture was poured into ammonium chloride solution to quench. The reaction mixture was concentrated
under reduced pressure. The residue was purified by column chromatography
(n-hexane: ethyl acetate = 3:1) to give 1.02g (yield: 66%, yellow oil) of the target compound. [1223] 1U NMR(400D, CDCI); δ 7.12(d, 2H, J=8.4Hz), 6.86(d, 2H, J=6.4Hz), 3.79(s, 3H),
3.62(s, 2H), 3.40(m, IH), 2.47 (q, 2H, J=7.2Hz), 1.00(t, 3H, J=7.2Hz) [1224]
[1225] Step 3. Preparation of l-(4-methoxy-phenyl)-propan-l-one
[1226]
[1227] The compound (1.02g, 5.77mmol) prepared in the step 2 was dissolved in dichloromethane (20ml). Therein, Dess-Martin-periodinane (2.45g, 5.77mmol) was added, and the reaction mixture was stirred at room temperature for 30minutes. Thereafter, the reaction mixture was poured into sodium hydrogen carbonate solution to quench. The reaction mixture was concentrated under reduced pressure. The residue was purified by column chromatography (n-hexane: ethyl acetate = 7:1) to give 812mg (yield: 78.8%, yellow oil) of the target compound.
[1228] 1U NMR(400D, CDCI); δ 7.12(d, 2H, J=8.4Hz), 6.86(d, 2H, J=6.4Hz), 3.79(s, 3H),
3.62(s, 2H), 2.47 (q, 2H, J=7.2Hz), 1.00(t, 3H, J=7.2Hz)
[1229]
[1230] Step 4. Preparation of
2-amino-4-ethyl-5-(4-methoxy-phenylVthiophen-3-carboxylic acid ethyl ester
[1231]
(0.071ml, 6.72mmol) and sulfur (18mg, 0.56mmol) were dissolved in ethanol (20ml). Therein, morpholine (57D, 0.58mmol) was added slowly, and the reaction mixture was stirred at 8O0C for 5 hours. After reaction, the reaction mixture was poured into ethyl acetate, and washed with water and saturated ammonium chloride aqueous solution. Combined organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by column chromatography (n-hexane: ethyl acetate = 5:1) to give 80mg (yield: 46.8%, yellow solid) of the target compound. [1233] 1U NMR(400D, CDCI); δ 7.27(d, 2H, J=8.8Hz), 6.90(d, 2H, J=8.8Hz), 6.13(br,
2H), 4.3 l(q, 2H, J=7.6Hz), 3.79(s, 3H), 2.70(q, 2H, J=7.2Hz), 1.37(t, 3H, J=7.2Hz), 1.13(t, 3H, J=7.2Hz)
[1234] [1235] Step 5. Preparation of 5-ethyl-6-(4-methoxy-phenyl)-2-thiopnen-2-yl-thieno[2.3-dl pyrimidin-4-ol
[1236]
[1237] The compound (500mg, 1.64mmol) prepared in the step 4 and 2-thiophene car- bonitrile (0.23ml, 2.46mmol) were dissolved in 3.6M HCl in 1,4-dioxane solution (6ml). The reaction mixture was stirred at 11O0C for 36 hours. After reaction, reaction mixture was poured into ethyl acetate, and washed with water and saturated sodium hydrogen carbonate aqueous solution. Combined organic layer was concentrated under reduced pressure to give 480mg (yield: 79.4%, brown solid) of the target compound.
[1238] 1U NMR(400D, CDCD; δ 8.06(d, IH, J=3.6Hz), 7.49(d, IH, J=5.2Hz), 7.43(d, 2H, J=8.8Hz), 7.15(d, IH, J=3.6Hz), 7.00(d, 2H, J=8.8Hz), 3.87(s, 3H), 3.00(q, 2H, J =7.2Hz), 1.37(t, 3H, J=7.2Hz)
[1239] [1240] Step 6. Preparation of 4-chloro-5-ethyl-6-(4-methoxy-phenylV2-thiophen-2-yl-thienor2.3-dlpyrimidine
[1241]
[1242] The compound (480mg, 1.30mmol) prepared in the step 5 was dissolved in phosphorus oxychloride (8ml). Thereafter, the reaction mixture was stirred at 1000C for 6 hours. After reaction, the reaction mixture was poured into ice water and ethyl acetate, and washed with water and saturated sodium hydrogen carbonate aqueous solution. Combined organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by column chromatography (n-hexane: ethyl acetate = 2:1) to give 160mg (yield: 31.7%, yellow solid) of the target compound.
[1243] 1U NMR(400D, CDCD; δ 8.06(d, IH, J=3.6Hz), 7.49(d, IH, J=5.2Hz), 7.43(d, 2H, J=8.8Hz), 7.15(d, IH, J=3.6Hz), 7.00(d, 2H, J=8.8Hz), 3.87(s, 3H), 3.00(q, 2H, J =7.2Hz), 1.37(t, 3H, J=7.2Hz)
[1244]
[ 1245 ] Step 7. Preparation of 4-(4-chloro-5-ethyl-2-thiophen-2-yl-thieno[2.3-d1 pyrimidin- β-ylVphenol [1246]
[1247] According to the similar procedure in the step 1 of example 84 by using the compound (160mg, 0.41mmol) prepared in the step 6, lOOmg (yield: 65.8%, yellow solid) of the target compound was obtained. [1248] 1U NMR(400D, CDCI); δ 8.07(d, IH, J=3.6Hz), 7.51(d, IH, J=5.2Hz), 7.43(d, 2H,
J=8.8Hz), 7.15(d, IH, J=3.6Hz), 6.95(d, 2H, J=8.8Hz), 5.20(s, IH), 3.02(q, 2H, J
=7.2Hz), 1.31(t, 3H, J=7.2Hz) [1249] [1250] Step 8. Preparation of l-(6-[4-(2-dimethylamino-ethoxy)-phenyll -
5-ethyl-2-thiophen-2-yl-thieno[2.3-dlpyrimidin-4-ylamino)-3-methyl-pyrrole-2.5-dion e hydrochloride [1251]
[1252] According to the similar procedure in the step 2,3,4,5 of example 84 by using the compound (lOOmg, 0.27mmol) prepared in the step 7, 41.0mg (yield: 26.7%, yellow solid) of the target compound was obtained. [1253] 1H-NMR (400D, DMSO-d) δ 10.73(s, IH), 9.52(s, IH), 7.69(m, 2H), 7.49(d, J
=8.8Hz, 2H), 7.16(m, 3H), 7.02(d, J=2.0Hz, IH), 4.45(t, J=4.4Hz, 2H), 3.59(m, 2H),
3.02(m, 2H), 2.85(s, 3H), 2.84(s, 3H), 2.18(d, J=1.6Hz, 3H), 1.24(t, J=7.6Hz, 3H) [1254] [1255] Compounds listed below were prepared according to the above procedure (See table
8). [1256] Example 127 . l-(6-{4-[2-(4-butyl-piperazin-l-yl)-ethoxy] - phenyl}-5-methyl-2-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-ylamino)-3-methyl-py rrole-2,5-dione dihydrochloride [1257] Example 128 . l-({6-[4-(2-dimethylamino-ethoxy)-phenyl] -
5-methyl-2-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-yl}-methyl-amino)-3-methyl-p yrrole-2,5-dione hydrochloride
[1258] Example 129 . methyl-
(2-{4-[5-methyl-4-(3-methyl-2,5-dioxo-2,5-dihydro-pyrrol-l-ylamino)-2-thiophen- 2-yl-thieno[2,3-d]pyrimidin-6-yl]-phenoxy}-ethyl-carbamic acid t-butyl ester
[1259] Example 130 . 3-methyl-l-{5-methyl-6-[4-(2-methylamino-ethoxy)-phenyl] - 2-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-ylamino)-pyrrole-2,5-dione hydrochloride
[1260] Example 131 . l-[6-(4-methoxy-phenyl)-5-methyl-2-thiophen-2-yl-thieno[2,3-d] pyrimidin-4-ylamino]-3-methylen-pyrrolidine-2,5-dione
[1261] Example 132 . 3-methylen-l-{5-methyl-6-[4-(2-methylamino-ethoxy)-phenyl] - 2-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-ylamino}-pyrrolidine-2,5-dione hydrochloride
[1262] Example 133 . l-{6-[4-(2-butylamino-ethoxy)-phenyl] -
5-methyl-2-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-ylamino}-3-methyl-pyrrole-2,5 -dione hydrochloride
[1263] Example 134 . l-[(6-{4-[2-(2-methoxy-ethylamino)-ethoxy] - phenyl}-5-methyl-2-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-yl)-methyl-amino]-3- methyl-pyrrole-2,5-dione hydrochloride
[1264] Example 135 . l-[(6-{4-[2-(2-hydroxy-ethylamino)-ethoxy] - phenyl}-5-methyl-2-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-yl)-methyl-amino]-3- methyl-pyrrole-2,5-dione hydrochloride
[1265] Example 136 . 3-methyl-l-(5-methyl-6-{4-[2-(3-methyl-butylamino)-ethoxy] - phenyl}-2-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-ylamino)-pyrrole-2,5-dione hydrochloride
[1266] Example 137 .
3-methyl-l-(5-methyl-2-thophen-2-yl-6-{4-[2-(2,2,2-trifluoro-ethylamino)-ethoxy]- phenyl}-thieno[2,3-d]pyrimidin-4-ylamino)-pyrrole-2,5-dione hydrochloride
[1267] Example 138 . 3-dimethylamino- N -
{4-[5-methyl-4-(3-methyl-2,5-dioxo-2,5-dihydro-pyrrol-l-ylamino)-2-thiophen-2-y l-thieno[2,3-d]pyrimidin-6-yl]-phenyl}-propionamide hydrochloride
[1268] Example 139 .
3-[methyl-(2-{4-[5-methyl-4-(3-methyl-2,5-dioxo-2,5-dihydro-pyrrol-l-ylamino)-2- thiophen-2-yl-thieno[2,3-d]pyrimidin-6-yl]-phenoxy}-ethyl)-amino]-propionic acid
[1269] Example 140 . isopropyl-
(2-{4-[5-methyl-4-(3-methyl-2,5-dioxo-2,5-dihydro-pyrrol-l-ylamino)-2-thiophen- 2-yl-thieno[2,3-d]pyrimidin-6-yl]-phenoxy}-ethyl)-amino]-carbamic acid t-butyl ester
[1270] Example 141 . l-{6-[4-(2-isopropylamino-ethoxy)-phenyl] -
5-methyl-2-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-ylamino}-3-methyl-pyrrole-2,5
-dione hydrochloride
[1271] Example 142 . 3-methyl-l-{5-methyl-6-[4-(piperidin-4-yloxy)-phenyl] - 2-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-ylamino}-pyrrole-2,5-dione hydrochloride
[1272] Example 143 . l-{6-[4-(2-benzylamino-ethoxy)-phenyl] -
5-methyl-2-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-ylamino}-3-methyl-pyrrole-2,5 -dione hydrochloride
[1273] Example 144 .
3-(2-{4-[5-methyl-4-(3-methyl-2,5-dioxo-2,5-dihydro-pyrrol-l-ylamino)-2-thiophe n-2-yl-thieno[2,3-d]pyrimidin-6-yl]-phenoxy}-ethylamino)-propionitrile hydrochloride
[1274] [Table 8]
[1275]
[1277] [1278] Experimental Example 1 : In vitro IKK enzyme assay
TM [1279] In vitro IKK assay was performed with IKK-β enzyme (PV3836) and Z' Lyte1 kinase assay kit-Ser/Thr 5 peptide (PV3178), purchased from Invitrogen. The kinase assay kit adopted the principle of FRET (Fluorescence-Resonance Energy Transfer) and the experiment was carried out according to the described protocol.
[1280] 2.5 D of test compound dissolved in 4-fold concentrated water was aliquotted onto each well of a low volume non-binding surface 384-well plate (Cat. No. 3676. Corning) manufactured by Corning, 5 D of the mixture of IKK-β(4ng) and 4 μM Ser/ Thr 5 peptide was added thereto, and stirred well on a plate stirrer for 30 seconds. The plate was left at room temperature. 2.5 D of 20 μM ATP was added thereto, and mixed well for 30 seconds. Subsequently, the plate was left at room temperature for 1 hour. 5 D of a development solution was added to each reaction solution and incubated at room temperature for 1 hour to decompose unphosphorylated peptide substrates. 5 D of a stop solution was added to each well to terminate the reaction. Fluorescent signals were measured using PerkinElmer En Vision™. A general dual (BS50/BS50) was used as a mirror block, a Photometric 405 (8 nm band width) as an excitation filter, Um- belliferone 460 (25 nm band width) and FITC 535 (25 nm band width) as an emission filter. An emission ratio and percent phosphorylation were determined from the fluorescent signals by following the protocol, in which the IC value of the compound was calculated using a SigmaPlot SAV (SPSS Inc.).
[1281] The results are shown in Table 9 (herein, A means IC 5J0 s<5 μM, B means IC 5J0 s<10 μM, and C means IC 's>10 μM).
50
[1282] [Table 9] [1283]
[1284] As shown in Table 9, it was found that the compounds of the present invention have an excellent inhibitory activity against IKKβ enzyme. [1285] [1286] Experimental Example 2 : NF-κB reporter gene assay
[1287] A549/NF B-luc cells (Panomics, #RC0002) were cultured in the medium
[DMEM/HG + 10% FBS + 100 unit/D of penicillin, 100 D/D of streptomycin and 2 mM
of L-glutamine (ATCC #30-2220) + 100 D/D of hygromycin B (Roche #10843555001)], and seeded to 96 well plate (1.4xlO5 to 1.5xlO5 cells per well) to culture in the hygromycin B -free medium for 20 hours. The compound of Example 1 was diluted with the hygromycin B- and FBS (fetal bovine serum)-free medium with various concentrations (0.1% DMSO final concentration), added to the cells, and the cells were pre-incubated. After 1 hour, the cells were treated with 50 ng/D of TNF-α (Peprotech #300-01A). After 6 hours, a luciferase test (Promega #E2610, Bright-Glo™ Luciferase assay kit) was carried out. Briefly, 100 D of Bright-GloM reagent was added to 100 D of the medium for cell lysis. After 2 minutes, fluorescent signals were measured using
PerkinElmer En Vision with a 700nm low pass luminescence filter (Perkinelmer, 2100 multilabel reader) (Reference: Moorthy S.S. etc, The design and synthesis of novel orally active inhibitors of AP- 1 and NF-κB Mediated transcriptional activation. SAR of in vitro and in vivo studies, Bioorganic & Medicinal Chemistry Letters, 13, 2003, P4077).
[1288] The results are shown in Table 10 (herein, A means IC 5J0 s<10 μM and B means IC 50 <20 μM).
[1289] [Table 10] [1290]
[1291] As shown in Table 10, it was found that the compounds of the present invention have an excellent inhibitory activity against NF-κB.
[1292] [1293] Experimental Example 3 : LPS-induced TNF-α production [1294] LPS-induced TNF-α production was evaluated by measuring the amount of TNF-α accumulated in the medium. Raw 264.7 cells (ATTC, USA), the mouse macrophage cell lines, were used in the assay.
[1295] Raw 264.7 cells were cultured in DMEM/HG medium containing 10% fetal bovine serum (FBS). For determination of TNF-α level, Raw 264.7 cells were seeded with an amount of 5xlO5 cells/D per 96 well plate and incubated for 24 hours at 37 0C in a numidified incubator with 5% CO The various concentrations of the compound (0.1 to 10 μM) was added thereto, and cells were activated with lipopoly saccharide (final concentration: 1D/D (Sigma, USA)). After a 24 hours incubation, the medium was collected. The amount of TNF-α in the collected medium was measured using ELISA
assay kit (Biosource international, USA). [1296] The results are shown in Table 11 (herein, AA is IC 50 's<l μM, A is IC 50 's<5 μM, B is IC 's<10 μM and C is IC 's>10 μM).
50 50
[1297] [Table 11] [1298]
[1299] «• NT: Not tested
[1300]
[1301] As shown in Table 11, it was found that the compounds of the present invention
have an excellent inhibitory activity against TNF-α production. [1302] [1303] Experimental Example 4 : Nitric oxide (NO) inhibition assay
[1304] Raw 264.7 cells were cultured in the medium (DMEM/HG, 10% FBS, 100 U/D of penicillin-streptomycin, 5% CO and 370C), and placed into 96 well plate in an amount of 5x10 to 1x10 cells per well, followed by culturing for 24 hours. The diluted compounds of Example 1 to 144 and LPS (1 D/D) were added to the medium. After 24 hours, 100 D was taken out from the medium to react with 100 D of a Griess solution for 10 minutes, and then the level of nitrite was determined at optical density (OD) 560 nm. The corresponding concentration of nitrite in the sample was determined from the standard curve of sodium nitrite (Reference: Schmidt, H.H., Determination of Nitric Oxide via measurement of nitrite and nitrate in culture media. Biochemica., 22, 1995).
[1305] The results are shown in Table 12 (herein, AA means IC 's<l μM, A means IC 's<
50 50
5 μM, B is IC 's<10 μM, and C means IC 's>10 μM). r 50 50
[1306] [Table 12] [1307]
[1308] •X NT: Not tested [1309] [1310] As shown in Table 12, it was found that the compounds of the present invention have an excellent inhibitory activity against NO production.
[1311] [1312] Experimental Example 5 : TNF -α inhibition assay in mouse [1313] An amount of TNF-α was measured from blood of 7 to 9 week old male BALB/c mice (Japan SLC, Inc.). The mice were abdominally administrated with
lipopolysaccharide (10 D/mouse, sigma, L-2880) to induce inflammation. The mice were fasted for 24 hours before lipopolysaccharide administration. The compounds prepared in Example 84 and 85 were dissolved in distilled water, and then orally administrated with a concentration of 30 mg/kg and 100 mg/kg (amount of administration: 10 D/kg). After 1 hour, Lipopolysaccharide was administrated. After 90 minutes, blood was collected from the mouse heart, and then serum was separated. The amount of TNF-α in the collected serum was measured using ELISA assay kit (Biosource International, USA).
[1314] The results were given in Fig. 1 and Table 13. [1315] [Table 13] [1316]
[1317]
[1318] As shown in Fig. 1 and Table 13, it was found that the compounds of the present invention have an excellent inhibitory activity against TNF-α production.
Industrial Applicability
[1319] The thienopyrimidine derivative of the present invention was found to inhibit IKK- β, NF-κB, TNF-α and Nitric oxide strongly through in vitro assays such as an IKK assay, NF-κB reporter gene assay, LPS-induced TNF-α production and nitric oxide (NO) inhibition assay, and through TNF-α inhibition assay in a mouse, which are associated with a chance of developing a therapeutic agent for inflammatory diseases and cancer. Accordingly, the compounds can be used as a pharmaceutical composition useful for treating and preventing pains and inflammation caused by inflammatory diseases, in particular, arthritis and cancer.
Claims
[1] A thienopyrimidine derivative having the following Formula 1, a pharmaceutically acceptable salt thereof, or an isomer thereof: <Formula 1>
X is O, S or NH,
R is hydrogen; linear or branched C to C alkyl; -(CH )n -OR; -(CH )n -
1 1 10 2 1 2 1
COOR; C to C heteroaryl substituted or unsubstituted with C to C alkyl or
5 20 J 1 3 J halogen, which comprise one or two heteroatom(s) selected from the group consisting of S, O and N; or
R2 is hydrogen; -(CH )n -Z; -(CH )n -OR; -(CH^n^COOR; -(CH^n^CONR'R"; -Y-(CH 2 )n 1 -NR1R"; -Y-(CH 2 )n 1 -OR; -Y-(CH2 )n 1 -COOR; C 5 to C 20 heteroaryl substituted or unsubstituted with C to C alkyl or halogen, which comprise one or two heteroatom(s) selected from the group consisting of S, O and N; or
R7\ /^=\
^-(CH2Jn1
R 3 is hy J drog °en; linear or branched C 1 to C 10 alkyl; linear or branched C 2 to C 10 alkeny Jl; ' C 3 to C ? cy Jcloalky Jl; -CH 2 -C3 to C ? cy Jcloalky Jl; -NR1R"; ' C 5 to C 20 heteroaryl or -CH -C to C heteroaryl substituted or unsubstituted with C to C
2 5 20 1 3 alkyl or halogen, which comprise one or two heteroatom(s) selected from the group consisting of S, O and N,; or
^HCH2)H1
R and R are each independently H; =CH ; linear or branched C to C alkyl; halogen; -OR; or connected to each other to form C to C aryl, C to C
6 20 5 7 cycloalkyl, or C to C heterocyclic comprising one or two heteroatom(s) selected from the group consisting of N, O or S,
R is H, or linear or branched C to C alkyl,
R is H, -OH, -NO , linear or branched C to C alkyl, -Y-C to C alkyl, -NR1R", -
7 2 1 5 1 5
CN, -COOR, halogen, -Y-(CH )n -NR1R", -Y-(CH )n -OR, -Y-(CH )n -COOR, -
2 2 2 2 2 2
Y-(CH )n -Z, -Y-(CH )n -M-R, -Y-(CH )n -M-(CH )n -NR1R", -Y-(CH )n - M-(CH )n -OR, -Y-(CH )n -M-(CH )n -COOR, -Y-(CH )n -M-(CH )n -CN or -
2 3 2 2 2 3 2 2 2 3
Y-(CH )n -M-(CH )n -Z,
R is H, linear or branched C to C alkyl, -OR, -NO , amine, mono- or di- alkylamine, -CN, -COOR, -0-(CH )n -NR1R", -0-(CH )n -OR, -0-(CH )n - COOR or -0-(CH )n -Z,
2 2
R 9 is H, linear or branched C 1 to C5 alkyl, -OR, -NO 2 , amine, mono- or di- alkylamine, -CN, -COOR, -(CH^-NR'R", -(CH^-OR, -(CH^-COR, -(CH2 )n 2 -COOR or -(CH 2 )n 2 -Z,
R and R are each independently hydrogen, linear or branched C to C alkyl, or halogen,
R, R' and R" are each independently hydrogen, linear or branched C to C alkyl, or -CH 2 CF 3 ;
M is O, S or -NR-,
Y is O, S, NH, -NH-CO- or -CO-NH-,
Z is pyrrolidine; piperidine; piperazine; morpholine; thiomorpholine; 2- or 3-oxo-pyrrolidine; 2-, 3- or 4-oxo-piperidine; oxazole; triazole; pyridine; imidazole; imidazolidine; 2,5-dioxo-pyrrolidine; 2- or 3-oxo-piperazine; 2,5-dioxo-2,5-dihydro-pyrrole; 2-oxo-imidazolidine; 4,4-ethylenedioxy-piperidine; 2- or 3-thienyl; 2- or 3-furyl;
— N N-R9 or
, and
n , n and n are each integer of 0 to 5.
[2] The thienopyrimidine derivative, a pharmaceutically acceptable salt thereof, or an isomer thereof according to claim 1, wherein X is O or S, R is hydrogen, methyl, -(CH )n -OR, -(CH )n -COOR, thiophenyl or
^-(CH2Jn1
R is hydrogen, -(CH )n -Z, -(CH )n -OR, -(CH )n -COOR, -(CH )n -CONR'R",
-Y-(CH )n -NR1R", thiophenyl or
R is hydrogen, methyl, ethyl, propyl, isobutyl, t-butyl, 2-propenyl, cyclopropyl, -CH -cyclopropyl, amine, 2-methylthiophenyl, -CH -thiophenyl, furanyl, pyridinyl or
R7^ /=\
^H -(CH2)H1
R and R are each independently H, =CH methyl, F, Cl, Br, I, or connected to each other to form phenyl or pyridine,
R is H or methyl,
R is H, -OH, -NO , methyl, -OCH , -NR1R", F, Cl, Br, I, -Y-(CH )n -NR1R", -
Y-(CH )n -OR, -Y-(CH )n -Z, -Y-(CH )n -M-(CH )n -NR1R", -Y-(CH )n -
M-(CH )n -OR, -Y-(CH )n -M-(CH )n -COOR, -Y-(CH )n -M-(CH )n -CN or -
2 3 2 2 2 3 2 2 2 3
Y-(CH )n -M-(CH )n -Z,
R is H,
R is H, methyl, butyl, -(CH )n -NR1R", -(CH )n -OR or -(CH )n -COR,
R and R are each independently hydrogen,
R, R' and R" are each independently hydrogen, methyl, ethyl, propyl, isopropyl, butyl, t-butyl, isopentyl or -CH CF ,
M is O or -NR-,
Y is O, -NH-CO- or -CO-NH-,
Z is pyrrolidine, piperidine, piperazine, morpholine, thiomorpholine, 2- or
3-oxo-pyrrolidine, 2,5-dioxo-pyrrolidine, 2- or 3-oxo-piperazine,
— N N-R9 or
, and n , n and n are each integer of 0 to 3.
[3] The thienopyrimidine derivative, a pharmaceutically acceptable salt thereof, or an isomer thereof according to claim 1, wherein the compound is selected from the group consisting of
1) 3-methyl-l-(5-thiophen-2-yl-thieno[2,3-d] pyrimidin- 4-ylamino)-pyrrole-2,5-dione,
2) 3,4-dichloro-l-(5-thiophen-2-yl-thieno[2,3-d] pyrimidin- 4-ylamino)-pyrrole-2,5-dione hydrochloride,
3) 2-(5-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-ylamino)-isoindole- 1 ,3-dione hydrochloride,
4) 2-(5-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-ylamino)-pyrrolo[3,4-c] pyridine- 1,3-dione hydrochloride,
5) 3-methyl-l-(5-thiophen-2-yl-thieno[2,3-d] pyrimidin- 4-ylamino)-pyrrole-2,5-dione hydrochloride,
6) l-(5-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-ylamino)-pyrrole-2,5-dione hydrochloride,
7) l-(2,6-di-thiophen-2-yl-thieno[2,3-d] pyrimidin- 4-ylamino)-3-methyl-pyrrole-2,5-dione hydrochloride,
8) l-(2,5-di-thiophen-2-yl-thieno[2,3-d] pyrimidin- 4-ylamino)-3-methyl-pyrrole-2,5-dione hydrochloride, 9) 3-methyl-l-[2-(5-methyl-thiophen-2-yl)-5-thiophen-2-yl-thieno[2,3-d] pyrimidin-4-ylamino] -pyrrole-2,5-dione hydrochloride,
10) l-[5-(4-methoxy-phenyl)-2-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-ylamino] -3-methyl-pyrrole-2,5-dione hydrochloride,
11) l-[5-(4-hydroxy-phenyl)-2-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-ylamino] -3-methyl-pyrrole-2,5-dione hydrochloride,
12) (2,5-di-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-yl)-hydrazine hydrochloride,
13) 3-methyl- l-(2-pyridin-4-yl-5-thiophen-2-yl-thieno[2,3-d] pyrimidin- 4-ylamino)-pyrrole-2,5-dione hydrochloride,
14) l-[2-(4-methoxy-phenyl)-5-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-ylamino] -3-methyl-pyrrole-2,5-dione hydrochloride,
15) 3-methyl- l-(5-thiophen-2-yl-2-p-tolyl-thieno[2,3-d] pyrimidin- 4-ylamino)-pyrrole-2,5-dione hydrochloride,
16) 3-methyl- l-(5-thiophen-2-yl-2-thiophen-2-ylmethyl-thieno[2,3-d] pyrimidin- 4-ylamino)-pyrrole-2,5-dione hydrochloride,
17) 3-methyl- l-(2-thiophen-2-yl-thieno[2,3-d] pyrimidin- 4-ylamino)-pyrrole-2,5-dione hydrochloride,
18) 3-methyl- l-(5-methyl-thieno[2,3-d]pyrimidin-4-ylamino)-pyrrole-2,5-dione hydrochloride,
19) l-(2-benzyl-5-thiophen-2-yl-thieno[2,3-d] pyrimidin- 4-ylamino)-3-methyl-pyrrole-2,5-dione hydrochloride,
20) 3-methyl- l-(5-methyl-2-thiophen-2-yl-thieno[2,3-d] pyrimidin- 4-ylamino)-pyrrole-2,5-dione hydrochloride,
21) 3-methyl- l-(2-phenyl-5-thiophen-2-yl-thieno[2,3-d] pyrimidin- 4-ylamino)-pyrrole-2,5-dione,
22) 3-methyl- l-(2-phenyl-5-thiophen-2-yl-thieno[2,3-d] pyrimidin- 4-ylamino)-pyrrole-2,5-dione hydrochloride,
23) l-[2-(4-hydroxy-phenyl)-5-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-ylamino] -3-methyl-pyrrole-2,5-dione hydrochloride,
24) l-[2-(4-fluoro-phenyl)-5-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-ylamino] - 3-methyl-pyrrole-2,5-dione hydrochloride,
25) l-[2-(3-fluoro-phenyl)-5-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-ylamino] - 3-methyl-pyrrole-2,5-dione hydrochloride,
26) 3-methyl- l-(2-thiophen-3-yl-5-thiophen-2-yl-thieno[2,3-d] pyrimidin- 4-ylamino)-pyrrole-2,5-dione hydrochloride,
27) 3-methyl- l-(2-thiophen-2-yl-5-thiophen-3-yl-thieno[2,3-d] pyrimidin- 4-ylamino)-pyrrole-2,5-dione hydrochloride,
28) 3-methyl- l-(5-thiophen-2-yl-2-thiophen-3-ylmethyl-thieno[2,3-d] pyrimidin- 4-ylamino)-pyrrole-2,5-dione hydrochloride,
29) 3-methyl- l-(5-phenyl-2-thiophen-2-yl-thieno[2,3-d] pyrimidin- 4-ylamino)-pyrrole-2,5-dione hydrochloride,
30) 3-methyl- l-(2-thiophen-2-yl-5-p-tolyl-thieno[2,3-d] pyrimidin- 4-ylamino)-pyrrole-2,5-dione hydrochloride,
31) l-[2-(4-methoxy-benzyl)-5-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-ylamino] -3-methyl-pyrrole-2,5-dione hydrochloride,
32) l-[2-(4-diethylaminophenyl)-5-thiophen-2-yl-thieno[2,3-d] pyrimidin- 4-ylamino]-3-methyl-pyrrole-2,5-dione hydrochloride,
33) l-[2-(3-hydroxy-phenyl)-5-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-ylamino] -3-methyl-pyrrole-2,5-dione hydrochloride,
34) l-[2-(4-methoxy-phenyl)-5-phenyl-thieno[2,3-d]pyrimidin-4-ylamino] - 3-methyl-pyrrole-2,5-dione hydrochloride,
35) l-[2-(3-methoxy-phenyl)-5-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-ylamino] -3-methyl-pyrrole-2,5-dione hydrochloride,
36) l-[2-(3-methoxy-phenyl)-5-phenyl-thieno[2,3-d]pyrimidin-4-ylamino] - 3-methyl-pyrrole-2,5-dione hydrochloride,
37) l-[2-(3-fluoro-phenyl)-5-phenyl-thieno[2,3-d]pyrimidin-4-ylamino] - 3-methyl-pyrrole-2,5-dione hydrochloride,
38) l-[2-(3-methoxy-benzyl)-5-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-ylamino] -3-methyl-pyrrole-2,5-dione hydrochloride,
39)
4-(3-methyl-2,5-dioxo-2,5-dihydro-pyrrole-l-ylamino)-2-thiophen-2-yl-thieno[2, 3-d]pyrimidine-5-carboxylic acid ethyl ester hydrochloride,
40) l-[5-(3-hydroxy-phenyl)-2-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-ylamino] -3-methyl-pyrrole-2,5-dione hydrochloride,
41) l-[5-(3-methoxy-phenyl)-2-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-ylamino] -3-methyl-pyrrole-2,5-dione hydrochloride,
42) l-[2-(4-dimethylamino-phenyl)-5-phenyl-thieno[2,3-d]pyrimidin-4-ylamino] -3-methyl-pyrrole-2,5-dione hydrochloride,
43) l-[2-(4-amino-phenyl)-5-phenyl-thieno[2,3-d]pyrimidin-4-ylamino] - 3-methyl-pyrrole-2,5-dione hydrochloride,
44) l-(2-furan-2-yl-5-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-ylamino] - 3-methyl-pyrrole-2,5-dione hydrochloride,
45) 3-methyl- l-(2-methyl-5-thiophen-2-yl-thieno[2,3-d] pyrimidin- 4-ylamino)-pyrrole-2,5-dione hydrochloride,
46) l-[2-(4-amino-phenyl)-5-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-ylamino] - 3-methyl-pyrrole-2,5-dione hydrochloride,
47) l-(2-amino-5-thiophen-2-yl-thieno[2,3-d] pyrimidin- 4-ylamino)-3-methyl-pyrrole-2,5-dione hydrochloride,
48) l-(2-cyclopropyl-5-thiophen-2-yl-thieno[2,3-d] pyrimidin- 4-ylamino)-3-methyl-pyrrole-2,5-dione,
49)
[4-(3-methyl-2,5-dioxo-2,5-dihydro-pyrrole-l-ylamino)-2-thiophen-2-yl-thieno[2 ,3-d]pyrimidin-5-yl] -acetic acid methyl ester hydrochloride,
50) l-(5-hydroxymethyl-2-thiophen-2-yl-thieno[2,3-d] pyrimidin- 4-ylamino)-3-methyl-pyrrole-2,5-dione hydrochloride,
51) l-(5-methoxymethyl-2-thiophen-2-yl-thieno[2,3-d] pyrimidin- 4-ylamino)-3-methyl-pyrrole-2,5-dione hydrochloride,
52) 3-methyl-l-{2-[4-(2-piperidin-l-yl-ethoxy)-phenyl] - 5-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-ylamino}-pyrrole-2,5-dione hydrochloride,
53) 3-methyl-l-{2-[3-(2-piperidin-l-yl-ethoxy)-phenyl] - 5-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-ylamino}-pyrrole-2,5-dione hydrochloride,
54) l-[6-(4-hydroxy-phenyl)-2-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-ylamino] -3-methyl-pyrrole-2,5-dione hydrochloride,
55) l-[6-(4-methoxy-phenyl)-2-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-ylamino] -3-methyl-pyrrole-2,5-dione hydrochloride,
56) l-{6-[4-(2-dimethylamino-ethoxy)phenyl] -
5-methyl-2-thiophen-2-yl-furo[2,3-d]pyrimidin-4-ylamino}-3-methyl-pyrrole-2,5 -dione hydrochloride,
57) l-[6-(4-methoxy-phenyl)-5-methyl-2-thiophen-2-yl-thieno[2,3-d] pyrimidin- 4-ylamino]-3-methyl-pyrrole-2,5-dione hydrochloride,
58) l-[6-(4-hydroxy-phenyl)-5-methyl-2-thiophen-2-yl-thieno[2,3-d] pyrimidin- 4-ylamino]-3-methyl-pyrrole-2,5-dione hydrochloride,
59)
[5-methyl-4-(3-methyl-2,5-dioxo-2,5-dihydro-pyrrole-l-ylamino)-2-thiophen-2-y l-thieno[2,3-d]pyrimidin-6-yl] -acetic acid methyl ester hydrochloride,
60) l-[6-(3-hydroxy-phenyl)-5-methyl-2-thiophen-2-yl-thieno[2,3-d] pyrimidin-
4-ylamino]-3-methyl-pyrrole-2,5-dione,
61)
5-methyl-4-(3-methyl-2,5-dioxo-2,5-dihydro-pyrrole-l-ylamino)-2-thiophen-2-yl
-thieno[2,3-d]pyrimidine-6-carboxylic acid amide hydrochloride,
62) l-[6-(3-methoxy-phenyl)-5-methyl-2-thiophen-2-yl-thieno[2,3-d] pyrimidin-
4-ylamino]-3-methyl-pyrrole-2,5-dione,
63)
5-methyl-4-(3-methyl-2,5-dioxo-2,5-dihydro-pyrrole-l-ylamino)-2-thiophen-2-yl
-thieno[2,3-d]pyrimidine-6-carboxylic acid methyl ester hydrochloride,
64) l-(6-methoxy-5-methyl-2-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-ylamino] - 3-methyl-pyrrole-2,5-dione hydrochloride,
65) l-[6-(4-methoxy-benzyl)-5-methyl-2-thiophen-2-yl-thieno[2,3-d] pyrimidin- 4-ylamino]-pyrrole-2,5-dione hydrochloride,
66) l-[6-(4-hydroxy-benzyl)-5-methyl-2-thiophen-2-yl-thieno[2,3-d] pyrimidin- 4-ylamino]-pyrrole-2,5-dione hydrochloride,
67) 3-methyl-l-[5-methyl-6-(4-nitrophenyl)-2-thiophen-2-yl-thieno[2,3-d] pyrimidin-4-ylamino] -pyrrole-2,5-dione hydrochloride,
68) 3-methyl-l-(6-phenyl-2-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-ylam ino)-pyrrole-2,5-dione hydrochloride,
69)
3-[5-methyl-4-(3-methyl-2,5-dioxo-2,5-dihydro-pyrrole-l-ylamino)-2-thiophen-2 -yl-thieno[2,3-d]pyrimidin-6-yl]-propionic acid ethyl ester,
70) l-(6-hydroxymethyl-5-methyl-2-thiophen-2-yl-thieno[2,3-d] pyrimidin- 4-ylamino)-3-methyl-pyrrole-2,5-dione hydrochloride,
71) l-(6-methoxymethyl-5-methyl-2-thiophen-2-yl-thieno[2,3-d] pyrimidin- 4-ylamino)-3-methyl-pyrrole-2,5-dione hydrochloride,
72) l-[6-(3-methoxybenzyl)-5-methyl-2-thiophen-2-yl-thieno[2,3-d] pyrimidin- 4-ylamino]-3-methyl-pyrrole-2,5-dione hydrochloride,
73) l-[6-(3-hydroxy-benzyl)-2-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-ylamino] -3-methyl-pyrrole-2,5-dione hydrochloride,
74) l-{6-[3-(2-dimethylamino-ethoxy)-benzyl]-2-thiophen-2-yl-thieno[2,3-d] pyrimidin-4-ylamino } -3-methyl-pyrrole-2,5-dione hydrochloride,
75)
5-methyl-4-(3-methyl-2,5-dioxo-2,5-dihydro-pyrrole-l-ylamino)-2-thiophen-2-yl -thieno[2,3-d]pyrimidine-6-carboxylic acid-(2-dimethylamino-ethyl)-amide hydrochloride,
76) 3-methyl-l-{5-[4-(2-piperidin-l-yl-ethoxy)-phenyl] - 2-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-ylamino}-pyrrole-2,5-dione hydrochloride,
77) 3-methyl-l-{5-[3-(2-piperidin-l-yl-ethoxy)-phenyl] - 2-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-ylamino}-pyrrole-2,5-dione hydrochloride,
78) 1 - { 5 - [3 - (2-dimethylamino-ethoxy ) -phenyl] -2-thiophen-2-yl- thieno [2, 3 -d] pyrimidin-4-ylamino } -3-methyl-pyrrole-2,5-dione hydrochloride,
79) l-{5-[3-(3-dimethylamino-propoxy)-phenyl]-2-thiophen-2-yl-thieno[2,3-d] pyrimidin-4-ylamino } -3-methyl-pyrrole-2,5-dione hydrochloride,
80) 3-methyl-l-{5-[3-(2-morpholin-4-yl-ethoxy)-phenyl] - 2-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-ylamino}-pyrrole-2,5-dione hydrochloride,
81) 3-methyl-l-{5-[3-(2-piperazin-l-yl-ethoxy)-phenyl] - 2-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-ylamino}-pyrrole-2,5-dione dihy-
drochloride,
82)
3-methyl- 1 - [5-methyl-6-(4-methyl-piperazin- 1 -ylmethyl)-2-thiophen-2-yl-thieno
[2,3-d]pyrimidin-4-ylamino]-pyrrole-2,5-dione dihydrochloride,
83) 3-methyl-l-(5-{3-[2-(4-methyl-piperazin-l-yl)-ethoxy] - phenyl}-2-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-ylamino)-pyrrole-2,5-dione dihydrochloride ,
84) l-{6-[4-(2-dimethylamino-ethoxy)phenyl] -
5-methyl-2-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-ylamino}-3-methyl-pyrrole- 2,5-dione hydrochloride,
85) 3-methyl- l-{5-methyl-6-[4-(2-piperidin-l-yl-ethoxy)-phenyl] - 2-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-ylamino}-pyrrole-2,5-dione hydrochloride,
86) l-{6-[4-(2-methoxy-ethoxy)-phenyl)-5-methyl-2-thiophen-2-yl-thieno[2,3-d] pyrimidin-4-ylamino] -3-methyl-pyrrole-2,5-dione hydrochloride,
87) l-{6-[3-(2-methoxy-ethoxy)-phenyl]-5-methyl-2-thiophen-2-yl-thieno[2,3-d] pyrimidin-4-ylamino } -3-methyl-pyrrole-2,5-dione,
88) 3-methyl-l-{5-methyl-6-[4-(2-morpholin-4-yl-ethoxy)-phenyl] - 2-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-ylamino}-pyrrole-2,5-dione hydrochloride,
89) l-{2-t-butyl-6-[4-(2-dimethylamino-ethoxy)-phenyl]-5-methyl-thieno[2,3-d] pyrimidin-4-ylamino } -3-methyl-pyrrole-2,5-dione hydrochloride,
90) l-{6-[4-(2-dimethylamino-ethoxy)-phenyl]-2-isobutyl-5-methyl-thieno[2,3-d ]pyrimidin-4-ylamino } -3-methyl-pyrrole-2,5-dione hydrochloride,
91) l-{2-allyl-6-[4-(2-dimethylamino-ethoxy)-phenyl]-5-methyl-thieno[2,3-d] pyrimidin-4-ylamino } -3-methyl-pyrrole-2,5-dione hydrochloride,
92) 3-methyl- l-{5-methyl-6-[4-(2-piperazin-l-yl-ethoxy)-phenyl] - 2-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-ylamino}-pyrrole-2,5-dione hydrochloride,
93) l-{6-[4-(3-dimethylamino-propoxy)-phenyl] -
5-methyl-2-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-ylamino}-3-methyl-pyrrole- 2,5-dione hydrochloride,
94) l-{6-[4-(2-amino-ethoxy)-phenyl]-5-methyl-2-thiophen-2-yl-thieno[2,3-d] pyrimidin-4-ylamino } -3-methyl-pyrrole-2,5-dione hydrochloride,
95) l-{6-[4-(2-diethylamino-ethoxy)-phenyl]-2-thiophen-2-yl-thieno[2,3-d] pyrimidin-4-ylamino } -3-methyl-pyrrole-2,5-dione hydrochloride,
96) 3-methyl- l-{5-methyl-6-[4-(2-pyrrolidin-l-yl-ethoxy)-phenyl] - 2-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-ylamino}-pyrrole-2,5-dione hy-
drochloride,
97) 3-methyl-l-{5-methyl-6-[4-(2-(4-methyl piperazin-l-yl)-ethoxy) -phenyl] - 2-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-ylamino}-pyrrole-2,5-dione hydrochloride,
98) l-(6-{4-[2-(ethyl-methyl-amino)-ethoxy] - phenyl}-5-methyl-2-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-ylamino)-3-methyl- pyrrole-2,5-dione hydrochloride,
99) 3-methyl- l-(5-methyl-6-{4-[2-(methyl-propyl-amino)-ethoxy] - phenyl}-2-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-ylamino)-pyrrole-2,5-dione hydrochloride,
100) 3-methyl- l-(5-methyl-6-{4-[2-(2-oxo-pyrrolidin- l-yl)-ethoxy] - phenyl}-2-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-ylamino)-pyrrole-2,5-dione hydrochloride,
101) l-(6-{4-[2-(isopropyl-methyl-amino)-ethoxy] - phenyl}-5-methyl-2-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-ylamino)-3-methyl- pyrrole-2,5-dione hydrochloride,
102) 3-methyl- l-(5-methyl-6-{4-(2-thiomorpholin-4-yl-ethoxy)-phenyl] - 2-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-ylamino)-pyrrole-2,5-dione hydrochloride,
103) l-{6-[4-(2-dimethylamino-ethoxy)-phenyl]-2,5-dimethyl-thieno[2,3-d] pyrimidin-4-ylamino } -3-methyl-pyrrole-2,5-dione hydrochloride,
104) l-{6-[4-(2-dimethylamino-ethoxy)-phenyl]-5-methyl-2-propyl-thieno[2,3-d ]pyrimidin-4-ylamino } -3-methyl-pyrrole-2,5-dione hydrochloride,
105) l-{6-[4-(2-dimethylamino-ethoxy)-phenyl] -
5-methyl-2-cyclopropyl-thieno[2,3-d]pyrimidin-4-ylamino}-3-methyl-pyrrole-2, 5-dione hydrochloride,
106) l-{6-[4-(2-dimethylamino-ethoxy)-phenyl]-5-methyl-2-ethyl-thieno[2,3-d] pyrimidin-4-ylamino } -3-methyl-pyrrole-2,5-dione hydrochloride,
107) l-{2-cyclopropylmethyl-6-[4-(2-dimethylamino-ethoxy)-phenyl] - 5-methyl-thieno[2,3-d]pyrimidin-4-ylamino}-3-methyl-pyrrole-2,5-dione hydrochloride
108) l-{6-[4-(2-dimethylamino-ethoxy)-phenyl] -
5-methyl-2-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-ylamino}-pyrrole-2,5-dione hydrochloride,
109) l-{6-[4-(2-dimethylamino-ethoxy)-phenyl] -
5-methyl-2-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-ylamino}-3,4-dimethyl-pyrr ole-2,5-dione hydrochloride,
110) 3,4-dichloro-l-{6-[4-(2-dimethylamino-ethoxy)-phenyl] -
5-methyl-2-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-ylamino}-pyrrole-2,5-dione hydrochloride,
111) l-[6-(4-{2-[4-(2-amino-ethyl)-piperazin-l-yl] - ethoxy}-phenyl)-5-methyl-2-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-ylamino]-3- methyl-pyrrole-2,5-dione hydrochloride,
112) l-[6-(4-{2-[2-amino-ethyl)-methyl-amino] - ethoxy}-phenyl)-5-methyl-2-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-ylamino]-3- methyl-pyrrole-2,5-dione hydrochloride,
113) l-[6-(4-{2-[(2-dimethylamino-ethyl)-methyl-amino] - ethoxy}-phenyl)-5-methyl-2-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-ylamino]-3- methyl-pyrrole-2,5-dione hydrochloride,
114) l-[6-(4-{2-[4-(2-dimethylamino-ethyl)-piperazin-l-yl] - ethoxy}-phenyl)-5-methyl-2-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-ylamino]-3- methyl-pyrrole-2,5-dione hydrochloride,
115) l-[6-(4-{2-[4-(2-methoxy-ethyl)-piperazin-l-yl] - ethoxy}-phenyl)-5-methyl-2-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-ylamino]-3- methyl-pyrrole-2,5-dione hydrochloride,
116) 3-methyl-l-(5-methyl-6-{4-[2-(2-piperazin-l-yl-ethoxy)-ethoxy] - phenyl}-2-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-ylamino)-pyrrole-2,5-dione hydrochloride,
117) 1 -(6- { 4- [2-(4-acetyl-piperazin- 1 -yl)-ethoxy] -phenyl } -5-methyl-2-thiophen- 2-yl-thieno[2,3-d]pyrimidin-4-ylamino)-3-methyl-pyrrole-2,5-dione hydrochloride,
118) l-(6-{4-[2-(2,5-dioxo-pyrrolidin-l-yl)-ethoxy] - phenyl}-5-methyl-2-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-ylamino)-3-methyl- pyrrole-2,5-dione,
119) l-[6-(4-{2-[4-(2-hydroxy-ethyl)-piperazin-l-yl] - ethoxy}-phenyl)-5-methyl-2-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-ylamino]-3- methyl-pyrrole-2,5-dione hydrochloride,
120) 3-methyl-l-(5-methyl-6-{4-[2-(3-oxo-piperazin-l-yl)-ethoxy] - phenyl}-2-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-ylamino)-pyrrole-2,5-dione hydrochloride,
121) l-[6-(4-{2-[(2-hydroxy-ethyl)-methyl-amino] - ethoxy}-phenyl)-5-methyl-2-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-ylamino]-3- methyl-pyrrole-2,5-dione hydrochloride,
122) l-[6-(4-{2-[(2-methoxy-ethyl)-methyl-amino] - ethoxy}-phenyl)-5-methyl-2-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-ylamino]-3- methyl-pyrrole-2,5-dione hydrochloride,
123) l-(6-{4-[2-(l,4-dioxa-8-aza-spiro[4,5]dec-8-yl)-ethoxy] - phenyl}-5-methyl-2-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-ylamino)-3-methyl- pyrrole-2,5-dione hydrochloride
124) l-(6-{4-[2-(2,5-dioxo-2,5-dihydro-pyrrole-l-yl)-ethoxy] - phenyl}-5-methyl-2-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-ylamino)-3-methyl- pyrrole-2,5-dione,
125) 3 -methyl- 1 - (5 -methyl- 6- { 4- [2- (2-oxo-imidazolidin- 1 -yl) -ethoxy ] - phenyl}-2-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-ylamino)-pyrrole-2,5-dione,
126) l-{6-[4-(2-dimethylamino-ethoxy)-phenyl] -
5-ethyl-2-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-ylamino}-3-methyl-pyrrole-2, 5-dione hydrochloride,
127) l-(6-{4-[2-(4-butyl-piperazin-l-yl)-ethoxy] - phenyl}-5-methyl-2-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-ylamino)-3-methyl- pyrrole-2,5-dione dihydrochloride,
128) l-({6-[4-(2-dimethylamino-ethoxy)-phenyl] -
5-methyl-2-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-yl}-methyl-amino)-3-methyl -pyrrole-2,5-dione hydrochloride,
129) methyl-
(2-{4-[5-methyl-4-(3-methyl-2,5-dioxo-2,5-dihydro-pyrrol-l-ylamino)-2-thiophe n-2-yl-thieno[2,3-d]pyrimidin-6-yl]-phenoxy}-ethyl)-carbamic acid ?-butyl ester,
130) 3-methyl-l-{5-methyl-6-[4-(2-methylamino-ethoxy)-phenyl] - 2-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-ylamino}-pyrrole-2,5-dione hydrochloride,
131) l-[6-(4-methoxy-phenyl)-5-methyl-2-thiophen-2-yl-thieno[2,3-d] pyrimidin- 4-ylamino]-3-methylene-pyrrolidine-2,5-dione,
132) 3-methylene- 1 - { 5-methyl-6- [4- (2-methylamino-ethoxy) -phenyl] - 2-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-ylamino}-pyrrolidine-2,5-dione hydrochloride,
133) l-{6-[4-(2-butylamino-ethoxy)-phenyl] -
5-methyl-2-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-ylamino}-3-methyl-pyrrole- 2,5-dione hydrochloride,
134) l-[(6-{4-[2-(2-methoxy-ethylamino)-ethoxy] - phenyl}-5-methyl-2-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-yl)-methyl-amino]- 3-methyl-pyrrole-2,5-dione hydrochloride,
135) l-[(6-{4-[2-(2-hydroxy-ethylamino)-ethoxy] - phenyl}-5-methyl-2-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-yl)-methyl-amino]- 3-methyl-pyrrole-2,5-dione hydrochloride,
136) 3-methyl- l-(5-methyl-6-{4-[2-(3-methyl-butylamino)-ethoxy] -
phenyl}-2-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-ylamino)-pyrrole-2,5-dione hydrochloride, 137)
3-methyl-l-(5-methyl-2-thiophen-2-yl-6-{4-[2-(2,2,2-trifluoro-ethylamino)-etho xy]-phenyl}-thieno[2,3-d]pyrimidin-4-ylamino)-pyrrole-2,5-dione hydrochloride,
138) 3-dimethylamino-Λf -
{4-[5-methyl-4-(3-methyl-2,5-dioxo-2,5-dihydro-pyrrol-l-ylamino)-2-thiophen- 2-yl-thieno[2,3-d]pyrimidin-6-yl]-phenyl}-propionamide hydrochloride, 139)
3-[methyl-(2-{4-[5-methyl-4-(3-methyl-2,5-dioxo-2,5-dihydro-pyrrol-l-ylamino) -2-thiophen-2-yl-thieno[2,3-d]pyrimidin-6-yl]-phenoxy}-ethyl)-amino]-propioni c acid,
140) isopropyl-
(2-{4-[5-methyl-4-(3-methyl-2,5-dioxo-2,5-dihydro-pyrrol-l-ylamino)-2-thiophe n-2-yl-thieno[2,3-d]pyrimidin-6-yl]-phenoxy}-ethyl)-carbamic acid ?-butyl ester,
141) l-{6-[4-(2-isopropylamino-ethoxy)-phenyl] -
5-methyl-2-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-ylamino}-3-methyl-pyrrole- 2,5-dione hydrochloride,
142) 3-methyl-l-{5-methyl-6-[4-(piperidin-4-yloxy)-phenyl] - 2-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-ylamino}-pyrrole-2,5-dione hydrochloride,
143) l-{6-[4-(2-benzylamino-ethoxy)-phenyl] -
5-methyl-2-thiophen-2-yl-thieno[2,3-d]pyrimidin-4-ylamino}-3-methyl-pyrrole- 2,5-dione hydrochloride, and
144)
3-(2-{4-[5-methyl-4-(3-methyl-2,5-dioxo-2,5-dihydro-pyrrol-l-ylamino)-2-thiop hen-2-yl-thieno[2,3-d]pyrimidin-6-yl]-phenoxy}-ethylamino)-propionitrile hydrochloride.
[4] A pharmaceutical composition for preventing and treating inflammatory diseases, comprising the compound, a pharmaceutically acceptable salt thereof or an isomer thereof according to any one of claims 1 to 3.
[5] The pharmaceutical composition according to claim 4, which the inflammatory disease is selected from the group consisting of rheumatoid arthritis, spondy- loarthopathies, gout, osteoarthritis, systemic lupus erythematosus, and juvenile arthritis.
[6] The pharmaceutical composition according to claim 4, wherein the inflammatory disease is selected from the group consisting of myositis, gingivitis, synovitis,
ankylosing spondylitis, burstitis, septic shock, burns, and injury. [7] The pharmaceutical composition according to claim 4, which is useful for treating inflammatory symptoms accompanied by inflammatory diseases selected from the group consisting of inflammatory bowel disease, Crohn's disease, Type
I diabetes, and psoriasis. [8] A pharmaceutical composition for preventing and treating cancer, comprising the compound, a pharmaceutically acceptable salt thereof or an isomer thereof according to any one of claims 1 to 3.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20060021128 | 2006-03-06 | ||
KR10-2006-0021128 | 2006-03-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2007102679A1 true WO2007102679A1 (en) | 2007-09-13 |
Family
ID=38475084
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2007/001074 WO2007102679A1 (en) | 2006-03-06 | 2007-03-05 | Novel thienopyrimidine derivatives or pharmaceutically acceptable salts thereof, process for the preparation thereof and pharmaceutical composition comprising the same |
Country Status (2)
Country | Link |
---|---|
KR (1) | KR100846988B1 (en) |
WO (1) | WO2007102679A1 (en) |
Cited By (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010103130A2 (en) | 2009-03-13 | 2010-09-16 | Katholieke Universiteit Leuven, K.U.Leuven R&D | Novel bicyclic heterocycles |
WO2011102399A1 (en) | 2010-02-17 | 2011-08-25 | 武田薬品工業株式会社 | Heterocyclic compound |
WO2011147753A1 (en) | 2010-05-26 | 2011-12-01 | Katholieke Universiteit Leuven, K.U.Leuven R&D | Antiviral activity of novel bicyclic heterocycles |
WO2012035423A1 (en) | 2010-09-15 | 2012-03-22 | Katholieke Universiteit Leuven, K.U. Leuven R&D | Anti-cancer activity of novel bicyclic heterocycles |
WO2012044993A1 (en) * | 2010-09-30 | 2012-04-05 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Compounds, pharmaceutical compositions, and methods of treating or preventing neurodegenerative diseases or disorders |
US8513263B2 (en) | 2008-10-22 | 2013-08-20 | Array Biopharma Inc. | Substituted pyrazolo[1,5-a]pyrimidine compounds as Trk kinase inhibitors |
WO2014078957A1 (en) * | 2012-11-20 | 2014-05-30 | The Royal Institution For The Advancement Of Learning/Mcgill University | Thienopyrimidine inhibitors of farnesyl and/or geranylgeranyl pyrophosphate synthase |
US9056877B2 (en) | 2011-07-19 | 2015-06-16 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
WO2015160192A1 (en) * | 2014-04-15 | 2015-10-22 | 연세대학교 산학협력단 | Pharmaceutical composition for treating and preventing leukemia, containing thienopyrimidine derivative or pharmaceutically acceptable salt thereof |
US9227975B2 (en) | 2008-09-22 | 2016-01-05 | Array Biopharma, Inc. | Method of treatment using substituted imidazo[1,2B]pyridazine compounds |
US9493476B2 (en) | 2010-05-20 | 2016-11-15 | Array Biopharma, Inc. | Macrocyclic compounds as trk kinase inhibitors |
US9682979B2 (en) | 2009-07-09 | 2017-06-20 | Array Biopharma, Inc. | Substituted pyrazolo [1,5-A] pyrimidine compounds as TRK kinase inhibitors |
US9782414B2 (en) | 2014-11-16 | 2017-10-10 | Array Biopharma, Inc. | Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate |
JP2018502899A (en) * | 2015-01-20 | 2018-02-01 | 无▲錫▼福祈制▲薬▼有限公司Wuxi Fortune Pharmaceutical Co.,Ltd | JAK inhibitor |
US10045991B2 (en) | 2016-04-04 | 2018-08-14 | Loxo Oncology, Inc. | Methods of treating pediatric cancers |
US10137127B2 (en) | 2016-04-04 | 2018-11-27 | Loxo Oncology, Inc. | Liquid formulations of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide |
US10370727B2 (en) | 2015-10-26 | 2019-08-06 | Loxo Oncology, Inc. | Point mutations in TRK inhibitor-resistant cancer and methods relating to the same |
US10588894B2 (en) * | 2017-06-21 | 2020-03-17 | SHY Therapeutics LLC | Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease |
US10688100B2 (en) | 2017-03-16 | 2020-06-23 | Array Biopharma Inc. | Macrocylic compounds as ROS1 kinase inhibitors |
US10870657B2 (en) | 2015-12-22 | 2020-12-22 | SHY Therapeutics LLC | Compounds for the treatment of cancer and inflammatory disease |
US11091486B2 (en) | 2016-10-26 | 2021-08-17 | Array Biopharma, Inc | Process for the preparation of pyrazolo[1,5-a]pyrimidines and salts thereof |
US11214571B2 (en) | 2016-05-18 | 2022-01-04 | Array Biopharma Inc. | Process for the preparation of (S)-N-(5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide and salts thereof |
US11324731B2 (en) | 2018-09-13 | 2022-05-10 | City Of Hope | TXNIP-TRX complex inhibitors and methods of using the same |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20190139640A (en) * | 2018-06-08 | 2019-12-18 | 재단법인 의약바이오컨버젼스연구단 | Composition for preventing or treating solid tumor comprising compound inhibiting interactions between AIMP2-DX2 and K-Ras and novel compound inhibiting interactions between AIMP2-DX2 and K-Ras |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20010020030A1 (en) * | 1998-06-04 | 2001-09-06 | Stewart Andrew O. | Cell adhesion-inhibiting antiinflammatory compounds |
WO2003103661A1 (en) * | 2002-06-06 | 2003-12-18 | Boehringer Ingelheim Pharmaceuticals, Inc. | SUBSTITUTED 3-AMINO-THIENO[2,3-b]PYRIDINE-2-CARBOXYLIC ACID AMIDE COMPOUNDS AND PROCESSES FOR PREPARING AND THEIR USES |
US6734180B1 (en) * | 1998-07-22 | 2004-05-11 | Daiichi Suntory Pharma Co., Ltd. | NF-κB inhibitor comprising an indan derivative as an active ingredient |
US20040097485A1 (en) * | 2002-10-31 | 2004-05-20 | Tularik Inc. | Antiinflammation agents |
-
2007
- 2007-03-05 KR KR1020070021373A patent/KR100846988B1/en active IP Right Grant
- 2007-03-05 WO PCT/KR2007/001074 patent/WO2007102679A1/en active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20010020030A1 (en) * | 1998-06-04 | 2001-09-06 | Stewart Andrew O. | Cell adhesion-inhibiting antiinflammatory compounds |
US6734180B1 (en) * | 1998-07-22 | 2004-05-11 | Daiichi Suntory Pharma Co., Ltd. | NF-κB inhibitor comprising an indan derivative as an active ingredient |
WO2003103661A1 (en) * | 2002-06-06 | 2003-12-18 | Boehringer Ingelheim Pharmaceuticals, Inc. | SUBSTITUTED 3-AMINO-THIENO[2,3-b]PYRIDINE-2-CARBOXYLIC ACID AMIDE COMPOUNDS AND PROCESSES FOR PREPARING AND THEIR USES |
US20040097485A1 (en) * | 2002-10-31 | 2004-05-20 | Tularik Inc. | Antiinflammation agents |
Cited By (75)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9227975B2 (en) | 2008-09-22 | 2016-01-05 | Array Biopharma, Inc. | Method of treatment using substituted imidazo[1,2B]pyridazine compounds |
US10590139B2 (en) | 2008-09-22 | 2020-03-17 | Array Biopharma Inc. | Method of treatment using substituted imidazo[1,2b]pyridazine compounds |
US10011604B2 (en) | 2008-09-22 | 2018-07-03 | Array Biopharma, Inc. | Method of treatment using substituted imidazo[1,2b]pyridazine compounds |
US9795611B2 (en) | 2008-09-22 | 2017-10-24 | Array Biopharma, Inc. | Method of treatment using substituted imidazo[1,2b]pyridazine compounds |
US9796723B2 (en) | 2008-09-22 | 2017-10-24 | Array Biopharma, Inc. | Method of treatment using substituted imidazo[1,2b]pyridazine compounds |
US10774085B2 (en) | 2008-10-22 | 2020-09-15 | Array Biopharma Inc. | Method of treatment using substituted pyrazolo[1,5-A] pyrimidine compounds |
US8513263B2 (en) | 2008-10-22 | 2013-08-20 | Array Biopharma Inc. | Substituted pyrazolo[1,5-a]pyrimidine compounds as Trk kinase inhibitors |
US11267818B2 (en) | 2008-10-22 | 2022-03-08 | Array Biopharma Inc. | Method of treatment using substituted pyrazolo[1,5-a] pyrimidine compounds |
US8865698B2 (en) | 2008-10-22 | 2014-10-21 | Array Biopharma Inc. | Method of treatment using substituted pyrazolo[1,5-a]pyrimidine compounds |
US9676783B2 (en) | 2008-10-22 | 2017-06-13 | Array Biopharma, Inc. | Method of treatment using substituted pyrazolo[1,5-A] pyrimidine compounds |
US10047097B2 (en) | 2008-10-22 | 2018-08-14 | Array Biopharma Inc. | Method of treatment using substituted pyrazolo[1,5-a] pyrimidine compounds |
US9447104B2 (en) | 2008-10-22 | 2016-09-20 | Array Biopharma, Inc. | Method of treatment using substituted pyrazolo[1,5-a]pyrimidine compounds |
US9127013B2 (en) | 2008-10-22 | 2015-09-08 | Array Biopharma, Inc. | Method of treatment using substituted pyrazolo[1,5-a] pyrimidine compounds |
US10005783B2 (en) | 2008-10-22 | 2018-06-26 | Array Biopharma Inc. | Method of treatment using substituted pyrazolo[1,5-a] pyrimidine compounds |
WO2010103130A2 (en) | 2009-03-13 | 2010-09-16 | Katholieke Universiteit Leuven, K.U.Leuven R&D | Novel bicyclic heterocycles |
US9796724B2 (en) | 2009-07-09 | 2017-10-24 | Array Biopharma, Inc. | Substituted pyrazolo[1,5-a]pyrimidine compounds as Trk kinase inhibitors |
US10758542B2 (en) | 2009-07-09 | 2020-09-01 | Array Biopharma Inc. | Substituted pyrazolo[l,5-a]pyrimidine compounds as Trk kinase inhibitors |
US9782415B2 (en) | 2009-07-09 | 2017-10-10 | Array Biopharma, Inc. | Substituted pyrazolo[1,5-a]pyrimidine compounds as Trk kinase inhibitors |
US10251889B2 (en) | 2009-07-09 | 2019-04-09 | Array BioPharm Inc. | Substituted pyrazolo[1,5-a]pyrimidine compounds as Trk kinase inhibitors |
US9682979B2 (en) | 2009-07-09 | 2017-06-20 | Array Biopharma, Inc. | Substituted pyrazolo [1,5-A] pyrimidine compounds as TRK kinase inhibitors |
EP3533797A1 (en) | 2010-02-17 | 2019-09-04 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
US9388195B2 (en) | 2010-02-17 | 2016-07-12 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
WO2011102399A1 (en) | 2010-02-17 | 2011-08-25 | 武田薬品工業株式会社 | Heterocyclic compound |
US8921354B2 (en) | 2010-02-17 | 2014-12-30 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
US8933069B2 (en) | 2010-02-17 | 2015-01-13 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
US8722660B2 (en) | 2010-02-17 | 2014-05-13 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
US9655900B2 (en) | 2010-02-17 | 2017-05-23 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
US9840519B2 (en) | 2010-05-20 | 2017-12-12 | Array Biopharma, Inc. | Macrocyclic compounds as TRK kinase inhibitors |
US9493476B2 (en) | 2010-05-20 | 2016-11-15 | Array Biopharma, Inc. | Macrocyclic compounds as trk kinase inhibitors |
US9902741B2 (en) | 2010-05-20 | 2018-02-27 | Array Biopharma Inc. | Macrocyclic compounds as TRK kinase inhibitors |
US10647730B2 (en) | 2010-05-20 | 2020-05-12 | Array Biopharma Inc. | Macrocyclic compounds as TRK kinase inhibitors |
US9750744B2 (en) | 2010-05-20 | 2017-09-05 | Array Biopharma, Inc. | Macrocyclic compounds as Trk kinase inhibitors |
US9718822B2 (en) | 2010-05-20 | 2017-08-01 | Array Biopharma, Inc. | Macrocyclic compounds as Trk kinase inhibitors |
WO2011147753A1 (en) | 2010-05-26 | 2011-12-01 | Katholieke Universiteit Leuven, K.U.Leuven R&D | Antiviral activity of novel bicyclic heterocycles |
WO2012035423A1 (en) | 2010-09-15 | 2012-03-22 | Katholieke Universiteit Leuven, K.U. Leuven R&D | Anti-cancer activity of novel bicyclic heterocycles |
WO2012044993A1 (en) * | 2010-09-30 | 2012-04-05 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Compounds, pharmaceutical compositions, and methods of treating or preventing neurodegenerative diseases or disorders |
US9056877B2 (en) | 2011-07-19 | 2015-06-16 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US9605003B2 (en) | 2011-07-19 | 2017-03-28 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
WO2014078957A1 (en) * | 2012-11-20 | 2014-05-30 | The Royal Institution For The Advancement Of Learning/Mcgill University | Thienopyrimidine inhibitors of farnesyl and/or geranylgeranyl pyrophosphate synthase |
WO2015160192A1 (en) * | 2014-04-15 | 2015-10-22 | 연세대학교 산학협력단 | Pharmaceutical composition for treating and preventing leukemia, containing thienopyrimidine derivative or pharmaceutically acceptable salt thereof |
US10172861B2 (en) | 2014-11-16 | 2019-01-08 | Array Biopharma Inc. | Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate |
US10285993B2 (en) | 2014-11-16 | 2019-05-14 | Array Biopharma Inc. | Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate |
US10813936B2 (en) | 2014-11-16 | 2020-10-27 | Array Biopharma, Inc. | Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-YL)-pyrazolo[1,5-A]pyrimidin-3-YL)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate |
US10799505B2 (en) | 2014-11-16 | 2020-10-13 | Array Biopharma, Inc. | Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate |
US9782414B2 (en) | 2014-11-16 | 2017-10-10 | Array Biopharma, Inc. | Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate |
JP2018502899A (en) * | 2015-01-20 | 2018-02-01 | 无▲錫▼福祈制▲薬▼有限公司Wuxi Fortune Pharmaceutical Co.,Ltd | JAK inhibitor |
US10655186B2 (en) | 2015-10-26 | 2020-05-19 | Loxo Oncology, Inc. | Point mutations in TRK inhibitor-resistant cancer and methods relating to the same |
US10378068B2 (en) | 2015-10-26 | 2019-08-13 | Loxo Oncology, Inc. | Point mutations in TRK inhibitor-resistant cancer and methods relating to the same |
US10907215B2 (en) | 2015-10-26 | 2021-02-02 | Loxo Oncology, Inc. | Point mutations in TRK inhibitor-resistant cancer and methods relating to the same |
US10724102B2 (en) | 2015-10-26 | 2020-07-28 | Loxo Oncology, Inc. | Point mutations in TRK inhibitor-resistant cancer and methods relating to the same |
US10370727B2 (en) | 2015-10-26 | 2019-08-06 | Loxo Oncology, Inc. | Point mutations in TRK inhibitor-resistant cancer and methods relating to the same |
US11560390B2 (en) | 2015-12-22 | 2023-01-24 | SHY Therapeutics LLC | Compounds for the treatment of cancer and inflammatory disease |
US10870657B2 (en) | 2015-12-22 | 2020-12-22 | SHY Therapeutics LLC | Compounds for the treatment of cancer and inflammatory disease |
US11484535B2 (en) | 2016-04-04 | 2022-11-01 | Loxo Oncology, Inc. | Liquid formulations of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a] pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide |
US11191766B2 (en) | 2016-04-04 | 2021-12-07 | Loxo Oncology, Inc. | Methods of treating pediatric cancers |
US10045991B2 (en) | 2016-04-04 | 2018-08-14 | Loxo Oncology, Inc. | Methods of treating pediatric cancers |
US10588908B2 (en) | 2016-04-04 | 2020-03-17 | Loxo Oncology, Inc. | Methods of treating pediatric cancers |
US10137127B2 (en) | 2016-04-04 | 2018-11-27 | Loxo Oncology, Inc. | Liquid formulations of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide |
US10668072B2 (en) | 2016-04-04 | 2020-06-02 | Loxo Oncology, Inc. | Liquid formulations of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide |
US11214571B2 (en) | 2016-05-18 | 2022-01-04 | Array Biopharma Inc. | Process for the preparation of (S)-N-(5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide and salts thereof |
US11091486B2 (en) | 2016-10-26 | 2021-08-17 | Array Biopharma, Inc | Process for the preparation of pyrazolo[1,5-a]pyrimidines and salts thereof |
US10688100B2 (en) | 2017-03-16 | 2020-06-23 | Array Biopharma Inc. | Macrocylic compounds as ROS1 kinase inhibitors |
US10966985B2 (en) | 2017-03-16 | 2021-04-06 | Array Biopharma Inc. | Macrocyclic compounds as ROS1 kinase inhibitors |
US11213515B1 (en) | 2017-06-21 | 2022-01-04 | SHY Therapeutics LLC | Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease |
US10940139B2 (en) | 2017-06-21 | 2021-03-09 | SHY Therapeutics LLC | Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease |
US10933054B2 (en) | 2017-06-21 | 2021-03-02 | SHY Therapeutics LLC | Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease |
US11026930B1 (en) | 2017-06-21 | 2021-06-08 | SHY Therapeutics LLC | Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease |
JP2020524703A (en) * | 2017-06-21 | 2020-08-20 | シャイ・セラピューティクス・エルエルシーShy Therapeutics Llc | Compounds that interact with the RAS superfamily for the treatment of cancer, inflammatory diseases, lasopathies, and fibrotic diseases |
AU2018288841B2 (en) * | 2017-06-21 | 2022-09-29 | SHY Therapeutics LLC | Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, Rasopathies, and fibrotic disease |
US11000515B2 (en) | 2017-06-21 | 2021-05-11 | SHY Therapeutics LLC | Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease |
US11541041B1 (en) | 2017-06-21 | 2023-01-03 | SHY Therapeutics LLC | Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, Rasopathies, and fibrotic disease |
US10588894B2 (en) * | 2017-06-21 | 2020-03-17 | SHY Therapeutics LLC | Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease |
JP7514005B2 (en) | 2017-06-21 | 2024-07-10 | シャイ・セラピューティクス・エルエルシー | Compounds that interact with the ras superfamily for the treatment of cancer, inflammatory diseases, rasopathy, and fibrotic diseases |
US11324731B2 (en) | 2018-09-13 | 2022-05-10 | City Of Hope | TXNIP-TRX complex inhibitors and methods of using the same |
US11974990B2 (en) | 2018-09-13 | 2024-05-07 | City Of Hope | TXNIP-TRX complex inhibitors and methods of using the same |
Also Published As
Publication number | Publication date |
---|---|
KR20070091546A (en) | 2007-09-11 |
KR100846988B1 (en) | 2008-07-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2007102679A1 (en) | Novel thienopyrimidine derivatives or pharmaceutically acceptable salts thereof, process for the preparation thereof and pharmaceutical composition comprising the same | |
EP3141552B1 (en) | Thienopyrimidine derivatives having inhibitory activity for protein kinase | |
CN1918137B (en) | Tetrazole compounds and their use as metabotropic glutamate receptor antagonists | |
CA2667487C (en) | Imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine derivatives and their use as protein kinase inhibitors | |
JP4555476B2 (en) | Condensed azepinone-type cyclin-dependent kinase inhibitor | |
JP6959663B2 (en) | Heterocyclic compounds as FGFR inhibitors | |
CN101687869A (en) | Tetracyclic lactam derivatives as the MK2 inhibitor | |
JP2010523637A (en) | Pharmaceutical compounds | |
MX2007004488A (en) | N-benzenesulfonyl substituted anilino-pyrimidine analogs. | |
RU2742485C2 (en) | Heterocyclic compound used as a fgfr inhibitor | |
CN112135611B (en) | Benzimidazole derivatives as modulators of retinoic acid-related orphan receptor gamma (ROR γ) and pharmaceutical uses thereof | |
EP2004638A1 (en) | Anilino-pyrimidine phenyl and benzothiophene analogs | |
JP2005515173A (en) | Pyrimido [4,5-b] indole derivatives | |
JP5583698B2 (en) | Azaindole derivatives as inhibitors of protein kinases ABL and SRC | |
WO2018086585A1 (en) | Nitrogen-containing heterocyclic compounds, preparation method therefor, pharmaceutical composition thereof, and applications thereof | |
WO2012139499A1 (en) | Urea compounds as well as preparation methods, intermediates and uses thereof | |
JP2010529129A (en) | Kinase inhibitor compounds | |
BRPI0616806A2 (en) | bicyclic aromatic compounds useful as inhibitors of mitogen-activated protein kinase-2 activated kinase-2, without as a use, process for the preparation and pharmaceutical composition and combination comprising said compounds | |
CA2010477A1 (en) | Medicament for treating cerebral insufficiency diseases novel 2-(1-piperazinyl)-4-phenylcycloalkanopyrimidine derivatives, and process for the production thereof | |
CN108368114B (en) | Pyrrolopyrimidine compounds as MNK inhibitors | |
EP3134405A1 (en) | Heteroaromatic compounds and their use as dopamine d1 ligands | |
US7579356B2 (en) | Thia-tetraazaacenaphthylene kinase inhibitors | |
Baraldi et al. | Synthesis of a new series of pyrazolo [1, 5‐a] pyrimidines structurally related to zaleplon | |
CN109810110A (en) | A kind of compound with 2- aminopyrimidine structure, preparation method and use | |
CN117295734A (en) | Methionine adenosyltransferase inhibitor, preparation method and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 07715477 Country of ref document: EP Kind code of ref document: A1 |